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A B S T R A C T
This thesis considers the prospects for hum an germ line gen etic  m odification  (H G G M ) 
via  a synthesis o f  scien tific  and bioethical concepts. E leven  published sc ien tific  and  
philosophical papers form  the basis for the thesis. The published  w ork deals w ith  the 
science, tech n ology  and w ider im plications o f  gene transfer. A  k ey  them e  
underpinning the thesis is  the notion that g en e  transfer is the central feature o f  tw o  
otherw ise disparate b iosc ien ce  fields -  anim al transgenesis and human gen e therapy. 
G ene transfer is the route to transgenic anim als, and hum an gene therapy depends  
upon gene transfer. The thesis argues that H G G M  is n ow  scien tifica lly  possib le: the 
tools o f  anim al gen etic  m odification  -  pronuclear m icroinjection , sperm -m ediated  
gene transfer (SM G T ), nuclear transfer, etc -  cou ld  in principle be applied to hum ans. 
H ow ever, serious technical obstacles rem ain to  be overcom e before H G G M  cou ld  be  
considered a practical therapeutic proposition. N everth eless, it is p ossib le  that gen e  
transfer tech n olog ies w ill im prove to the point at w h ich  it b ecom es easier and safer to  
perform  H G G M  than to carry out em bryo pre-screening. In this futuristic scenario o f  
expanded genetic k n ow led ge coupled w ith  effectiv e  g en e  transfer technology , H G G M  
w ould  b ecom e the preferred route. This prospect o f  g en etica lly  m od ify in g  hum ans 
raises several v ex in g  b ioeth ical issues, including questions o f  responsib ility  towards 
future generations, d ifficu lties o f  d istinction  b etw een  g en e therapy and genetic  
enhancem ent, and the spectre o f  eugenics. O f  the m any ph ilosoph ical approaches 
available to  deal w ith  such issues, utilitarianism  is an internally consistent and h igh ly  
consensib le ethical system , and it is  an approach that is  often  em ployed  (ex p lic itly  or 
im plicitly) in  m ed ical decision-m aking. This thesis argues for and adopts 
utilitarianism  as a valuable, albeit im perfect, p h ilosop h ica l approach w ith  w h ich  to  
address such issu es. The utilitarian argum entation in this thesis generates several 
conclusions in  the context o f  HG G M , includ ing that: [a] the developm ent o f  effec tiv e  
SM G T tech n ology  w ou ld  largely n u llify  eth ical concerns based  on  cost and access;
[b] the em bryo m anipulation, genetic sequence alteration and anim al experim entation  
entailed b y  the developm ent and application o f  H G G M  are all eth ically  perm issib le;
[c] the notion o f  risk  to future generations, although real, is  not unique to H G G M , is  
likely  to be tech n olog ica lly  m anageable, and is thus o f  low er ethical sa lience than  
prima facie consideration m ay suggest; [d] H G G M  for enhancem ent (rather than for 
therapy) w ould  be ju stified  w here u sed  as prophylaxis against d isease  or 
disadvantage; and [e] the u se o f  H G G M  for entirely non-m edical enhancem ents is  
unlikely  to have p ositive  utility, and is thus eth ica lly  objectionable, ev en  in  the 
futuristic scenario o f  effective  SM GT b ecom in g  available. T he overall con clu sion  o f  
this thesis is that it w ou ld  be unethical to  proscribe m ed ica lly  e ffective  H G G M .
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The purpose o f  this thesis is to  exp lic itly  integrate and unify k ey  aspects from  the 
accom panying portfolio  o f  published w ork (S ection  1.2). The published  w ork deals  
w ith  the scien ce , tech n ology  and w ider im plications o f  gene transfer applied  to h igher  
anim als, including humans. This thesis is  based  on the concept that gene transfer is  
the central feature o f  tw o otherw ise disparate b iosc ien ce  fields -  anim al transgenesis  
and hum an gene therapy. In this (applied) context, gene transfer represents a 
tech n ology  for the genetic m odification  (G M ) o f  higher anim al gen om es. H um an  
germ line genetic  m odification  represents the ultim ate potential u se  o f  G M  tech n ology . 
H um an germ line genetic m odification  form s the central focus o f  this thesis. 
A ccord ingly , this thesis considers the prospects for human germ line gen e therapy v ia  
a synthesis o f  scien tific  and b ioeth ical concepts.
1.2 Published Work
1. Sm ith K.R. Sperm  C ell M ediated Transgenesis: A  R eview . Animal 
Biotechnology 1999; 10(1-2): 1-13.
2. Sm ith K.R. Theoretical M echanism s in  Targeted and R andom  Integration o f  
Transgene D N A . Reproduction Nutrition Development 2001; 4 1 (6 ) :465-485 .
3. Sm ith K.R. A nim al G enetic m odification  - A  Utilitarian R esponse. Bioethics 
2002; 16(1): 55-71.
4. Sm ith K.R. G ene Transfer in H igher A nim als: Theoretical C onsiderations and  
K ey C oncepts. Journal o f Biotechnology 2002; 99(1): 1-22.
5. Sm ith K.R. The R ole o f  Sperm -M ediated G ene Transfer in G enom e M utation  
and E volution. Medical Hypotheses 2002; 59 (4): 433-437 .
6. Sm ith K.R. G ene Therapy: Theoretical and B ioeth ica l C oncepts. Archives o f 
Medical Research 2003; 34(4): 247-2 6 8 .
9
7. Sm ith K.R. G ene Therapy: The Potential A pplicab ility  o f  G ene Transfer
tech n o logy  to  the Hum an Germ line. International Journal o f Medical Science
2004; 1(2): 76-91 .
8. Sm ith K .R . &  Spadafora, C. Sperm -m ediated G ene Transfer: A pplications and
Im plications. BioEssays 2005; 27(5): 5 5 1 -5 6 2 .
A dditionally , one further m anuscript o f  relevance has been  accepted for publication:
9. Sm ith K .R . H um an G erm line G enetic M od ification  - a U tilitarian B ioeth ica l
Perspective. This is a chapter in an edited  b ook  entitled Trends in Gene Therapy
Research, published by N ova  Science Publishers, N ew  York. IS B N  1-59454-
306-2 . Publication is expected  m id-2005.
1.3 Contribution to ‘Original Knowledge’ in the 
Published Work
The above publications rev iew  and analyse relevant areas o f  sc ien ce and associated  
bioeth ics, and contain n ovel theoretical insights. Thus, each o f  the publications  
contributes to ‘original k n ow led ge’. The fo llo w in g  sections (1 .3 .1 -1 .3 .9 ) provide an 
outline o f  the contribution to original k n ow led ge m ade by  each publication, additional 
notes on  citations and journal rankings, and a facsim ile  o f  each publication.
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The published papers cited on pages 9-10 have 
been removed from the e-thesis due to 
copyright restrictions
1.3.1 Sperm Cell Mediated Transgenesis: A Review. Animal 
Biotechnology (1999)
This paper provides an original rev iew  o f  the status o f  a particular form  o f  germ line  
G M , sperm cell m ediated transgenesis, or sperm -m ediated gen e transfer (SM G T ). 
Contribution to original kn ow led ge is m ade b y  evaluating and syn th esising  a range o f  
k ey  experim ental and theoretical considerations. Thus, the paper functions as a m eta­
analysis o f  available inform ation. C onclusions drawn include that: (a) ‘augm ented’ 
SM G T, em ploying delivery system s such as liposom es or electroporation, is, 
conceptually , the m ore prom ising approach; (b) thorough ev idence o f  the 
effectiven ess o f  SM G T is required, by dem onstration o f  transgene transm ission to  
descendant animals; and (c) the potential im portance o f  SM G T g iv es  reason to  pursue 
this G M  approach, despite its theoretical and em pirical lim itations.
N otes: This paper has been  cited  several tim es b y  independent authors. The journal 
Animal Biotechnology is ranked 64  (from  131 journals) by im pact factor in the
‘B io tech n o lo g y ’ category o f  the m ost recently available (2002) ISI Journal Citation  
Reports.
11
1.3.2 Theoretical Mechanisms in Targeted and Random
Integration of Transgene DNA. Reproduction Nutrition 
Development (2001)
This paper provides an original review of the underlying mechanisms involved in the 
integration of transgenes. The paper’s central theme is that gene targeting is the key to 
surmounting problems associated with randomly integrated transgenes. The potential 
for gene targeting in the GM contexts of animal transgenesis and gene therapy are 
explored. The paper takes a meta-analysis approach to available research findings and 
concepts. The paper postulates and adapts theoretical models of transgene integration, 
thus providing original contributions to knowledge. Analysis of the evidence supports 
the notion that multiple pathways of homologous recombination (HR) are operative in 
targeted transgene integration. Chimeric oligonucleotides (COs) are small, highly 
specialised transgene molecules that have recently been used for gene targeting. 
However, the mechanism of CO integration has not been elucidated. The paper 
proposes that CO integration is most likely to involve a form of HR, and goes on to 
postulate a novel putative model for this process. A simple novel model for 
nonconservative HR between circularly permuted transgene molecules is also 
presented. The paper suggests that gene targeting in non-selective systems would be a 
critically important development for future gene therapy applications. The overall 
conclusion is that further biomolecular investigation and concomitant model-building 
will be required in order to provide a basis for the control of HR such that gene 
targeting can be used routinely in GM applications such as gene therapy.
Notes: This paper has been cited by independent authors. The journal Reproduction 
Nutrition Development is ranked 20 (from 23 journals) by impact factor in the 
‘Reproductive Biology’ category of the most recently available (2002) ISI Journal 
Citation Reports.
25
1.3.3 Animal Genetic Modification - A Utilitarian Response. 
Bioethics (2002)
B y  considering the underlying scientific aspects, this paper explores the b ioeth ics o f  
anim al G M . A  utilitarian stance is  adopted throughout. A lthough there exists m uch  
published literature dealing w ith  ethical aspects o f  various forms o f  GM , a ded icated  
utilitarian response to anim al G M  based on a consideration  o f  the underlying  
scien tific  aspects has not previously  been published. A ccord ingly , this paper 
represents a primary contribution to original k n ow led ge. A fter exam ining a num ber o f  
ethical issu es associated  w ith  anim al GM , the paper com es to the radical con clu sion  
that, w h ile  it w ou ld  be w rong to prohibit anim al G M  per se, utilitarians ought to  
support a ‘default prohibition’ on  transgenic experim ents that entail sign ificant  
suffering.
N otes: T his paper has been  cited  elsew here. The journal Bioethics is ranked am ong
the top 10 journals by  im pact factor in the ‘E th ics’ category o f  the m ost recently  
available (2 0 0 2 ) ISI Journal C itation Reports, as the num ber 6 top journal (from  28  
journals).
47
1.3.4 Gene Transfer in Higher Animals: Theoretical 
Considerations and Key Concepts. Journal of 
Biotechnology (2002)
This paper integrates a broad range o f  scien tific  concepts to provide a un ified  account 
o f  gen e transfer technology. The paper stresses that gene transfer tech n ology
com prises a com m on set o f  too ls that can be used  to ach ieve the disparate goa ls o f  
anim al transgenesis, som atic gene therapy and (in  principle) germ line gene therapy. 
Thus, the paper exam ines the different ce ll types - eggs, gam etes, em bryonic stem  
ce lls  (E SC s), som atic cells  - into w hich  transgenes m ay be transfected en route to
particular G M  goals. Thus, this paper m akes its m ain contribution to original 
kn ow led ge b y  evaluating, synthesising and integrating k ey  inform ation and concepts. 
The paper draws attention to k ey  aspects for attention, including im proved control o f  
target ce ll range, im proved transgene uptake e ffic ien cies, the ab ility  to loca lise  
transgenes to the nucleus and im provem ents in gen e targeting to  enable the effic ien t  
integration o f  transgenes into chosen  genom ic loc i. The overall con clusion  m ade by  
the paper is that im provem ents in gene transfer are urgently required, particularly i f  
hopes o f  effective  gene therapies are to be realised.
N otes: T his paper has been  cited  several tim es b y  independent authors. The Journal o f  
Biotechnology is ranked 33rd (from  131 journals) b y  im pact factor in the
‘B io tech n o lo g y ’ category o f  the m ost recently available (2002) ISI Journal C itation  
Reports.
65
1.3.5 The Role of Sperm-Mediated Gene Transfer in
Genome Mutation and Evolution. Medical Hypotheses
(2002)
This is an entirely original theoretical b io lo g y  paper. A ccord ingly , it provides a 
sign ificant contribution to original k now ledge. The paper’s central them e is that, i f  the 
reports o f  successfu l SM G T -based anim al G M  are not erroneous, it fo llo w s that the 
genom e o f  sexually  reproducing anim als, includ ing humans, should  be subject to  
alteration by  naturally occurring exogen ou s D N A  sequences carried b y  sperm  cells. 
The paper considers experim ental findings from  G M  experim ents com bined  w ith  k ey  
theoretical concepts surrounding transgene integration. The overall con clu sion  m ade  
is  that geneticists w ould  be w ise  to be v ig ilan t to the potential evolutionary and 
m edical consequences o f  SM G T.
N ote: The journal Medical Hypotheses is  ranked 6 0 th (from  74  journals) by  im pact 
factor in the ‘M edicine, R esearch and E xperim ental’ category o f  the m ost recently  
available (2002) ISI Journal Citation Reports.
88
1.3.6 Gene Therapy: Theoretical and Bioethical Concepts. 
Archives of Medical Research (2003)
Hum an gen e therapy, particularly germ line gen e therapy, represents an ultim ate u se  o f  
G M  tech n ology . This paper provides a m eta-analysis o f  k ey  research findings and 
theoretical concepts in the context o f  gene therapy, and these scien tific  considerations  
are integrated w ith  a b ioeth ical analysis o f  gen e therapy, present and future. The  
bioeth ica l approach is exp lic itly  utilitarian. A lthough  there ex ists m uch published  
literature dealing w ith ethical aspects o f  gen e therapy (esp ecia lly  som atic gen e  
therapy), a dedicated utilitarian response to a ll form s o f  gene therapy based on  a 
unified  consideration o f  the underlying scien tific  aspects has not previously  b een  
published. A ccord ingly , this paper provides an original contribution to k n ow led ge. A  
n o v el aspect o f  this paper is that it considers h ow  a com m on set o f  gene transfer too ls  
can in principle be used  for both som atic and germ line forms o f  gene therapy. 
S cien tific  aspects o f  germ line gene therapy have not hitherto been  w id e ly  considered  
in  p eer-review ed  literature. In this respect, the paper concludes that germ line G M  
could  b e ach ieved  by  relatively m inor adaptations o f  presently available anim al G M  
tech n ology . H ow ever, from  a b ioethical perspective, the paper su ggests that hum an  
germ line gene therapy should not be undertaken at the present tim e, in v iew  o f  the 
relatively  lo w  effic ien cy  and safety o f  current gene transfer technology . H ow ever , the 
paper m akes the radical claim  that germ line gen e therapy, together w ith  som e form s 
o f  gen etic  enhancem ent, prom ises great benefits to hum anity and thus ought to  be
pursued.
N otes: A ccord ing  to inform ation supplied (in July 2 0 0 4 ) to the author b y  the Archives 
o f Medical Research journal, this paper appeared am ong the 25 m ost h igh ly  requested
articles in  the journal (o f  all tim e), as the num ber 2 3 rd top article in  the journal. The  
journal its e lf  is ranked 62nd (from  74  journals) b y  im pact factor in the ‘M ed icin e, 
R esearch and Experim ental’ category o f  the m ost recently available (2 0 0 2 ) ISI 
Journal C itation Reports.
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1.3.7 Gene Therapy: The Potential Applicability of Gene 
Transfer Technology to the Human Germline. 
International Journal o f Medical Science (2004)
T h is  p a p e r  e x p lo r e s  t h e  t h e o r e t ic a l  p o s s i b i l i t y  o f  a p p ly in g  g e n e  t r a n s fe r  
m e t h o d o l o g i e s  t o  th e  h u m a n  g e r m lin e .  T r a n s g e n ic  m e t h o d s  o f  g e n e t i c  m a n ip u la t io n  
a r e  r e v i e w e d  a n d  e v a lu a t e d  in  te r m s  o f  t h e  p o s s i b i l i t i e s  f o r  a p p ly in g  s u c h  m e t h o d s  t o  
th e  h u m a n  g e r m l in e .  T h u s ,  th is  p a p e r  r e p r e s e n t s  a  u n iq u e ly  f o c u s e d  a n a ly s i s  a n d  
s y n t h e s i s  o f  c o n t e m p o r a r y  s c i e n c e  a n d  t e c h n o l o g y .  T h e  c o n c l u s i o n  i s  d r a w n  th a t  
h u m a n  g e r m l in e  g e n e  th e r a p y  r e m a in s ,  f o r  a l l  p r a c t ic a l  p u r p o s e s ,  a  fu tu r e  p o s s i b i l i t y  
th a t  m u s t  a w a it  s ig n i f i c a n t  a n d  im p o r ta n t  a d v a n c e s  in  g e n e  tr a n s fe r  t e c h n o l o g y .  
B i o e t h i c a l  c o n s id e r a t io n s  a r e  d e l ib e r a t e ly  s e t  a s id e  in  t h i s  p a p e r , t o  p e r m it  a  p u r e ly  
s c i e n t i f i c  a c c o u n t  t o  b e  d e v e lo p e d .  B y  s e r v in g  a s  a  u n iq u e  a n a ly s i s ,  t h is  p a p e r  
p r o v id e s  a  s ig n i f i c a n t  c o n tr ib u t io n  t o  o r ig in a l  k n o w l e d g e .
N o t e :  T h e  I n t e r n a t i o n a l  J o u r n a l  o f  M e d i c a l  S c i e n c e  w a s  n o t  e s t a b l i s h e d  a t  t h e  t im e  
w h e n  d a ta  w a s  b e in g  c o l l e c t e d  f o r  th e  m o s t  r e c e n t ly  a v a i la b le  ( 2 0 0 2 )  I S I  J o u r n a l  
C it a t io n  R e p o r t s .
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1.3.8 Sperm-mediated Gene Transfer: Applications and 
Implications. BioEssays (2005)
T h is  p a p e r  w a s  c o - a u t h o r e d  b y  D r  C o r r a d o  S p a d a f o r a  o f  th e  I t a l ia n  N a t io n a l  I n s t i t u t e  
o f  H e a lth .  D r  S p a d a fo r a  i s  a  p io n e e r  in  t h e  f i e l d  o f  S M G T , a n d  h a s  p u b l i s h e d  a  la r g e  
b o d y  o f  e m p ir ic a l  a n d  t h e o r e t ic a l  w o r k  o n  S M G T . D r  S p a d a fo r a  a n d  I  c o n t r ib u t e d  
e q u a l ly  to  th e  m a n u s c r ip t .  T h e  p a p e r  p r o v id e s  a  s u b s t a n t ia l  r e v i e w  a n d  a n a ly s i s  o f  
S M G T . R e c e n t  a d v a n c e m e n t s  in  t h e  t e c h n o l o g y  a r e  h ig h l ig h t e d ,  in c lu d in g  th e  
in n o v a t io n  o f  t r a n s g e n I C S I  a n d  th e  d e v e lo p m e n t  o f  i n  v i v o  g e n e  tr a n s fe r . D r a w in g  
u p o n  v a r io u s  r e s e a r c h  f in d in g s ,  a  p o s s ib l e  m e c h a n i s m  o f  S M G T - s p e c i f i c  t r a n s g e n e  
in t e g r a t io n  i s  p o s i t e d .  A  u n iq u e  fe a tu r e  o f  t h is  m o d e l  i s  t h e  n o t io n  th a t  t r a n s g e n ic  
a n im a ls  m a y  b e  g e n e r a t e d  v i a  e x o g e n o u s  R N A  r a th e r  th a n  D N A .  T h e  e s t a b l i s h m e n t  
o f  a  p la u s ib le  m e c h a n i s m  o f  S M G T - s p e c i f i c  t r a n s g e n e  in t e g r a t io n  i s  s ig n i f i c a n t ,  
b e c a u s e  c la r i f i c a t io n  o f  t h e  m o le c u la r  b a s i s  o f  S M G T  p r o c e s s e s  w a s  o n e  o f  th e  m a in  
r e q u e s t s  th a t  t h e  s c i e n t i f i c  c o m m u n i t y  m a d e  y e a r s  a g o  w h e n  t h e  S M G T  c o n t r o v e r s y  
f ir s t  a r o s e . I n  a d d it io n  t o  d e t a i l e d  m o le c u la r - l e v e l  c o n s id e r a t io n  o f  t r a n s g e n e  
b e h a v io u r ,  t h e  p a p e r  c o n s id e r s  a  v a r ie t y  o f  p o s s i b l e  im p l ic a t io n s  o f  S M G T , i n c lu d in g  
t h o s e  th a t  w o u l d  a r is e  i f  th is  p r o c e s s  s h o u ld  o c c u r  s p o n t a n e o u s ly .  A l l  t h e s e  a s p e c t s  
h a v e  n e v e r  b e e n  d e e p l y  e v a lu a t e d  b e f o r e  in  th e  f r a m e  o f  o n e  b r o a d  r e v i e w / a n a l y s i s  
a r t ic le .  T h u s ,  t h is  p a p e r  r e p r e s e n t s  a  s ig n i f i c a n t  c o n t r ib u t io n  t o  o r ig in a l  k n o w l e d g e .
N o t e :  th e  jo u r n a l  B i o E s s a y s  i s  r a n k e d  1 st ( f r o m  6 2  j o u r n a ls )  b y  im p a c t  fa c t o r  in  t h e  
‘B i o l o g y  ( G e n e r a l ) ’ c a t e g o r y  o f  th e  m o s t  r e c e n t ly  a v a i la b le  ( 2 0 0 2 )  I S I  J o u r n a l  
C ita t io n  R e p o r t s .
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1.3.9 Human Germline Genetic Modification - a Utilitarian 
Bioethical Perspective. Trends in Gene Therapy 
Research (2005 -  in press.)
This paper and Chapter 7 o f  this thesis are c lo se ly  related. The paper is prem ised  on  
the v ie w  that it is inevitable that both tech n ology  and genetic k n ow led ge w ill advance  
to the point at w hich  potential hum an germ line genetic  m odification  applications  
becom e real possib ilities. K ey  ethical aspects o f  hum an germ line genetic  m odification  
are identified  and explored, including safety, consent, public acceptability, cost and 
access, human em bryos, deliberate sequence alteration, and gen etic  enhancem ent. The 
paper concludes that it w ou ld  be unethical to proscribe m ed ica lly  effective  and safe  
hum an germ line genetic m odification . The paper contributes to original k n ow led ge by  




In addition to appraising the published w ork (above), Chapter 1 provides an 
introductory account o f  gen e transfer from a scien tific  and a b ioeth ica l perspective. 
The organising them e o f  gen e transfer tech n ology  representing a com m on set o f  too ls  
is outlined. The b ioeth ica l approach used in this thesis, utilitarianism , is briefly  
introduced.
Chapter 2  rev iew s the scien tific  basis o f  gene transfer (transfection). The basis for the  
genetic m odification  o f  h igher anim al genom es lies  in  the range o f  transfection  
approaches that can be used  to  deliver exogen ou s D N A  to host cells . A  broad range o f  
transfection approaches ex ists, and this armamentarium m ay be applied to a broad  
range o f  host ce ll types, from  germ line ce lls  to em bryonic ce lls  to term inally  
differentiated cells. Thus, gene transfer is  the route to transgenic anim als, and hum an  
gene therapy depends upon gene transfer.
A  k ey  distinction b etw een  the outcom es o f  gen e transfer lies in  the nature o f  transgene  
uptake: in m ost cases w here transgene sequences integrate into the host D N A , the 
integration loci are essen tia lly  random. H ow ever, gene targeting is a lso p ossib le, 
w hereby transgenes are induced to integrate into p recise ly  defined  gen om ic loci. 
Clearly, gene targeting, w here possib le, is to be preferred over random  integration, 
given  the inherent degree o f  control available from  the form er process. G ene targeting  
is exam ined in Chapter 3.
Chapter 4 considers the scien tific  and technical feasib ility  o f  applying G M  techniques  
to the human germ line. G erm line gene therapy is n ow  scien tifica lly  possib le: the too ls  
o f  anim al GM  (pronuclear m icroinjection, sperm -m ediated g en e transfer, nuclear  
transfer, etc) could  in principle be applied to hum ans. H ow ever, serious technical 
obstacles remain to be overcom e before germ line gene therapy cou ld  be considered  a 
practical proposition.
Chapter 5 considers answers to a crucial question concerning germ line gen e  therapy:
W hy do it? G iven the lo w  transfer effic ien cies and safety  risks available at present
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(i.e . extrapolating from  anim al transgenesis), candidate disorders w ou ld  have to be  
severe and otherw ise unavoidable. H ow ever, there is in  effect a ‘go lden  ru le’ applying  
to disorders potentially  am enable to germ line g en e therapy: in  any disorder w ith  
enough m olecular kn ow led ge available to a llo w  the prospect o f  germ line gene  
therapy, that sam e k n ow led ge w ill also b e su fficien t to  a llow  detection  o f  the d isease-  
causing sequences v ia  em bryo pre-screening. It is p o ssib le  that gene transfer 
tech n ologies w ill im prove to the point at w h ich  it b ecom es easier and safer to perform  
germ line gene therapy than to carry out em bryo pre-screening. In this futuristic 
scenario o f  expanded genetic know ledge coupled  w ith  effective  G M  tech n ology , 
germ line G M  w ould  becom e the preferred route.
Chapter 6 introduces b ioeth ical concepts. N on-utilitarian form s o f  ethical reason ing  
are exam ined. U tilitarianism  is presented as a p lausib le ethical approach to m od em  
biom edical issues. The u se o f  such a  system  is explored, as are its k ey  problem s. The  
resultant chapter is an original general account o f  utilitarianism  in  the context o f  
biom edical issues.
Chapter 7 d iscusses b ioeth ical issu es sp ecifica lly  arising from  the p ossib ility  o f  
human germ line genetic  m odification. In both its deliberate and accidental gu ises, 
hum an germ line genetic  m odification  raises several vex in g  b ioeth ica l issu es, 
including questions o f  responsib ility  towards future generations, d ifficu lties o f  
distinction b etw een  gen e therapy and genetic  enhancem ent, and the spectre o f  
eugenics. Thus, hum an germ line genetic m odification  is far m ore contentious than 
som atic gene therapy.
Chapter 8 concludes the thesis. It appears inevitable that both tech n ology  and gen etic  
know ledge w ill advance to the point at w hich  potential hum an germ line gen etic  
m odification  applications b ecom e real p ossib ilities . I argue that it w ou ld  b e unethical 
to proscribe m ed ically  effective  and safe hum an germ line genetic  m odification . 
B iom edical scientists and b ioethicists w ill undoubtedly bear a heavy  burden o f  
responsib ility  for objectively  inform ing so c iety  o f  the probable consequences o f  u sin g  
or m isusing tomorrow's too ls o f  human germ line gen etic  m odification .
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1.5 The Science of Gene Transfer
During the 1970s it becam e p ossib le to introduce exogen ou s D N A  constructs into  
higher eukaryotic cells  in vitro. M am m alian (germ line) transgenesis w as first
ach ieved  in the early E ighties, m ice being the subject species. Transgenic m em bers o f  
a w id e range o f  anim al (and plant) classes and sp ecies have n o w  been  produced, 
including am phibians, cattle, chickens, fish , in sects, nem atodes, p igs, rabbits, and sea  
urchins. Transgenic anim als m ay in principle be u tilised  in either o f  tw o broad w ays: 
(a) as m odels for fundam ental or applied scien tific  study; and (b) as n ovel sources o f
pharm aceutical agents, or hum an-com patible organs for xenotransplantation.
G ene transfer m ethods have been  used  in som atic gen e therapy attempts on  hum ans 
since 1990. G ene therapy approaches have so  far focu sed  primarily on m on ogen ic  
disorders and cancers. To date, lim ited clin ica l su ccess has been  achieved. H ow ever, 
som atic gene therapy is in its infancy and holds great prom ise for the future.
G ene transfer in h igher eukaryotes m ay in principle be applied d irectly for therapeutic 
purpose to the hum an germ line. In contrast to som atic gene therapy, hum an germ line  
gene therapy has never (yet) been  attempted w ith  hum ans (unless one includes the 
transfer o f  foreign  m itochondria during som e form s o f  artificial fertilisation), hum an  
germ line gene therapy m ay be v iew ed  as the m ost advanced potential u se o f  gen e  
transfer tech n ology  possib le. G ene therapy represents the ultim ate form  o f  gen etic  
m odification , and it has the potential to eventually  revolution ise the treatment and  
prevention o f  hum an disease. H ow ever, the prospect o f  human germ line gen e therapy  
raises serious, n o v el and perplexing ethical concerns.
This thesis considers: (a) k ey  technical and scien tific  aspects o f  gene transfer; (b) 
human germ line gene therapy possibilities; and (c) m ajor b ioeth ical issu es associated  
w ith the p ossib ility  o f  human germ line gen e therapy.
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1.6 Bioethics and Gene Transfer
It is  com m only held  that o n e’s eth ics are a matter o f  personal b e lie f, and that there are 
as m any ethical positions as there are individuals. In b ioeth ics this v iew  has som e  
w eight: it enjoins us to respect the v iew s o f  patients them selves, and it supports the 
dem ocratisation and plurality o f  m em bership o f  eth ics com m ittees. N everth eless, the 
v iew  that eth ics are purely a matter o f  individual b e lie f  is h igh ly  problem atic, 
prim arily because it provides absolutely no guide for deciding w hat course o f  action  
to take w hen  faced  w ith  ethical dilem m as. (A s a m em ber o f  an ethics com m ittee, one  
m ay ponder: on w hat basis ought I to  proceed?) O ne p ossib le solution  to this problem  
is an appeal to intuition: w e ought to  let our intuitive responses guide our eth ical 
judgem ents. H ow ever, w hile  this approach m ay have its u ses in everyday life , it is 
severely  lim ited  in the context o f  b ioeth ics. Scien tific  and technologica l advances 
produce n ovel, h igh ly  esoteric ethical problem s. It seem s clear that our intuitive  
ethical responses, insofar as such responses are an inherent part o f  our ev o lv ed  hum an  
nature, sim ply cannot cope reliably w ith  n o v el issu es such as hum an genetic  
m odification , hum an stem  ce ll research, hum an sex  selection , hum an clon ing , or other 
sim ilar p ossib ilities thrown up b y  contem porary sc ien ce and technology.
A s an alternative to intuition, various m etaphysical and religious doctrines hold  
ethical v iew s on b iom edical issues. In particular, the debate about hum an gen etic  
m odification  abounds w ith  rhetorical p leas, such as those concerning the cla im ed  
reprehensibility o f  “p laying G od.” W hile  such v ie w s  have rhetorical force, they  are 
rendered in effective as general guides to  ethical action b y  (a) the major problem  o f  
fundam ental lack  o f  agreem ent betw een  different relig ions, and (b) their lack  o f  m oral 
purchase on secular persons. Thus, as far as b ioeth ics are concerned, there m ay be  
little hope o f  taking the d iscussion  any further w ith  those w ho  hold  such v iew s.
I suggest that, i f  progress is to be m ade, judgem ents o f  ethical 
acceptability/reprehensibility need to focu s on  the predictable consequences arising
from  a course o f  action, where ‘g o o d ’ con seq u en ces are those in w hich  w ellb e in g  -  in  
the form  o f  happiness -  is m axim ised. This approach, often referred to as 
‘utilitarianism ’, is an internally consistent and h igh ly  consensib le ethical system , and
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it is  an approach that is often  em ployed  (ex p lic itly  or im plicitly) in m ed ical d ecision ­
m aking.
In this thesis I adopt a utilitarian perspective w hen  considering the eth ics o f  hum an  
germ line gene therapy. I hold  utilitarianism  to  be a pow erful ethical approach in  this 
context. H ow ever, m y purpose is not one o f  advocacy: this thesis does not cla im  to  
establish  utilitarianism  as being  the on ly  va lid  -  or even  necessarily  the b est -  ethical 
approach to hum an germ line gene therapy. Instead, I em ploy utilitarianism  as a tool 
for the exploration and evaluation o f  key b ioeth ical issu es arising from  the future 
prospect o f  hum an germ line gen e therapy. D oubtless, the scien tific  issu es surrounding  
hum an germ line gene therapy w ou ld  be addressed in a different m anner u sin g  an 
alternative m oral system  or approach. For exam ple, a Catholic theologian  w o u ld  no  
doubt u se entirely different arguments and com e to quite different con clusion s from  
those presented herein. H ow ever, the th eo log ica l approach w ou ld  form  the basis for 
another thesis on human germ line gene therapy, not the present one. O f  course, it 
w ou ld  be legitim ate (and interesting) to com pare the argum ents and con clusion s that 
alternative ethical approaches m ight generate in the context o f  hum an germ line gene  
therapy. H ow ever, a single thesis w ould  be insu fficient to accom m odate such  an 
endeavour.
Thus, although the conclusions reached in this thesis are designed  to be consisten t 
w ith  utilitarianism , those w ho  reject the underlying principles o f  utilitarianism  m ay  
leg itim ately  reject these conclusions.
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Chapter 2: Molecular and 




G erm line G M  requires that transgenes be delivered w h ile  the h ost organism  is at a 
very early stage o f  developm ent. D evelopm ental stages applicable for transgene  
delivery in principle include gam etes (oocytes or sperm ) and early em bryos (zygotes  
or early m orulae). A s  an alternative to these natural b io lo g ica l entities, gene transfer 
m ay be perform ed on ce lls  m aintained in vitro that are able to  gen etica lly  contribute 
toward an em bryo. Such cells  include (a) em bryonic stem  ce lls  (E SC s) and (b) 
som atic cells  the nuclei o f  w h ich  are placed into recipient zy g o te  ce lls  by  nuclear  
transfer (N T ).
2.1.1 Microinjection
Jon Gordon in 1980 dem onstrated that exogen ou s D N A  could  b e introduced into the 
germ line sim ply by  the physical injection o f  a solution  o f  cloned  D N A  into zygote  
pronuclei (Gordon et al. 1980). Subsequently, pronuclear m icroinjection  has b ecom e  
the m ost w id ely  used  m ethod o f  germ line gen e transfer, despite the fact that it rem ains 
an intrinsically costly  and laborious approach. The technique is m ost established w ith  
m ice , how ever gene transfer v ia  pronuclear m icroinjection  has a lso  been  carried out 
w ith  a w id e range o f  other m am m als including rats, rabbits, and agricultural anim als. 
A ccordingly , it is to be expected  that the hum an zygote  should  in principle be  
sim ilarly am enable to gen e transfer via pronuclear m icroinjection.
The m icroinjection technique is intrinsically sim ple, although it requires exp en sive  
equipm ent and h igh  leve ls  o f  sk ill (H ogan et al. 1994). A  fine g lass need le is loaded  
w ith  D N A  solution. U nder the m icroscope, the need le is  guided through the 
cytoplasm  towards one o f  the zy g o te ’s pronuclei. A  nanolitre quantity o f  D N A  
solution  is injected, bringing typ ically  tw o hundred D N A  m olecu les into the 
pronucleus. Som e zygotes die fo llow in g  m icroinjection , probably due to the p h ysica l 
trauma o f  being  penetrated by the m icropipette, h ow ever the m ajority o f  zygotes
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survive. Surviving zygotes are transferred to the uterus o f  a surrogate mother. For  
m ice, typ ically  around 15% (range 0-40% ) o f  the offspring w ill be transgenic. T hese  
values should b e interpreted w ith  caution how ever, because m icroinjected  em bryos 
are prone to: (a) ly sis  im m ediately  fo llow in g  m icroinjection; (b) death in vitro 
fo llow in g  m icroinjection; and (c) death in vivo during gestation  in the recipient 
fem ale. A ccordingly , w hen  the numbers o f  zygotes used  is taken into account, the 
effic ien cy  values are less  im pressive: typ ically  on ly  ca. 2% (range 0-6% ) o f  
m icroinjected zy g o tes  w ill becom e transgenic anim als (B agis and P apuccuoglu  1997; 
Brinster et al. 1985; Page et al. 1995). M oreover, reported e ffic ien cy  values are 
sign ificantly  low er for m ost m am m als other than m ice. Com pared w ith  m urine 
effic ien cies, the rate o f  porcine and ovine transgenesis through pronuclear 
m icroinjection is ca. 5 -fo ld  low er, and b ovin e effic ien c ies  are ca. 17-fo ld  low er  
(Hirabayashi et al. 2001; Seamark 1994; W all 2002; W all et al. 1997).
B eyon d  the u se o f  m icroinjection  for transgene delivery  to zygotes, it is worth noting  
that m icroinjection is a lso effective as a m eans to deliver transgenes to the gen om es o f  
n on -zygotic  cells , such as E SC s or som atic ce lls  for N T . H ow ever, g iven  that the  
norm al use o f  such ce lls  is  w ith  in vitro selection  system s requiring en masse 
transgene delivery to m illion s o f  cells, non -zygote  m icroinjection  is not a practical 
m eans o f  producing transgenic animals.
O ocytes m ay in  principle be suitable targets for transgenesis. H ow ever, fundam ental 
practical problem s have so  far precluded their use. O ocytes co llected  fo llow in g  
ovulation w ould  have to be fertilised after transgenic m anipulation. This w ou ld  entail 
the use o f  in vitro fertilisation (IVF). Potentially-transgenic oocytes w ou ld  thus have  
to endure a further, ex ten sive  ex vivo procedure. S ince this cou ld  on ly  be detrim ental 
to the oocytes, it is  d ifficu lt to see any role for transgenesis directed at this le v e l rather 
than at the zygote . Attem pts to produce transgenic anim als b y  D N A  m icroinjection  
into oocytes have never or very rarely resulted in su ccess (H oudebine 2002a).
Transgene D N A  delivered  b y  m icroinjection integrates into the host c e l l’s 
endogenous D N A . Integration is random and usually  occurs at on ly  one chrom osom al 
site in each transgenic. The number o f  cop ies o f  the transgene at an integration site  
m ay range from one to thousands. For m ultip le cop y  inserts, the m ost com m on
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arrangement is an array o f  m olecu les jo in ed  head-to-tail (Sm ith 2 001). L ess usually , 
tail-to-tail and head-to-head arrangements occur. D eletions, duplications and other 
rearrangements m ay occur at the junctions betw een  chrom osom al and transgenic  
D N A  sequences (B ishop  1996). O nly a lim ited  am ount is know n about the 
m echanism s o f  transgene integration.
Transgene sequences integrating random ly into the host genom e tend to g iv e  poor  
levels  o f  expression , or exhibit inappropriate expression , in the form  o f  tem porally or 
spacially  (ectop ic) aberrant expression. The prim ary reason for such problem s is the 
‘position  e ffec t’, w hereby the particular gen etic  environm ent at any point o f  insertion  
is likely  to in fluence the expression  o f  the integrated transgene. In som e cases the 
rem edy lies  w ith  transgene design: for exam ple by  ensuring that an appropriate 
enhancer sequence is included in  the transgene construct. B eyond  this, it m ay be  
p ossib le to insulate a gene from  the position  effect. M atrix attachment regions  
(M A R s) are sequences w hich , w hen  placed on  either side o f  a gen e w ith in  a transgene  
construct, appear to a llow  the gen e(s) w ith in  an integrated transgene to occu p y  a 
separate chrom osom al dom ain. A lternative ‘insulator’ sequences (for exam ple, locus  
control regions (L C R s)) are a lso under investigation. U ltim ately , how ever, the best 
solution to transgene expression  problem s w ou ld  b e to avoid  the position  effect  
entirely. This is achievable through gene targeting: a transgene targeted to a ch osen  
genom ic locus w ill b y  defin ition  avoid the position  effect. R eliable w ays o f  germ line  
gene targeting do exist. H ow ever, gene targeting is  not p ossib le at present w ith  
pronuclear m icroinjection, due to the inability to se lec t for zygotes that contain rare 
targeted integrations.
There is no particular restriction on the size  o f  D N A  m olecu le u sed  for  
m icroinjection. Y east artificial chrom osom e (Y A C ) based transgene constructs 
consisting o f  > 1 0 0  kb o f  D N A  have been  su ccessfu lly  introduced into the m ouse  
germ line b y  pronuclear m icroinjection (Lam b and Gearhart 1995). B ecau se there are 
no special problem s w ith  m icroinjecting large transgene constructs, it is p ossib le  to  
incorporate structural gene-plus-prom oter (plus other potentially  usefu l sequences  
such as enhancers) com binations into the host genom e. Indeed, it m ay b ecom e  
p ossib le (pending developm ent o f  the necessary transgene constructs) to m icroinject 
autonom ous artificial ‘m in i-chrom osom es’, (m am m alian artificial ch rom osom es,
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M A C s) com plete w ith  centrom eres, telom eres and replication origins in addition to  
structural gen es, prom oters and enhancers. T hese sp ecia lized  constructs w ou ld  be  
expected  to g iv e  a number o f  benefits com pared w ith  integrated transgenes, the m ost 
important o f  w hich  w ou ld  probably be the absence o f  chrom osom al p osition -effects  
on transgenic expression  (Sgaram ella and Eridani 1996).
It has recently  becom e apparent that the m ajority (ca. 85% ) o f  pronuclear  
m icroinjection-derived transgenic founders are m osa ics o f  transgenic and  
nontransgenic cells  (W hitelaw  et al. 1993). This surprising finding m ay be exp lained  
by postulating that (endogenous) D N A  replication  is required for chrom osom al 
integration. The relatively few  nonm osaic founders that do arise m ay p lausib ly  be  
accounted for b y  assum ing that the nontransgenic daughter ce ll (in  a 2 -ce ll zygote)  
has died. This explanation is consistent w ith  the fact that m icroinjected D N A  per se 
has a negative effect on em bryo viab ility  (Brinster et al. 1985). In ca.15% -25%  o f  
m osaic founders, the foreign D N A  apparently integrates at later stages o f  the em bryo  
ce ll replication, resulting in m ice that contain  the transgene in  varyingly  sm all 
proportions o f  their cells.
A s w ith  other m osaics, transm ission o f  the transgene is dependent upon the ex isten ce  
and extent o f  germ line colonisation  by transgene-containing cells . In the vast m ajority  
o f  cases w here transm ission occurs (w hether from  fu lly  transgenic founders, from  
m osaic founders or from  subsequent generations o f  transgenics), the transgene is  
inherited in a stable M endelian fashion, although exceptions have been  found  
(Palm iter et al. 1984). D ue to the h em izygou s nature o f  transgene insertion, even  a 
nonm osaic founder w ill transmit its transgene to on ly  (on  average) 50%  o f  its 
offspring.
G iven that pronuclear m icroinjection seem s to be effective  in  all m am m alian sp ecies, 
it seem s certain that the technique could  in principle be readily applied to hum an  
germ line gene therapy.
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2.1.2 Retroviral Transfer
R etroviruses are found in m any species, including m ost m am m als (L azo and T sich lis
1990). Retroviruses have R N A  as their gen etic  material. F o llow in g  in fection , the 
virus-encoded  enzym e, reverse transcriptase, transcribes the R N A . The resultant 
single-stranded D N A  (ssD N A ) is replicated as double-stranded D N A  (d sD N A ). The  
d sD N A  viral genom e has the important property o f  b ein g  able to  linearly integrate (as 
a provirus) into the chrom osom al D N A  o f  the host cell. The site o f  integration appears 
to be essen tia lly  random, although there m ay ex ist som e preferred integration sites, at 
least in  som e ce ll types (Laufs et al. 2003).
The genom e o f  retroviruses can be m anipulated to  carry exogenous D N A . Z ygotes  
m ay b e incubated in m edia containing h igh  concentrations o f  the resultant retroviral 
vector. A lternatively, retroviral vector-producing ce ll m onolayers m ay b e u sed , upon  
w hich  zygotes are co-cultivated . In either case, up to ca.90%  o f  (surviving) em bryos 
w ill be infected. F o llow in g  zy g o te  transfer into pseudopregnant fem ales, the in fected  
em bryos should g ive  rise to transgenic offspring. M olecular genetic  analysis o f  
transgenics produced in this w ay  usually  sh ow  integration o f  a sin g le  proviral cop y  
into a g iven  chrom osom al site. Rearrangem ents o f  the host gen om e are norm ally  
restricted to short direct repeats at the site o f  integration. In m any em bryos the 
germ line ce lls  contain viral integrants: thus, transm ission o f  the transgene to the next 
generation w ill often  occur. M ethods have also  been developed  to a llo w  in fection  into  
postim plantation em bryos. In this context, virus uptake is  effective  for m any som atic  
ce ll lines, how ever germ line ce lls  are in fected  at lo w  frequency, due to a h igh  lev e l o f  
m osaicism  (Braas et al. 1996; M organ and French A nderson 1993).
The major advantages o f  retroviral vectors ( R W s )  are: (a) the e ffic ien cy  o f  gen e  
transfer; (b) the lo w  equipm ent/expertise requirements; and (c) the unitary form  o f  
integration.
H ow ever, retroviral vectors are lim ited or problem atic in  a num ber o f  respects. 
P ossib ly  the m ost fundam ental lim itation is the inability to carry large transgenes. The
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upward length o f  transgene sequence that m ay be incorporated into the retroviral 
genom e is  in the order o f  9 -10  kb (H u and Pathak 2000).
The degree o f  control over the expression  o f  transgenes carried by  R V V s is another 
problem . There is less scop e for control in  R W -b a s e d  transgenes com pared w ith  the 
control p ossib le in transgenes delivered b y  physica l m ethods such as pronuclear 
m icroinjection. S ince R W s  integrate into the host D N A  in a largely random  fashion, 
each particular chrom osom al integration site is lik e ly  to have a particular effect on  the  
transcription o f  the transgene. A dditional factors a lso  interfere w ith  expression , such  
as prom oter effic ien cy  in particular tissues, R N A  m essage effic ien cy , and D N A  
m ethylation. The net result is inconsistency  o f  expression  (Pannell and E llis 2001; 
Pannell et al. 2000; Sw indle and K lug 2 0 0 2 ). U nfortunately, because transgene  
expression  in the provirus is  driven by the viral 5 ’ long  direct term inal repeat (LTR ), 
it is problem atic to engineer into the construct the ability  for it to b e controlled  tissue- 
sp ecifica lly , tem porally, or b y  external (clin ical) influence. N everth eless, various 
tissu e-sp ecific  and n on -sp ecific  control elem ents have been  incorporated into R W s ,  
and the effic ien cy  o f  these prom oters in  particular ce ll types is the subject o f  intense  
investigation  (H oatlin et al. 1995; H u and Pathak 2000; Pannell and E llis 2001; S o lly  
et al. 2003; V ile  e ta l. 1996).
G iven  the essentia lly  random  (nonhom ologous) m ode o f  integration o f  natural 
retroviruses, retroviral vectors do not appear to h old  m uch prom ise for applications in  
w hich  gene targeting is  required. H ow ever, u sing  integration-deficient retroviral 
vectors, E llis and Bernstein (E llis and B ernstein  1989) w ere able to  target genom ic  
lo c i such that vector sequences h om ologou sly  recom bined w ith  endogenous  
sequences. H ow ever, the frequency o f  targeting w as very lo w  (approxim ately 1 
targeted event per 3 x 1 06 in fected  cells).
O nly actively  d ivid ing cells  are infectable b y  m ost retroviral vectors (M iller et al. 
1990). This m eans that, in practice, in fection  does not occur at h igh  effic ien cy  until 
around the eight-cell stage. The m osaicism  arising in such em bryos w ou ld  be o f  a 
m ore profound variety than that associated  w ith  pronuclear m icroinjection , b ecause  
each resultant individual w ould  likely  con sist o f  several cell types, w ith  each ce ll type
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containing the transgene in  a different genom ic site. H ow ever, a n ew  class o f  
retroviral vectors based  on lentiviruses has recently been  developed . Lentiviruses are 
unusual am ongst retroviruses in that they are able to in fect qu iescent cells . T ransgenic  
m ice have been produced at h igh  e ffic ien cy  (70-80%  o f  anim als b om ) by exp osin g  
zy g o tes  to lentiv im s-based  vectors, thus avoid ing the problem s o f  m osa icism  
norm ally associated  w ith  retroviral vectors (Ikawa et al. 2003; L ois et al. 2002; P feifer  
et al. 2002).
It is p ossib le  for integrated retroviral D N A  to be spontaneously reactivated (W eiss et 
al. 1985), leading to the production o f  n ew  integration w ith in  the D N A  o f  the ce ll, to  
n ew  infection  o f  other cells  or potentially  to in fection  o f  other individuals. Such  
instability again m ay result in  transgene expression  problem s and safety  concerns  
(C om etta et al. 1991; Gunter et al. 1993; T em in 1990). H ow ever, retroviral vectors 
m ay be engineered such that they lack the genetic sequences required for a norm al life  
cy c le  (V ile  et al. 1996). The creation o f  such ‘d e fectiv e’ retroviral vectors g o es  a long  
w a y  towards curing instability-related expression  and safety  problem s. H ow ever, the 
risk o f  reactivation can probably never be com p letely  elim inated, because  
com plem entation b y  a com petent ‘helper’ retrovirus cannot be m led  out. In a 
controlled laboratory environm ent this m ay w e ll represent o n ly  a m inor concern. 
H ow ever, for hum ans treated w ith  gene therapy (som atic or germ line) entering the 
outside environm ent, the risk m ay be m ore acute. In addition to the risks o f  releasing  
in fectious agents into the general environm ent, there are concerns for patients w ho  
have been treated w ith  retroviral vector-based gen e therapeutic agents. In such cases, 
retroviral reactivation cou ld  con ceivab ly  lead to on cogen esis.
D esp ite  the lim itations and safety concerns referred to above, retrovirus-m ediated  
gene therapy has already been  used  in a num ber o f  som atic gen e therapy attem pts, and  
appears to hold  a g o o d  deal o f  prom ise in  this regard. A dditionally , retrovirus- 
m ediated gene transfer has been  used  su ccessfu lly  for (nonhum an) germ line  
m odifications. H ow ever, concerns over the safety  and effectiv en ess  o f  retroviral 
vectors are likely  to lim it the u se o f  the approach for hum an germ line gene therapy.
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2.1.3 Other Viruses
V iruses other than retroviruses hold  som e prom ise as germ line vectors. A denoviru ses  
(A d) have a num ber o f  properties that m ake them  potential candidates for hum an  
germ line gene therapy. A d are able to in fect d iv id ing  and quiescent ce lls . A d  are able  
to carry large transgenes (up to  c. 38kb) w ithout adversely  affecting their in fectiv ity  
(B ett et al. 1993). A d  have a lo w  host ce ll/sp ec ies-sp ec ific ity , suggesting  that various 
ce lls  (E SC s, som atic ce lls  for N T , zygotes) from  a w id e  range o f  species m ay be  
am enable to A d-m ediated  gene transfer. The production o f  transgenic m ice  fo llo w in g  
the in fection  o f  zona-free zygotes with a rep lication-defective A d  vector has been  
reported (Tsukui et al. 1996). This intriguing result suggests the p ossib ility  o f  a 
prom ising n ew  strategy for germ line GM . H ow ever, further research is required in  
order to determ ine basic parameters and m axim ise the e ffic ien cy  o f  this form  o f  
adenoviral gene transfer (G ordon 2002).
L ike the adenoviruses upon w hich  they are naturally dependent, adeno-associated  
viruses (A A V ) exhibit lo w  h ost ce ll sp ecific ity  and are able to  in fect both d iv id ing  
and quiescent cells . A  unique property o f  A A V  is the ability to  undergo site -sp ecific  
genom ic integration in  chrom osom e 19, m ediated  v ia  the viral R ep protein. This 
property offers predictable transgene expression . A A V  gene delivery  vectors are 
under in tensive developm ent, and it is to be hoped  that som e vectors m ight prove  
useable w ith  germ line cells (Carter and Sam ulski 2000; Lai et al. 2002a; M onahan  
and Sam ulski 2000).
R etroviruses, adenoviruses and adeno-associated  viruses are certainly not the on ly  
types o f  viruses that are under scrutiny as transgene vectors. N o  sin gle virus has the 
necessary characteristics for all applications. N o t even  a fraction o f  the p ossib le  types  
o f  viruses has been  assessed  for potential u tility  in  germ line transgenesis. A s  v iro lo g y  
research continues, it is to be expected that other types o f  viruses w ill be added to  the 
current store o f  potential germ line gene transfer vectors.
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2.1.4 Liposome-mediated Gene Transfer
L iposom es are artificial v es ic le s  that can act as delivery  agents for exogen ou s  
m aterials includ ing transgenes (Ilies and Balaban 2001; N ico lau  et al. 1987; W atw e  
and B ellare 1995). L ike their natural cellu lar counterparts, liposom es com prise a lip id  
bilayer sim ilar to that o f  natural cells, surrounding a sm all vo lum e o f  aqueous 
solution. L ip osom es for use as gene transfer v eh ic les  are prepared by  adding an 
appropriate m ix  o f  b ilayer constituents to an aqueous solution  o f  D N A  m olecu les . A  
self-organising process creates discrete spheres o f  continuous lipid  b ilayer m em brane 
envelop ing  a sm all quantity o f  D N A  solution. (F eigner 1996; M ahato et al. 1997). 
W hen they com e into contact w ith  a target cell, lip osom es interact w ith  the ce ll 
m em brane to a llow  the exogenous D N A  to enter the cell, by en d ocytosis or m em brane  
fusion  (C onnor et al. 1984; Lamb 1993).
It is d ifficu lt to generalise about liposom es, since they  have b een  produced in a w id e  
diversity o f  form s. D ifferences include: (a) s ize  (nanom eter to  m icrom eter scale); (b ) 
shape (spheres or lipoplexes); (c) charge (p ositive or negative); (d) coat structure 
(bilayer or m ultilam ellar); and (e) the presence o f  particular accessory  m o lecu les  (e .g . 
Sendai g lycoprotein , ce ll-sp ec ific  ligands, nuclear localisation  signals).
The capacity o f  liposom es varies greatly depending upon  type. H ow ever, the size  
(length) o f  transgene that m ay be carried is a lw ays m uch low er than w ith  pronuclear  
m icroinjection.
Som e liposom e-based  gene transfer system s are often  able to deliver transgenes to the 
cytop lasm  w ith  a reasonable degree o f  effic ien cy . H ow ever, on ly  in a m inority o f  
cells  w ill transgenes reach the nucleus. A m ongst transgene m olecu les that do reach  
the nucleus, on ly  a sm all m inority integrate into the host cell chrom osom es. This 
relatively lo w  integration frequency renders liposom e-m ediated  transfection  
im practical for u se w ith  m am m alian zygotes, although som e experim ental su ccess has 
been claim ed (Carballada et al. 2002).
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A lthough  liposom es are not suitable for the delivery  o f  transgenes to zygotes, 
lip osom es m ay be used  to deliver transgenes to E SC s or som atic ce lls  for N T , thus 
producing germ line alterations (Pain et al. 1999). This approach has the advantage o f  
b ein g  an en masse gene transfer too l, in  that m any m illions o f  ce lls  m ay b e  treated  
sim ultaneously. M oreover, g iven  that the host ce lls  are m aintained in vitro, it is 
p ossib le  to  u se  in vitro selection  to enrich for cells  containing rare desired integration  
outcom es. A ccord ingly , liposom es m ay be incorporated into germ line gen e targeting  
protocols.
F inally , an indirect approach to  the germ line v ia  the zygote  rem ains a putative  
p ossib ility , w here liposom es w ould  be u sed  to deliver transgenes to  sperm  cells . Som e  
su ccess has been  claim ed for the in vitro u se o f  liposom es in this w a y  (Sm ith  1999). 
L iposom es m ay also  be able to deliver transgenes to sperm in vivo (Sato et al. 1999a). 
Sperm -m ediated gene transfer is d iscussed  in Section  2 .1 .7  (b elow ).
2.1.5 Electroporation
Electroporation is a process b y  w hich  h igh-in tensity  electric fie ld  pu lses tem porarily  
destabilise cellu lar m em branes. During the destabilisation period, D N A  m olecu les  
present in the surrounding m edia are able to perm eate the c e ll’s external and internal 
m em branes to enter the cytoplasm  and nucleop lasm  (Lurquin 1997).
Electroporation provides a fast and inexpensive m eans o f  introducing exogen ou s  
D N A  into cultured cells. The process can be equilibrated to y ie ld  co p y  num bers (o f  
integrated transgenes) o f  b etw een  1 and 2 0  cop ies per genom e - an advantage  
com pared w ith  m icroinjection. Large transgene m olecu les (> 150 kb) can be  
transferred. In addition to the advantages o f  b ein g  able to  transfer large con ven tion al 
transgenes, the D N A  transfer capabilities o f  electroporation m ay in  future a llow  
transfer o f  M A C s, as w ith  pronuclear m icroinjection. The m ain drawbacks o f  
electroporation are that: (a) specialised  equipm ent is required; (b) each ce ll type and  
culture system  requires fairly extensive em pirical optim isation; and (c) typ ica lly  on ly
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around 0.01%  o f  treated cells  show  genom ic integration o f  transgene (C hang 1992; 
Lurquin 1997; Potter and C ooke 1992).
In term s o f  germ line G M , electroporation is an effective  m ethod o f  introducing  
exogen ou s D N A  into E SC s (Chu et al. 1987). The advantage o f  electroporation over  
m icroinjection  in  the context o f  E SC s is that electroporation a llow s the en masse 
treatment o f  large numbers o f  cells. This is  extrem ely usefu l w here a rare integration  
event requires selection  from  a background o f  unw anted integrations, as in  gene  
targeting. Sim ilarly, electroporation has been  su ccessfu l w ith  nuclear transfer 
transgenesis (M cCreath et al. 2000; Schnieke et al. 1997).
The relatively  lo w  effic ien cy  o f  electroporation renders it im practical for u se  w ith  
m am m alian zygotes. The best superovulation protocols deliver around thirty zy g o tes  
per anim al for m ice and p igs, and ten for cattle and sheep (W all et al. 1992). 
Extrapolating from  these figures, a 0.01%  effic ien cy  rate w ould  n ecessitate on  
average 3 0 0 +  m ice or p igs, and ca. 1 ,000 cattle or sheep in order to obtain ju st one  
transgenic. H ow ever, for (m am m alian) species that produce large num bers o f  easily  
recovered zygotes, electroporation show s m ore prom ise in terms o f  transgenesis.
M any fish  species are potentially  useful in  this respect, and som e su ccesses  have been  
claim ed. For exam ple, M urakami et al. (M urakam i et al. 1995) report the su ccessfu l 
use o f  electroporation to create transgenic m edaka, as do Ono et al. (O no et al. 1997), 
w ith  the latter also reporting successfu l transm ission o f  transgenes to Fi progeny.
A n attractive putative use o f  electroporation for transgenesis w ou ld  be to enhance the 
transfer o f  transgene m olecu les into sperm ce lls  (see  Section  2 .1 .7 , b e lo w ). For 
exam ple, G agne et al. (G agne et al. 1991) report an increase from  12% to 19% o f  
transgenic b ovin e b lastocysts w hen  electroporation is included in  an otherw ise p assive  
sperm -D N A  uptake protocol. Sim ilar findings w ere reported b y  R ieth et al. (R ieth  et 
al. 2 000), again w ith transgenic bovine b lastocysts. Several experim ents have  
indicated that fish  species m ay be able to be gen etica lly  m anipulated in this w a y  (Patil 
and H ong W oo 1996; W alker et al. 1995). H ow ever, these results aw ait replication , 
and b ig  questions rem ain over the effectiven ess or otherw ise o f  sperm  ce lls  as vectors  
per se (Sm ith 1999).
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I f  it turns out that there is substance to claim s that sperm  cells can be induced to carry 
transgenes, then the techniques’ e ffic ien cy  w ould  have to be high. O therw ise, 
electroporation o f  sperm  cells cou ld  be as lim ited  as it is (in principle) for zygotes, 
w ith  ex cess iv e ly  h igh  numbers o f  anim als needed  in order to obtain each transgenic. 
The on ly  w ay  around this lim itation w ou ld  be v ia  the developm ent o f  a se lection  
system  for ‘p o sitiv e ’ sperm cells  in vitro - a h igh ly  un likely  possib ility , g iv e  that 
sperm  ce lls  ex ist in a quiescent state as far as gene expression  is concerned.
F inally , it is  worth noting that electroporation also  has the potential to be u sed  in vivo. 
This fie ld  is at a very early stage o f  developm ent, but em pirical im provem ents m ay in  
future perm it electroporation to be used  to deliver transgenes to particular tissues  
(H ofm ann et al. 1999; Swartz et al. 2 001). G iven  that there is no ev id en ce that any  
particular som atic ce ll types are inherently unable to be su ccessfu lly  electroporated, it 
m ight in  future b ecom e p ossib le to direct in vivo electroporation to the sperm atogenic  
(or sperm -storing) tissues, as an indirect route to the germ line.
2.1.6 Naked DNA Auto-uptake
Em pirical studies have show n that transgene constructs injected into m uscle tissu e or 
liver tissue in vivo, in the form  o f  naked D N A  m olecu les m ay be taken up and 
expressed  b y  the m uscle and liver cells. The sam e surprising e ffect has b een  obtained  
via  intravascular injection o f  naked D N A . Cellular uptake o f  naked transgenes is  
b elieved  to occur through m icrolesions w ith in  the ce ll mem brane (H erw eijer and  
W o lff  2003).
There have been  no reports o f  naked D N A  auto-uptake into zygotes, E SC s or cultured  
cells  for N T . H ow ever, several reports o f  sperm  cells  associating w ith  naked D N A  
have been published, as have reports o f  su ccessfu l transgenesis in  a broad range o f  
anim als fo llow in g  sperm auto-uptake o f  naked D N A . H ow ever, others have had  
difficu lty  replicating such work, and there are as yet no clear answ ers to the questions: 
(a) Is it possib le; and (b) I f  so, h ow  can it be reliably achieved? (Sm ith  1999). The
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p ossib ility  that sperm  cells m ay be able to p ick  up naked transgenes is d iscu ssed  in  
m ore detail w ith in  the fo llo w in g  section  (2 .1 .7 ).
2.1.7 Sperm-mediated Gene Transfer
The scien tific  literature contains over seven ty  reports o f  the su ccessfu l in vitro uptake  
o f  exogen e constructs (transgenes) by  anim al sperm  ce lls  (G andolfi 2000; Sm ith  
1999; Sm ith and Spadafora 2 005). A  m ajority o f  these reports provide ev id en ce o f  
post-fertilisation transfer and m aintenance o f  transgenes. Several o f  the studies report 
the subsequent generation o f  v iable progeny anim als, the cells o f  w h ich  contain  
transgene D N A  sequences. W hile a m inority o f  studies have used  ‘augm entation’ 
techniques (electroporation or liposom es) to  ‘fo rce ’ sperm  to capture exogen es, the 
standard m eth od ology  is very straightforward: prior to  in vitro fertilisation (IV F ) or 
artificial insem ination  (A I), ‘w ash ed ’ sperm  ce lls  are sim ply incubated in a D N A -  
containing solution. A s  a potential tool for gen etica lly  m anipulating anim als, sperm - 
m ediated gene transfer (SM G T ) has the advantages o f  sim plicity  and cost- 
effectiven ess, in contrast w ith  m ore established m ethods o f  transgenesis such as 
pronuclear m icroinjection.
H ow ever, despite the above su ccesses and regardless o f  its potential utility, SM G T  
has not y e t b ecom e established as a reliable form  o f  genetic m odification . C oncerted  
attempts to u tilise  SM G T have often  produced negative results. The m ost notable  
exam ple o f  such a failure is to be found in the co llated  results o f  several independent 
research groups: o f  890 m ice analysed, not a s in g le  anim al contained transgene D N A  
(Brinster et al. 1989b).
Indeed, som e b io log ists have expressed scep tic ism  o f  the fundam ental basis for  
SM G T (B im stie l and B usslinger 1989; Chen and Chen 1996). Such scep ticism  is 
posited  on  the assum ption that major evolutionary chaos w ould  result i f  sperm  ce lls  
w ere able to act as exogen e vectors. G iven that the reproductive tracts contain ‘free’ 
D N A  m olecu les (originating from natural ce ll death and breakage), it seem s
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reasonable to expect sperm  ce lls  to be h igh ly  resistant to the risk o f  p ick ing  up such  
m olecu les (Sm ith 2002d).
N everth eless, there exists a fairly w e ll established body o f  em pirical data sh ow ing  
that sperm  cells  are able, at least under particular experim ental circum stances, to 
interact w ith  and carry exogen es (M aione et al. 1998; Zani et al. 1995a). Furthermore, 
iso lated  reports o f  the su ccessfu l u se o f  SM G T for genetic  m odification  continue to be  
published. A  notable recent exam ple is the generation o f  several transgenic p igs  
fo llo w in g  the artificial insem ination  o f  so w s w ith  sperm  cells preincubated w ith  
transgene D N A  (Lavitrano et al. 1999; L azzeresch i et al. 2000).
There are tw o p ossib le w ays to m ake sen se o f  the above experim ental and theoretical 
considerations. The first p ossib le explanation is that SM G T is fundam entally  
unattainable. I f  so , the em pirical ev idence in  support o f  SM G T m ust be faulty. For 
exam ple, perhaps sperm can associate w ith  exogen ou s D N A  but cannot co n v ey  the 
D N A  into the oocyte; and transgene sequences m ay have been erroneously identified  
in  tissue sam ples, perhaps due to D N A  contam ination affecting sen sitive  detection  
m ethods such as PCR. This scenario is certainly not im possible: scien tific  research  
contains several exam ples o f  theory being m isled  b y  m istaken data. Indeed, early  
reports o f  SM G T w ere com pared w ith the (then contem porary) cla im s o f  “cold  
fu sion ” in physics (B im stie l and B usslinger 1989). B y  contrast, the secon d  p ossib le  
explanation is that SM G T is viab le, and that the claim s o f  experim ental su ccess w ere  
not m ade in error. In this case, the explanation for the su ccessfu l results m ust be that 
certain favourable factors applied in  the fortuitous cases in w hich  transgenes w ere  
taken up and transferred by  sperm. A ccord ingly , several researchers have m ade 
efforts to elucidate such hidden parameters.
U nderpinning such research into hidden factors has been  the notion  o f  the ex isten ce o f  
‘inhibitory’ factors (IFs) associated  w ith sperm  cells . These IFs are en v isaged  to  
prevent exogenous D N A  uptake so as to  protect the genetic integrity o f  the conceptus. 
The corollary o f  this notion is that su ccessfu l instances o f  sperm ce lls  taking up  
exogen ou s D N A  m ay be attributed to the fortuitous rem oval or inhibition o f  IF(s)
(Zani et al. 1995b).
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Sem inal fluid reportedly contains an inhibitory factor (IF-1) that appears to  actively  
b lock  the binding o f  exogen ou s D N A  to sperm  and to the above-m entioned  proteins 
(Lavitrano et al. 1992). A dditionally , three classes o f  proteins identified  in  sperm  
cells  have been cla im ed to exh ib it D N A -b ind ing  properties (Lavitrano et al. 1992; 
Lavitrano et al. 1997). There is  a lso  som e ev idence that the b inding o f  transgene D N A  
can trigger the activation o f  endogenous nucleases in  sperm ce lls , w hich  c leave  both  
transgene and sperm  chrom osom al D N A  (S oto lon go  et al. 2003; Spadafora 1998; 
S zczy g ie l et al. 2003). The p ossib le  ex istence o f  IF(s) or other m echanism s against 
foreign  D N A  m ay explain  the varied and often  negative results obtained from  
attempts to use sperm to act as transgene vectors.
A  superficial binding o f  exogen ou s D N A  to sperm  ce lls  w ould  be very u n lik ely  to  
result in  successfu l transgenesis, g iven  the rigours o f  fertilisation. C onceptually, 
therefore, it is necessary to  en v isage the exogen ou s D N A  being  actively  taken up b y  
the sperm  cell. Ultrastructural autoradiographic studies have indicated that exogen ou s  
D N A  b ecom es concentrated w ith in  the posterior part o f  the nuclear area o f  the head, 
the inference being  that b inding o f  D N A  by the sperm  is fo llo w ed  by internalisation  
(C am aioni et al. 1992; Francolini et al. 1993).
O ne very interesting p ossib ility  is  the com bination o f  naked D N A  auto-uptake w ith  
m icroinjection, a process that has been term ed ‘tra n sg en icS I’. In this recent approach, 
sperm exposed  to naked transgene m olecu les are m icroinjected into oocytes. S u ccess  
has been  reported w ith  m ice, w ith  approxim ately 20%  o f  founder anim als integrating  
and expressing the transgene (Perry et al. 1999; S zczy g ie l et al. 2 0 0 3 ). Transgene  
uptake and expression  fo llow in g  transgenICSI has a lso  been  reported in rhesus 
m onkey em bryos (Chan et al. 2000a; Chan et al. 2000b ) and porcine em bryos (Lai et 
al. 2001; N agashim a et al. 2 0 0 3 ), although transgenic offspring did  not result.
The success o f  transgenICSI provides support for the notion  that sperm  are indeed  
able to act as transgene vectors. H ow ever, som e caution is required in m aking such a 
conclusion . Firstly, the experim ents conducted n eed  to be repeated and built upon  
before it can be said w ith  certainty that the effect is a real one. Second ly, it cou ld  be  
the case that the transgene m olecu les bound on ly  w eak ly  to the sperm  ce lls , such that 
on ly  direct delivery (by ICSI) permitted the D N A  to remain in p lace. I f  so , then this
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w ould  not support the notion  that SM G T can w ork w hen  used w ith  IV F or A I, 
because w eak ly  bound or superficially  located  D N A  m ight be stripped aw ay  and lost 
from  the incom ing pronucleus during fertilisation. I f  it w ere correct that IC SI is  an 
indispensable part o f  the process, then SM G T  w ould  appear to have little advantage  
over pronuclear m icroinjection in terms o f  inherent technical d ifficu lties and expense. 
H ow ever, the effic ien cy  o f  the process does appear to be som ew hat better than that o f  
pronuclear m icroinjection. The available experim ental data on  standard hum an ICSI 
(i.e . not in vo lv in g  genetic m odification) indicate that: (a) the m ajority (ca. 75% ) o f  
eg g s are su ccessfu lly  fertilised; and (b) ly s is  fo llo w in g  ICSI occurs at a relatively  lo w  
rate (ca. 10%) (Joris et al. 1998; M ansour 1998; V an Steirteghem  et al. 1998). For 
transgenICSI, the reported rates o f  su ccess (i.e . transgenics per transfer) vary, but a 
figure o f  around ca. 35%  is fairly typical (Chan et al. 2000a; Chan et al. 2000b ; Lai et 
al. 2001; N agash im a et al. 2003; Perry et al. 1999; S zczy g ie l et al. 2 0 0 3 ).
W hereas it w ould  be som ew hat surprising i f  sperm  cells  have the inherent ab ility  to  
easily  capture and transfer naked transgene m olecu les such that the D N A  rem ains in  
place during fertilisation, it rem ains conceptually  p ossib le  to u se  transfection  
techniques to ‘force’ sperm ce lls  to capture (and thus transfer) exogen ou s D N A . 
S u ccess has been claim ed in this regard u sin g  electroporation and liposom e-m ed iated  
gene transfer. S ince 1990, several reports cla im ing su ccessfu l transgene uptake and/or 
transfer fo llow in g  electroporation o f  sperm  ce lls  have been published, and there have  
been  a num ber o f  reports o f  sperm  ce lls  taking up liposom e-encapsu lated  D N A  
(Sm ith 1999). M ore research is clearly need ed  to determ ine w hether and to  w hat 
extent transfection techniques such as liposom e-m ediated  gene transfer or 
electroporation m ay be able to augm ent SM G T. N evertheless, g iv en  that th ese gen e  
transfer techniques have been show n to w ork w ith  a w id e  range o f  som atic ce ll types, 
in vitro and in vivo, there is no reason to presum e that sperm ce lls  are inherently  
unable to be transfected using such m ethods.
A n  alternative p ossib ility  cou ld  be to introduce the transgene into testicular (sperm ) 
stem  ce lls  in vivo. This w ould  in principle rem ove the need to co llect, m anipulate or 
transfer eggs, thus providing a major stream lining o f  germ line GM . Prelim inary  
results have been  reported in m ice , w here transgene constructs w ere d irectly  injected  
into the testis. For exam ple, 60-70%  o f  sperm  w ere reported to carry the transgene
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fo llo w in g  injection o f  naked D N A  into the vas deferens (H uguet and Esponda 1998), 
w ith  a fo llow -up  report cla im ing detection o f  the transgene in the cells  o f  7.5%  o f  
offspring anim als produced fo llo w in g  fertilisation w ith  the transgene-bearing sperm  
(H uguet and Esponda 2000). S im ilar results w ere reported by Sato et al, u sing  
liposom e-encapsu lated  transgene m olecu les injected c lo se  to the ep id idym is (Sato et 
al. 1999a; Sato et al. 2002; Sato et al. 1999b).
In vitro gen e delivery into ex vivo sperm atogonial stem  cells o f  both  adult and  
immature anim als has recently b een  reported (Brinster 2002). N agano et al. obtained  
stable transgene integration and expression  in up to  20%  o f  m urine sperm atogonial 
stem  ce lls  fo llow in g  retroviral transgene delivery (N agano et al. 2 0 0 1 ). G enetically  
m odified  stem  cells w ere transferred into the testes o f  infertile recip ient m ice , leading  
to transgeneity in ca. 4.5%  o f  the resultant progeny, p lus su ccessfu l transm ission to 
subsequent generations. Sim ilar results w ere obtained by  Orwig et al. in  rats (O rw ig et 
al. 2 002). A lthough this form  o f  transgenesis is  at an early stage o f  developm ent, 
prelim inary w ork w ith sperm atogonial stem  cells  in  other m am m als such as p igs and  
goats suggests that the approach is like ly  to be w id e ly  applicable (H onaram ooz et al. 
2003; H onaram ooz et al. 2 002). I f  hum an ex vivo sperm atogonial stem  ce lls  are 
sim ilarly able to p ick  up and transmit transgenes, an exciting  potential route to  
germ line gene therapy m ight em erge.
2.1.8 Combined Methods
It is p ossib le to com bine m icroinjection w ith  one (or m ore) o f  the above transfection  
m ethods. A  com bination o f  m icroinjection w ith  retroviral vectors has proved  
su ccessfu l w ith bovines (Chan et al. 1998) and prim ates (Chan et al. 2 0 0 1 ). In the 
primate case, m icroinjection w as used  to deliver a retroviral vector into the 
perivitelline space o f  224  mature rhesus m onkey oocytes (the oocytes w ere  
subsequently fertilized by  intracytoplasm ic sperm  injection). The retroviral vector  
particles had an envelope type know n to recogn ise and bind to the m em brane o f  all 
ce ll types. The retroviral vector w as m icroinjected  at a developm ental stage at w hich  
the oocyte  nuclear membrane w as absent, thus perm itting nuclear entry. From  20
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em bryo transfers, three anim als w ere bom , one o f  w h ich  w as transgenic. A dditionally , 
a m iscarried pair o f  tw ins w as transgenic. A lthough  this ‘com bined’ m ethod  o f  gen e  
transfer is laborious, it is the on ly  approach that has permitted the generation o f  
transgenic prim ates thus far.
One very interesting possib ility  is the com bination o f  naked D N A  auto-uptake w ith  
m icroinjection, a process that has been term ed ‘tra n sg en icS I’. In this recent approach, 
sperm exp osed  to naked transgene m olecu les are m icroinjected into oocytes. S u ccess  
has been  reported w ith  m ice, w ith  approxim ately 20%  o f  founder anim als integrating  
and expressing the transgene (Perry et al. 1999; S zczy g ie l et al. 2 0 0 3 ). Transgene  
uptake and expression  fo llow in g  transgenICSI has a lso  been reported in rhesus 
m onkey em bryos (Chan et al. 2000a; Chan et al. 2000b ) and porcine em bryos (Lai et 
al. 2001; N agash im a et al. 2 0 0 3 ), although transgenic offspring did not result.
Other delivery com binations that have been  u sed  to produce transgenic m am m als  
include m icroinjection  o f  b ov in e papillom a viral vectors (M annik et al. 2 0 0 3 ), 
m icroinjection o f  adenoviral vectors (K ubisch et al. 1997) and m icroinjection  o f  
transposable elem ents (D upuy et al. 2002).
2.1.9 Novel Methods
Finally, it is worth considering a h igh ly  n ovel technique, as an illustration o f  the m any  
and varied m eans by  w hich  em erging tech n o log ies are enabling gene transfer. In  
particle bom bardm ent, D N A  m ay be adsorbed onto spherical tungsten or g o ld  
particles (diam eter c .4  pm ) and transferred into a m ass o f  cells by a particle gun; o n ce  
inside the target ce lls , the D N A  is so lub ilised  and m ay be expressed  (P ecorino 1995). 
This approach, som etim es know n as ‘b io lis tic s ’, w as originally d eveloped  for plant 
transgenesis but has been show n to be effectiv e  for transferring transgenes into  
m am m alian cells  in vivo (C heng et al. 1993). Indeed, there are indications that 
bio listics m ay be m ore effic ien t than alternative m ethods such as liposom e-m ed iated  
transfection and recom binant viral in fection  (G ainer et al. 1996), although the am ount 
o f  research data presently available is too  little to perm it defin itive com parisons. I f  the
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m ethod does prove to  be effective  in vivo, tum ours are the m ost like ly  targets for  
particle bom bardm ent (M ahvi et al. 1997).
B io listics  then, is a prom ising m ethod for treating ce lls  en masse, and looks m ost 
usefu l in term s o f  som atic gene therapy. There have b een  no reported attempts to  
utilise b io listics for altering zygotes. The en masse nature o f  the approach p laces it in  
a sim ilar position  to that o f  electroporation or liposom e-b ased  m ethods in respect o f  
zygotes: im practically large numbers o f  zy g o tes  w ou ld  undoubtedly b e required per  
su ccessfu l transgenic event. H ow ever, in  principle it m ight be p ossib le  to apply  
b io listics to E SC s or som atic cells  for N T  as a route to the germ line.
2.2 Transgene Design
Transgenes are u sually  designed  to express a particular gene product. In gene therapy, 
this w ould  in principle be aim ed at replacing a m issin g  gene product in recessive  Toss  
o f  function’ disorders. A lternatively, transgenes m ay be designed  to elim inate an 
endogenous gene function. This w ould  in principle be aim ed at preventing an 
unwanted gene product causing dam age in dom inant ‘gain  o f  function’ disorders.
2.2.1 Promoters
‘H ousekeep ing g en e ’ prom oters, such as the p-actin  prom oter (B eddington et al.
1989) and the h istone H 4 prom oter (C hoi et al. 1991), can b e fused  w ith  chosen  
structural genes. The ‘housekeep ing g en e ’ prom oters in such genetic constructs 
generally drive a fairly h igh  leve l o f  constant transcription in m ost ce ll types and  
developm ental stages w hen  these constructs are integrated as transgenes.
B eyon d  sim ply driving gene expression, prom oters m ay be chosen  to  a llow  sp ec ific ity  
in, or control over, patterns o f  expression. A  transgene com prising a particular 
structural gene fused  w ith  a tissue-specific  prom oter should  on ly  produce its gen e  
product in the tissu e(s) sp ecified  by that prom oter. In terms o f  hum an germ line g en e
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therapy, this m ight allow  treatment to  be directed ex c lu siv e ly  to the required tissues or 
organs.
2.2.2 Control of Transgene Expression
I f  outside (i.e. experim enter) m anipulation o f  gene expression  is required, an 
inducib le prom oter m ay be used. Inducible prom oters are able to respond to sp ecific  
environm ental cues such as temperature, or to dietary factors such as zinc. Thus the 
structural gene w ith in  a transgene can be sw itched  on or o f f  at w ill. For instance, a 
m etallothionein  (M T ) promoter fused  w ith  a grow th horm one (G H ) gen e (Palm iter et 
al. 1982) should a llow  GH production to be sw itched  on sim ply b y  providing the 
transgenic w ith  a zinc-supplem ented diet. This m ight avoid the p ossib le  p h ysio log ica l 
difficu lties associated  w ith continuous g lob al production - particularly in utero - o f  
transgene products such as GH. Potential applications for inducible prom oters in  
terms o f  gene therapy are conceivable.
M ore recently, inducible system s em ploying  prokaryotic tetracycline resistance gene  
com ponents have been developed  (G ossen  et al. 1995; K istner et al. 1996; Park and  
RajBhandary 1998; Schultze et al. 1996; Shockett et al. 1995). T hese system s usually  
require tw o separate transgenes: thus, for u se  w ith  transgenic anim als (as opposed  to  
ce lls  in vitro) these system s usually  require the establishm ent o f  tw o separate 
transgenic lines, each line containing one o f  the tw o  transgenes. D oub le h eterozygotes  
(contain ing both transgenes) are obtained b y  m ating the tw o lines. O ne transgene  
(Transgene I) includes a prom oter construct consisting  o f  (a) an array o f  tet operator 
sequences and (b) a m inim al promoter sequence; (a) and (b) are coup led  to the gen e  
that is  to be controlled (G ene W ). The other transgene (Transgene II) com prises a 
hybrid transcriptional transactivator gene fused  to a suitable (e .g . tissu e-sp ec ific )  
promoter. The hybrid transactivator gene product consists o f  a viral transcription­
activating dom ain coupled  w ith a tetracyline-binding dom ain. There are tw o m ain  
variants o f  the basic system: an ‘o n ’ system  and an ‘o f f  system . T hese variants are 
based  upon functionally different transactivators. In the ‘on ’ system , in cells  in  w hich  
Transgene II is active, exogen ou sly  adm inistered tetracycline (or its analogue
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d oxycyclin e) binds to the transactivator protein: this renders the transactivator able to  
bind to the tet sequences on  Transgene I, thereby activating expression  o f  G ene W . B y  
contrast, the transactivator in the ‘o f f  system  binds to the tet sequences on ly  in the 
absence o f  tetracycline: thus, adm inistration o f  tetracycline prevents expression  o f  
gene W .
Several other prom oter-based system s for the control o f  transgene expression  are in  
the developm ental stage. Prom ising areas include natural prom oters inducib le b y  aryl 
hydrocarbons and prom oter constructs inducib le b y  steroid horm ones (F ussenegger  
2001; N o  et al. 1996; Saez et al. 1997; Sm ith et al. 1995; W ang et al. 1997; W ang et 
al. 1994).
S ite-sp ecific  recom bination provides a n o v e l m eans o f  controlling transgene 
expression  (Kuhn et al. 1995; Stark et al. 1992; U tom o et al. 1999). A s  w ith  the 
tetracycline approach (above), tw o separate transgenes are usually  required, 
necessitating the m ating together o f  separate transgenic lines to  produce double  
heterozygotes (w here transgenic anim als are required). O ne transgene (Transgene I) 
consists o f  an appropriate (e.g . tissu e-sp ecific) prom oter coupled  to the g en e that is to  
be controlled (G ene X ), engineered to contain  a strong stop signal flanked on each  
side b y  a recom binase recognition site (e .g . loxP from  bacteriophage P I ) . The other  
transgene (Transgene II) consists o f  a recom binase gene (Cre in the case o f  
bacteriophage P I )  fused to an inducible promoter. E xogenous adm inistration o f  
inducer drives the production o f  Cre recom binase from  Transgene II. The Cre 
recom binase binds to the loxP sites on Transgene I and catalyses the ex c isio n  o f  the 
flanked stop signal, thereby rendering G ene X  com petent for expression . A  variant o f  
this system  can be used  to inactivate a transgene, in  w hich  G ene X  (or an essentia l 
com ponent thereof) is flanked by  recom binase recognition  sites. In this case, 
recom binase production results in  the rem oval o f  essentia l sequences, thereby  
elim inating expression  o f  gene X .
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2.2.3 Episomal Vectors
V arious extrachrom osom al p lasm id vectors (ep isom es) have been  u sed  as transgenes  
(C olosim o et al. 2002; S toll and C alos 2 002). Such vectors have b een  em p loyed  to  
produce transgenic anim als, v ia  a variety o f  routes including pronuclear  
m icroinjection and SM G T (C eleb i et al. 2002; K hoo et al. 1992; M annik et al. 2 0 0 3 ). 
H ow ever, ep isom al plasm id vectors tend to behave in an unstable fashion in  
transgenic anim als (C eleb i et al. 2002; M annik et al. 2 0 0 2 ). During developm ent, 
plasm id cop y  num bers fluctuate and plasm ids are lo st from  som e cells. P lasm id  
inheritance to subsequent generations o f  anim als is  sim ilarly problem atic. M oreover, 
worrying health problem s (such as tumour form ation) have been associated  w ith  som e  
episom al vectors (L acey et al. 1986). O f course, the behaviour o f  an ep isom e m ust 
relate in large part to its genetic constitution, and therefore stability problem s and  
safety lim itations m ay in principle be surm ounted b y  im proved p lasm id  design .
A utonom ous artificial ‘m in i-chrom osom es’, (m am m alian artificial chrom osom es, 
M A C s) have been  constructed and su ccessfu lly  introduced into m am m alian ce lls  (de  
Jong et al. 2001; G rim es and C ooke 1998). M A C s com prise centrom eres, telom eres  
and replication origins, and are m aintained autonom ously  w ithin  the host cell. 
Structural genes, prom oters and enhancers (etc) can be included in  M A C s.
Prelim inary research indicates that M A C s can be used , v ia  pronuclear m icroinjection , 
to create transgenic anim als in w hich  the M A C s are m aintained autonom ously  (C o et 
al. 2000).
2.3 Random Integration of Transgenes
Transgenes usually  integrate into a random p osition  w ith in  the h ost genom e. The  
arrangements o f  exogen ou s D N A  integrated into the chrom osom es o f  cultured  
m am m alian som atic ce lls  are very sim ilar to the arrangements found in transgenic  
anim als (Brinster et al. 1985; Folger et al. 1982; G ordon and R uddle 1985). T his is  
true regardless o f  w hether the transgenic anim als have been  derived from  o n e-ce ll
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em bryos or ESC s. This suggests that the underlying m olecular m echanism s o f  random  
integration are essen tia lly  the sam e in all ce ll types.
The m ain features o f  random ly integrated exogen ou s D N A  are as fo llow s:
•  Integration occurs at a frequency o f  b etw een  10 - 30%  o f  ce lls  in w hich  transgene 
D N A  is delivered to the nucleus;
•  Integration occurs at one or, rarely, a few  chrom osom al sites per nucleus;
•  Integrated D N A  is usually  present in the form  o f  a m ulticopy array;
•  The vast m ajority o f  arrays consist o f  head-to-tail associations.
The precise m olecular m echanism s o f  random  integration are not known. H ow ever, 
experim ental data such as that outlined above has a llow ed  the construction o f  m odels  
o f  random integration. A  general m odel is presented b elow .
2.3.1 Concatenation
The fact that transgenes are usually  present as arrays (concatem ers) indicates that 
extrachrom osom al events (concatenation) take p lace prior to chrom osom al 
integration.
R andom  end-to-end jo in in g  (ligation) o f  transgene m olecu les should  generate head- 
to-tail, head-to-head and tail-to-tail associations in a ratio o f  2:1:1. H ow ever, as 
m entioned above (S ection  2 .3 ), the vast m ajority o f  arrays take the form  o f  head-to- 
tail associations. Therefore, end-to-end jo in in g  cannot be an adequate explanation o f  
concatenation. H ow ever, rare head-to-head/tail-to-tail associations do occur, so  
ligation  w ould  appear to be a possib ility . The sim plest explanation lies  in the k inetics  
o f  free transgene m olecules: it m ust be stochastically  infrequent for any tw o transgene  
m olecu les to m eet together in an end-to-end fashion, and stay together long enough  
for a m olecu le o f  D N A  ligase to unite them  (B ishop  1996).
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I f  end-to-end jo in in g  cannot explain  the m ajority o f  concatenation events, another 
form o f  interaction b etw een  transgene m olecu les m ust be operative. The m ost lik e ly  
process is extrachrom osom al H R  betw een  circular and linear m olecu les. This 
m echanism  can be show n, in form al geom etric terms, to generate ex c lu siv e ly  head-to- 
tail concatem ers (B ishop  1996).
A  prerequisite for concatenation by  extrachrom osom al H R  is the co-ex isten ce o f  both  
circular and linear transgene m olecu les. Experim ental data sh ow s that head-to tail 
arrays result (w ith  equal frequency) fo llow in g  the introduction o f  either circular or 
linear m olecu les (Brinster et al. 1985; F olger et al. 1982). Therefore it is  n ecessary  to 
postulate the ex isten ce o f  tw o nuclear processes: (1) circularisation (by ligation  o f  the 
free ends o f  a transgene m olecule); and (2) linearisation (by random  n uclease action).
Linearisation w ou ld  generate circularly perm uted m olecu les. H R  could  then occur  
betw een  circularly perm uted and circular m olecu les, or betw een  circularly perm uted  
and input linear m olecu les, or betw een  individual (different) circularly perm uted  
m olecules: in all cases the effect w ould  be the form ation o f  a head-to-tail concatem er. 
R epeated rounds o f  H R  w ould  extend the array (i.e . increase the num ber o f  transgene  
cop ies therein).
Several cultured ce ll studies have dem onstrated that linear D N A  m olecu les are 
circularised b y  intracellular ligation, and a num ber o f  sim ilar studies have indicated  
that circular D N A  m olecu les are random ly cleaved  (B ishop  and Sm ith 1989). Thus, 
circularly perm uted m olecu les w ill be produced fo llo w in g  introduction o f  exogen ou s  
D N A  m olecules.
C oncatenation o f  circularly perm uted m olecu les can m ost sim p ly  be exp lained  b y  the  
fo llow in g  events: (1) h om ology  pairing; (2) exposure o f  single-strand substrates at the  
end o f  each duplex; (3) form ation o f  a duplex b etw een  exp osed  com plem entary  
strands; and (4) resolution  (by repair o f  the duplex).
The fact that extrachrom osom al H R occurs w ith  h igh  frequency am ongst individual
transgene m olecu les contrasts sharply w ith  the lo w  frequency o f  H R  betw een
transgenes and hom ologou s chrom osom al sequences. There w ou ld  appear to be tw o
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p ossib le explanations, as fo llow s: (a) the ‘free’ nature o f  the interacting transgene  
m olecu les in som e w ay  enables H R  to proceed  very efficien tly; and/or (b) the free 
(non-telom eric) ends o f  the interacting transgene m olecu les are very good  substrates 
for recom binase enzym e activities. H ow ever, the m olecular/b iochem ical details o f  H R  
rem ain to be elucidated; thus it is not yet p ossib le  to g iv e  a precise explanation for the  
contrast that ex ists betw een  extrachrom osom al H R  and the H R  that underlies gen e  
targeting.
2.3.2 Illegitimate Recombination
Transgene or transgene array integration on ly  occurs in a m inority o f  surviving  
transfected ce lls , suggesting  that (nontargeted) integration is the result o f  a rare 
intranuclear event. The sim plest m odel w ou ld  suppose that the rare intranuclear event 
is chrom osom al (double-strand) breakage fo llo w ed  b y  end-joining betw een  the 
transgene ends and the chrom osom al broken ends. Certainly, the frequency o f  D N A  
integration is  increased by  irradiation o f  the transfected ce lls  (Perez et al. 1985).
A n  alternative m ode o f  chrom osom al integration cou ld  b e ‘illeg itim ate’ 
recom bination betw een  very poorly  m atched sequences. Studies o f  the nucleotide  
sequences at exogenous-endogenous D N A  junctions have show n illegitim ate  
recom bination in  a num ber o f  cases, although the overall number o f  studies is  sm all 
(B ishop  1996).
Interestingly, a d iverse range o f  chrom osom al sequence disturbances has been  found  
in  junctional studies. T hese include, in order o f  frequency: deletions, duplications, 
inversions and m ore com p lex  rearrangements including the appearance o f  sequences  
from  elsew here in the genom e or even  o f  unknow n origin. B ishop  (B ishop  1996) has 
proposed an explanation o f  these observations that sees exposed  single-stranded ends  
o f  transgene m olecu les initiating recom bination by  invading D N A  duplexes.
It is n ow  know n that the m ajority o f  transgenic founder anim als are m osaics. T his 
suggests that integration occurs during D N A  replication. W ilk ie & Palm iter (W ilk ie
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and Palmiter 1987) have proposed that the free ends of the transgene initiate 
recombination by invading a replication ‘eye’.
It may be that more than one integration route is possible for randomly integrated 
transgenes. A full understanding of the mechanisms of random transgene integration 
awaits further study at the molecular/biochemical level. Such understanding is 
important from the perspective of gene targeting, because it may be that targeting 
frequencies could be enhanced by somehow blocking ‘background’ (i.e. random) 
integration events.
2.3.3 Problems Associated with Random Transgene 
Integration
Random integration poses the risk of insertional mutagenesis, where a transgene 
integrates into or close to an important endogenous gene. Although this is a real risk, 
in practice transgenic animals rarely suffer from insertional mutagenesis. This is 
partly because ‘important’ genes are often most important during development: 
insertional inactivation of such a gene at the start of development (i.e. at the time 
when germline gene transfer occurs) would simply lead to embryonic death. For 
other, less crucial genes, haplosufficiency may counterbalance insertional 
inactivation. And the probability of a transgene inserting randomly into an 
endogenous gene is relatively low for each integration event, given the fact that genes 
represent only a minority of the sequences within the mammalian genome. 
Nevertheless, insertional mutagenesis has on occasion been observed to impact upon 
the health of transgenic animals: physiological, behavioural and oncogenic effects 
have been noted.
A second problem for randomly integrated transgenes concerns transgene expression. 
Randomly integrated transgenes tend to give poor levels of expression, or exhibit 
inappropriate expression, in the form of temporally or spacially (ectopic) aberrant 
expression. Moreover, random integration leads to inconsistent outcomes: individual 
transgenic animals produced using an identical approach (i.e. same transgene, same
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transfection method, same genetic background of host animal) differ greatly from 
each other in terms of transgene expression.
There are three main reasons for such problems with expression. Firstly, the particular 
genetic environment at any point of insertion is likely to influence the expression of 
the integrated transgene, a phenomenon known as the ‘position effect’. Secondly, the 
multicopy transgene arrays that predominate in random integration outcomes exhibit a 
paradoxical expression pattern: the larger the array, the poorer the level of expression. 
The number of transgene copies within an array is thought to positively correlate with 
the degree to which the array will be methylated by the host cell. Finally, the high 
level of mosaicism associated with random integration leads to expression difficulties: 
generally low expression results from the absence of transgene in all tissues and, 
given that patterns of mosaicism are themselves random, expression is variable and 
inconsistent between individual transgenics.
Approaches to circumvent or mitigate expression difficulties exist or are emerging. In 
some cases the remedy lies with transgene design: for example by ensuring that an 
appropriate enhancer sequence is included in the transgene construct. Beyond this, it 
may be possible to insulate a gene from the position effect. Matrix attachment regions 
(MARs) are sequences which, when placed on either side of a gene within a transgene 
construct, appear to allow the gene(s) within an integrated transgene to occupy a 
separate chromosomal domain. Locus control regions (LCR) have a similar effect. 
However, results with transgenic animals have been variable, and the extent to which 
‘insulator’ sequences may be able to avoid the position effect remains to be 
determined.
It is clear that random integration of transgenes is associated with serious drawbacks. 
Although the risk of insertional mutagenesis is low in the case of animal transgenesis, 
the same level of risk in human germline gene therapy would present more of a 
problem. Even if the risk was deemed acceptable (perhaps in the case of gene therapy 
for a very serious candidate disorder), the problem of unreliable and inconsistent 
expression associated with random integration would remain, unless significant 
advances in transgene design are forthcoming.
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Ultimately, the best solution to aberrant transgene expression and insertional 
mutagenesis would be to avoid the problems associated with random integration 
entirely. This is achievable through gene targeting: a transgene targeted to a chosen 
genomic locus will by definition avoid the position effect, it will normally be present 
as a single copy rather than as a multicopy array, and mosaicism will not normally be 
a problem. Moreover, gene targeting can be used to precisely alter endogenous 
genetic sequences, such that problematic (i.e. disease-causing) endogenous genes can 
be ‘knocked-out’, or even repaired. Thus, gene targeting would be of the very greatest 
importance in human germline gene therapy. Gene targeting is the topic of the next 
chapter.
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Chapter 3: Gene 
T argeting
2 0 2
Gene targeting may be defined as the directed genetic modification of a chosen 
endogenous genomic locus. Gene targeting is an achievable goal in mammalian cells. 
However, progress has been limited by a lack of targeting efficiency. Studies on 
mammalian cells in vitro demonstrate that the vast majority of interactions between 
transgene and endogenous DNA result in random rather than targeted integrations. 
The reported ratio of random to targeted integration varies enormously, from around 
1:4 to more than 1,000,000:1. In most cases, the ratio is between 1000:1 and 10,000:1 
(Bollag et al. 1989; Capecchi 1989; Frohman and Martin 1989; Sedivy and Dutriaux 
1999; Thomas et al. 1992; Vasquez et al. 2001). It is noteworthy that the low 
efficiency of targeted integration in mammalian cells is in marked contrast to that 
which occurs when DNA is transfected into lower eukaryotes such as yeast: under 
appropriate empirical conditions, targeting is the norm and random integration the 
exception for such organisms.
3.1 Cell Types and Gene Targeting
Due to the low efficiency of targeting, it is normally necessary to select for targeted 
outcomes against a background of random outcomes. Such selection can only be 
applied to somatic cells growing and dividing in vitro: thus, selection-based gene 
targeting is not applicable with zygotes or sperm cells. However, methods have been 
developed whereby cultured cells can, following selection for gene targeting, be used 
to produce transgenic animals.
3.1.1 Zygotes
Targeted outcomes cannot be selected for in zygotes. This does not, however, mean 
that targeted events are impossible in zygotes. Very few studies have looked at gene 
targeting in zygotes, probably due to the expense of gene transfer and analysis. A 
landmark study by Brinster et al. (Brinster et al. 1989a) involved the analysis of 506 
transgenic founder mice. These animals were produced by microinjecting zygotes
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from mice containing a deletion in the major histocompatibility (MHC) class II Ecu 
gene. The transgene construct was based on sequences from this gene and included 
the sequences absent in the host mice. A single mouse was found to have undergone 
targeted correction of the Ea gene deletion. This study shows that gene targeting is 
possible in zygotes. Although it is not possible to determine an accurate frequency of 
gene targeting in zygotes from this work, it appears that the rate of targeting (1 in 506 
animals), although quite high compared with cultured cells (see above), is too low to 
permit the efficient use of gene targeting in zygotes.
3.1.2 Embryonic Stem Cells
Inner cell mass (ICM) cells from the mouse blastocyst can be propagated in vitro as 
embryonic stem cells (ESCs) (Abbondanzo et al. 1993; Brook and Gardner 1997). In 
contrast to other cultured cell lines, ESCs retain their normal karyotype even after 
many months in culture, during which time they remain totipotent (able to contribute 
to both somatic and germ lines). Furthermore, ESCs are capable of colonising the 
embryo. These unique properties allow ESCs to form chimeras when injected into 
blastocysts or aggregated with morulae. The resultant embryos can be transferred to 
the uterus of a pseudopregnant female mouse for gestation. In cases where an ESC 
has successfully contributed to the embryo, the resultant offspring will be chimeric 
(up to ca. 50% of animals). The ESC contribution to a mouse can high (up to ca. 80% 
of the cells), and will often include the germline cells. However, it should be noted 
that, with some transgenes, and for reasons that are not understood, the production of 
chimeras can be problematic or even unattainable, especially when germline 
transmission is required to breed pure lines of heterozygous or homozygous animals 
(Abbondanzo et al. 1993; Brook and Gardner 1997; Robertson 1987; Torres 1998).
It is during the in vitro culture stage that ESCs may be transgenically manipulated 
(Pirity et al. 1998; Torres 1998). Many gene delivery systems are effective with ESCs, 
including viral vectors, liposomes, and electroporation. The great advantage of ESCs 
is that they can be subjected to a range of selective agents in vitro, which allows the 
selection of particular transgenic modifications. This ability makes ESCs extremely
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useful for gene targeting experiments and applications (Metzger and Feil 1999;
Muller 1999).
However, the use of ESCs is limited because, to date, the mouse is the only animal 
from which ESC lines have been unequivocally established. It would be surprising if 
this limitation represents a fundamental biological barrier. However, further empirical 
work is needed before totipotent ESC lines become available for other species.
Indeed, efforts to isolate non-murine ESCs have been ongoing for nearly two decades 
but to date no germline-competent ESCs have been isolated in other vertebrates 
(Prelie et al. 1999; Wheeler et al. 2003).
3.1.3 Nuclear Transfer
The successful transfer of ‘reprogrammed’ sheep donor nuclei has recently been 
achieved (Campbell et al. 1996; Schnieke et al. 1997; Wilmut 1997). Unfertilised, 
metaphase-stage enucleated (‘universal recipient’) eggs received the transferred 
nuclei. Donor nuclei originated from somatic cells that had been forced into a form of 
cell cycle stasis (by incubating the cells in a minimal nutrient medium), such that 
DNA replication and gene expression were halted (or virtually so). Nuclear transfer 
was conducted by depositing a donor cell under the zona pellucida of a universal 
recipient egg, and fusing the two cells by electrical stimulation. This process resulted 
(in some cases) in successful embryo development, the donor nuclei having been 
‘reprogrammed’ into totipotency. Offspring were produced following the transfer of 
such ‘reconstructed’ embryos to recipient ewes. Subsequent molecular genetic testing 
showed that the lambs’ DNA had originated from the donor cells. In some of the 
experiments, the donor nuclei were obtained from embryo-derived cultured cell lines. 
Following these groundbreaking experiments, successful cloning from cultured cells 
of various mammals including cattle, goats and pigs has been reported (Tsunoda and 
Kato 2000; Wolf et al. 2000). Interestingly, a human ESC line has recently been 
derived from cloned human blastocysts produced by NT (Hwang et al. 2004), pointing 
to a possible new field of application for NT technology.
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The prospects for germline GM via NT are very significant: transgenes can be 
introduced to somatic donor cells in vitro, permitting germline genetic modifications. 
This has been achieved in animals such as sheep (Schnieke et al. 1997). Several gene 
delivery systems are applicable to NT donor cells, including liposomes and 
electroporation. Moreover, because selection can be applied to cultured donor cells, 
NT can be used to achieve germline gene-targeting. Gene targeted transgenic animals 
have been created in this way (Clark et al. 2000; McCreath et al. 2000). Thus, NT is 
potentially able to provide the same range of transgenic manipulations presently 
available in mice (via the ESC route) to all mammal species.
However, in comparison with ESC transgenesis, NT has thus far proved to be 
relatively inefficient: only a small proportion of reconstructed embryos survive to 
become live animals. For example, McCreath et al. produced live targeted sheep at an 
efficiency of less than 4% (McCreath et al. 2000), and Lai et al. produced live 
targeted pigs at an efficiency of less than 2% (Lai et al. 2002b).
The health status of NT-derived animals is also proving to be problematic (Renard et 
al. 2002; Smith et al. 2000). Developmental abnormalities are very common, with a 
high birth weight being the predominant feature, a phenomenon known as “large 
offspring syndrome” (LOS). The abnormalities frequently result in death (foetal or 
postnatal) or debility. For example, of fourteen live-bom lambs, seven died within 30 
hours of birth, and four died within twelve weeks (McCreath et al. 2000). Similarly, 
out of seven piglets, two piglets died shortly after birth, and one died at 17 days; only 
one appeared to be entirely free of developmental abnormalities (Lai et al. 2002b). 
Transgenesis and gene targeting are not of themselves implicated: the health problems 
are associated with NT per se. During the in vitro (cell culture) stage, the pattern of 
chromosomal imprinting may change; there are indications that inappropriate 
expression of imprinted genes following such epigenetic alteration may be mainly 
responsible for the poor health of NT-derived animals (Kono 1998; Rideout et al. 
2001; Wakayama and Yanagimachi 2001). Research into epigenetic reprogramming 
in NT embryos is in progress, and it is to be hoped that developmental abnormalities 
arising from NT will eventually be eliminated or reduced in frequency. Meanwhile, it 
is anticipated that NT-related health problems, to the extent that the basis for such is 
epigenetic, are unlikely to affect the offspring of surviving first-generation animals.
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3.1.4 Non-selective Gene Targeting
In embryonic stem cells and in certain somatic cells in vitro, unusually high levels of 
gene targeting have been reported. Isogenic transgenes, derived from the same 
(syngenic) laboratory animal strain as the target animal, contain homology blocks that 
are genetically identical (or virtually identical) to the target homology regions. Riele 
et al. (Riele et al. 1992) reported a 20-fold improvement in targeting efficiency when 
an isogenic transgene was used to target the retinoblastoma susceptibly gene (Rb) in 
murine ESCs, yielding a remarkably favourable ratio of random to targeted 
integration (approximately 1:4). Similar results were obtained from a systematic study 
by Van Deursen and Wieringa (Van Deursen and Wieringa 1992), in which the 
creatine kinase M gene (CKM) in ESCs was targeted.
More recently, adeno-associated virus (AAV) vectors have been used to gene target 
somatic cells at high frequencies. Hirata et al. used AAV vectors to introduce 
transgenes into the hypoxanthine phosphoribosyl transferase (HPRT) and Type I 
collagen (COL1A1) loci in normal human fibroblasts (Hirata et al. 2002). The 
transgenes were targeted at high frequencies, such that the majority of transgene- 
containing cells had undergone gene targeting with an appropriately designed vector. 
AAV targeting frequencies have been further improved by selective creation of 
double-strand DNA breaks in the target site (Miller et al. 2003; Porteus et al. 2003). 
Most recently, adult human mesenchymal stem cells (MSCs) have also been targeted 
with high efficiency using AVV vectors (Chamberlain et al. 2004).
3.2 Targeted Integration
The utility of gene targeting as a means of gene therapy requires systematic study into 
the mechanisms of the process. Given the many variables involved in any gene 
targeting experiment (i.e. cell type, transfection method, transgene design, target site,
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etc.), it is unsurprising that progress towards a detailed understanding has been 
relatively slow.
Nevertheless, various studies have provided important insights into several aspects of 
mammalian gene targeting. Initial studies involved the use of artificially introduced 
selectable target sites in mammalian cell lines, such that rare targeting events could be 
recovered. Later studies have used targets of natural loci in mammalian cell lines, 
ESCs and mammalian zygotes. Various observations and inferences from such studies 
are considered in the following sections (3.2.1 - 3.2.8).
3.2.1 Transfection Method
In methods other than microinjection, the exogenous DNA molecules must somehow 
migrate through the cytoplasm of the host cell in order to reach the nucleus. Of the 
DNA that survives this journey, a substantial proportion sustains some degree of 
endonucleolytic or exonucleolytic damage. In contrast, virtually no damage occurs to 
DNA delivered directly into the nucleus by microinjection (Lebkowski et al. 1984; 
Wake et al. 1984).
Gene targeting using a damaged transgene is unlikely to be desirable in gene therapy. 
Beyond this concern, it may be the case that damage sustained by incoming transgene 
molecules renders them less able to undergo HR. The reasons for this are not known, 
but the effect seems to exist. For example, separate studies were conducted by Lin et 
al. (Lin et al. 1985) and Thomas et al. (Thomas et al. 1986) both involving gene 
targeting of artificially introduced defective genes in mouse fibroblasts. Lin et al. 
reported a ratio of random integration to gene targeting of 100,000:1 whereas Thomas 
et al. reported a ratio of 100:1. The major difference between the two sets of studies 
lies in the method of transfection, with Lin et al. using calcium phosphate co­
precipitation, and Thomas et al. using microinjection. Similarly, in a systematic study 
using the adenine phosphoribosyltransferase (APRT) locus in Chinese hamster ovary 
cells, Vasquez et al. (Vasquez et al. 2001) compared the targeting efficiencies 
associated with various transfection methods. In these experiments, mass-delivery
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methods (elecroporation, co-precipitation, liposomes) yielded an average ratio of 
random integration to gene targeting of 200,000:1 (range 2,400:1 to 350,000:1) 
compared with a ratio of 1:15 for microinjection. In addition to the possibility that HR 
frequency is reduced due to DNA damage associated with the mass-transfection 
methods, it has been suggested that the larger numbers of transgene molecules 
delivered by the mass-transfection methods may overwhelm the HR machinery 
(Vasquez et al. 2001).
3.2.2 Transgene Sequences
Gene targeting is dependent on HR, which is in turn dependent on shared homology 
between recombining DNA sequences. The question is, how much homology is 
required for optimal efficiency of gene targeting? There is at present no complete 
answer to this question, because systematic studies are lacking, and comparison 
between separate studies is very problematic due to the existence of several variables 
other than the extent of homology. Such variables include other transgene sequences, 
the physical state of the transgene, the cell type used, the target gene and the actual 
nature (rather than simply the extent) of homology. Nevertheless, several studies 
have provided a partial answer. Thomas and Capecchi (Thomas and Capecchi 1987), 
targeting the HPRT gene in ESCs, found that targeting efficiency appeared to be 
strongly dependent upon the degree of homology possessed by the transgene (and 
shared with the target locus). Specifically, an increase in homology from 4 kb to 9.1 
kb correlated with 40-fold increase in the rate of targeting, as measured by the ratio of 
targeted:random integration. Shulman et al. (Shulman et al. 1990), targeting an 
immunoglobulin gene in hybridoma cell lines, varied the extent of homology from 1.2 
to 9.5 kb. Again the degree of homology correlated with targeting efficiency, with a 
25-fold increase seen over the range from 2.5 to 9.5 kb. No increase in targeting 
efficiency was observed between 1.2 and 2.5 kb. From these studies it can be 
concluded that the frequency of gene targeting is roughly proportional to the extent of 
homology shared by the transgene and its target locus. However, it is notable that the 
effects of very large (> 9.5 kb) homologies are not known.
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Besides homology length, base pair variation may affect the rate of targeting. This is 
evident from experiments comparing isogenic and nonisogenic transgenes. The 
homology region(s) in an isogenic transgene is derived from the same (syngenic) 
laboratory animal strain as the target animal. Therefore, isogenic transgenes contain 
homology blocks that are genetically identical (or virtually identical) to the target 
homology regions. By contrast, a homology stretch in a nonisogenic transgene will 
typically be interrupted by a number of slight sequence divergences, such as base-pair 
mismatches and small deletions / insertions. In a series of experiments designed to 
compare isogenic and nonisogenic transgenes, Riele et al. (Riele et al. 1992) reported 
a 20-fold improvement in targeting efficiency when an isogenic transgene was used, 
yielding a remarkably favourable ratio of random to targeted integration 
(approximately 1:4). The target site was the retinoblastoma susceptibly gene (Rb) in 
an ESC line derived from mouse strain 129. The isogenic and nonisogenic transgene 
constructs contained 17 kilobases of homology, derived respectively from (a) mouse 
strain 129 and (b) mouse strain BALB/c. Similar results were obtained from a 
systematic study by Van Deursen and Wieringa (Van Deursen and Wieringa 1992), in 
which the creatine kinase M gene (CKM) in ESCs was targeted with transgenes 
sharing 9 kb of homology with the target site. In these experiments, an increase in 
targeting efficiency of approximately 25-fold was observed when isogenic transgenes 
were used. Thus, the use of isogenic DNA in transgenes appears to hold promise for 
improving gene-targeting efficiencies. However, it has not been established whether 
the outcomes described above are applicable to other target genes in other cell types. 
Moreover, there exists a dearth of systematic knowledge concerning the nature, 
frequency and extent of heterologies that may affect targeting efficiencies. 
Nevertheless, it is reasonable to conclude that, all other factors being equal, 
transgenes employing perfect homology are likely to yield better targeting efficiencies 
in comparison with those using interrupted homology.
3.2.3 Physical State of the Transgene
In keep ing w ith yeast data (see Section  3 .2 .8 ), all studies agree that linearization o f
the transgene (in the region o f  hom ology) greatly enhances targeting effic ien cy
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(Kucherlapati et al. 1984). This finding is supportive of the double-strand break-repair 
model as an explanation of the mechanism of gene targeting (Smith 2001). Beyond 
linearization, stripping the transgene ends to expose around 200 nucleotides of single- 
stranded DNA appears to further enhance targeting (Vasquez et al. 2001). Although 
the underlying mechanism is not understood, the finding that single-stranded 
transgene tails enhance targeting fits well with the notion that HR involves single- 
stranded DNA ends invading target duplex DNA (Sun et al. 1991).
3.2.4 Transgene Copy Number
A targeting transgene molecule presumably has to ‘search’ through the host genome 
until it ‘finds’ its target sequence. Therefore, it might be expected that targeting 
efficiency would be enhanced by increasing the number of transgene molecules 
introduced to the host cell. An increasing cytotoxic effect is observed where 
increasingly large quantities of DNA are microinjected into the nucleus (Hogan et al,
1994). However, the targeting efficiency can still be obtained, by calculating the 
proportion of surviving cells that have been successfully targeted. No study has 
demonstrated a correlation between transgene copy number and targeting frequency. 
This area has not been extensively researched, but at least two studies have positively 
determined that there appears to be no relationship whatsoever between the number of 
copies introduced and the efficiency of gene targeting (Rommerskirch et al. 1988; 
Thomas et al. 1986). The inference must be that the initial search for homology does 
not seem to be the rate-limiting step for targeting. This conclusion is also supported 
by experiments involving amplification of the target site (see Section 3.2.8): an 
increased target copy number does not appear to enhance the frequency of targeting. 
Indeed, if Vasquez et al. (Vasquez et al. 2001) are correct in postulating that too many 
transgene molecules may overwhelm the HR machinery (see Section 3.2.1 above), it 
may turn out to be the case that an inverse relationship exists between transgene copy 
number and targeting efficiency.
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3.2.5 Position of Target Site
The position of the target site within the genome does not strongly influence the 
frequency of HR. For example, twelve independent recipient cell lines were produced 
by Thomas et al. (Thomas et al. 1986), each line containing a defective neomycin- 
resistance gene integrated at a different chromosomal position. Introduction of 
targeting DNA constructs gave similar gene targeting frequencies in all twelve lines.
3.2.6 Recombination Hotspots
Targeting the endogenous P2-microglobulin gene in ESCs, Zijlstra et al. (Zijlstra et al.
1989) achieved a very high frequency of gene targeting (a ratio of about 1: 25 
targeting to random integration). Other investigators for the P2-microglobulin target 
gene (Roller and Smithies 1989) and for the Hox 3.1 target gene (Lemouellic et al.
1990) have reported similarly high targeting frequencies. Such studies support the 
existence of recombination ‘hotspots’. However, the sequences involved in such 
hotspots remain to be elucidated.
3.2.7 Target Gene Activity
There is no evidence that the level of expression of the target gene correlates with the 
frequency of gene targeting (Roller and Smithies 1989).
3.2.8 Target Copy Number
As noted in Section 3.2.4, experimental amplification of the target site does not 
appear to enhance the frequency of targeting. For example, Zheng and Wilson (Zheng 
and Wilson 1990) used two mammalian cell lines, one of which contained 2 target 
gene copies. The second line contained around 800 target gene copies, located in three
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clusters on different chromosomes. Gene targeting rates were the same in both cell 
lines. Similarly, Thomas et al. (Thomas et al. 1986) used three cell lines containing 
integrated target plasmid sequences present as one copy, four dispersed copies or five 
tandem copies. Again, the rates of gene targeting were similar in all three lines. Such 
results infer, as suggested previously (Section 3.2.4), that the initial search for 
homology does not appear to be the rate-limiting step for targeting. Interestingly, 
some target amplification experiments in yeast have suggested that the frequency of 
gene targeting does depend on the number of target copies. Indeed, Wilson et al. 
(Wilson et al. 1994) report a linear relationship between target site copy number and 
the rate of targeting in yeast. The reason for this difference between yeast cells and 
mammalian cells remains to be established.
3.3 Concluding Remarks
Although major progress in model building has been made in recent decades, 
extensive biochemical analysis of the molecular mechanism(s) of HR will be required 
if gene targeting is to be better understood. On a different level, the phenomenology 
of gene targeting also requires extensive systematic analysis.
Absolute frequencies of gene targeting in mammalian cells remain low, and the ratio 
of targeted to random integration is still heavily weighted in favour of the latter. Until 
the frequencies are improved, the potential use of gene targeting in non-selective 
systems will be limited. Such improvement is likely to depend upon a more detailed 
understanding of gene targeting, which is in turn dependent upon systematic analysis 
of the sort described above.
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Chapter 4: Potential 
Applicability of Genetic 
Modification Technology 
to the Human Germline
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4.1 Introduction
The previous chapter introduced and discussed the major transfection methods, 
transgene design principles and forms of transgene integration involved in the 
production of transgenic animals. The purpose of the present chapter is to consider 
how such technology might be used to achieve human germline GM.
4.2 Criteria for Assessing Applicability to Human 
Germline Gene Therapy
An ideal gene transfer system in the context of human germline gene therapy would 
have the following features: (a) the ability to deliver transgenes in a highly efficient 
manner; (b) non-prohibitive cost and expertise requirements; (c) minimal risk of 
causing insertional DNA damage; (d) low rate of mosaicism; (e) high DNA carrying 
capacity; (f) the ability to permit adequate and controlled transgene expression; and 
(g) the ability to target transgenes to precise genomic loci.
Unfortunately, no single system amongst the presently available systems is able to 
provide all of features (a-g) above. Indeed, some gene transfer systems are so 
thoroughly unsuited to human germline gene therapy that they are not considered 
here. Of the systems that offer some positive features, in every case major drawbacks 
exist. In each case, particular scientific advances are required before the methods 
would be suitable for use in human germline gene therapy. In this respect, methods 
that require a relatively small degree of scientific research should be seen as more 
plausible than methods requiring many years of progress towards distant -  possibly 
unobtainable -  goals (Smith 2004).
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4.3 Gene Transfer to Human Embryos
Most transgenic animals have been produced via the introduction of transgenes into 
embryos, and the associated technology and underpinning science is accordingly well 
developed. Thus, the human embryo is a potential candidate for human germline gene 
therapy.
Unless dramatic improvements in the technologies are forthcoming, certain 
transfection methods are not at present a realistic proposition for gene transfer into 
human zygotes. Such methods include liposome-mediated gene transfer, 
electroporation, naked DNA uptake and many viral vectors. The problem is one of 
low transfection frequencies, coupled with fact that zygotes must be harvested (as 
opposed to grown in vitro). This leaves pronuclear microinjection and retroviral 
transfer as the only contenders presently available that might be adapted for use with 
embryos in human germline gene therapy.
4.3.1 Pronuclear Microinjection
Pronuclear microinjection would be an obvious choice of transgene delivery method 
for human embryos. The technique is well established in animals, and is likely to be 
directly applicable to the human zygote (Houdebine 2002; Wall 1996). Zygotes from 
various mammalian species have particular characteristics that necessitate 
amendments to the basic (murine) technique. For example, bovine and porcine 
zygotes are optically opaque, due to the presence of lipid granules in the cytoplasm; 
this necessitates centrifugation to displace the obscuring cytoplasmic material such 
that the pronuclei become visible. Similarly, the pronuclei in ovine zygotes are very 
difficult to visualise, due to sharing a very similar refractive index with the cytoplasm; 
this necessitates the use of top-quality optics, such as differentiation interference 
contrast (DIC) microscopy, instead of standard phase contrast microscopy. Thus, 
empirical adjustments enable pronuclear microinjection to be employed with zygotes 
from essentially any mammal. It would be surprising and unfortunate if the human
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zygote proved to be an exception to this rule. Indeed, visualisation of the pronuclei in 
human fertilised eggs is not problematic.
Although pronuclear microinjection would probably be usable with human zygotes, 
the major inherent problems of the method render it less than ideal for human 
germline gene therapy. A major problem is the relatively low rate of transgene 
integration: in mice, the overall efficiency of transgenesis (taking into account embryo 
loss in vitro and in vivo) is typically ca. 2% (Bagis and Papuccuoglu 1997;
Hirabayashi et al. 2001; Page et al. 1995). This level of efficiency is perfectly 
practicable for animal transgenesis, but it would be problematic for humans. 
Moreover, murine pronuclear microinjection transgene uptake values are several 
times higher than those achieved with other (non-rodent) species. Accordingly, even 
with hormonal induction of superovulation, the numbers of zygotes available per 
woman would be a strongly limiting factor in the potential use of pronuclear 
microinjection for human germline gene therapy.
Embryo pre-screening (preimplantation genetic screening) might be one possible way 
around the problem of low transgene uptake efficiency. Using established techniques, 
one or two blastomeres could be taken from 8 cell stage embryos and analysed by 
PCR for the presence of transgene DNA. However, such pre-screening would not be 
100% reliable, due to mosaicism within the early embryo. Following microinjection 
and successful integration of the transgene sequences, the transgene would be 
expected to be present in only 50% of the resulting blastomeres. Assuming that in 
humans, as with mice, 3 blastomeres are recruited to form the entire inner cell mass 
(ICM) (Bishop 1999; Gilbert 1997), then 1 in 8 of the resulting individuals would 
contain no transgene sequences, another 1 in 8 would contain transgene sequences in 
100% of their cells, and the remaining 6 from 8 individuals would be mosaics, 
consisting of l/3rd or 2/3rd transgene-containing cells. Accordingly, pre-screening 
would have a failure rate of more than 50%. The only feasible way that pre-screening 
might work at an acceptable level of efficiency would be to screen blastocyst-stage 
embryos. However, blastocyst biopsy techniques are in their infancy, and it remains to 
be seen whether such techniques could be applied to ICM cells (as opposed to 
trophoblast cells).
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Extrapolating from murine data, it would typically require ca. 50 zygotes to produce 
one genetically modified individual. Assuming 8 eggs per superovulation cycle, it 
would take approximately 6 months per woman to obtain 50 eggs. Pronuclear 
microinjection involving such a period of time, if coupled with effective blastocyst 
pre-screening to select for the small number of transgene-containing embryos, might 
be a feasible means of performing human germline gene therapy. However, reported 
pronuclear microinjection efficiency values are significantly lower for most mammals 
other than mice. If human pronuclear microinjection turned out to have a similar 
efficiency as that obtained with sheep or pigs, then the time taken per genetically 
modified individual would be ca. 5-fold longer -  i.e. more than 2.5 years. And if the 
rate of transgenesis turned out to be similar to that obtained with cattle, the time 
would extend beyond 8 years. The efficiency of transgene uptake through pronuclear 
microinjection is simply not known for humans, nor can it be known a priori. Thus, a 
circular problem exists: only if the efficiency turned out to be fortuitously high (i.e. 
similar to murine rates) would there be any point in attempting the technique with 
humans -  but the necessary data on efficiency could only come from actual attempts 
with humans.
Another problem associated with pronuclear microinjection concerns transgene 
expression. Only around 60% of pronuclear microinjection-derived mice show 
transgene expression. Furthermore, in the animals showing expression, there are 
frequently problems of low-level expression or inappropriate expression (e.g. non- 
tissue-specific, non-temporal). Accordingly, pronuclear microinjection as a means to 
human germline gene therapy requires improvements in transgene expression. It is the 
non-targeted nature of transgene integration associated with pronuclear microinjection 
that is the root cause of expression problems. Some improvements may come from 
advances in transgene design, such as the use of matrix attachment regions (MARs) or 
locus control regions (LCRs): placed on either side of a gene within a transgene 
construct, these ‘insulator’ sequences appear to allow the gene to occupy a separate 
chromosomal domain and thus avoid position-related expression problems (Smith 
2002c). However, the best solution would be to target transgenes to precise genomic 
loci, and at present this is not possible with pronuclear microinjection. Given the fact 
that even the best designs of targeting transgene undergo random integration more 
frequently than targeted integration, the only foreseeable way to achieve high
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efficiency gene targeting with pronuclear microinjection would be to stimulate 
homologous recombination (HR) by co-injecting appropriate recombinase enzymes 
with the transgene. However, elucidation of such enzymes is at an early stage, and it 
remains to be seem whether this approach could ever provide the quantum leap 
improvements in targeting efficiency that would be required in the case of human 
germline gene therapy.
Random integration also raises the concern that an endogenous gene will be damaged 
by transgene insertion. The degree of risk for any one insertion event must 
approximate to the proportion of coding sequences (plus controlling elements) within 
the human genome, a figure of no more than 2%. Thus, endogenous gene damage 
may be expected to occur in around 1 in every 50 human zygotes integrating 
transgene DNA. In embryos sustaining such damage, there are several possible 
outcomes: (a) where a developmentally crucial gene is damaged, the result is likely to 
be embryo death, and the subsequent non-appearance of a genetically modified 
individual; (b) where one allele of an important gene is affected, haplosufficiency 
may permit the development of a normal or near-normal genetically modified 
individual; (c) where a non-essential gene is affected (such as an allele for hair colour, 
or a repeated gene), the resulting genetically modified individual may contain a 
phenotypic change that has no health implications; or (d) where an important gene is 
affected, debility is likely to occur in the resulting genetically modified individual. 
Outcomes (a-c), while not desirable, would not necessarily be highly problematic, and 
the occurrence of these outcomes means that the undesirable outcome (d) would occur 
at a frequency significantly lower than 1 in 50 genetically modified individuals. 
Nevertheless, such magnitude of risk implies that pronuclear microinjection in its 
present stage of development is not acceptable as a means to human germline gene 
therapy.
4.3.2 Retroviral Transfer
Retroviral transfer rem ains an alternative to pronuclear m icroinjection  in  the context
o f  human germ line gene therapy. Traditional R W s  w ou ld  b e o f  m inim al potential
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use, due to the high levels of mosaicism associated with these vectors. However, the 
new generation of lentiviral vectors would avoid such problems (Ikawa et al. 2003; 
Lois et al. 2002; Pfeifer et al. 2002). These vectors have the additional advantage of 
high gene transfer rates (70-80% of animals bom are transgenic). Accordingly, 
lentiviral vectors represent plausible candidates for human germline gene therapy. 
However, the small insert capacity (9-10 kb) would preclude the transfer of many 
human genes. Additionally, control possibilities are less with R W  delivered 
transgenes compared with transgenes delivered by microinjection.
The safety problems associated with R W s (insertional oncogenesis, viral 
reactivation) would also be a major concern (Cometta et al. 1991; Gunter et al. 1993; 
Temin 1990). In principle, judicious genetic alteration of the lentivims genome would 
ensure that the resultant vector would have a very high level of safety. However, 
given the critical context of human germline gene therapy, one would have to 
question whether our basic scientific understanding of retroviruses is sufficiently 
advanced to empower rational vector design. Somatic gene therapy provides a 
salutary lesson here. Human trials involving several hundred patients have been 
carried out for over a decade using R W s. Despite the theoretical risks referred to 
above, a lack of reports of serious adverse affects has resulted in a growing 
acceptance of the practical safety of RW s. However, it has been recently reported 
that two patients (both young children) being treated for X-linked severe combined 
immunodeficiency disease (SCID-X) using RW -based vectors have developed 
leukaemia. In both patients, R W  had integrated into a gene (LM02) known to cause 
leukaemia if activated inappropriately. It is not known why the same endogenous 
gene had been targeted by the R W  concerned. The full cause of leukaemia in these 
patients is still under investigation, however the fact that both patients share the same 
integration site, coupled with the fact that the patients were both from the same (10- 
patient) trial, strongly implicates the particular R W s employed in this trial (Buckley 
2002; Gansbacher et al. 2003; Kaiser 2003). Indeed, clinical trials involving this 
particular RW-based therapy have been halted pending further investigations and 
pre-clinical trials (Fox 2003). It is to be hoped that enhanced R W  design will prevent 
any recurrence of iatrogenic leukaemia or similar serious adverse affects in somatic 
gene therapy. However, the occurrence of such adverse R W  effects lends weight to 
the argument that more basic virology is needed before any potential human germline
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gene therapy RVV could be deemed sufficiently safe. At the very least, extensive in 
vitro (cell culture) and in vivo (mammalian transgenesis) experimentation would be 
required in order to establish the safety of any proposed R W  (lentiviral-based or 
otherwise) for human germline gene therapy.
4.4 Microinjection of Retroviral Vector
As discussed previously (Section 2.1.8), a combination of microinjection with 
retroviral vectors has been the only approach that has permitted the generation of 
transgenic primates thus far.
Given the success with primates of microinjection of R W  into oocytes, this approach 
is likely to be effective for human germline gene therapy. The drawbacks would be 
similar to those associated with (a) microinjection (i.e. embryo loss) and (b) R W s 
(i.e. transgene size limitations, problems with control of expression, safety risks). The 
process would also be laborious, but it would be expected to avoid the problems of 
mosaicism associated with most R W s. Additionally, this form of gene transfer might 
require fewer eggs than required for pronuclear microinjection. The reported overall 
rate of transgenesis with rhesus monkeys was 1.3%; although this compares 
unfavourably with murine efficiencies (up to ca. 6% transgenic), it is significantly 
better than the rates achieved for animals such as sheep, cows and pigs. Moreover, 
this ‘combined’ technique is in its infancy, and its efficiency may well improve with 
use.
4.5 Sperm-mediated Gene Transfer
The fundamental principles of sperm-mediated gene transfer (SMGT) were discussed 
in Section 2.1.7. If SMGT does indeed work as reported by some researchers, or if it 
can be made to work, then this would have very profound implications for human 
germline gene therapy. Gene transfer into embryos (using pronuclear microinjection 
or R W s) is inherently very costly and technically demanding, due in large part to the
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need to remove embryos from the female, to manipulate the embryos and finally to 
return the embryos to the reproductive tract. By contrast, SMGT coupled with AI 
would permit germline GM with minimum levels of expense and expertise, as would 
SMGT coupled with testicular injections. Thus, SMGT would in principle permit the 
widespread use of human germline gene therapy: relatively poor countries would be 
able to use the technique, and highly centralised facilities would not be required. Of 
course, such easily available human germline gene therapy would raise serious ethical 
concerns.
However, even if SMGT were to prove effective as a means to gene transfer, it would 
be fundamentally limited in the context of human germline gene therapy due to its 
unsuitability as a means of gene targeting. This limitation is of course shared with the 
embryo-based gene transfer methods considered above. However, there are at least 
some glimmers of hope for future gene targeting possibilities in the case of embryo- 
based approaches: some (albeit very limited) success has been achieved with targeting 
R W s (Ellis and Bernstein 1989), and the low natural rate of HR in zygotes might 
conceivably be increased if appropriate recombinase enzymes were to be discovered 
and co-injected (Smith 2001). By contrast, there have been no reports of gene 
targeting using SMGT, and it is difficult to envisage even in outline how this might 
ever be achieved.
4.6 Episomal Possibilities
As discussed previously, various extrachromosomal plasmid vectors (episomes) have 
been used as transgenes (Section 2.2.3). In the context of human germline gene 
therapy, such vectors offer the potential advantage of eliminating the threat to genome 
integrity associated with uncontrolled genomic integration. However, the previously- 
mentioned issues of plasmid instability observed in transgenic animals (i.e. fluctuating 
copy numbers, plasmid loss, abnormal inheritance) represent a major problem. Of 
similar concern are the health problems (such as tumour formation) that have been 
associated with some episomal vectors. Of course, the behaviour of an episome must 
relate in large part to its genetic constitution, and therefore stability problems and
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safety limitations may in principle be surmounted by improved plasmid design. 
However, until such improvements are realised, episomal plasmid vectors could not 
be considered for human germline gene therapy.
Autonomous artificial mammalian artificial chromosomes (MACs) have been 
constructed and successfully used to create transgenic animals in which the MACs are 
maintained autonomously (Section 2.2.3). In the context of human germline gene 
therapy, these specialised constructs would be expected to give a number of benefits 
compared with integrated transgenes, including higher and more controllable 
expression. More speculatively, MACs may be able to function as genetic ‘platforms’ 
for the safe subsequent receipt of incoming transgenes. Although this technology is in 
its infancy, MACs would appear to hold significant future potential for human 
germline gene therapy (Choo 2001; Co et al. 2000; Grimes et al. 2002; Hadlaczky 
2001; Lipps et al. 2003).
4.7 Totipotent Cells
At present, gene targeting requires the use of in vitro selection in order to enrich for 
rare targeted cells amongst a majority of random integration cells. In vitro selection 
cannot be conducted on embryos or sperm cells. Consequently, gene targeting in the 
context of human germline gene therapy would require gene transfer to be carried out 
with some form of dividing cells in vitro.
4.7.1 Embryonic Stem Cells
As previously discussed, embryonic stem cells (ESCs) can be used to produce gene 
targeted transgenic mice (Section 3.1.2). In 1998, Thomson et al. isolated ESCs from 
human blastocysts (Thomson et al. 1998). Subsequently many other researchers have 
also isolated human ESCs (Amit et al. 2004; Conley et al. 2004; Park et al. 2003; 
Reubinoff et al. 2000), and a new field in biology has resulted. Furthermore, gene 
targeting has been achieved in human ESCs (Zwaka and Thomson 2003). However,
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totipotency has not been demonstrated in any human ESC line. Unfortunately, this 
may prove to be a rather intractable situation: proof of totipotency could only (given 
current technology) come from the establishment of a chimeric human being. It is 
manifest that the necessary experiments required to pursue this goal would be 
ethically unacceptable. Thus, the ESC route presently remains firmly closed against 
human germline gene therapy.
4.7.2 Nuclear Transfer Possibilities
As discussed previously (Section 3.1.3), transgenes can be introduced to somatic 
donor cells in vitro, permitting targeted germline genetic modifications in transgenic 
animals following nuclear transfer (NT). Accordingly, it seems probable that the 
technique could in principle be readily applied to humans as a means to achieving 
germline modifications.
However, the previously mentioned low efficiencies obtained using NT with animal 
systems would, presuming reconstructed human embryos to behave similarly, 
represent a potential problem for human NT-based germline gene therapy. Although 
embryo pre-selection could be used to ensure that only transgene-containing embryos 
were allowed to gestate, the problem would remain that a large number of valuable 
donor eggs would be required for each GM attempt.
The poor health status of first generation NT-derived animals (Section 3.1.3) 
represents a critical problem for human NT-based germline gene therapy. Until such 
time as the health problems are solved, NT appears to be too dangerous to consider 
for human germline gene therapy. This is unfortunate, because without NT (or human 
ESCs) the in vitro selection required for germline gene targeting cannot be conducted. 
Thus, germline GM in humans would be restricted to ‘add-in’ alterations; gene 
knockout and gene repair germline alterations in humans are not a practical 
proposition with the technology available at present.
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4.7.3 Non-selective Gene Targeting Possibilities
As discussed in Section 3.1.4, unusually high levels of gene targeting have been 
reported following the use of (a) isogenic transgenes and (b) adeno-associated virus 
(AAV) vectors. These reports suggest that in ESCs and in certain somatic cells the 
efficiency of gene targeting can be sufficient to bypass the need for selection. 
Selection-based gene targeting places limits on transgene design, due to the need to 
engineer the requisite selective elements into the transgene. Therefore, the ability to 
conduct gene targeting in somatic cells without the need for selection would be a 
welcome addition to the armamentarium of gene transfer technologies that may in 
future permit human germline gene therapy.
4.8 Conclusions
It is probable that the human germline could be readily manipulated using current 
transgenic techniques. To achieve this, pronuclear microinjection would probably be 
effective, as would retroviral transfer, particularly using lentivirus-based vectors. A 
combination of microinjection and RVVs would probably be most effective -  indeed 
such a combination has recently given rise to the first transgenic primates. SMGT 
may be effective also, at least in some forms of the approach, such as transgenICSI. 
However, Al-based SMGT is not yet an established method of transgenesis, therefore 
the prospects for this potentially very important form of gene transfer are less certain. 
Totipotent human ESCs have not been established for humans, thus ESC-based gene 
transfer remains -  despite its effectiveness in mice -  unavailable for human germline 
gene therapy. The lack of human ESCs leaves NT-based gene transfer as the only 
method that might be able to permit gene targeting in human germline gene therapy. 
NT could probably be readily applied to humans; however, the high level of health 
problems observed in first generation NT-derived animals render the approach in its 
present form unfeasible for human germline gene therapy. Table 1 summarises the 
key features of the major candidate methods that might serve to achieve human 
germline gene therapy.
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If human gene transfer technology is limited to adding-in gene functions via non- 
targeted transgene integration, and if the process needs be performed on individual 
embryos isolated from the reproductive tract, it is likely that human germline gene 
therapy will remain insufficiently safe, excessively inefficient and of inadequate 
clinical value to permit its use. The widespread availability and applicability of safe 
and effective human germline gene therapy would require the development of gene 
transfer methods that would (a) permit gene targeting while (b) avoiding the need for 
ex vivo embryo isolation and manipulation. Unfortunately, at present these two 
requirements are mutually exclusive. Laborious manipulations involving large 
numbers of embryos would in principle best be avoided by the use of SMGT, either in 
vivo or ex vivo. However, high-efficiency gene targeting is not available at present 
without the use of in vitro selection. Thus, the widespread use of human germline 
gene therapy does not appear likely to flow from incremental improvements in current 
GM methods. Rather, widespread human germline gene therapy would appear to be a 
future possibility that must await substantial scientific advancement. Naturally, it is 
impossible to predict when such improvements might be forthcoming.
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Chapter 5: Potential 




For any human germline therapy application to be sanctioned, it ought to offer 
considerable benefits to humans. In respect of therapeutic benefits for living patients, 
germline approaches could of course offer no hope. Rather, only (unborn) offspring 
could hope to benefit. For such individuals, hereditary genetic diseases would be the 
main candidates for treatment: disorders such as infectious diseases or most cancers 
affect people in largely unpredictable, non-genetic ways.
5.2 Germline vs. Somatic Approaches
Two distinct approaches are possible when attempting to genetically alter somatic 
cells. One approach involves the removal of cells from the patient's body; the cells are 
then genetically manipulated and subsequently returned to the patient's body. The 
other approach involves the manipulation of cells where they reside naturally in the 
patient's body. These two approaches are termed ex vivo and in vivo therapies, 
respectively. For both ex vivo or in vivo approaches, and regardless of the cell type 
involved, the central feature of all somatic gene therapies is the need to successfully 
deliver therapeutic genetic material to the target cells.
Both ex vivo and in vivo somatic gene therapies are under investigation and have been 
attempted in respect of a wide range of conditions. To date only a handful of patients 
have shown clear clinical improvements attributable to gene therapy. However, some 
promising results have recently been obtained.
Severe combined immunodeficiency disease (SCID) provides a prime example of 
successful somatic gene therapy. Children who inherit two defective alleles for 
adenosine deaminase (ADA) develop this disorder. Similarly, male children who 
inherit a single defective copy of an X-linked interleukin receptor subunit (yC) gene 
develop severe combined immunodeficiency disease (SCID-X). Several clinical trials 
of gene therapy for both ADA-SCID and SCID-X have been conducted, using ex vivo
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a p p r o a c h e s .  T h e  g e n e r a l  a p p r o a c h  h a s  b e e n  t o  i n f e c t  p e r i p h e r a l  b l o o d  l y m p h o c y t e s  o r  
b o n e  m a r r o w  s t e m  c e l l s  in v itro  w i t h  r e t r o v i r u s e s  e n g i n e e r e d  t o  c o n t a i n  t h e  r e q u i r e d  
g e n e  ( A D A  o r  y C ) ,  t h e  g e n e t i c a l l y  m a n i p u l a t e d  c e l l s  t h e n  b e i n g  t r a n s p l a n t e d  t o  
p a t i e n t s .  R e s u l t s  f r o m  t h e  A D A - S C I D  t r i a l s  d e m o n s t r a t e  t h a t  s o m e  o f  t h e  t r e a t e d  
c h i l d r e n  p r o d u c e  A D A ,  w i t h  t h e  c l i n i c a l  c o n d i t i o n  o f  t h e s e  c h i l d r e n  b e i n g  m a r k e d l y  
i m p r o v e d .  S o m e  c a u t i o n  i s  r e q u i r e d  w h e n  in t e r p r e t i n g  t h e  c l i n i c a l  im p r o v e m e n t s  
b e c a u s e  s o m e  o f  t h e  p a t i e n t s  a l s o  r e c e i v e d  A D A  p r o t e i n  a s  a  t r e a t m e n t .  R e s u l t s  f r o m  
r e c e n t  S C I D - X  t r i a l s  h a v e  b e e n  e s p e c i a l l y  p r o m i s i n g :  T - c e l l ,  B - c e l l  a n d  N K  c e l l  
c o u n t s  h a v e  b e e n  r e s t o r e d  i n  s e v e r a l  p a t i e n t s ,  t o  t h e  e x t e n t  t h a t  t h e  d i s o r d e r  h a s  
a p p a r e n t l y  b e e n  c o m p l e t e  c u r e d  ( A i u t i  e t  a l .  2 0 0 2 ;  C a v a z z a n a - C a l v o  e t  a l .  2 0 0 0 ;  
C a v a z z a n a - C a l v o  e t  a l .  2 0 0 1 ;  H o o g e r b r u g g e  e t  a l .  1 9 9 8 ;  O t s u  a n d  C a n d o t t i  2 0 0 2 ) .  
H o w e v e r ,  i t  i s  s a l u t a r y  t o  n o t e  t h a t  t w o  p a t i e n t s  h a v e  d e v e l o p e d  l e u k a e m i a  f o l l o w i n g  
R W - b a s e d  g e n e  t h e r a p y  f o r  S C I D - X .
M a n y  o t h e r  r e c e s s i v e  s i n g l e  g e n e  d i s o r d e r s  a r e  c u r r e n t l y  u n d e r  i n t e n s i v e  i n v e s t i g a t i o n  
f o r  g e n e  t h e r a p y .  P r o m i s i n g  p r e l i m i n a r y  r e s u l t s  h a v e  b e e n  o b t a i n e d  i n  r e s p e c t  o f  
s e v e r a l  d i s o r d e r s  i n c l u d i n g  D u c h e n n e  m u s c u l a r  d y s t r o p h y  ( C h a m b e r l a i n  2 0 0 2 ) ,  
e m p h y s e m a  ( S t e c e n k o  a n d  B r i g h a m  2 0 0 3 ) ,  p h e n y l k e t o n u r i a  ( E i s e n s m i t h  e t  a l .  1 9 9 9 ) ,  
r e t i n i t i s  p i g m e n t o s a  ( D e j n e k a  a n d  B e n n e t t  2 0 0 1 ) ,  a n d  s i c k l e  c e l l  a n a e m i a  ( P a w l i u k  e t  
a l .  2 0 0 1 ) .  A l t h o u g h  c l i n i c a l  s u c c e s s  to  d a t e  h a s  b e e n  l i m i t e d ,  g e n e  t h e r a p y  i s  c e r t a i n l y  
i n  it s  i n f a n c y :  a  l a c k  o f  s p e c t a c u l a r  r e s u l t s  a t  s o  e a r l y  a  s t a g e  s h o u l d  n o t  b e  t a k e n  t o  
i n d i c a t e  t h a t  g e n e  t h e r a p y  w i l l  n o t  b e c o m e  h i g h l y  e f f i c a c i o u s  g i v e n  t i m e .  S i n g l e  g e n e  
r e c e s s i v e  d i s o r d e r s  r e m a i n  g o o d  c a n d i d a t e s  f o r  t h e  d e v e l o p m e n t  o f  g e n e  t h e r a p y  
s t r a t e g ie s  a n d ,  g i v e n  t h a t  a  g r e a t  d e a l  o f  p r e l i m i n a r y  w o r k  h a s  a l r e a d y  b e e n  c a r r i e d  o u t  
w i t h  t h i s  c l a s s  o f  d i s o r d e r s ,  i t  s e e m s  r e a s o n a b l e  t o  e x p e c t  p r o g r e s s  i n  t h i s  a r e a  b e f o r e  
o t h e r s .  N e v e r t h e l e s s ,  s o m a t i c  g e n e  t h e r a p y  h a s  a l s o  b e e n  p r o p o s e d  f o r  d o m i n a n t  a n d  
p o l y g e n i c  d is o r d e r s .
S o m a t i c  g e n e  t h e r a p y  a l s o  h o l d s  p r o m i s e  f o r  n o n - i n h e r i t e d  c o n d i t i o n s ,  s u c h  a s  c a n c e r .  
A  m u l t i t u d e  o f  in v ivo  a n d  ex v ivo  a n t i c a n c e r  t h e r a p i e s  a r e  c u r r e n t l y  u n d e r  
d e v e l o p m e n t  ( H e o  2 0 0 2 ;  M c C o r m i c k  2 0 0 1 ;  W a d h w a  e t  a l .  2 0 0 2 ) .  I n d e e d ,  t h e  
m a j o r i t y  o f  a l l  h u m a n  g e n e  t r i a l s  t o  d a t e  h a v e  b e e n  a i m e d  a t  t h e  t r e a t m e n t  o f  c a n c e r .  
T h e  f i e l d  i s  r a p i d l y  a d v a n c i n g  a n d  e c l e c t i c ,  a n d  p r o g r e s s  i s  l i k e l y  t o  a c c e l e r a t e  a s
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b a s i c  k n o w l e d g e  o f  c a n c e r  b i o l o g y  i n c r e a s e s .  O t h e r  d i s e a s e  c a t e g o r i e s  t h a t  m a y  i n  
p r i n c i p l e  b e  t r e a t a b l e  b y  s o m a t i c  g e n e  t h e r a p y  i n c l u d e  i n f e c t i o u s  d is e a s e s  ( B u n n e l l  
a n d  M o r g a n  1 9 9 8 ;  M a u t i n o  a n d  M o r g a n  2 0 0 2 ;  S t a t h a m  a n d  M o r g a n  1 9 9 9 ) ,  
a u t o i m m u n e  d i s o r d e r s  ( F a t h m a n  2 0 0 2 ;  T a m e r  a n d  F a t h m a n  2 0 0 2 ) ,  a n d  e v e n  t r a u m a  
( i n j u r y )  ( B l i t s  e t  a l .  2 0 0 2 ;  P a l m e r  e t  a l .  2 0 0 2 ;  Y a n g  e t  a l .  1 9 9 7 ) .  I n d e e d  it  i s  d i f f i c u l t  
t o  n a m e  c a t e g o r i e s  o f  d i s e a s e  t h a t  c o u l d  n o t  i n  p r i n c i p l e  b e  s e e n  a s  p o t e n t i a l l y  
t r e a t a b l e  b y  s o m a t i c  g e n e  t h e r a p y ,  s u c h  i s  it s  p o t e n t i a l  p o w e r .
T h u s ,  a l t h o u g h  i n  i t s  i n f a n c y ,  s o m a t i c  g e n e  t h e r a p y  h o l d s  g r e a t  p r o m i s e  f o r  t r e a t i n g  
d i s e a s e .  G i v e n  it s  p o t e n t i a l  p o w e r ,  i t  i s  t e m p t i n g  t o  t a k e  t h e  v i e w  t h a t  s o m a t i c  g e n e  
t h e r a p y  r e n d e r s  it s  g e r m l i n e  e q u i v a l e n t  s u p e r f l u o u s .  H o w e v e r ,  g e r m l i n e  g e n e  t h e r a p y  
h a s  s e v e r a l  i n t r i n s i c  a d v a n t a g e s  o v e r  it s  s o m a t i c  c o u n t e r p a r t .
A  m a j o r  p o t e n t i a l  a d v a n t a g e  o f  g e r m l i n e  t h e r a p y  i s  t h e  p e r m a n e n t  n a t u r e  o f  t h e  
g e n e t ic  a lt e r a t io n .  I n  m a n y  d i s o r d e r s ,  t r a n s g e n e - c o n t a i n i n g  c e l l s  w o u l d  g r a d u a l l y  b e  
r e p l a c e d  b y  n o n - t r a n s g e n i c  c e l l s .  T h i s  p r o b l e m  w o u l d  a p p l y  t o  a l l  d i s o r d e r s  e x c e p t  
t h o s e  i n v o l v i n g  q u i e s c e n t  c e l l s  -  s o m e  C N S  d i s o r d e r s  m i g h t  f i t  in t o  t h i s  c a t e g o r y .  
T h i s  p r o b l e m  c o u l d  o n l y  b e  a v o i d e d  i f  s t e m  c e l l s  f o r  t h e  a f f e c t e d  t i s s u e s  w e r e  
g e n e t i c a l l y  a lt e r e d .  T h i s  i s  p r o b l e m a t i c  f o r  in v ivo  a p p r o a c h e s  b e c a u s e ,  a s  a  m l e ,  s t e m  
c e l l s  t e n d  t o  r e s i d e  d e e p l y  w i t h i n  t is s u e s  a n d  a r e  t h e r e f o r e  l e s s  a c c e s s i b l e  t o  t r a n s g e n e  
v e c t o r s  i n  c o m p a r i s o n  w i t h  t h e i r  ( f u n c t i o n a l )  d a u g h t e r  c e l l s .  E x v ivo  s o m a t i c  g e n e  
t h e r a p y  m a y  b e  u s e d  i n  s o m e  c a s e s ,  s u c h  a s  h a e m a t o l o g i c a l  d i s o r d e r s  i n  w h i c h  
p l u r i p o t e n t  c l o n o g e n i c  s t e m  c e l l s  m a y  b e  s u b j e c t  t o  ex v ivo  m a n i p u l a t i o n  f o r  
s u b s e q u e n t  r e t u r n  t o  t h e  b o d y  t o  r e c o l o n i s e  t h e  b o n e  m a r r o w .  H o w e v e r ,  i t  w o u l d  b e  
i m p l a u s i b l e  t o  s u p p o s e  t h a t  a l l  t y p e s  o f  s t e m  c e l l s  c o u l d  b e  t r e a t e d  i n  t h i s  w a y .  
M o r e o v e r ,  m a n y  o f  t h e  in v ivo  g e n e  t r a n s f e r  m e t h o d s  a p p l i c a b l e  f o r  s o m a t i c  g e n e  
t h e r a p y  r e s u l t  i n  a  n o n - p e r m a n e n t  p r e s e n c e  o f  t h e  t r a n s g e n e  i n  m o s t  o r  a l l  o f  t h e  c e l l s  
t r e a t e d . S u c h  m e t h o d s  i n c l u d e  m o s t  v i r a l  v e c t o r s  ( w i t h  t h e  n o t a b l e  e x c e p t i o n  o f  
R W s ) ,  l i p o s o m e s  a n d  e le c t r o p o r a t io n .  O f  c o u r s e ,  r e p e a t e d  a p p l i c a t i o n  o f  a  s o m a t i c  
g e n e  t h e r a p y  m a y  n o t  b e  a  m a j o r  p r o b l e m .  F o r  e x a m p l e ,  i n  t h e  c a s e  o f  l u n g  d i s o r d e r s  
s u c h  a s  c y s t i c  f i b r o s i s  ( C F )  o r  e m p h y s e m a ,  i n t e n s i v e  r e s e a r c h  i s  u n d e r w a y  t o  d e v e l o p  
g e n e  d e l i v e r y  s y s t e m s  b a s e d  o n  i n h a l i n g  v i r a l  v e c t o r s  o r  l i p o s o m e s .  I f  s u c h  s y s t e m s  
p r o v e  e f f e c t i v e ,  t h e n  i t  i s  u n p r o b l e m a t i c  t o  c o u n t e n a n c e  r e p e a t e d  u s e  o f  i n h a l a t i o n -  
b a s e d  s o m a t i c  g e n e  t h e r a p y  b y  i n d i v i d u a l  p a t i e n t s ,  c o n s i d e r i n g  t h a t  i n h a l e r s  a r e
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i n t r i n s i c a l l y  n o n - i n v a s i v e  a n d  a r e  i n  c o m m o n  u s e  t o  d e l i v e r  c o n v e n t i o n a l  d r u g s .  
H o w e v e r ,  l e s s  a c c e s s i b l e  o r g a n s  o r  t i s s u e s  w o u l d  r e q u i r e  m o r e  i n v a s i v e  p r o c e d u r e s  
f o r  r e - d e l i v e r y  o f  t r a n s g e n e s .  G e r m l i n e  g e n e  t h e r a p y  s h o u l d  a v o i d  a l l  p r o b l e m s  o f  
n o n - p e r m a n e n c e ,  r e g a r d l e s s  o f  t h e  o r i g i n  o f  t h e  p r o b l e m  ( i . e .  t r a n s g e n e  l o s s  t h r o u g h  
c e l l  r e p l a c e m e n t  o r  t r a n s i e n t  t r a n s f e c t i o n ) .
A s  i n d i c a t e d  p r e v i o u s l y ,  ex v ivo  G M  a p p e a r s  t o  b e  t h e  m o s t  p r o m i s i n g  s o m a t i c  g e n e  
t h e r a p y  a p p r o a c h ,  g i v e n  p r e s e n t l y  a v a i l a b l e  g e n e  d e l i v e r y  t e c h n o l o g y .  H o w e v e r ,  
m a n y  c e l l s  i n  t h e  b o d y  a r e  n o n - r e m o v a b l e ,  o r  a r e  n o n - d i v i d i n g  ( o r  a t  l e a s t  n o n -  
c l o n o g e n i c ) .  E x v ivo  a p p r o a c h e s  a r e  n o t  a p p l i c a b l e  t o  d i s e a s e s  i n v o l v i n g  s u c h  c e l l s .  
T h u s ,  f o r  s e v e r a l  d i s o r d e r s  p o t e n t i a l l y  a m e n a b l e  t o  s o m a t i c  g e n e  t h e r a p y ,  g e n e  
t r a n s f e r  w o u l d  h a v e  t o  b e  o f  t h e  l e s s  e f f e c t i v e  in v ivo  v a r i e t y .  I n d e e d  t h e  r a n g e  o f  
d i s o r d e r s  n o t  s u i t a b l e  f o r  ex v ivo  g e n e  t r a n s f e r  i s  v e r y  b r o a d ,  a n d  i n c l u d e s  d i s o r d e r s  o f  
t h e  m u s c u l a r  s y s t e m  ( e .g .  D u c h e n n e  m u s c u l a r  d y s t r o p h y  ( D M D ) ) ,  t h e  r e s p i r a t o r y  
s y s t e m  ( e .g .  C F )  a n d  t h e  b r a i n  ( e .g .  L e s c h - N y h a n  s y n d r o m e ) .  I n  s u c h  c a s e s ,  e x c e p t  
w h e r e  in v ivo  s o m a t i c  g e n e  t h e r a p y  ( a n d  c o n v e n t i o n a l  m e d i c a l  a p p r o a c h e s )  p r o v e s  
e f f e c t i v e ,  a  g e r m l i n e  g e n e  t h e r a p y  m i g h t  b e  t h e  b e s t  o r  o n l y  o p t io n .
I n  m a n y  d i s o r d e r s ,  m o r e  t h a n  o n e  p a r t  o f  t h e  b o d y  i s  a f f e c t e d .  F o r  e x a m p l e ,  i n  D M D  
t h e  e n t i r e  s k e l e t a l  m u s c u l a r  s y s t e m  is  a f f e c t e d .  M o r e o v e r ,  i n  s o m e  d i s o r d e r s  d i s p a r a t e  
t i s s u e  o r  o r g a n  t y p e s  a r e  a f f e c t e d .  F o r  e x a m p l e ,  i n  C F  t h e  g a s t r o i n t e s t i n a l  t r a c t  ( G I T )  
i s  a f f e c t e d  ( o f t e n  s e v e r e l y )  i n  a d d i t i o n  t o  t h e  r e s p i r a t o r y  s y s t e m .  T h u s ,  c u r i n g  s u c h  
d i s o r d e r s  b y  s o m a t i c  g e n e  t h e r a p y  w o u l d  r e q u i r e  t r a n s g e n e s  t o  b e  d e l i v e r e d  t o  a  l a r g e  
n u m b e r  o f  s i t e s  i n  t h e  b o d y ,  w i t h  s u c h  s i t e s  o f t e n  c o m p r i s i n g  d if f e r e n t  c e l l  t y p e s .  T h i s  
p r e s e n t s  f o r m i d a b l e  p r o b l e m s  i n  t e r m s  o f  i n v a s i v e n e s s  a n d  v e c t o r  d e s i g n .  B y  c o n t r a s t ,  
g e r m l i n e  g e n e  t h e r a p y  h a s  t h e  p o t e n t i a l  t o  p l a c e  t r a n s g e n e s  i n  c e l l s  t h r o u g h o u t  t h e  
b o d y ,  a n d  b y  o n l y  o n e  g e n e  t r a n s f e r  o p e r a t io n .  T h u s ,  g e r m l i n e  g e n e  t h e r a p y  m a y  b e  
t h e  b e s t  o r  o n l y  o p t io n  f o r  d i s o r d e r s  i n  w h i c h  m a n y  b o d y  s i t e s  r e q u i r e  t r e a t m e n t .
M a n y  o f  t h e  s e r i o u s  g e n e t ic  c o n d i t i o n s  p o t e n t i a l l y  a m e n a b l e  t o  s o m a t i c  g e n e  t h e r a p y  
o f t e n  k i l l  o r  s e r i o u s l y  d a m a g e  p a t ie n t s  i n  t h e i r  f i r s t  m o n t h s  o r  y e a r s  o f  l i f e .  I n d e e d ,  a s  
a  g e n e r a l i s a t i o n ,  c o n c e p t u a l l y  t h e r e  e x i s t s  a n  i n v e r s e  c o r r e l a t i o n  b e t w e e n  t h e  a g e  o f  
t h e  p a t i e n t  a n d  t h e  p r o b a b l e  e f f e c t i v e n e s s  o f  g e n e  t h e r a p y .  A c c o r d i n g l y ,  t h e  f o e t u s  i s  
o f t e n  v i e w e d  a s  a n  i d e a l  d e v e l o p m e n t a l  s t a g e  f o r  s o m a t i c  g e n e  t h e r a p y .  I n  a d d i t i o n  t o
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p e r m i t t i n g  t r e a t m e n t  p r i o r  t o  i r r e v e r s i b l e  d i s o r d e r - i n d u c e d  d a m a g e ,  f o e t a l  s o m a t i c  
g e n e  t h e r a p y  h a s  a  n u m b e r  o f  p o t e n t i a l  a d v a n t a g e s  c o m p a r e d  w i t h  l a t e r -s t a g e  
a p p r o a c h e s  ( C o u t e l l e  a n d  R o d e c k  2 0 0 2 ;  K a p l i t t  e t  a l .  1 9 9 8 ) .  T h e s e  a d v a n t a g e s  
i n c l u d e :  ( a )  b e t t e r  t r a n s g e n e  u p t a k e  e f f i c i e n c i e s  d u e  t o  t h e  h i g h  p e r c e n t a g e  o f  r a p i d l y  
d i v i d i n g  c e l l s  p o p u l a t i n g  t h e  f o e t u s  ( a s  d i s c u s s e d  p r e v i o u s l y ,  s o m e  g e n e  t r a n s f e r  
a p p r o a c h e s  d o  n o t  f u n c t i o n  w e l l  w i t h  n o n - d i v i d i n g  c e l l s ) ;  ( b )  t h e  p o s s i b i l i t y  o f  
g e n e r a t in g  w h o l e - t i s s u e / o r g a n  a lt e r a t io n s  b y  g e n e t i c a l l y  a l t e r i n g  a  s m a l l  n u m b e r  o f  
a p p r o p r ia t e  c l o n o g e n i c  c e l l s  ( s u c h  c e l l - t y p e s  a r e  a  f e a t u r e  o f  e a r l y  f o e t a l  
d e v e l o p m e n t ) ;  a n d  ( c )  t h e  a v o i d a n c e  o f  a n  i m m u n e  r e s p o n s e  a g a i n s t  t r a n s g e n e  v e c t o r s  
d u e  t o  t h e  p r e i m m u n e  s t a t u s  o f  t h e  e a r l y  f o e t u s .  T h u s ,  g i v e n  t h e  s c i e n t i f i c  a d v a n t a g e s  
a s s o c i a t e d  w i t h  t h e  f o e t u s ,  s o m a t i c  g e n e  t h e r a p y  m a y  w e l l  c o m e  t o  b e  f r e q u e n t l y  
t a r g e t e d  a t  t h e  u n b o r n  c h i l d .  I n  f o e t a l  g e n e  t h e r a p y  t h e r e  c a n  o b v i o u s l y  b e  n o  c o n s e n t  
f r o m  t h e  ‘ p a t i e n t ’ a f f e c t e d  ( b e n e f i c i a l l y  o r  d e t r i m e n t a l l y )  f r o m  t h e  t r e a t m e n t .  
H o w e v e r ,  f o e t a l  g e n e  t h e r a p y  i s  f a r  l e s s  d e v e l o p e d  t h a n  o t h e r  f o r m s  o f  s o m a t i c  g e n e  
t h e r a p y .  T h u s ,  t h e  e f f i c a c y  o f  f o e t a l  s t a g e  i n t e r v e n t i o n  r e m a i n s  t o  b e  e s t a b l i s h e d .  
W o r s e ,  g i v e n  t h e  s e n s i t i v e  s t a g e  o f  d e v e l o p m e n t  i n v o l v e d ,  t h e  r i s k  o f  i a t r o g e n i c  
d a m a g e  ( p o s s i b l y  i n c l u d i n g  a n  e n h a n c e d  r i s k  o f  i n a d v e r t e n t l y  t r a n s f e c t i n g  g e r m l i n e  
t i s s u e s )  i s  i n t r i n s i c a l l y  g r e a t e r  t h a n  t h e  r i s k  a t t a c h e d  t o  t r e a t i n g  c h i l d r e n  o r  a d u l t s .  
C o n s e q u e n t l y ,  g e r m l i n e  g e n e  t h e r a p y  m a y  b e  p r e f e r a b l e  o v e r  f o e t a l  s o m a t i c  g e n e  
t h e r a p y  a s  a  m e a n s  o f  e a r l y  i n t e r v e n t i o n  i n  d i s o r d e r s  i n v o l v i n g  d e v e l o p m e n t a l  
d a m a g e .
I f  b o t h  s o m a t i c  a n d  g e r m l i n e  a p p r o a c h e s  w e r e  e q u a l l y  a b l e  t o  c u r e  ( o r  a v o i d  a  p a t i e n t  
d e v e l o p i n g )  a  g i v e n  d i s e a s e ,  t h e n  t h e  l a t t e r  a p p r o a c h  m a y  b e  p r e f e r a b l e ,  b e c a u s e  a  
g e r m l i n e  c o r r e c t i o n  w o u l d  p r e v e n t  i n h e r i t a n c e  o f  t h e  h i t h e r t o  d a m a g e d  o r  m i s s i n g  
g e n e .  T h u s ,  t h e  o f f s p r i n g  o f  t h e  g e r m l i n e  g e n e  t h e r a p y  ‘ p a t i e n t ’ w o u l d  h a v e  a  g r e a t l y  
r e d u c e d  r i s k  o f  d e v e l o p i n g  t h e  d is o r d e r .  ( F o l l o w i n g  g e r m l i n e  g e n e  t h e r a p y ,  t h e  
r e s u l t a n t  ‘ p a t i e n t ’ w o u l d  e it h e r  b e  ( a )  f r e e  f r o m  t h e  d i s e a s e  g e n e  o r  ( b )  h a v e  t h e  
c a r r i e r  g e n o t y p e ,  i n  t h e  c a s e  o f  r e c e s s i v e  d i s o r d e r s  d e a l t  w i t h  b y  s i m p l e  g e n e -  
a d d i t i o n . )  T h u s ,  g e r m l i n e  g e n e  t h e r a p y  h a s  t h e  m a r k e d  a d v a n t a g e  o v e r  s o m a t i c  g e n e  
t h e r a p y  o f  o f f e r i n g  a  p e r m a n e n t  e l i m i n a t i o n  o f  d i s e a s e - c a u s i n g  g e n e s .  L o o k i n g  w i d e r  
t h a n  t h e  b e n e f i t s  t h a t  g e r m l i n e  g e n e  t h e r a p y  ( a s s u m i n g  i t  t o  b e  s a f e  a n d  e f f i c a c i o u s )  
w o u l d  b r i n g  t o  t h e  l i n e  o f  d e s c e n d a n t s  f r o m  t h e  t r e a t e d  ‘ p a t i e n t ’ , g e r m l i n e  g e n e  
t h e r a p y  w o u l d  h a v e  a  p o s i t i v e  e f f e c t  o n  t h e  h u m a n  g e n e  p o o l .  C l e a r l y ,  t h e  m a g n i t u d e
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o f  t h i s  e f f e c t  w o u l d  b e  a  f u n c t i o n  o f  ( a )  t h e  e x t e n t  t o  w h i c h  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  i s  e m p l o y e d  w i t h i n  t h e  h u m a n  p o p u l a t i o n  a n d  ( b )  t h e  f r e q u e n c y  o f  e a c h  
d i s e a s e - c a u s i n g  g e n e  i n  t h e  p o p u l a t i o n .  G e r m l i n e  i n t e r v e n t i o n s  i n v o l v i n g  o n l y  a  f e w  
f a m i l i e s  f o r  a  v e r y  r a r e  g e n e t ic  d i s o r d e r  w o u l d  h a v e  m i n i m a l  i m p a c t  o n  t h e  g e n e  p o o l ,  
w h e r e a s  w i d e s p r e a d  h u m a n  g e r m l i n e  g e n e  t h e r a p y  a g a i n s t  a  c o m m o n  d i s e a s e  ( C F  f o r  
e x a m p l e )  w o u l d  b e  e x p e c t e d  t o  h a v e  a  g r e a t e r  e f f e c t  o n  t h e  g e n e  p o o l .  R e g a r d l e s s  o f  
t h e  m a g n i t u d e  o f  e f f e c t ,  e a c h  i n s t a n c e  o f  s u c c e s s f u l  g e r m l i n e  g e n e  t h e r a p y  a g a i n s t  a n y  
s e r i o u s  g e n e t i c  d i s o r d e r  w o u l d  c o n t r i b u t e  a  m e a s u r e  o f  i m p r o v e m e n t  i n  t h e  h u m a n  
g e n e  p o o l .
5.3 Human Germline Gene Therapy vs. Pre-screening
I n  c a s e s  w h e r e  t w o  h e t e r o z y g o t e s  w i s h  t o  h a v e  c h i l d r e n ,  m e d i c a l  s c i e n c e  a l r e a d y  
p r o v i d e s  m e t h o d s  f o r  p r e - s c r e e n i n g  e m b r y o s  o r  f o e t u s e s  f o r  g e n e t i c  d e f e c t s ,  s u c h  t h a t  
t h e  p a r e n t s  o f  h o m o z y g o u s  f o e t u s e s  c a n  d e c i d e  w h e t h e r  t h e  c h i l d  s h o u l d  b e  b o m .  
S i m i l a r  c o n s i d e r a t i o n s  w o u l d  a p p l y  t o  X - l i n k e d  d i s o r d e r s ,  w i t h  t h e  a d d i t i o n a l  
p o s s i b i l i t y  o f  s e x  s e l e c t i o n .  P o l y g e n i c  d i s o r d e r s  s h o u l d  a l s o  b e  a m e n a b l e  t o  p r e ­
s c r e e n i n g .  F o r  d o m i n a n t l y  c o n f e r r e d  d i s o r d e r s ,  p r e - s c r e e n i n g  o f  e m b r y o s  w o u l d  a g a i n  
b e  t h e  l o g i c a l  r o u t e .  I n  c a s e s  w h e r e  i n d i v i d u a l s  w e r e  h o m o z y g o u s  f o r  d o m i n a n t l y  
c o n f e r r e d  d is o r d e r s ,  g e r m l i n e  g e n e  t h e r a p y  m i g h t  b e  t h e  o n l y  o p t io n ,  b e c a u s e  1 0 0 %  o f  
o f f s p r i n g  w o u l d  i n c l u d e  a  d i s e a s e - c a u s i n g  a l l e l e .  H o w e v e r ,  v e r y  f e w  i f  a n y  a u t o s o m a l  
d o m i n a n t  d is o r d e r s  h a v e  b e e n  d e s c r i b e d  w h e r e  t h e  h o m o z y g o t e  i s  a l i v e  a n d  i n  a  f i t  
e n o u g h  s t a t e  to  r e p r o d u c e  w h i l e  t h e  h e t e r o z y g o u s  c o m b i n a t i o n  y i e l d s  a  s e r i o u s  
m e d i c a l  c o n d i t i o n .
I n d e e d ,  t h e r e  i s  i n  e f f e c t  a  ‘ g o l d e n  r u l e ’ a p p l y i n g  t o  d i s o r d e r s  p o t e n t i a l l y  a m e n a b l e  t o  
g e r m l i n e  g e n e  t h e r a p y :  i n  a n y  d i s o r d e r  w i t h  e n o u g h  m o l e c u l a r  k n o w l e d g e  a v a i l a b l e  t o  
a l l o w  t h e  p r o s p e c t  o f  g e r m l i n e  g e n e  t h e r a p y ,  t h a t  s a m e  k n o w l e d g e  w i l l  a l s o  b e  
s u f f i c i e n t  t o  a l l o w  d e t e c t io n  o f  t h e  d i s e a s e - c a u s i n g  s e q u e n c e s  v i a  g e n e t i c  p r e ­
s c r e e n i n g .
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A c c o r d i n g l y ,  a s  f a r  a s  i n d i v i d u a l  p a r e n t s  a r e  c o n c e r n e d ,  g e n e t i c  p r e - s c r e e n i n g  o f f e r s  a  
m o r e  v i a b l e  a l t e r n a t i v e  t o  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  O f  c o u r s e ,  i n  p r i n c i p l e  t h i s  
c o u l d  c h a n g e  i f  g e r m l i n e  m a n i p u l a t i o n  w a s  t o  b e n e f i t  f r o m  a  ' q u a n t u m - l e a p ’ 
i m p r o v e m e n t  i n  t e r m s  o f  i t s  p r e c i s i o n  a n d  e f f i c i e n c y ,  a r i s i n g  f r o m  d r a m a t i c  f u t u r e  
t e c h n o l o g i c a l  i m p r o v e m e n t s .  I f  s u c h  a  s p e c u l a t i v e  a d v a n c e  w a s  t o  o c c u r ,  i t  c o u l d  i n  
p r i n c i p l e  m a k e  g e r m l i n e  g e n e  t h e r a p y  e a s i e r  t h a n ,  a n d  t h e r e f o r e  p r e f e r a b l e  t o ,  p r e ­
s c r e e n i n g .  H o w e v e r ,  w i t h  p r e s e n t  g e n e  t r a n s f e r  e f f i c i e n c y  l e v e l s ,  p r e - s c r e e n i n g  w o u l d  
c l e a r l y  b e  a  b e t t e r  c h o i c e  t h a n  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  I t  i s  c o n c e i v a b l e  t h a t  
‘ p r o - l i f e ’ p a r e n t s ,  i m p l a c a b l y  o p p o s e d  t o  a b o r t io n  o r  e m b r y o  d i s c a r d  m i g h t  p r e f e r  
h u m a n  g e r m l i n e  g e n e  t h e r a p y  t o  p r e - s e l e c t i o n  ( a l t h o u g h  s u c h  p a r e n t s  w o u l d  h a v e  t o  
e m b r a c e  a  d o c t r i n e  o f  d o u b l e - e f f e c t  i n  o r d e r  t o  a c c e p t  t h e  ‘ a c c i d e n t a l ’ l o s s  o f  e m b r y o s  
l i k e l y  t o  b e  e n t a i l e d  b y  h u m a n  g e r m l i n e  g e n e  t h e r a p y ) .  N e v e r t h e l e s s ,  i t  s e e m s  
r e a s o n a b l e  t o  p r e s u m e  t h a t  a  m a j o r i t y  o f  p a r e n t s  w o u l d  s i m p l y  c h o o s e  t h e  m o s t  
e f f e c t i v e  m e a n s  o f  e n s u r i n g  t h a t  t h e i r  o f f s p r i n g  a r e  f r e e  f r o m  d i s e a s e .  C o n s e q u e n t l y ,  
g i v e n  p r e s e n t  g e n e  t r a n s f e r  e f f i c i e n c i e s ,  p r e - s e l e c t i o n  w o u l d  s e e m  t o  t a k e  p r e c e d e n c e  
o v e r  h u m a n  g e r m l i n e  g e n e  t h e r a p y .
5.4 Candidate Conditions for Human Germline Gene 
Therapy?
N o t w i t h s t a n d i n g  t h e  a b o v e - m e n t i o n e d  a d v a n t a g e s  o f  p r e - s c r e e n i n g  o v e r  h u m a n  
g e r m l i n e  g e n e  t h e r a p y ,  i t  i s  p o s s i b l e  t o  i d e n t i f y  a  n u m b e r  o f  i m p o r t a n t  c o n t e x t s  i n  
w h i c h  g e r m l i n e  g e n e  t h e r a p y  m a y  p l a u s i b l y  o f f e r  a  p o t e n t i a l  r o l e  t o  i n d i v i d u a l  
p a r e n t s .  O n e  a t t r a c t i v e  p o s s i b i l i t y  c o n c e r n s  i n f e r t i l i t y .  I n  s o m e  g e n e t i c  f o r m s  o f  m a l e  
i n f e r t i l i t y ,  s p e c i f i c  m u t a t i o n s  c a u s e  i m m o t i l i t y  o f  s p e r m  c e l l s .  I n  m e n  w i t h  s u c h  
i n f e r t i l i t y ,  S M G T  m i g h t  b e  u s e d  t o  d e l i v e r  c o r r e c t i v e  ( s i m p l e  a d d - i n  o f  f u n c t i o n )  
t r a n s g e n e s  t o  s p e r m a t o g o n i a  in v ivo .  A s s u m i n g  t h e  l e v e l s  o f  s u c c e s s  r e p o r t e d  w i t h  
m i c e  ( S e c t i o n  2 . 1 . 7 ) ,  m o r e  t h a n  5 0 %  o f  s p e r m  m a y  p i c k  u p  t r a n s g e n e  D N A ;  s u c h  h i g h  
e f f i c i e n c i e s  w o u l d  p r o d u c e  a d e q u a t e  n u m b e r s  o f  s p e r m  f o r  I V F .  A m o n g s t  e j a c u l a t e d  
s p e r m ,  i t  s h o u l d  o n l y  b e  t h e  s u c c e s s f u l l y  m o d i f i e d  s p e r m  t h a t  s h o u l d  b e  m o t i l e .  T h u s ,  
t r a n s g e n i c  s p e r m  w o u l d  b e  a b l e  t o  f e r t i l i s e  a n  e g g ,  b u t  n o n - t r a n s g e n i c  s p e r m  a n d  
s p e r m  i n  w h i c h  t h e  t r a n s g e n e  w a s  p r e s e n t  b u t  n o t  e x p r e s s i n g  w o u l d  r e m a i n  i m m o t i l e
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a n d  h e n c e  u n a b l e  t o  p a r t i c i p a t e  i n  f e r t i l i s a t i o n .  A t  p r e s e n t ,  g e n e t i c  f o r m s  o f  m a l e  
i n f e r t i l i t y  i n v o l v i n g  s p e r m  i m m o t i l i t y  c a n  b e  s u c c e s s f u l l y  t r e a t e d  c o n v e n t i o n a l l y  u s i n g  
I C S I .  H o w e v e r ,  t h e  d i s a d v a n t a g e  o f  I C S I  i s  t h a t  t h e  a b e r r a n t  ( i n f e r t i l i t y )  g e n e  s t a n d s  a  
h i g h  p r o b a b i l i t y  o f  b e i n g  p a s s e d  o n  to  t h e  n e x t  g e n e r a t io n .  B y  c o n t r a s t ,  h u m a n  
g e r m l i n e  g e n e  t h e r a p y  b y  in v ivo  S M G T  o f f e r s  t h e  p o t e n t i a l  a d v a n t a g e  o f  t r a n s m i t t i n g  
t h e  t r a n s g e n e  t o  t h e  n e x t  g e n e r a t io n ,  t h u s  p r o v i d i n g  a  p e r m a n e n t  s o l u t i o n  t h a t  w o u l d  
b e n e f i t  s u b s e q u e n t  d e s c e n d a n t s  o f  t h e  o r i g i n a l  p a t i e n t .
A n o t h e r  im p o r t a n t  c o n t e x t  f o r  t h e  p o t e n t ia l  u s e  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  i s  
w h e r e  s e v e r a l  d e l e t e r i o u s  g e n e s  a r e  b e i n g  c o n s i d e r e d  s i m u l t a n e o u s l y  i n  o n e  
( p o t e n t ia l )  i n d i v i d u a l .  C u t t i n g  e d g e  g e n e t ic  a d v a n c e s  s u c h  a s  t h e  h u m a n  g e n o m e  
p r o j e c t  a r e  f a c i l i t a t i n g  t h e  e l u c i d a t i o n  o f  a  g r o w i n g  a r r a y  o f  d e l e t e r i o u s  g e n e s ,  m a n y  
o f  w h i c h  p r o b a b l y  o p e r a t e  a s  r i s k  f a c t o r s ,  a n d  i t  i s  l i k e l y  t h a t  m a n y  o r  e v e n  m o s t  
h u m a n s  w i l l  e a c h  h a v e  i n  t h e i r  g e n o m e  a  n u m b e r  o f  t h e s e  d e l e t e r i o u s  g e n e s .  T o  t a k e  a  
h y p o t h e t i c a l  e x a m p l e ,  c o n s i d e r  a  p a i r  o f  p r o s p e c t i v e  p a r e n t s :  t h e  g e n o m e  o f  o n e  
p a r e n t  c o n t a i n s  a  g e n e  t h a t  a c t s  a s  a  s t r o n g  r i s k  f a c t o r  f o r  t h e  d e v e l o p m e n t  o f  s e n i l e  
d e m e n t i a ,  w h i l e  t h e  o t h e r  p a r e n t ’ s  g e n o m e  c o n t a i n s  ( a )  a  g e n e  t h a t  a c t s  a s  a  r i s k  f a c t o r  
f o r  a u t i s m  a n d  ( b )  a n  o n c o g e n e  p r e d i s p o s i n g  t h a t  i n d i v i d u a l  t o  a  c e r t a i n  f o r m  o f  
c a n c e r .  C l e a r l y ,  i t  w o u l d  b e  d e s i r a b l e  t o  a v o i d  a n y  o f  t h e s e  t h r e e  d e l e t e r i o u s  g e n e s  i n  
t h e  o f f s p r i n g  f r o m  t h e s e  p a r e n t s .  I n  p r i n c i p l e ,  p r e - s c r e e n i n g  e a r l y  e m b r y o s  c o u l d  
a c h i e v e  t h is .  H o w e v e r ,  a s  s o o n  a s  m o r e  t h a n  o n e  g e n e  n e e d s  t o  b e  a v o i d e d ,  t h e  
n u m b e r  o f  e m b r y o s  r e q u i r e d  f o r  p r e - s c r e e n i n g  i n c r e a s e s .  I n  t h e  p r e s e n t  e x a m p l e ,  o n  
a v e r a g e  o n l y  o n e  i n  e ig h t  e m b r y o s  w o u l d  b e  f r e e  f r o m  a l l  t h r e e  d e l e t e r io u s  g e n e s .  
T h u s ,  i n  c a s e s  i n  w h i c h  i t  i s  d e s i r a b l e  t o  d e a l  w i t h  s e v e r a l  d e l e t e r i o u s  g e n e s  a t  o n c e ,  
p r e - s c r e e n i n g  b e c o m e s  i n h e r e n t l y  l e s s  e f f e c t i v e ,  s i m p l y  d u e  t o  t h e  l i m i t e d  n u m b e r s  o f  
h u m a n  e m b r y o s  a v a i l a b l e  ( f r o m  e a c h  w o m a n )  f o r  a n a l y s i s .  I n  s u c h  c a s e s ,  g e r m l i n e  
g e n e  t h e r a p y  m i g h t  b e  t h e  b e s t  -  o r  o n l y  -  t o o l  a v a i l a b l e .
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5.5 Genetic Enhancement
I n  c o n t r a s t  t o  g e r m l i n e  g e n e  therapy, i n  w h i c h  t h e  g o a l  i s  to  a v o i d  o r  m i t i g a t e  a n  
o t h e r w is e  i n e v i t a b l e  d i s o r d e r ,  g e n e t ic  enhancem en t  i m p l i e s  t h e  m a n i p u l a t i o n  o f  
g e n e r a l  p h e n o t y p i c  t r a it s  ( w h e r e  s u c h  t r a it s  a r e  u n d e r  g e n e t i c  c o n t r o l ,  a n d  h e n c e  
p o t e n t i a l l y  a m e n a b l e  t o  G M )  t o  p r o d u c e  ‘ i m p r o v e d ’ i n d i v i d u a l s .  S u c h  p h e n o t y p i c  
t r a it s  m i g h t  i n c l u d e  n a t u r a l  l i f e  s p a n ,  h e i g h t ,  d i s e a s e  r e s i s t a n c e ,  I Q ,  b o d y - s h a p e ,  s i z e  
o f  f a c i a l  f e a t u r e s ,  e t c .  O n e  c o m m o n l y  e x p r e s s e d  f e a r  c o n c e r n i n g  h u m a n  g e r m l i n e  
g e n e  t h e r a p y  i s  t h a t  t h e  t e c h n i q u e s  o f  G M  n e c e s s a r y  f o r  h u m a n  g e r m l i n e  g e n e  t h e r a p y  
m i g h t  b e  u s e d  f o r  s u c h  n o n - t h e r a p e u t i c  r e a s o n s .
A s s u m i n g  t h a t  g e r m l i n e  G M  t e c h n i q u e s  b e c o m e  e f f e c t i v e  i n  d e a l i n g  w i t h  h u m a n  
d i s e a s e ,  i t  i s  u n d o u b t e d l y  t r u e  t h a t  t h e  s a m e  t e c h n i q u e s  c o u l d  b e  a p p l i e d  f o r  
e n h a n c e m e n t  p u r p o s e s .  T h u s ,  t h e  i s s u e  b e c o m e s  a n  e t h i c a l  o n e ,  i n v o l v i n g  s e v e r a l  
q u e s t i o n s  i n c l u d i n g :  ( a )  s h o u l d  g e r m l i n e  e n h a n c e m e n t  b e  p e r m i t t e d ?  ( b )  i f  g e r m l i n e  
e n h a n c e m e n t  o u g h t  t o  b e  t o t a l l y  p r o s c r i b e d ,  s h o u l d  t h e r a p e u t ic  f o r m s  o f  g e r m l i n e  G M  
a l s o  b e  b a n n e d  l e s t  o n  t h e  g r o u n d s  t h a t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  w o u l d  f u n c t i o n  
a s  a  ‘ s l i p p e r y  s l o p e ’ t o w a r d s  g e r m l i n e  e n h a n c e m e n t ?  A n d  ( c )  i f  so m e  g e r m l i n e  
e n h a n c e m e n t  i s  p e r m i s s i b l e ,  w h e r e  s h o u l d  t h e  l i m i t s  b e  s e t ?  S u c h  e t h i c a l  q u e s t i o n s  a r e  
a d d r e s s e d  l a t e r  i n  t h i s  t h e s is .
A t  t h i s  p o i n t ,  i t  s h o u l d  b e  r e c o g n i s e d  t h a t  n o  c l e a r  b o u n d a r y  n e c e s s a r i l y  e x i s t s  
b e t w e e n  t h e r a p e u t ic  G M  a n d  e n h a n c e m e n t  G M .  F o r  e x a m p l e ,  g e r m l i n e  G M  u s e d  
a g a i n s t  A l z h e i m e r ’ s  d i s e a s e  m i g h t  a l s o  b e  e f f e c t i v e  i n  e n h a n c i n g  m e m o r y  p e r  se, i n  
p e o p l e  n o t  p r e d i s p o s e d  t o  t h e  d is o r d e r .  S i m i l a r l y ,  g e r m l i n e  G M  u s e d  a g a i n s t  a  
p a r t i c u l a r  i n h e r i t e d  c a n c e r  m i g h t  a ls o  p r o v i d e  a  g e n e r a l  r e s i s t a n c e  a g a i n s t  c a n c e r  i n  
n o n - s u s c e p t i b l e  p e o p l e .  A n o t h e r  e x a m p l e  w o u l d  b e  g e r m l i n e  G M  t o  t r e a t  m u s c u l o ­
s k e l e t a l  d i s o r d e r s ,  w h e r e  s i m i l a r  G M  a p p l i e d  n o n - c l i n i c a l l y  m i g h t  e n h a n c e  b o d y -  
s h a p e  o r  e v e n  a t h l e t i c  p o t e n t ia l .  A l t h o u g h  t h e s e  e x a m p l e s  a r e  n e c e s s a r i l y  s p e c u l a t i v e  
a n d  f u t u r i s t i c ,  t h e y  s e r v e  t o  d e m o n s t r a t e  t h a t  g e r m l i n e  G M  c a n n o t  b e  s i m p l y  d i v i d e d  
in t o  t h e r a p e u t ic  v e r s u s  e n h a n c e m e n t  c a t e g o r ie s .
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5.6 Gene Pool Improvement
A  d i s t i n c t i o n  c a n  b e  m a d e  b e t w e e n  t h e  u s e  o f  g e r m l i n e  G M  t e c h n i q u e s  f o r  ( a )  
i n d i v i d u a l  p a r e n t / c h i l d  b e n e f i t s  a n d  ( b )  i m p r o v e m e n t  o f  t h e  h u m a n  g e n e  p o o l .  T h i s  
d i s t i n c t i o n  c u t s  a c r o s s  t h e  t h e r a p y  v s .  e n h a n c e m e n t  i s s u e ,  b e c a u s e  t h e  g e n e t i c  c h a n g e s  
i n v o l v e d  a t  b o t h  p a r e n t / c h i l d  a n d  g e n e  p o o l  l e v e l s  c o u l d  b e  f o r  e it h e r  t h e r a p e u t i c  o r  
e n h a n c e m e n t  p u r p o s e s .
O n  f i r s t  s i g h t ,  t h e  n o t i o n  o f  a p p l y i n g  g e r m l i n e  G M  t o  t h e  e n t i r e  h u m a n  p o p u l a t i o n  
w o u l d  a p p e a r  i m p r a c t i c a b l e .  H o w e v e r ,  s i m i l a r l y  a m b i t i o u s  p u b l i c  h e a l t h  p r o g r a m s  
h a v e  b e e n  p r o p o s e d  o r  e m p l o y e d  i n  c o n v e n t i o n a l  m e d i c i n e .  T h e  c l e a r e s t  e x a m p l e s  
c o m e  f r o m  a t t e m p t s  t o  p r e v e n t  s e r io u s  i n f e c t i o u s  d i s e a s e s :  v a c c i n a t i o n  p r o g r a m s  h a v e  
b e e n  a i m e d ,  w i t h  g r e a t  s u c c e s s ,  a g a in s t  c h i l d h o o d  d is e a s e s  s u c h  a s  s m a l l p o x  a n d  
p o l i o .
G i v e n  s a f e ,  e f f i c a c i o u s  a n d  l o w - c o s t  g e r m l i n e  g e n e  t r a n s f e r  t e c h n o l o g y ,  f u t u r e  g l o b a l  
h e a l t h  p r o g r a m s  m i g h t  i n  p r i n c i p l e  b e  u s e d  t o  i m p r o v e  t h e  h u m a n  g e n e  p o o l .
C e r t a i n l y ,  i t  w o u l d  b e  e r r o n e o u s  t o  a s s u m e  t h a t  t h e  h u m a n  g e n o m e  p e r  s e  i s  n o t  
p o t e n t i a l l y  a m e n a b l e  t o  i m p r o v e m e n t .  F o r  e x a m p l e ,  i t  i s  n o w  w e l l  a c c e p t e d  t h a t  
e v o l u t i o n a r y  p r e s s u r e s  h a v e  b e e n  r e l a t i v e l y  w e a k  i n  t h e  c o n t e x t  o f  l a t e - o n s e t  ( p o s t -  
r e p r o d u c t i v e  a g e )  d i s o r d e r s  s u c h  a s  c a n c e r ,  t h e  r e s u l t  b e i n g  t h a t  h u m a n s  p o s s e s s  o n l y  
a  m o d e s t  d e g r e e  o f  c a n c e r  r e s is t a n c e .  G e r m l i n e  G M  t e c h n o l o g y  c o u l d  i n  p r i n c i p l e  b e  
u s e d  t o  a d d  ‘ a n t i - c a n c e r ’ g e n e t ic  s e q u e n c e s  ( s u c h  a s  e x t r a  c h e c k p o i n t  g e n e s  o r  
t u m o u r - s u p p r e s s o r  g e n e s )  in t o  t h e  h u m a n  g e n o m e .  A s s u m i n g  t h a t  t h e s e  a d d i t i o n a l  
a n t i - c a n c e r  g e n e s  w o u l d  g r e a t l y  r e d u c e  t h e  r i s k  o f  c a n c e r ,  t h i s  f o r m  o f  g e r m l i n e  
m o d i f i c a t i o n ,  c a r r i e d  o u t  a s  w i d e l y  a s  p o s s i b l e ,  w o u l d  e n s u r e  t h a t  f u t u r e  g e n e r a t i o n s  
o f  p e o p l e  in h e r i t e d  e n h a n c e d  l e v e l s  o f  p r o t e c t i o n  a g a i n s t  c a n c e r .
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A t  t h e  o u t s e t ,  i t  i s  im p o r t a n t  t o  n o t e  t h a t  t h i s  c h a p t e r  ( a n d  t h e  n e x t )  d i f f e r s  
f u n d a m e n t a l l y  f r o m  t h e  f o r e g o i n g  c h a p t e r s .  W h i l e  C h a p t e r s  2 - 5  a r e  c o n c e r n e d  w i t h  
sc ien tific  i s s u e s  r e la t e d  t o  h u m a n  g e r m l i n e  g e n e  t h e r a p y ,  t h e  C h a p t e r s  6  &  7  o f  t h i s  
t h e s i s  d e a l  w i t h  e th ica l  i s s u e s .  T h i s  i s  m o s t  o b v i o u s  i n  t e r m s  o f  r e f e r e n c e  c i t a t i o n s .  
D u e  t o  a  c u s t o m / p r a c t i c e  m i s m a t c h  b e t w e e n  e t h i c s  a n d  s c i e n c e ,  e t h i c s  a r t i c l e s  t e n d  t o  
c o n t a i n  f a r  f e w e r  r e f e r e n c e  c i t a t i o n s .  T h i s  m i s m a t c h  i s  l o g i c a l ,  i n  t h a t  f e w  o f  t h e  b a s i c  
i d e a s  e m p l o y e d  i n  e t h i c s  d i s c o u r s e  c a n  b e  c l e a r l y  a t t r ib u t e d  t o  o n e  p a r t i c u l a r  
a u t h o r / o r i g i n a l  a r t i c l e .  T h i s  i s  i n  c o n t r a s t  t o  s c i e n t i f i c  f i n d i n g s  &  t h e o r i e s ,  w h i c h  a r e  
m o r e  d i s t i n c t  a n d  t h u s  h a v e  c l e a r e r - c u t  o r i g i n s  i n  t h e  l i t e r a t u r e .  M o r e o v e r ,  s o m e  o f  t h e  
i d e a s  a r e  s o  w e l l  k n o w n  ( b y  e t h i c i s t s )  t h a t  r e f e r e n c e  c i t a t i o n  i s  r e n d e r e d  l a r g e l y  
r e d u n d a n t .  T h i s  i s  a n a l o g o u s  t o  t h e r e  b e i n g  n o  n e e d  f o r  s c i e n c e  t o  c i t e  r e f e r e n c e s  f o r  
w e l l - k n o w n  m a t t e r s ,  e .g .  " v i r u s e s  a r e  i n f e c t i v e  a g e n t s  s m a l l e r  t h a n  c o m m o n  
m i c r o o r g a n i s m s ,  r e q u i r i n g  l i v i n g  c e l l s  f o r  m u l t i p l i c a t i o n " .  F u r t h e r m o r e ,  i n  t h i s  t h e s i s ,  
m a n y  o f  t h e  i d e a s  a n d  e x a m p l e s  i n  t h e  f o l l o w i n g  c h a p t e r s  a r e  i n  f a c t  o r i g i n a l  i d e a s  ( o r  
o r i g i n a l l y  s y n t h e s i s e d  i d e a s )  p r o d u c e d  b y  t h e  p r e s e n t  a u t h o r .
A c c o r d i n g l y ,  t h e  r e a d e r  c a n  e x p e c t  to  f i n d  f a r  f e w e r  r e f e r e n c e  c i t a t i o n s  i n  C h a p t e r s  6  
a n d  7  i n  c o m p a r i s o n  w i t h  t h e  p r e v i o u s  c h a p t e r s .  W h e r e  c i t a t i o n s  d o  o c c u r ,  t h e s e  r e f e r  
e it h e r  t o  ( a )  o r i g i n a l ,  s e m i n a l  w o r k s  i n t r o d u c i n g  o r  d e v e l o p i n g  m a j o r  c o n c e p t s ;  ( b )  
r e c e n t  w o r k s  t h a t  p l a c e  c o r e  c o n c e p t s  i n  a  r e l e v a n t  c o n t e x t ;  ( c )  p u b l i c a t i o n s  t h a t  
a r t i c u l a t e  a  s p e c i f i c  p o i n t  o r  e x a m p l e ;  o r  ( d )  g e n e r a l  w o r k s  t h a t  p r o v i d e  u s e f u l  
b a c k g r o u n d .  N o t e  t h a t  a l l  t h e  e x a m p l e s  ( c a s e s )  g i v e n  a r e  o r i g i n a l ,  e x c e p t  w h e r e  
s p e c i f i c a l l y  r e f e r e n c e d .  T h i s  m i n i m a l  u s e  o f  r e f e r e n c e s  i s  c o n s i s t e n t  w i t h  t h e  u s a g e  i n  
m y  p a p e r s  t h a t  d e a l  w i t h  b i o e t h i c a l  i s s u e s  s u b m it t e d  a s  p a r t  o f  t h e  p o r t f o l i o  o f  
p u b l i s h e d  w o r k  a c c o m p a n y i n g  t h i s  t h e s is :  A n im al G enetic  M anipu la tion : A  
U tilitarian  R espon se  ( S m i t h  2 0 0 2 c ) ;  G ene Therapy: T h eore tica l a n d  B io e th ica l  
C on cep ts  ( S m i t h  2 0 0 3 b ) ;  H um an G erm line G enetic  M odifica tion : A  U tilitarian  
B io e th ica l P ersp ec tiv e  ( S m i t h  2 0 0 5 ) .
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A  s e c o n d  f u n d a m e n t a l  d i f f e r e n c e  b e t w e e n  C h a p t e r s  2 - 5  a n d  C h a p t e r s  6  &  7  i s  t h a t  
f i r s t - p e r s o n  l a n g u a g e  i s  c o m m o n p l a c e  i n  t h a t  la t t e r ,  b u t  a v o i d e d  i n  t h e  f o r m e r .  T h i s  
d i f f e r e n t i a l  u s e  o f  f i r s t - p e r s o n  l a n g u a g e  i s  d e l i b e r a t e .  S c i e n t i f i c  p u b l i c a t i o n s  a r e  
c u s t o m a r i l y  w r i t t e n  i n  i m p e r s o n a l  s t y l e .  T h i s  r e f l e c t s  t h e  i m p e r s o n a l  n a t u r e  o f  t h e  
d a t a ,  f i n d i n g s  a n d  t h e o r ie s  w i t h  w h i c h  s c i e n c e  i s  c o n c e r n e d .  B y  c o n t r a s t ,  e t h i c s  
j o u r n a l  a r t i c l e s ,  i n c l u d i n g  m e d i c a l / b i o e t h i c s  j o u r n a l  p a p e r s ,  a r e  c o m m o n l y  w r i t t e n  
u s i n g  f i r s t  p e r s o n  l a n g u a g e .  F o r  e x a m p l e ,  t h i s  p e r s o n a l  s t y l e  i s  t h e  n o r m  i n  a r t i c l e s  i n  
t h e  j o u r n a l  B ioeth ics , i n c l u d i n g  t h e  a r t i c l e  i n  t h a t  j o u r n a l  s u b m it t e d  a s  p a r t  o f  t h e  
p o r t f o l i o  o f  p u b l i s h e d  w o r k  f o r  t h i s  t h e s is  ( S m i t h  2 0 0 2 b ) .  S u c h  u s e  o f  f i r s t  p e r s o n  
l a n g u a g e  i n  e t h i c a l  d i s c o u r s e  i s  u s e f u l ,  b e c a u s e  i t  a l l o w s  r e a d e r s  t o  o b s e r v e  a n  a u t h o r  
c o n s t r u c t i n g  h i s / h e r  e t h i c a l  a r g u m e n t s .  I n  c o n t r a s t  t o  t h e  d a t a / f a c t - d r i v e n  d e v e l o p m e n t  
o f  s c i e n t i f i c  a r g u m e n t s ,  e t h i c a l  a r g u m e n t s  i n e v i t a b l y  r e q u ir e  a  d e g r e e  o f  s u b j e c t i v i t y .
A c c o r d i n g l y ,  t h e  c u s t o m  o f  u s i n g  p e r s o n a l  l a n g u a g e  i n  e t h i c a l  d i s c o u r s e  h a s  b e e n  
m a i n t a i n e d  i n  C h a p t e r s  6  &  7  o f  t h i s  t h e s is .
6.2 Ethics
A l t h o u g h  i t  w o u l d  b e  l e g i t i m a t e  a n d  in t e r e s t in g  t o  c o m p a r e  i n  d e t a i l  a  b r o a d  r a n g e  o f  
c o m p e t i n g  e t h i c a l  a p p r o a c h e s ,  s u c h  a n  e n d e a v o u r  w o u l d  b e  b e y o n d  t h e  s c o p e  o f  t h e  
p r e s e n t  d i s c u s s i o n .  M o r e o v e r ,  e v e n  t h e  m o s t  t h o r o u g h ,  e x t e n s i v e  e v a l u a t i o n  o f  
c o m p e t i n g  e t h i c a l  a p p r o a c h e s  w o u l d  b e  i n s u f f i c i e n t  t o  d e m o n s t r a t e  t h e  u n e q u i v o c a l  
s u p e r i o r i t y  o f  o n e  p a r t i c u l a r  s y s t e m .  A c c o r d i n g l y ,  t h e  f o l l o w i n g  d i s c u s s i o n  ( S e c t i o n s
6 . 3  &  6 . 4 )  i s  l i m i t e d  t o  ( a )  p r o v i d i n g  a n  o u t l i n e  o f  t h e  k e y  f e a t u r e s  o f  m a j o r  
c o m p e t i n g  e t h i c a l  a p p r o a c h e s  a n d  ( b )  d e s c r i b i n g  a n d  e v a l u a t i n g  t h e  c o r e  p r i n c i p l e s  o f  
t h e  e t h i c a l  a p p r o a c h  e m p l o y e d  b y  t h e  p r e s e n t  t h e s i s  -  u t i l i t a r i a n i s m .
A s  p r e v i o u s l y  s t a t e d  ( S e c t i o n  1 . 6 ) ,  t h i s  t h e s i s  d o e s  n o t  c l a i m  t o  e s t a b l i s h  u t i l i t a r i a n i s m  
a s  b e i n g  t h e  o n l y  v a l i d  -  o r  e v e n  n e c e s s a r i l y  t h e  b e s t  -  e t h i c a l  a p p r o a c h .  I n s t e a d ,  I  
e m p l o y  u t i l i t a r i a n i s m  a s  a  to o l  f o r  t h e  e x p l o r a t i o n  a n d  e v a l u a t i o n  o f  k e y  b i o e t h i c a l  
i s s u e s  a r i s i n g  f r o m  t h e  f u t u r e  p r o s p e c t  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  T h u s ,  
a l t h o u g h  t h e  b i o e t h i c a l  c o n c l u s i o n s  r e a c h e d  i n  t h i s  t h e s i s  ( s e e  C h a p t e r  7 )  a r e  d e s i g n e d
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t o  b e  c o n s i s t e n t  w i t h  u t i l i t a r i a n i s m ,  t h o s e  w h o  r e j e c t  t h e  u n d e r l y i n g  p r i n c i p l e s  o f  
u t i l i t a r i a n i s m  m a y  l e g i t i m a t e l y  r e j e c t  t h e s e  c o n c l u s i o n s .
N e v e r t h e l e s s ,  I  a m  i n c l i n e d  t o  h o l d  a  u t i l i t a r i a n  p o s i t i o n .  I  s u g g e s t  t h a t  t h e  u t i l i t a r i a n  
p o s i t i o n  i s  a  m i n i m a l  o n e ,  a n  i n i t i a l  p o i n t  r e a c h e d  b y  s e a r c h i n g  f o r  c o r e  p r i n c i p l e s  t h a t  
c o u l d  i n  p r i n c i p l e  b e  a d o p t e d  b y  a n y  r a t i o n a l  p e r s o n  o r  l e g i s l a t i v e  b o d y .  T o  b e  
p e r s u a d e d  t o  g o  b e y o n d  u t i l i t a r i a n i s m  a n d  a c c e p t  n o n - u t i l i t a r i a n  p r i n c i p l e s  ( s u c h  a s  
t h e  s a n c t i t y  o f  l i f e ,  u n a l i e n a b l e  i n d i v i d u a l  r i g h t s ,  p u r i t y ,  e t c )  w o u l d  r e q u i r e  s t r o n g  
r e a s o n s  f o r  d o i n g  s o .  I  s u g g e s t  t h a t  n o n - u t i l i t a r i a n  m o r a l  p r i n c i p l e s  h a v e  n o t  b e e n  
e s t a b l i s h e d  a s  u n e q u i v o c a l l y  v a l i d .  A c c o r d i n g l y ,  I  s u g g e s t  t h a t  t h e r e  a r e  v a l i d  g r o u n d s  
f o r  a d o p t i n g  u t i l i t a r i a n i s m ,  a t  l e a s t  p r o v i s i o n a l l y ,  a s  a n  a p p r o x i m a t e  g u i d e  t o  d e c i s i o n ­
m a k i n g .
6.3 The Diversity of Ethical Approaches
E t h i c a l  c o n s i d e r a t i o n s  o f  a n y  p r o b l e m  o r  i s s u e  m a y  u s e f u l l y  b e  d i v i d e d  i n t o  ( a )  n o n -  
c o n s e q u e n t i a l i s t  a n d  ( b )  c o n s e q u e n t i a l i s t  a p p r o a c h e s .  N o n - c o n s e q u e n t i a l i s m  c o n s i d e r s  
t h a t  t h e  a c t i o n  ( o r  e v e n  j u s t  t h e  m o t i v a t i o n  b e h i n d  a n  a c t i o n )  i s  t h e  c r u c i a l  e t h i c a l  
c o n s i d e r a t i o n .  I n  o t h e r  w o r d s ,  t h e  a c t i o n  i t s e l f  i s  m o r e  i m p o r t a n t  t h a n  t h e  a c t u a l  
o u t c o m e  ( c o n s e q u e n c e )  o f  t h e  a c t i o n .  B y  c o n t r a s t ,  c o n s e q u e n t i a l i s t  a p p r o a c h e s  
h o l d  t h a t  o u t c o m e s  ( a s  o p p o s e d  t o  a c t i o n s )  s h o u l d  b e  t h e  c r u c i a l  d e t e r m i n a n t s  o f  
e t h i c a l  d e c i s i o n s .
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6.4 Non-consequentialism
T h e  m a j o r  f o r m s  o f  n o n - c o n s e q u e n t i a l i s m  m a y  b e  c a t e g o r i s e d  a s  f o l l o w s :
• I n t u i t i v e  R e s p o n s e s
• R e l i g i o u s  L a w s
• R i g h t s
T h e  f o l l o w i n g  s e c t i o n s  c o n s i d e r  e a c h  o f  t h e s e  c a t e g o r i e s .
6.4.1 Intuitive Responses
A n  e t h i c s  b a s e d  u p o n  i n t u i t i v e  r e s p o n s e s  p l a c e s  p a r a m o u n t  i m p o r t a n c e  o n  p e o p l e ’ s  
“ i n s t i n c t s ”  a n d / o r  “ w h a t  f e e l s  r i g h t  ( d e e p  d o w n ) ”  ( A t k i n s o n  1 9 9 0 ;  K e k e s  1 9 8 6 ;  L e v y  
2 0 0 3 ;  M i l l e r  2 0 0 4 ;  P o r t m o r e  1 9 9 8 ;  S e n c e r z  1 9 8 6 ;  W i l s o n  1 9 9 6 ) .  F o r  e x a m p l e ,  s o m e  
i n d i v i d u a l s  w o u l d  ( a )  c l a i m  t o  h a v e  a  s t r o n g  i n s t i n c t  a g a i n s t  a n i m a l  t r a n s g e n e s i s ,  a n d  
t h u s  ( b )  t o  h o l d  t h a t  a n i m a l  t r a n s g e n e s is  i s  e t h i c a l l y  w r o n g .  I n  e t h i c a l  d e c i s i o n ­
m a k i n g ,  i n t u i t i v e  r e s p o n s e s  h a v e  s o m e  a d v a n t a g e s :  t h e y  a r e  ‘ n a t u r a l ’ a n d  e a s y  -  t h e r e  
m a y  b e  n o  n e e d  f o r  r a t i o n a l  d i s c o u r s e  i n  d e c i d i n g  w h i c h  a c t i o n s  t o  t a k e .  H o w e v e r ,  
t h e r e  a r e  s e v e r a l  p r o b l e m s  a s s o c i a t e d  w i t h  i n t u i t i v e  r e s p o n s e s  i n  e t h i c s .  S u c h  
p r o b l e m s  i n c l u d e  ( a )  t h e  r i s k  t h a t  a p p a r e n t l y  ‘ n a t u r a l ’ i n s t i n c t s  m i g h t  h a v e  b e e n  
u n d u l y  i n f l u e n c e d  b y  ( s a y )  s o c i a l ,  p o l i t i c a l  o r  c u l t u r a l  p r e s s u r e s ;  ( b )  t h e  d i f f i c u l t i e s  
t h a t  a r is e  w h e n  o n e  p e r s o n ’ s  i n s t i n c t s  c l a s h  w i t h  a n o t h e r  p e r s o n ’ s  i n s t i n c t s ;  a n d  ( c )  t h e  
r e l i a n c e  f o r  e t h i c a l  g u i d a n c e  u p o n  a  m y s t e r i o u s  ‘ b l a c k  b o x ’ m e n t a l  p r o c e s s .
6.4.2 Religious Laws
Religious laws hold that God is the origin o f all ethical rules, therefore religious
scriptures or rules must form the basis of ethical decision making (Cahill 2003; Green
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1 9 9 7 ;  M e s s i k o m e r  e t  a l .  2 0 0 1 ;  R a s m u s s e n  2 0 0 0 ;  T u r n e r  2 0 0 3 ) .  A c c o r d i n g l y ,  e t h i c a l  
d i r e c t i o n  a r i s i n g  f r o m  r e l i g i o u s  l a w s  is  o f  a n  a b s o l u t i s t  n a t u r e .  F o r  e x a m p l e ,  i f  a  
p a r t i c u l a r  r e l i g i o u s  l a w  s t a t e d  “ d o  n o t  ‘ p l a y  G o d ’ w i t h  n a t u r e ” , t h i s  w o u l d  d e e m  a l l  
a t t e m p t s  a t  g e n e t i c  m o d i f i c a t i o n  ‘ w r o n g ’ , e v e n  i f  i t  t h e  r e s u l t a n t  t r a n s g e n i c  o r g a n i s m s  
w o u l d  p r o d u c e  a  p h a r m a c e u t i c a l  p r o d u c t  o f  g r e a t  b e n e f i t  t o  p e o p l e  s u f f e r i n g  f r o m  a  
s e r io u s  d i s e a s e .  R e l i g i o u s  l a w s  h a v e  t h e  a d v a n t a g e  o f  b e i n g  ( a t  l e a s t  i n  s o m e  c a s e s )  
c l e a r  a n d  u n a m b i g u o u s .  H o w e v e r ,  t h e r e  a r e  m a j o r  ( p e r h a p s  i n s u r m o u n t a b l e )  p r o b l e m s  
w i t h  t h e  u s e  o f  r e l i g i o u s  l a w s  a s  t h e  b a s i s  f o r  e t h i c a l  d e c i s i o n - m a k i n g .  O n e  s u c h  
p r o b l e m  i s  t h e  s e r i o u s  l a c k  o f  a g r e e m e n t  t h a t  e x i s t s  b e t w e e n  d i f f e r e n t  r e l i g i o n s  o n  
e t h i c a l  q u e s t i o n s .  R e l a t e d  t o  t h i s ,  t h e  p a r t i c u l a r  G o d  o r  G o d s  f r o m  w h i c h  e t h i c a l  r u l e s  
a r e  s u p p o s e d  t o  h a v e  o r i g i n a t e d  w i l l  v a r y  d e p e n d i n g  o n  t h e  r e l i g i o n  o f  e a c h  m o r a l  
a g e n t .  M o r e  f u n d a m e n t a l l y ,  r e l i g i o u s  l a w s  a r e  i n e s c a p a b l y  f o u n d e d  u p o n  a  h i g h l y  
q u e s t i o n a b l e  b a s i s ,  n a m e l y  t h e  b e l i e f  i n  t h e  e x i s t e n c e  o f  a  s u p e r n a t u r a l  G o d ( s ) .  A n d ,  
e v e n  f o r  t h o s e  w h o  a r e  b e l i e v e r s ,  t h e r e  r e m a i n s  a  m a j o r  p r o b l e m :  w h y  s h o u l d  G o d ’ s  
r u l e s  b e  s e e n  a s  e th ica lly  co rrec t  r u l e s ?
6.4.3 Rights
T h e  l a n g u a g e  o f  ‘ r i g h t s ’ i s  i n  w i d e s p r e a d  u s a g e .  I n  t h e  e t h i c a l  c o n t e x t ,  a  ‘ r i g h t ’ i s  
s o m e t h in g  ( a n  ‘ e t h i c a l  e n t i t y ’ )  t h a t  a n  i n d i v i d u a l  ( o r  g r o u p )  p o s s e s s e s ;  i t  i s  t h i s  e t h i c a l  
e n t i t y  t h a t  i s  t o  b e  r e s p e c t e d  ( d 'O r o n z i o  2 0 0 1 ;  K n o w l e s  2 0 0 1 ;  R a w l s  1 9 7 1 ;  T h o m a s m a  
2 0 0 1 ;  T h o m a s m a  a n d  L o e w y  1 9 9 7 ) .  F o r  e x a m p l e ,  o n e  p e r s o n  m a y  w i s h  t o  p r e v e n t  t h e  
d e v e l o p m e n t  o f  g e n e t i c a l l y  m o d i f i e d  p i g s  b e c a u s e  t h a t  p e r s o n  b e l i e v e s  t h a t  t h e  p i g s  
h a v e  a  ‘ r i g h t ’ n o t  t o  b e  u s e d  i n  t h i s  w a y .  A t  t h i s  p o i n t ,  t h e  u s e  o f  t h e  t e r m  ‘ r i g h t s ’ 
m u s t  b e  d i s t i n g u i s h e d  f r o m  it s  u s e  i n  n o n - e t h i c a l  c o n t e x t s .  I n  n o n - e t h i c a l  c o n t e x t s ,  
r i g h t s  a r e  n o t  i n t r i n s i c  p r o p e r t ie s  o f  i n d i v i d u a l s  ( o r  g r o u p s ) ;  r a t h e r  r i g h t s  a r e  c o n ferred  
( b y  s o c i e t y  o r  g o v e r n m e n t ,  e t c ) .  F o r  e x a m p l e ,  i t  m a y  b e  t h a t  i n  a  p a r t i c u l a r  c o u n t r y  t h e  
c r e a t i o n  o f  g e n e t i c a l l y  m o d i f i e d  p i g s  i s  p r o h i b i t e d  b y  l a w ;  i n  t h i s  c a s e ,  o n e  w o u l d  b e  
e n t i t l e d  t o  s a y  t h a t  t h e  p i g s  h a v e  a  leg a l  r i g h t  ( a s  o p p o s e d  t o  a n  e t h i c a l  r i g h t )  n o t  t o  b e  
s u b j e c t e d  t o  g e n e t i c  m o d i f i c a t i o n  ( h o w e v e r ,  i t  i s  w o r t h  n o t i n g  t h a t  l e g a l  r i g h t s  a r e  
o f t e n  b a s e d  o n  e t h i c a l  c o n s i d e r a t i o n s ) .
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E t h i c a l  r i g h t s  a r e  u s u a l l y  c l e a r  a n d  u n a m b i g u o u s .  H o w e v e r ,  t h e r e  a r e  s e r i o u s  
p r o b l e m s  w i t h  t h e  w h o l e  n o t i o n  o f  e t h i c a l  r i g h t s .  D i s a g r e e m e n t  b e t w e e n  d if f e r e n t  
p e o p l e  o v e r  r i g h t s  i s  a  m a j o r  i s s u e .  F o r  e x a m p l e ,  o n e  p e r s o n  m a y  t h i n k  t h a t  d e s t r o y i n g  
b o v i n e  e m b r y o s  o f  a n  u n d e s i r e d  s e x  ( e .g .  m a l e  e m b r y o s  i n  d a i r y  a g r i c u l t u r e )  
a c c e p t a b l e  o n  t h e  g r o u n d s  t h a t  t h e  e m b r y o s  d o  n o t  h a v e  a  r i g h t  t o  l i f e ,  b u t  a n o t h e r  
p e r s o n  m a y  b e l i e v e  t h a t  t h e  d e s t r u c t i o n  i s  w r o n g  b e c a u s e  t h i s  p e r s o n  b e l i e v e s  t h a t  t h e  
e m b r y o s  do  h a v e  a  r i g h t  t o  l i f e .  I t  i s  d i f f i c u l t  t o  s e e  h o w  s u c h  p o s i t i o n s  c a n  b e  
r e c o n c i l e d ,  w i t h o u t  r e c o u r s e  t o  e t h i c a l  p r i n c i p l e s  b e y o n d  ‘ r i g h t s ’ . A n d  i f  a d d i t i o n a l  
e t h i c a l  p r i n c i p l e s  a r e  r e q u i r e d ,  t h e n  t h e  f u n d a m e n t a l  v a l i d i t y  o f  e t h i c a l  r i g h t s  i s  c a l l e d  
in t o  q u e s t i o n  — w h y  i n v o k e  r i g h t s  a t  a l l ,  i f  o t h e r  e t h i c a l  c o n s i d e r a t i o n s  a r e  n e e d e d ?  
F u r t h e r m o r e ,  r i g h t s  c a n  c o n f l i c t  w i t h  e a c h  o t h e r ,  o f t e n  w i t h  n o  o b v i o u s  r e s o l u t i o n  
p o s s i b l e .  F o r  e x a m p l e ,  w h i l e  a c c e p t i n g  t h a t  b o v i n e  e m b r y o s  h a v e  a  r i g h t  t o  l i f e ,  h i g h -  
t e c h  f a r m e r s  m a y  a t  t h e  s a m e  t i m e  c l a i m  t h a t  th ey  h a v e  t h e  r i g h t  t o  d e a l  w i t h  t h e  
e m b r y o s  -  i . e .  a s  p a r t  o f  a  r i g h t  t o  c o m m e r c i a l  f r e e d o m .  T h u s  i t  a p p e a r s  t h a t  a n y  
a c c e p t a b l e  ( e t h i c a l )  ‘ r i g h t ’ w o u l d  i t s e l f  h a v e  t o  b e  b a s e d  o n  s o u n d  e t h i c a l  p r i n c i p l e s .  
B u t  t h i s  r e q u i r e m e n t  s u g g e s t s  t h a t  ( e t h i c a l )  ‘ r i g h t s ’ a r e  n o t  in d e p e n d e n t  e n t i t i e s  
i n t r i n s i c a l l y  h e l d  b y  i n d i v i d u a l s  ( o r  g r o u p s ) .
6.5 Consequentialism
C o n s e q u e n t i a l i s m  h o l d s  t h a t  o u t c o m e s  ( a s  o p p o s e d  t o  a c t i o n s )  s h o u l d  b e  t h e  c r u c i a l  
d e t e r m i n a n t s  o f  e t h i c a l  d e c i s i o n s .  T w o  m a i n  f o r m s  m a y  b e  d i s c e r n e d :
• ‘ N o n - s e n t i e n c e  b a s e d ’ c o n s e q u e n t i a l i s m
• ‘ S e n t i e n c e - b a s e d ’ c o n s e q u e n t i a l i s m
T h e  f o l l o w i n g  s e c t i o n s  c o n s i d e r  e a c h  o f  t h e s e  c a t e g o r i e s .
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6.5.1 ‘Non-sentience based’ consequentialism
P o s s i b l e  d e s i r a b l e  n o n - s e n t i e n c e  o u t c o m e s  i n c l u d e  e c o n o m i c  c o n s e q u e n c e s  ( e .g .  h i g h  
g r o s s  d o m e s t i c  p r o d u c t  ( G D P ) ,  e n e r g y  a v a i l a b i l i t y  p e r  c a p i t a ,  a v a i l a b i l i t y  o f  c o n s u m e r  
g o o d s )  a n d  a e s t h e t ic  c o n s e q u e n c e s  ( e .g .  b e a u t y  i n  t h e  n a t u r a l  w o r l d ,  h i g h l y  c u l t u r e d  
c i t i z e n s ,  a r t i s t i c  a r t e f a c t s  p e r  c a p i t a ) .  ‘N o n - S e n t i e n c e  B a s e d ’ c o n s e q u e n t i a l i s m  i s  
r a r e l y  s t a t e d  a s  a n  e x p l i c i t  m o r a l  s y s t e m .  R a t h e r ,  i t  i s  e x i s t s  a s  a n  i m p l i c i t  a s s u m p t i o n  
i n  s e v e r a l  a r e a s  o f  h u m a n  a c t i v i t y ,  i n c l u d i n g  e c o n o m i c s ,  a r t  a n d  e n v i r o n m e n t a l i s m .  A  
m a j o r  p r o b l e m  w i t h  ‘ n o n - S e n t i e n c e  B a s e d ’ c o n s e q u e n t i a l i s m  i s  t h a t  i t  i s  d i f f i c u l t  t o  
f i n d  a g r e e m e n t  o v e r  w h i c h  c o n s e q u e n c e s  a r e  t h e  m o s t  d e s i r a b l e  o n e s .  V a l u e s  s u c h  a s  
b e a u t y ,  c u l t u r e  a n d  a r t  a r e  h i g h l y  s u b j e c t i v e :  i t  i s  i n e v i t a b l e  t h e  i m p o r t a n c e  o f  s u c h  
v a l u e s  w i l l  v a r y  g r e a t l y  b e t w e e n  d if f e r e n t  p e o p l e ,  d e p e n d i n g  o n  m a n y  f a c t o r s  s u c h  a s  
a g e ,  n a t i o n a l i t y ,  s o c i a l  g r o u p ,  s e x ,  e t c .  E c o n o m i c  v a l u e s  m a y  b e  m o r e  c o n s e n s i b l e  
t h a n  t h e i r  a e s t h e t ic  c o u n t e r p a r t s  ( a l t h o u g h  t h e r e  n e v e r t h e l e s s  e x i s t s  a  g r e a t  d e a l  o f  
s u b j e c t i v i t y  -  f o r  e x a m p l e ,  s h o u l d  a  p l e n t i f u l  s u p p l y  o f  c h e a p  c o n s u m e r  g o o d s  b e  
f a v o u r e d  o v e r  a n  u n p o l l u t e d  u r b a n  e n v i r o n m e n t ? )  H o w e v e r ,  e v e n  h i g h l y  c o n s e n s i b l e  
e c o n o m i c  v a l u e s  r e q u i r e  f u r t h e r  p h i l o s o p h i c a l  j u s t i f i c a t i o n .  T h e  q u e s t i o n  i s :  W h y  
s h o u l d  a n  e c o n o m i c  v a l u e  b e  e t h i c a l l y  d e s i r a b l e ?  F o r  e x a m p l e ,  i t  i s  w e l l  a c c e p t e d  b y  
m o s t  p e o p l e  t h a t  a  h i g h  G D P  i s  d e s i r a b l e .  B u t  t h e  q u e s t i o n  t h e n  n e e d s  t o  b e  a s k e d :  
W h y  s h o u l d  w e  v a l u e  a  h i g h  G D P ?  T h e r e  a r e  o f  c o u r s e  m a n y  p l a u s i b l e  a n s w e r s  to  
t h i s  q u e s t i o n .  F o r  e x a m p l e ,  a  h i g h  G D P  m a y  a l l o w  a  b e t t e r  h e a l t h c a r e  s y s t e m .  I t  m a y  
p e r m i t  m o r e  e n j o y a b l e  u s e  o f  l e i s u r e  t im e .  I t  m a y  a l l o w  b e t t e r  n u t r i t i o n  f o r  m o r e  
p e o p l e .  T h e  p o i n t  h e r e  i s  t h a t  n o n - s e n t i e n t  c o n s e q u e n c e s  ( s u c h  a s  h i g h  G D P )  a r e  n o t  
g o o d s  o f  them selves. R a t h e r ,  t h e  e t h i c a l  b a s i s  o f  e a c h  n o n - s e n t i e n t  c o n s e q u e n c e  
d e p e n d s  o n  f u r t h e r  e t h i c a l  p r i n c i p l e s ,  s u c h  a s  ( t o  c o n t i n u e  w i t h  t h e  e x a m p l e  o f  G D P )  
t h e  d e s i r a b i l i t y  o f  g o o d  h e a l t h c a r e ,  n u t r i t i o n  a n d  l e i s u r e  o p p o r t u n i t i e s  f o r  a  c o u n t r y ’ s  
p o p u l a c e .  Y e t  t h i s  o n c e  a g a i n  b e g s  t h e  q u e s t i o n ,  b e c a u s e  t h e  d e s i r a b i l i t y  o f  g o o d  
h e a l t h c a r e ,  n u t r i t i o n ,  l e i s u r e  t h e m s e l v e s  r e q u i r e  ( a t  l e a s t  a t  a  p h i l o s o p h i c a l  l e v e l )  
f u r t h e r  j u s t i f i c a t i o n .  W h y  i s  g o o d  h e a l t h c a r e  d e s i r a b l e ?  W h y  i s  g o o d  n u t r i t i o n  
d e s i r a b l e ?  T o  a n s w e r  s u c h  a  s e r ie s  o f  r e c u r s i v e  q u e s t i o n s ,  f u n d a m e n t a l  e t h i c a l  
p r i n c i p l e s  a r e  r e q u i r e d .  A c c o r d i n g l y ,  i t  i s  d i f f i c u l t  t o  a v o i d  t h e  c o n c l u s i o n  t h a t  n o n -  
s e n t ie n t  c o n s e q u e n t i a l i s m  -  a l t h o u g h  c o m m o n p l a c e  -  i s  i n t r i n s i c a l l y  w e a k  a s  a n
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e t h i c a l  a p p r o a c h  b e c a u s e  i t  i s  n o t  u n d e r p i n n e d  p e r  s e  b y  f u n d a m e n t a l  e t h i c a l  
p r i n c i p l e s .
6.5.2 ‘Sentience-Based5 Consequentialism: Utilitarianism
S e n t i e n c e  i s  t h e  a b i l i t y  t o  e x p e r i e n c e  s e n s a t i o n s .  S e n t i e n c e  i s  p o s s e s s e d  b y  h u m a n s  
a n d ,  t o  v a r y i n g  d e g r e e s ,  b y  m a n y  n o n - h u m a n  a n i m a l s .  ‘ S e n t i e n c e - b a s e d ’ 
c o n s e q u e n t i a l i s m ,  o r  u t i l i t a r i a n i s m ,  i s  b a s e d  o n  t h e  c o n c e p t  t h a t  a l l  v a l u e s  d e r i v e  
u l t i m a t e l y  f r o m  s e n t ie n c e .  S e n s a t i o n s  m a y  b e  g r o u p e d  in t o  t w o  c a t e g o r i e s ,  h a p p i n e s s  
a n d  m i s e r y .  I n  u t i l i t a r i a n i s m ,  e t h i c a l l y  c o r r e c t  d e c i s i o n s  a r e  t h o s e  t h a t  m a x i m i s e  t h e  
o v e r a l l  a m o u n t  o f  h a p p i n e s s ,  o r  r e d u c e  t h e  o v e r a l l  a m o u n t  o f  s u f f e r i n g  ( H a r e  1 9 6 3 ;  
M i l l  1 8 7 1 ;  Q u i n t o n  1 9 7 3 ;  S i d g w i c k  1 9 0 7 ;  S m a r t  1 9 7 3 ) .  F o r  e x a m p l e ,  a  u t i l i t a r i a n  
m a y  v i e w  i t  a s  w r o n g  t o  p r o d u c e  a  p a r t i c u l a r  s t r a i n  o f  c o s m e t i c - p r o d u c i n g  t r a n s g e n i c  
a n i m a l s  b e c a u s e  o f  t h e  a n i m a l  s u f f e r i n g  e n t a i l e d  b y  t h e  p r o c e s s  o f  t r a n s g e n e s i s .  O n  
t h e  o t h e r  h a n d ,  t h e  s a m e  u t i l i t a r i a n  m a y  c o n s i d e r  i t  r i g h t  t o  p r o d u c e  a  p a r t i c u l a r  s t r a i n  
o f  p h a r m a c e u t i c a l - p r o d u c i n g  t r a n s g e n i c  a n i m a l s  b e c a u s e  it  i s  l i k e l y  t h a t  t h e  a n i m a l  
s u f f e r i n g  w o u l d  b e  o u t w e i g h e d  b y  t h e  r e d u c t i o n  i n  s u f f e r i n g  o b t a i n e d  f r o m  t h e  
p h a r m a c e u t i c a l  p r o d u c t  ( n o t e  t h a t  u t i l i t a r i a n i s m  d o e s  n o t  s u g g e s t  t h a t  ‘ a n i m a l ’ 
s e n t ie n c e  i s  i n h e r e n t l y  l e s s  im p o r t a n t  t h a n  ‘ h u m a n ’ s e n t i e n c e ;  i n  f a c t ,  u t i l i t a r i a n i s m  
m u s t  r e j e c t  t h is  v i e w  a s  ‘ s p e c i e s i s t ’ ) .  R e g a r d l e s s  o f  o n e ’ s  c u l t u r a l  a n d  s o c i o - p o l i t i c a l  
b a c k g r o u n d ,  i t  i s  d i f f i c u l t  t o  d e n y  t h a t  h a p p i n e s s  i s  h i g h l y  d e s i r a b l e ,  a n d  m i s e r y  
e x t r e m e l y  u n d e s i r a b l e .  I n  u t i l i t a r i a n i s m ,  t h e  p a r a m o u n t  i m p o r t a n c e  o f  s e n t i e n c e  i s  
t a k e n  a s  a x i o m a t i c .  A c c o r d i n g l y ,  u t i l i t a r i a n i s m  r e g a r d s  s e n t i e n c e  a s  a n  ‘ u l t i m a t e  
p r i n c i p l e ’ , b e c a u s e  p e o p l e  d o  n o t  n e e d  t o  p r o v i d e  f u r t h e r  r e a s o n s  f o r  b e l i e v i n g  t h a t  
h a p p i n e s s  i s  g o o d  a n d  s u f f e r i n g  b a d .  F l o w i n g  f r o m  t h i s ,  u t i l i t a r i a n i s m  p r o p o n e n t s  m a y  
b e  o p t i m i s t i c  t h a t  ( i n  p r i n c i p l e )  e t h i c a l  a g r e e m e n t  i s  p o s s i b l e  b e t w e e n  a l l  p e o p l e .  
I n d e e d ,  u t i l i t a r i a n i s m  m a y  b e  u s e d  i n  o r d e r  t o  g e n e r a t e  ‘ r i g h t s ’ t h a t  w e  c o u l d  ( i n  
p r i n c i p l e )  a l l  a g r e e  u p o n .
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6.5.2.1 Key Features of Utilitarianism
U t i l i t a r i a n i s m ,  l i k e  a l l  e t h i c a l  s y s t e m s ,  e x i s t s  i n  v a r i o u s  f o r m s .  A  t a x o n o m y  o f  t h e  
s u b s p e c i e s  o f  u t i l i t a r i a n i s m  l i e s  o u t s id e  t h e  s c o p e  o f  t h e  p r e s e n t  d i s c u s s i o n .  H o w e v e r ,  
i t  i s  u s e f u l  t o  c o n s i d e r  c e r t a i n  c o r e  i d e a s  t h a t  a r e  c o m m o n  t o  a l l  o r  m o s t  f o r m s  o f  
u t i l i t a r i a n i s m :
• A c t i o n s  a r e  j u d g e d  i n  t e r m s  o f  h a p p i n e s s / m i s e r y
• O v e r a l l  s e n t i e n c e  m u s t  b e  c o n s i d e r e d
• S e n t i e n c e  i m p l i e s  r e s p e c t  f o r  e q u a l i t y  o f  in t e r e s t s
• P o s s i b i l i t i e s  m u s t  b e  c o m p a r e d
• P r o b a b i l i t i e s  m u s t  b e  c o n s i d e r e d
• ‘ S i d e  e f f e c t s ’ m u s t  b e  c o n s i d e r e d
T h e s e  k e y  f e a t u r e s  a r e  d i s c u s s e d  i n  t h e  f o l l o w i n g  s e c t i o n s .
6.5.2.1.1 Actions are judged in terms of happiness/misery
T h i s  i d e a  i s  t h e  m o s t  f u n d a m e n t a l  f e a t u r e  o f  u t i l i t a r i a n i s m :  a s  d e s c r i b e d  p r e v i o u s l y ,  a  
c o u r s e  o f  a c t i o n  i s  e t h i c a l l y  l a u d a b l e  w h e r e  i t s  c o n s e q u e n c e  i s  a n  i n c r e a s e  i n  
h a p p i n e s s ,  o r  a t  l e a s t  a  d e c r e a s e  i n  u n h a p p i n e s s  ( H a r e  1 9 6 3 ;  M i l l  1 8 7 1 ;  Q u i n t o n  1 9 7 3 ;  
S i d g w i c k  1 9 0 7 ;  S m a r t  1 9 7 3 ) .  T o  t a k e  a  s i m p l e  e x a m p l e ,  i t  w o u l d  b e  e t h i c a l l y  c o r r e c t  
( a n d  t h e  c o n v e r s e  e t h i c a l l y  m o n s t r o u s )  f o r  a n  a n a e s t h e t i c  t o  b e  a d m i n i s t e r e d  t o  a  
p a t i e n t  a b o u t  t o  u n d e r g o  m a j o r  a b d o m i n a l  s u r g e r y .
S o m e  f o r m s  o f  u t i l i t a r i a n i s m  v i e w  h a p p i n e s s  a s  s o m e t h i n g  t h a t  i s  c o r r e l a t i v e  t o  d e s ir e  
o r  w a n t .  A c c o r d i n g l y ,  s u c h  f o r m s  o f  u t i l i t a r i a n i s m  c o n s i d e r  t h e  m a x i m a l  s a t i s f a c t i o n  
o f  h u m a n  p r e f e r e n c e s  a s  t h e  c e n t r a l  c o n c e r n  o f  u t i l i t a r i a n  t h e o r y .  H o w e v e r ,  
p r e f e r e n c e - s a t i s f a c t i o n  f u n c t i o n s  a s  a  r o u t e  ( a l b e i t  a n  i n d i r e c t  r o u t e )  t o  m a x i m i s i n g  
h a p p i n e s s  /  r e d u c i n g  s u f f e r i n g  ( B r a n d t  1 9 7 9 ;  H a r s a n y i  1 9 7 7 ;  S c a n l o n  1 9 9 3 ) .  S u c h  
d e s i r e - f u l f i l m e n t  v a r i a n t s  o f  u t i l i t a r i a n i s m  a r e  p r o b a b l y  m o s t  u s e f u l  i n  t h e  c o n t e x t  o f
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p e r s o n a l  e t h i c s  a n d  p o l i t i c a l  p h i l o s o p h y .  D e s i r e - f u l f i l m e n t  i s  l e s s  u s e f u l  f o r  b i o e t h i c a l  
q u e s t i o n s  o f  t h e  s o r t  c o n s i d e r e d  i n  t h i s  t h e s i s ,  w h e r e  d i r e c t  e f f e c t s  o n  s e n t ie n c e  a r e  
g e n e r a l l y  m o r e  r e le v a n t .
6.5.2.1.2 Overall sentience must be considered
T h i s  i d e a  a v o i d s  t h e  u s e  o f  t h e  f o r e g o i n g  c o r e  i d e a  i n  a n  e x c e s s i v e l y  n a r r o w  f a s h i o n .
I n  m a n y  s i t u a t i o n s  i t  c a n n o t  b e  g o o d  e n o u g h  t o  c o n s i d e r  t h e  s e n t i e n c e  o f  j u s t  o n e  
p e r s o n  o r  o f  o n e  p a r t i c u l a r  g r o u p  o f  p e o p l e  ( S c a r r e  1 9 9 6 ;  S i n g e r  1 9 9 3 ) .  F o r  e x a m p l e ,  
a  b a t t l e f i e l d  s u r g e o n  w o u l d  b e  w r o n g  t o  a d m i n i s t e r  s c a r c e  a n a l g e s i c  t o  a  l i g h t l y  
i n j u r e d  p a t i e n t  e x p e r i e n c i n g  m i l d  p a i n  i f  t h is  w o u l d  d e n y  a d e q u a t e  p a i n  r e l i e f  t o  a  
b a d l y  w o u n d e d  p a t i e n t  e n d u r i n g  t e r r ib l e  p a i n .  I t  w o u l d  n o t  b e  g o o d  e n o u g h  t o  c l a i m  
t h a t  t h e  i m p r o v e m e n t  i n  o v e r a l l  h a p p i n e s s  i n  t h e  f i r s t  p a t i e n t  j u s t i f i e s  a n a l g e s i a  f o r  
t h a t  p a t i e n t  b e c a u s e ,  i f  t h e  o v e r a l l  s e n t ie n c e  c h a n g e  w e r e  c o n s i d e r e d ,  t h e  b e s t  o u t c o m e  
w o u l d  b e  o b t a i n e d  b y  r e s e r v i n g  t h e  a n a l g e s i c  f o r  t h e  s e c o n d  p a t i e n t  ( t h e  f i r s t  p a t i e n t  
w o u l d  b e  m i l d l y  m i s e r a b l e ,  b u t  t h e  d e c r e a s e  i n  s u f f e r i n g  e x p e r i e n c e d  b y  t h e  s e c o n d  
p a t i e n t  w o u l d  o u t w e i g h  t h e  f i r s t  p a t i e n t ’ s  u n h a p p i n e s s ) .
6.5.2.1.3 Sentience implies respect for equality of interests
R e s p e c t  f o r  e q u a l i t y  o f  in t e r e s t s  d o e s  n o t  i m p l y  a  p o l i t i c a l  d e f e n c e  o f  e g a l i t a r i a n i s m .  
R a t h e r ,  t h e  n o t i o n  o f  e q u a l  in t e r e s t s  i n  u t i l i t a r i a n i s m  a r i s e s  l o g i c a l l y  f r o m  t h e  c e n t r a l  
b a s i s  o f  u t i l i t a r i a n i s m ,  n a m e l y  s e n t ie n c e .  I f  s e n t i e n c e  i s  t h e  o v e r r i d i n g  m o r a l  
p r i n c i p l e ,  i t  f o l l o w s  t h a t  o t h e r ,  n o n - s e n t i e n t  c h a r a c t e r i s t i c s  o f  t h e  i n d i v i d u a l s  i n  
q u e s t i o n  a r e  n o t  e t h i c a l l y  r e l e v a n t .  T h u s ,  n o n - s e n t i e n t  f e a t u r e s  s u c h  a s  a g e ,  s e x ,  s o c i a l  
p o s i t i o n ,  e d u c a t i o n a l  b a c k g r o u n d ,  p e r s o n a l i t y  o r  I Q  d o  n o t  o f  t h e m s e l v e s  c a r r y  a n y  
w e i g h t  i n  u t i l i t a r i a n  d e l i b e r a t i o n s  ( H a r s a n y i  1 9 9 1 ;  L a n g f o r d  1 9 9 2 ;  S t e i n  2 0 0 2 ) .  F o r  
e x a m p l e ,  t h e  s u f f e r i n g  o f  a n  i l l i t e r a t e  o c t o g e n a r i a n  i s  n o  l e s s  s e r i o u s  t h a n  t h e  s a m e  
d e g r e e  o f  s u f f e r i n g  e x p e r i e n c e d  b y  a  4 0 - y e a r  o l d  h i g h  c o u r t  j u d g e .  S i m i l a r l y ,  t h e  
b a t t l e f i e l d  s u r g e o n  i n  t h e  p r e v i o u s  e x a m p l e  w o u l d  b e  w r o n g  t o  a l l o w  a  p a t i e n t ’ s  
m i l i t a r y  r a n k  t o  i n f l u e n c e  t h e  o u t c o m e  o f  d e l i b e r a t i o n s  o n  t h e  a l l o c a t i o n  o f  s c a r c e  
a n a l g e s i a .
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6.5.2.1.4 Possibilities must be compared
U t i l i t a r i a n s  s h o u l d  n o t  s i m p l y  a c c e p t  t h e  f i r s t  c o u r s e  o f  a c t i o n  t h a t  a lt e r s  t h e  b a l a n c e  
o f  s e n t ie n c e  i n  a  p o s i t i v e  d i r e c t i o n .  I n s t e a d ,  t h e  u t i l i t a r i a n  s h o u l d  in v e s t i g a t e  a n d  
c o m p a r e  a l t e r n a t i v e  c o u r s e s  o f  a c t io n ,  s u c h  t h a t  t h e  m o s t  h a p p i n e s s - e n h a n c i n g  o p t i o n  
m a y  b e  c h o s e n  ( G l o v e r  1 9 7 7 ;  S i n g e r  1 9 9 3 ) .  F o r  e x a m p l e ,  s u p p o s e  a n  u n c o m f o r t a b l e  
a n d  d i s t r e s s i n g  m e d i c a l  p a e d i a t r i c  p r o c e d u r e  w o u l d  d e f i n i t e l y  in c r e a s e  h a p p i n e s s  b y  
i m p r o v i n g  t h e  l o n g - t e r m  h e a l t h  o f  t h e  c h i l d ;  h o w e v e r ,  t h e  g a s t r i c  p r o c e d u r e  w o u l d  n o t  
b e  e t h i c a l l y  j u s t i f i e d  i f  t h e  s a m e  m e d i c a l  e n d s  c o u l d  b e  m e t  b y  a  m o r e  h u m a n e  ( e . g .  
n o n - i n v a s i v e )  p r o c e d u r e .
6.5.2.1.5 Probabilities must be considered
T h e  n e e d  t o  c o n s i d e r  p r o b a b i l i t i e s  i n c o r p o r a t e s  s i m p l e  p r o b a b i l i t y  t h e o r y  in t o  
u t i l i t a r i a n i s m .  T h e  l e s s  p r o b a b l e  a  d e s i r a b l e  o u t c o m e  i s ,  t h e  l e s s  w e i g h t  s h o u l d  b e  
a t t a c h e d  t o  t h e  p r o p o s e d  c o u r s e  o f  a c t i o n  d e s i g n e d  to  d e l i v e r  t h a t  o u t c o m e  
( B e a u c h a m p  a n d  C h i l d r e s s  2 0 0 1 ;  H a r e  1 9 9 3 ;  K u h s e  a n d  S i n g e r  1 9 9 9 ;  S c a r r e  1 9 9 6 ) .  
F o r  e x a m p l e ,  a  s u r g i c a l  i n t e r v e n t i o n  m a y  b e  p r o p o s e d  t o  s e p a r a t e  a  p a i r  o f  c o n j o i n e d  
t w i n s .  T h e  s e p a r a t io n  o f  t h e  t w i n s  w o u l d  b e  a  d e s i r a b l e  o u t c o m e ,  b e c a u s e  t h e  t w i n s  
w o u l d  b e  h a p p i e r  i f  a b l e  t o  l e a d  in d e p e n d e n t  l i v e s  s e p a r a t e  f r o m  e a c h  o t h e r .  O n  t h i s  
b a s i s ,  t h e  s u r g e r y  o u g h t  t o  b e  p e r m it t e d .  H o w e v e r ,  s u p p o s e  t h a t  e x p e r t  o p i n i o n  p l a c e d  
t h e  p r o b a b i l i t y  o f  s u c c e s s  a t  a p p r o x i m a t e l y  3 5 % ,  w i t h  f a i l u r e  i n e v i t a b l y  r e s u l t i n g  i n  
t h e  d e a t h  o f  a t  l e a s t  o n e  o f  t h e  t w i n s .  G i v e n  t h i s  l o w  p r o b a b i l i t y  o f  s u c c e s s ,  t h e  e t h i c a l  
c a s e  f o r  p r o c e e d i n g  w i t h  t h e  s u r g e r y  i s  d e b a t a b l e .  A n d  i f  t h e  e x p e r t  o p i n i o n  h a d  
i n d i c a t e d  a  m u c h  l o w e r  c h a n c e  o f  s u c c e s s ,  s a y  5 % ,  t h e n  t h e  c a s e  f o r  s u r g e r y  w o u l d  b e  
c o n c o m i t a n t l y  w e a k e r  s t i l l .  I n  m a n y  c a s e s ,  t h e  b a l a n c i n g  o f  d e s i r e d  o u t c o m e  w i t h  t h e  
p r o b a b i l i t y  o f  s u c c e s s  w i l l  b e  a n  in h e r e n t l y  s u b j e c t i v e  m a t t e r :  i n  t h e  c o n j o i n e d  t w i n s  
e x a m p l e ,  i t  m a y  b e  b e s t  t o  f u l l y  i n f o r m  t h e  p a t i e n t s  o f  t h e  r i s k s  a n d  t h e n  a l l o w  t h e  
p a t i e n t s  t o  d e c i d e  w h e t h e r  t o  p r o c e e d .  H o w e v e r ,  s i m p l e  c a l c u l a t i o n s  a r e  p o s s i b l e  a n d  
u s e f u l  i n  s o m e  c i r c u m s t a n c e s .  F o r  e x a m p l e ,  s u p p o s e  t h a t  t h e  f o l l o w i n g  s t a t i s t i c s  o n  
t w o  ( h y p o t h e t i c a l )  d r u g s  a r e  a v a i l a b l e  ( a n d  r e l i a b l e ) :  d r u g  A  s a v e s  t h e  l i v e s  -  a n d
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h e n c e  p e r m i t s  a n  a v e r a g e  o f  3 0  f u r t h e r  y e a r s  o f  h a p p i n e s s  p e r  p a t i e n t  -  o f  7 0 %  o f  
p a t i e n t s  w h o  w o u l d  o t h e r w i s e  h a v e  d i e d  w i t h i n  a n  a v e r a g e  o f  5  y e a r s ;  s u p p o s e  a l s o  
t h a t  t h e  d r u g  l e a d s  t o  t h e  d e a t h  w i t h i n  a n  a v e r a g e  o f  1  y e a r  o f  2 0 %  o f  p a t i e n t s  t h r o u g h  
a d v e r s e  r e a c t i o n s .  D r u g  B ,  b y  c o n t r a s t ,  s a v e s  o n l y  5 0 %  o f  p a t i e n t s  ( g i v i n g  a n  a v e r a g e  
o f  3 0  f u r t h e r  y e a r s  o f  h a p p i n e s s  p e r  p a t i e n t ) ;  b u t  s u p p o s e  a l s o  t h a t  t h i s  d r u g  i s  m u c h  
s a f e r  t h a n  d r u g  A ,  a c c i d e n t a l l y  k i l l i n g  ( w i t h i n  1  y e a r )  o n l y  2 %  o f  p a t i e n t s  t h r o u g h  
a d v e r s e  r e a c t i o n s .  F r o m  t h e s e  s t a t i s t i c s ,  i t  i s  p o s s i b l e  t o  c o m p u t e  t h e  a v e r a g e  i n c r e a s e  
i n  l i f e  a s s o c i a t e d  w i t h  e a c h  d r u g ,  a s  f o l l o w s :
D r u g  A :  [ 3 0 y r .  x  7 0 % ]  +  [ l y r .  x  2 0 % ]  +  [ 5 y r .  x  1 0 % ]  =  2 1 . 7 y r .
D r u g  B :  [ 3 0 y r .  x  5 0 % ]  +  [ l y r .  x  0 2 % ]  +  [ 5 y r .  x  4 8 % ]  =  1 7 . 4 y r .
A c c o r d i n g l y ,  i t  w o u l d  b e  e t h i c a l l y  c o r r e c t  t o  p r e s c r i b e  d r u g  A  r a t h e r  t h a n  d r u g  B  
b e c a u s e ,  t a k i n g  t h e  r e l e v a n t  p r o b a b i l i t i e s  in t o  a c c o u n t ,  d r u g  A  w i l l  d e l i v e r  a  h i g h e r  
a v e r a g e  q u a n t i t y  o f  h a p p i n e s s  ( i . e .  4 . 3  e x t r a  y e a r s  o f  l i f e  l i v e d  p e r  p a t i e n t ) .
6.5.2.1.6 ‘Side effects’ must be considered
U t i l i t a r i a n  d e l i b e r a t i o n s  m u s t  t a k e  in t o  a c c o u n t  t h e  ‘ s i d e - e f f e c t s ’ t h a t  a  p r o p o s e d  
c o u r s e  o f  a c t i o n  m a y  c a u s e  ( G l o v e r  1 9 7 7 ) .  F o r  e x a m p l e ,  s o m e  e t h i c i s t s  h a v e  c l a i m e d  
t h a t  i n f a n t i c i d e  o u g h t  t o  b e  p e r m i s s i b l e  f o r  i n f a n t s  b o m  w i t h  d e v a s t a t i n g  m e d i c a l  
d i s o r d e r s ,  w h e r e  s u c h  d i s o r d e r s  w o u l d  c a u s e  a  l i f e  n o t  w o r t h  l i v i n g  ( d u e  t o  a  n e g a t i v e  
b a l a n c e  o f  s e n t ie n c e ) .  U t i l i t a r i a n  c o n s i d e r a t i o n s  g i v e  p r im a  fa c ie  s u p p o r t  t o  t h i s  c l a i m :  
e l i m i n a t i o n  o f  a  l i f e  i n  w h i c h  p a i n  a n d  m i s e r y  o u t w e i g h  p l e a s u r e  w o u l d  g i v e  a  
p o s i t i v e  c o n t r i b u t i o n  t o  t h e  o v e r a l l  b a l a n c e  o f  s e n t i e n c e .  H o w e v e r ,  t h e  p r o b a b l e  s i d e -  
e f f e c t s  o f  s u c h  i n f a n t i c i d e  w o u l d  n e e d  t o  b e  c o n s i d e r e d .  S u c h  s i d e - e f f e c t s  m i g h t  
i n c l u d e  d is t r e s s  f o r  t h e  m e d i c a l  p e r s o n n e l  d e a l i n g  w i t h  s u c h  c a s e s ,  s o c i e t a l  
d i s a p p r o v a l  d i r e c t e d  a t  ( a n d  t h u s  i n f l i c t i n g  s u f f e r i n g  o n )  t h e  i n f a n t s ’ p a r e n t s ,  a n d  t h e  
p o s s i b i l i t y  t h a t  t h e  g e n e r a l l y  h i g h  r e s p e c t  a c c o r d e d  t o  l i f e  b y  s t a t e  a n d  s o c i e t y  m i g h t  
b e  j e o p a r d i s e d  -  t h u s  l e a d i n g  t o  w i d e s p r e a d  s u f f e r i n g ,  d u e  p e r h a p s  t o  a n  e x c e s s i v e  u s e  
o f  i n f a n t i c i d e  a n d  e u t h a n a s i a .  S u c h  p o t e n t ia l  s i d e - e f f e c t s  w o u l d  n e e d  t o  b e  c o n s i d e r e d  
a n d ,  w h e r e  d e e m e d  v a l i d ,  o u g h t  t o  b e  f a c t o r e d  i n t o  u t i l i t a r i a n  d e l i b e r a t i o n s  o n  t h e  
e t h i c a l  p e r m i s s i b i l i t y / r e p r e h e n s i b l y  o f  t h e  p r o p o s e d  i n f a n t i c i d e .
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A n o t h e r  f o r m  o f  s i d e - e f f e c t  i s  t h e  a d d i t i v e  e f f e c t  o f  i n d i v i d u a l  p e r s o n a l  d e c i s i o n s  
a m p l i f i e d  t h r o u g h o u t  s o c i e t y .  F o r  e x a m p l e ,  f u t u r e  t e c h n o l o g y  m a y  p e r m i t  t h e  e f f i c i e n t  
s e p a r a t io n  o f  Y - b e a r i n g  a n d  X - b e a r i n g  s p e r m ,  t h u s  e n a b l i n g  p a r e n t s  t o  e a s i l y  c h o o s e  
t h e  s e x  o f  t h e i r  c h i l d r e n .  U t i l i t a r i a n i s m  w o u l d  s e e m  t o  p r o v i d e  p r im a  fa c ie  s u p p o r t  f o r  
t h e  f r e e d o m  o f  p a r e n t s  t o  u t i l i s e  s u c h  t e c h n o l o g y ,  s i n c e  f r e e d o m  o f  c h o i c e  i s  g e n e r a l l y  
c o m m e n s u r a t e  w i t h  h a p p i n e s s .  A n d ,  i f  o n l y  a  s m a l l  n u m b e r  o f  p a r e n t s  u s e d  s e x  
s e l e c t i o n ,  t h e n  t h e  e f f e c t s  o n  t h e  h u m a n  p o p u l a t i o n  w o u l d  b e  n e g l i g i b l e .  B u t  
p e r m i t t i n g  t h e  w h o l e s a l e  u s e  o f  t h i s  t e c h n o l o g y  ( p e r h a p s  a s  a  c o m m e r c i a l  s e r v i c e )  
m i g h t  w e l l  r e s u l t  i n  t h e  d e v e l o p m e n t  o f  s e r i o u s  i m b a l a n c e s  i n  t h e  s e x  r a t i o s  o f  h u m a n  
p o p u l a t i o n s .  A s s u m i n g  s u c h  i m b a l a n c e s  t o  l e a d  t o  a  r e d u c t i o n  i n  o v e r a l l  h a p p i n e s s ,  
t h e n  t h i s  s i d e - e f f e c t  w o u l d  c o u n t  a g a i n s t  t h e  p o s s i b i l i t y  o f  m a k i n g  s e x  s e l e c t i o n  
a v a i l a b l e  f o r  t h e  g e n e r a l  p o p u l a t i o n  ( D u n s t a n  1 9 8 8 ) .
A  t h i r d  f o r m  o f  s i d e - e f f e c t  t a k e s  t h e  f o r m  o f  a  ‘ s p i r a l ’ , i n  w h i c h  o u t c o m e s  f r o m  a  
c o u r s e  o f  a c t i o n  ‘ s p i r a l ’ i n  a  s e l f - r e i n f o r c i n g  c y c l e  t o  g e n e r a t e  d i s p r o p o r t i o n a t e l y  
s t r o n g  e f f e c t s .  F o r  e x a m p l e ,  I  h a v e  a r g u e d  e l s e w h e r e  t h a t  s e v e r a l  n e g a t i v e  o u t c o m e s  
a r e  l i k e l y  t o  a r i s e  f r o m  s u p p o r t  ( o r  t o l e r a n c e )  a f f o r d e d  t o  i n e f f e c t i v e ,  a n o m a l o u s  o r  
i m p l a u s i b l e  ‘ a l t e r n a t i v e ’ m e d i c a l  t h e r a p i e s  s u c h  a s  c r y s t a l  h e a l i n g ,  r e f l e x o l o g y  o r  
h o m e o p a t h y  ( S m i t h  2 0 0 3 a )  -  s e e  A p p e n d i x  I .  S u c h  o u t c o m e s  i n c l u d e  ( a )  a  d i v e r s i o n  
o f  p u b l i c  a n d  p r i v a t e  r e s o u r c e s  t o w a r d s  u n c o n v e n t i o n a l  t h e r a p i e s  a t  t h e  e x p e n s e  o f  
t h e r a p e u t ic  a p p r o a c h e s  p r e d i c a t e d  u p o n  l o g i c  a n d  e v i d e n c e ,  t o g e t h e r  w i t h  ( b )  a  
w e a k e n i n g  o f  g e n e r a l  c o m m i t m e n t  t o w a r d s  s c i e n c e - b a s e d  m e d i c i n e .  T h e s e  o u t c o m e s  
m a y  in t e r a c t  s y n e r g i s t i c a l l y  a n d  ‘ s p i r a l ’ t o  p r o d u c e  a n  e t h i c a l l y  n e g a t i v e  o u t c o m e  t h a t  
i s  s i g n i f i c a n t l y  w o r s e  t h a n  t h e  a d d i t i v e  e f f e c t s  o f  e a c h .  T h u s ,  c o n s i d e r a t i o n s  o f  t h e  
e t h i c s  o f  p e r m i t t i n g  i n d i v i d u a l s  t h e i r  f r e e  c h o i c e  i n  a c c e s s i n g  ‘ a l t e r n a t i v e ’ m e d i c a l  
t h e r a p i e s  o u g h t  t o  t a k e  in t o  a c c o u n t  t h e  r i s k  o f  a  ‘ s p i r a l ’ s i d e - e f f e c t  o c c u r r i n g .
F i n a l l y ,  i t  s h o u l d  b e  n o t e d  t h a t  s o m e  s i d e - e f f e c t s  m a y  b e  p o s i t i v e ,  r a t h e r  t h a n  
n e g a t i v e .  F o r  e x a m p l e ,  u t i l i t a r i a n s  u s u a l l y  s u p p o r t  v o l u n t a r y  e u t h a n a s i a  f o r  t e r m i n a l l y  
i l l  p a t i e n t s  ( G l o v e r  1 9 7 7 ;  S i n g e r  1 9 9 3 ) .  T h e  u t i l i t a r i a n ’ s  a r g u m e n t ,  p u t  s i m p l y ,  i s  t h a t  
t h e  o v e r a l l  b a l a n c e  o f  h a p p i n e s s  w o u l d  b e  i n c r e a s e d  i f  v o l u n t a r y  e u t h a n a s i a  w e r e  
p e r m it t e d ,  b e c a u s e  p a t i e n t s  w o u l d  h a v e  t h e i r  f r e e d o m  o f  c h o i c e  e n h a n c e d  a n d  t h e i r  
s u f f e r i n g  e l i m i n a t e d .  O p p o n e n t s  o f  v o l u n t a r y  e u t h a n a s i a  m a y  c l a i m  t h a t  c e r t a i n  s i d e -
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e f f e c t s  i n v a l i d a t e  t h i s  p r o - e u t h a n a s i a  p o s i t i o n .  S u c h  s i d e - e f f e c t s  a r e  s i m i l a r  t o  t h o s e  
o u t l i n e d  a b o v e  i n  t h e  i n f a n t i c i d e  e x a m p l e ,  a n d  i n c l u d e  d i s t r e s s  f o r  t h e  m e d i c a l  
p e r s o n n e l ,  a  w i d e s p r e a d  f e a r  o f  b e i n g  p r e s s u r e d  in t o  a c c e p t i n g  e u t h a n a s i a ,  a n d  a  
r e d u c t i o n  i n  s t a t e  a n d  s o c i e t i e s  n o r m a l l y  h i g h  r e g a r d  f o r  p r e s e r v i n g  l i f e ,  p o s s i b l y  
l e a d i n g  t o  c o m p u l s o r y  e u t h a n a s i a .  T h e s e  s i d e - e f f e c t s  m u s t  b e  a s s e s s e d  a n d  f a c t o r e d  
i n t o  t h e  u t i l i t a r i a n  d e b a t e ,  i n s o f a r  a s  t h e y  a r e  v a l i d .  ( I n  m y  v i e w  s u c h  c l a i m s  a r e  
s c a r c e l y  v a l i d  a n d  t h u s  f a i l  t o  t o r p e d o  t h e  p r o - e u t h a n a s i a  u t i l i t a r i a n  a r g u m e n t ;  
h o w e v e r  a n  i n - d e p t h  d i s c u s s i o n  a n d  r e f u t a t io n  o f  s u c h  c l a i m e d  s i d e - e f f e c t s  i s  b e y o n d  
t h e  s c o p e  o f  t h i s  t h e s i s . )  B u t  i n  a d d i t i o n  t o  t h e s e  n e g a t i v e  c l a i m e d  s i d e - e f f e c t s ,  
p o s it iv e  s i d e - e f f e c t s  f r o m  t h e  a d o p t io n  o f  v o l u n t a r y  e u t h a n a s i a  a r e  a l s o  p l a u s i b l e .  
P a t i e n t s  m i g h t  c o m e  t o  f e a r  i n f i r m i t y  a n d  t e r m i n a l  i l l n e s s  l e s s ,  s e c u r e  i n  t h e  
k n o w l e d g e  t h a t  t h e  m e d i c a l l y  p r o v i d e d  p a i n l e s s  d e a t h  i s  a v a i l a b l e  a s  a  f i n a l  r e l e a s e  
f r o m  s u f f e r i n g ,  i f  s o  d e s i r e d  b y  t h e  p a t ie n t .  S i m i l a r l y ,  r e l a t i v e s  a n d  f r i e n d s  o f  
t e r m i n a l l y  i l l  p a t i e n t s  m i g h t  b e  g r e a t l y  r e l i e v e d  b y  t h e  k n o w l e d g e  t h a t  t h e r e  i s  a  
m e d i c a l  w a y  o f  a v o i d i n g  e n d - o f - l i f e  s u f f e r i n g .  A n d  m e d i c a l  s t a f f  w o u l d  n o  l o n g e r  
h a v e  t o  s u f f e r  t h e  s t r e s s  o f  e f f e c t i v e l y  p r o l o n g i n g  t h e  s u f f e r i n g  o f  t e r m i n a l l y  i l l  
p a t i e n t s  w h o  r e q u e s t  v o l u n t a r y  e u t h a n a s ia .
6.5.2.2 Problems with Utilitarianism
A s  w i t h  a l l  e t h i c a l  s y s t e m s ,  u t i l i t a r i a n i s m  i s  a s s o c i a t e d  w i t h  c e r t a i n  c r i t i c i s m s  a n d  
l i m i t a t i o n s :
• H a p p i n e s s / m i s e r y  a r e  d i f f i c u l t  t o  q u a n t i f y
• U t i l i t a r i a n  d e l i b e r a t i o n s  c a n  b e  h i g h l y  c o m p l e x
• D r u g - i n d u c e d  h a p p i n e s s
• I n d i v i d u a l  h a p p i n e s s  v s .  t h e  h a p p i n e s s  o f  m a n y
• A g e n t s  v s .  a c t i o n s
• U n l i m i t e d  m o r a l  d e m a n d s
• R a d i c a l ,  n o n - i n t u i t i v e  c o n c l u s i o n s
• U t i l i t a r i a n i s m  c o u l d  b e  u s e d  w r o n g l y
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T h e  f o l l o w i n g  s e c t i o n s  d i s c u s s  t h e s e  p r o b l e m s .
6.5.2.2.1 Happiness/misery are difficult to quantify
I t  i s  a  f a c t  t h a t  h a p p i n e s s  a n d  m i s e r y  a r e  d i f f i c u l t  t o  q u a n t i f y  ( D o l a n  2 0 0 1 ;  E a s t e r l i n  
2 0 0 3 ;  H a y b r o n  2 0 0 1 ;  N g  2 0 0 0 ;  V a n  P r a a g  e t  a l .  2 0 0 3 ;  Z i z z o  2 0 0 2 ) .  T h i s  i s  a  p r o b l e m  
f o r  u t i l i t a r i a n i s m .  S o m e  e m p i r i c a l  r e s e a r c h  s u g g e s t s  t h a t  q u a n t i f i c a t i o n  m i g h t  i n  f u t u r e  
b e c o m e  p o s s i b l e ,  g i v e n  m a j o r  t e c h n i c a l  i m p r o v e m e n t s  i n  f i e l d s  s u c h  a s  
n e u r o e n d o c r i n o l o g y  a n d  b r a i n  i m a g i n g .  M e a n w h i l e ,  i t  r e m a i n s  t h e  c a s e  t h a t  d e g r e e s  
o f  h a p p i n e s s  a n d  u n h a p p i n e s s  c a n  o n l y  b e  e s t im a t e d .  O n e  w a y  f o r w a r d  m a y  b e  t o  
e m p l o y  s u i t a b l e  p s y c h o l o g i c a l  r e s e a r c h  m e t h o d s  s u c h  a s  q u e s t i o n n a i r e  a p p r o a c h e s .
F o r  e x a m p l e ,  f o r  s o m e  g e n e t ic  d i s o r d e r s ,  a b o r t i o n  o r  e v e n  i n f a n t i c i d e  m a y  b e  
c o n s i d e r e d  a p p r o p r ia t e  b y  u t i l i t a r i a n s  i n  c a s e s  w h e r e  t h e  l i f e  o f  t h e  r e s u l t i n g  p e r s o n  
w a s  d e s t i n e d  t o  c o n t a i n  m o r e  s u f f e r i n g  t h a n  h a p p i n e s s .  I n  s u c h  c a s e s ,  p s y c h o l o g i c a l  
r e s e a r c h  in t o  t h e  a c t u a l  d e g r e e  o f  s u f f e r i n g  ( v s .  h a p p i n e s s )  e x p e r i e n c e d  b y  r e a l  p e o p l e  
w i t h  t h e  d i s o r d e r  w o u l d  b e  i n d i c a t e d  -  i d e a l l y  b y  s o l i c i t i n g  r e s p o n s e s  f r o m  t h e  
p a t i e n t s  t h e m s e l v e s  o r ,  w h e r e  t h e  p a t i e n t s  w e r e  n o n - c o m p e t e n t ,  f r o m  t h e i r  p a r e n t s  o r  
c a r e r s .
I t  s e e m s  c l e a r  t h a t  p s y c h o l o g i c a l  i n v e s t i g a t i o n  a n d  ( m o r e  f u t u r i s t i c a l l y )  
n e u r o b i o l o g i c a l  a n a l y s i s  a r e  t o o l s  t h a t  s h o u l d  w h e r e v e r  p o s s i b l e  b e  e m p l o y e d  i n  
a t t e m p t s  t o  d e t e r m i n e  h a p p i n e s s / m i s e r y  l e v e l s .  I t  i s  a l s o  a p p a r e n t  t h a t  s u c h  a p p r o a c h e s  
a r e  a t  p r e s e n t  i n s u f f i c i e n t l y  d e v e l o p e d  t o  o b t a i n  r e l i a b l e  q u a n t i t a t i v e  d a t a  i n  m o s t  
e t h i c a l  d i l e m m a s .  H o w e v e r ,  t h i s  i s  n o t  a n  i n s u r m o u n t a b l e  p r o b l e m .  I n  m a n y  c a s e s ,  t h e  
b a l a n c e  o f  h a p p i n e s s  v s .  s u f f e r i n g  i s  q u i t e  o b v i o u s ,  w i t h o u t  r e q u i r i n g  q u a n t i f i c a t i o n .  
F o r  e x a m p l e ,  r e p e a t e d  r e s u s c i t a t i o n  o f  a  t e r m i n a l l y  i l l  p a t i e n t  a g a i n s t  h i s  i n s t r u c t i o n s ,  
u s i n g  i n v a s i v e  e m e r g e n c y  p r o c e d u r e s ,  w o u l d  c l e a r l y  c a u s e  s e r i o u s  s u f f e r i n g  t o  t h e  
p a t i e n t ,  w i t h o u t  a  c o u n t e r b a l a n c i n g  g e n e r a t io n  o f  h a p p i n e s s .  A c c o r d i n g l y ,  u t i l i t a r i a n s  
w o u l d  j u d g e  i t  w r o n g  t o  u s e  r e s u s c i t a t i o n  i n  s u c h  p a t i e n t s ,  d e s p i t e  t h e  l a c k  o f  a n y  
f o r m  o f  q u a n t it a t iv e  d a t a  o n  t h e  d e g r e e  o f  s u f f e r i n g .  S i m i l a r l y ,  i t  i s  o f t e n  c l e a r  w h i c h  
o f  t w o  ( o r  m o r e )  o p t io n s  w i l l  c a u s e  t h e  l e a s t  s u f f e r i n g .  T o  t a k e  a  v e r y  s i m p l e  e x a m p l e ,  
s u p p o s e  t h a t  a  y o u n g  c h i l d  w i l l  d i e  u n l e s s  a  d i s e a s e d  l u n g  i s  o p e r a t e d  u p o n ,  b u t  t h a t  
t h e  o p e r a t io n  i s  v e r y  i n v a s i v e  a n d  w i l l  c a u s e  t h e  c h i l d  a  g r e a t  d e a l  o f  p o s t - s u r g e r y
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s u f f e r i n g .  T h e  c h o i c e  -  t o  o p e r a t e  o r  n o t  -  s h o u l d  b e  c l e a r  f o r  u t i l i t a r i a n s :  t h e  o p e r a t io n  
s h o u l d  t a k e  p l a c e ,  b e c a u s e  t h e  ( u n q u a n t i f i a b l e )  a m o u n t  o f  s h o r t - t e r m  s u f f e r i n g  c a u s e d  
b y  t h e  s u r g e r y  w i l l  b e  h e a v i l y  o u t w e i g h e d  b y  t h e  h a p p i n e s s  ( a g a i n  u n q u a n t i f i a b l e )  t h a t  
t h e  c h i l d  s h o u l d  e x p e r i e n c e  t h r o u g h o u t  t h e  s u b s e q u e n t  y e a r s  o f  s a v e d  l i f e .  O f  c o u r s e ,  
s i m p l e  e x a m p l e s  s u c h  a s  t h e  f o r e g o i n g  g i v e  e a s y  a n s w e r s :  i n  m a n y  c a s e s ,  t h e  b a l a n c e  
o f  h a p p i n e s s  a n d  m i s e r y  i s  l e s s  e a s y  to  a s c e r t a i n ,  a n d  it  m a y  b e  c o n t e n t i o u s .  H o w e v e r ,  
t h e r e  i s  n o  o p t i o n  i n  s u c h  c a s e s  o t h e r  t h a n  t o  e v a l u a t e  a l l  r e l e v a n t  e v i d e n c e  a n d  d e b a t e  
t h e  l i k e l y  e f f e c t s  o n  h a p p i n e s s / s u f f e r i n g  o f  a l t e r n a t i v e  w a y s  o f  p r o c e e d i n g .  E t h i c a l  
d e c i s i o n s  s o m e t i m e s  n e e d  t o  b e  r e a c h e d  o n  t h e  b a s i s  o f  l e s s  t h a n  p e r f e c t  i n f o r m a t i o n .  
H o w e v e r ,  t h e  f a c t  t h a t  h a p p i n e s s  a n d  m i s e r y  c a n n o t  b e  a c c u r a t e l y  q u a n t i f i e d  d o e s  n o t  
a m o u n t  t o  g r o u n d s  f o r  a  r e j e c t i o n  o f  u t i l i t a r i a n i s m .
6.5.2.2.2 Utilitarian deliberations can be highly complex
T h e  c o n c e r n  t h a t  u t i l i t a r i a n  d e l i b e r a t i o n s  c a n  b e  h i g h l y  c o m p l e x  i s  d i r e c t l y  r e l a t e d  t o  
t h e  p r e v i o u s  p r o b l e m .  J u s t  a s  i t  i s  t r u e  t h a t  h a p p i n e s s / m i s e r y  a r e  d i f f i c u l t  t o  q u a n t i f y ,  
i t  i s  a l s o  t r u e  t h a t  d e l i b e r a t i o n s  d e s i g n e d  a t  d e t e r m i n i n g  t h e  lik e lih o o d  o f  i n c r e a s i n g  
h a p p i n e s s  ( o r  r e d u c i n g  m i s e r y )  a r e  f r e q u e n t l y  f r a u g h t  w i t h  c o m p l e x i t y .  A s  d i s c u s s e d  
i n  t h e  l a s t  s e c t io n ,  u t i l i t a r i a n  d e l i b e r a t i o n s  m u s t  c o n s i d e r  s e v e r a l  f a c t o r s ,  i n c l u d i n g  
o v e r a l l  s e n t ie n c e ,  a l t e r n a t i v e  p o s s i b i l i t i e s  a n d  s i d e  e f f e c t s .  A c c o r d i n g l y ,  a p p a r e n t l y  
s i m p l e  c a s e s  m a y  u p o n  d e e p e r  c o n s i d e r a t i o n  t u r n  o u t  t o  b e  m o r e  c o m p l i c a t e d  t h a n  
w a s  i n i t i a l l y  a p p a r e n t .  F o r  e x a m p l e ,  t h e  a d o p t i o n  o f  a n  ‘ o p t - o u t ’ o r g a n  d o n o r  r e g i s t e r  
( t o  r e p l a c e  t h e  ‘ o p t - i n ’ s y s t e m  p r e v a l e n t  i n  m a n y  c o u n t r i e s ,  s u c h  a s  t h e  U K )  w o u l d  
s e e m  t o  b e  c l e a r l y  s u p p o r t e d  b y  u t i l i t a r i a n  c o n s i d e r a t i o n s :  i n c r e a s i n g  t h e  o r g a n  s u p p l y  
w o u l d  s a v e  l i v e s ,  r e d u c e  t i m e  s p e n t  o n  d i a l y s i s  a n d  o t h e r  ‘ h o l d i n g ’ p r o c e d u r e s ,  a n d  
t h u s  in c r e a s e  o v e r a l l  h a p p i n e s s .  H o w e v e r ,  u p o n  r e f l e c t i o n  t h e r e  a r e  f u r t h e r  q u e s t i o n s  
t h a t  n e e d  t o  b e  c o n s i d e r e d ,  i n c l u d i n g  t h e  f o l l o w i n g :  ( a )  w o u l d  s u c h  a  s y s t e m  c a u s e  
s u f f e r i n g  a m o n g s t  n o n - c o n s e n t i n g  r e l a t i v e s ?  ( b )  W o u l d  t h e  p o p u l a c e  b e  p l a c e d  i n  f e a r  
o f  o v e r z e a l o u s  o r g a n  r e c o v e r y ?  ( c )  W o u l d  t h e  m e d i c a l  i n f r a s t r u c t u r e  b e  a b l e  t o  u t i l i s e  
t h e  e x t r a  o r g a n s ,  o r  s h o u l d  t h e  m o n e y  i n v e s t e d  i n  t h e  d a t a b a s e  b e  b e t t e r  s p e n t  
e l s e w h e r e  ( e .g .  o n  r e s e a r c h  i n t o  a lt e r n a t i v e s  t o  a l l o t r a n s p l a n t a t i o n  s u c h  a s  
x e n o t r a n s p l a n t a t i o n ) ?  T h u s ,  w h a t  a p p e a r e d  i n i t i a l l y  a s  a  c l e a r - c u t  c h o i c e  b e c o m e s  
c o m p l i c a t e d  a s  m o r e  p o s s i b i l i t i e s  a n d  c o n c e r n s  a r e  r a i s e d  ( o f  c o u r s e ,  s u c h  c o m p l e x i t y
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d o e s  n o t  n e c e s s a r i l y  c h a n g e  t h e  o r i g i n a l  c o n c l u s i o n :  t h e  u t i l i t a r i a n ,  h a v i n g  w e i g h e d  u p  
t h e  v a r i o u s  n e w  f a c t o r s ,  m a y  s t i l l  b e  j u s t i f i e d  i n  a p p r o v i n g  a n  ‘ o p t - o u t ’ d o n o r  s y s t e m ) .  
A s  w i t h  t h e  d i f f i c u l t y  o f  d e t e r m i n i n g  l e v e l s  o f  h a p p i n e s s / m i s e r y ,  t h e  p r o b l e m  o f  
c o m p l e x i t y  d o e s  n o t  g i v e  c a u s e  f o r  a b a n d o n i n g  u t i l i t a r i a n i s m .  R a t h e r ,  i t  s h o u l d  s e r v e  
a s  a  w a r n i n g  f o r  u t i l i t a r i a n s  t o  a p p r o a c h  e t h i c a l  d i l e m m a s  i n  a  m a x i m a l l y  r e f l e c t i v e  
a n d  d i s c u r s i v e  m a n n e r ,  a n d  t o  o b t a i n  a s  m u c h  r e l e v a n t  e m p i r i c a l  e v i d e n c e  a s  p o s s i b l e ,  
i n  o r d e r  t o  d e c i d e  u p o n  t h e  e t h i c a l l y  c o r r e c t  c o u r s e  o f  a c t io n .
6.5.2.2.3 Drug-induced happiness
T h e  p r o b l e m  o f  d r u g - i n d u c e d  h a p p i n e s s  i s  o f t e n  u s e d  i n  a t t e m p t s  t o  r e f u t e  
u t i l i t a r i a n i s m  ( N o z i k  1 9 7 4 ;  S c a r r e  1 9 9 6 ) .  O p p o n e n t s  o f  u t i l i t a r i a n i s m  c o m m o n l y  
p r e s e n t  t h e  f o l l o w i n g  a s  a  k n o c k d o w n  a r g u m e n t :
A .  H a p p i n e s s  a s  t h e  p i v o t a l l y  i m p o r t a n t  f e a t u r e  o f  u t i l i t a r i a n i s m .
B .  H a p p i n e s s  c o u l d  b e  i n d u c e d  s i m p l y  b y  a d d i n g  a n  a p p r o p r ia t e  d r u g  t o  t h e  
w a t e r  s u p p l y .
C .  T h e r e f o r e  u t i l i t a r i a n i s m  is  t o p p l e d  a s  a  m o r a l  s y s t e m .
B u t  t h i s  i s  a n  o v e r l y  s i m p l i s t i c  a r g u m e n t .  S e n t i e n c e  i s  a n  e v o l v e d - i n  f e a t u r e s  o f  
a n i m a l s ;  p o s i t i v e  e m o t i o n a l  s t a t e s  ( h a p p i n e s s ,  p l e a s u r e ,  e c s t a s y ,  e t c )  s e r v e  t o  s i g n a l  
t h a t  a l l  i s  w e l l ,  w h e r e a s  n e g a t i v e  e m o t i o n a l  s t a t e s  ( p a i n ,  h u n g e r ,  t e r r o r ,  e t c )  s e r v e  t o  
s p u r  a c t i o n  ( i . e .  s e e k i n g  s h e l t e r ,  l o c a t i n g  f o o d ,  a v o i d i n g  d a n g e r ,  e t c ) .  I n  t h e  a b s e n c e  o f  
t h i s  c o r r e l a t io n  b e t w e e n  r e a l - w o r l d  s i t u a t i o n s  a n d  e m o t i o n a l  s t a t e s ,  s e n t ie n t  b e i n g s  
w o u l d  b e  u n a b l e  t o  s u r v i v e .  I f  a  t r u l y  e f f e c t i v e  h a p p i n e s s - i n d u c i n g  d r u g  w e r e  a d d e d  t o  
t h e  p u b l i c  w a t e r  s u p p l y ,  t h e  p o p u l a c e  w o u l d  p r e s u m a b l y  r e m a i n  h a p p y  w h i l e  f o o d  r a n  
o u t ,  w h i l e  d i s e a s e  s p r e a d  a n d  w h i l e  c h i l d r e n  w e r e  n e g l e c t e d ;  i n  t h e  p r e s e n c e  o f  s u c h  
d r u g - i n d u c e d  h a p p i n e s s  t h e r e  w o u l d  b e  n o  i m p e t u s  t o  p u r s u e  m i s e r y - r e d u c i n g  
m e a s u r e s .  T h u s ,  t h e  d r u g - i n d u c e d  h a p p i n e s s  w o u l d  b e  v e r y  s h o r t  l i v e d ,  a s  t h e  
p o p u l a t i o n  d w i n d l e d .  A c c o r d i n g l y ,  u t i l i t a r i a n i s m  i m p l i c i t l y  r e j e c t s  a s  u n e t h i c a l  s u c h  
d r u g - i n d u c e d  h a p p i n e s s ,  o n  a c c o u n t  o f  t h e  l o n g - t e r m  r e d u c t i o n  i n  h a p p i n e s s  e n t a i l e d  
b y  t h e  u s e  o f  a  h a p p i n e s s  d r u g .
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O f  c o u r s e ,  i t  i s  p o s s i b l e  t o  e n v i s a g e  a  f u t u r i s t i c  s i t u a t i o n  i n  w h i c h  s o m e  f o r m  o f  
e f f e c t i v e  m a c h i n e  ( o f  g l o b a l  m a g n i t u d e )  s u p p l i e s  a l l  t h e  m a t e r i a l  n e e d s  o f  h u m a n i t y ,  
w h i l e  h u m a n s  e x i s t  i n  a  s t a t e  o f  d r u g - i n d u c e d  h a p p i n e s s .  A s i d e  f r o m  i s s u e s  o f  
i m p l a u s i b i l i t y ,  t h e  m a j o r  p r o b l e m  f o r  t h i s  s c e n a r i o  i s  t h a t  it  c o n v e r t s  p e o p l e  f r o m  
i n d i v i d u a l s  p o s s e s s i n g  t h e  p o t e n t i a l  to  a c t  a s  m o r a l  a g e n t s  in t o  p a s s i v e  b e i n g s  u n a b l e  
t o  c o n t r i b u t e  t o  e t h i c a l  d e c i s i o n s .  T h u s ,  t h e  a d o p t i o n  o f  s u c h  a  ‘ u t i l i t y  m a c h i n e ’ w o u l d  
i m p l y  t h e  e n d  o f  a n y  p o s s i b i l i t y  o f  e t h i c a l  p r o g r e s s .  A c c o r d i n g l y ,  i t  a p p e a r s  t h a t ,  
i n s t e a d  o f  u n d e r m i n i n g  u t i l i t a r i a n i s m ,  h a p p i n e s s  d r u g s  a n d  ‘ u t i l i t y  m a c h i n e s ’ a r e  
t h e m s e l v e s  i n v a l i d a t e d  o n  t h e  u t i l i t a r i a n  p e r s p e c t i v e .
A l t h o u g h  it  c a n  b e  e f f e c t i v e l y  a r g u e d  t h a t  t h e  n o t i o n  o f  d r u g - i n d u c e d  h a p p i n e s s  f a i l s  
t o  t o p p l e  u t i l i t a r i a n i s m ,  i t  n e e d  n o t  b e  c o n c l u d e d  t h a t  d r u g - i n d u c e d  h a p p i n e s s  p e r  s e  i s  
o f  n o  u t i l i t y .  C o n s i d e r  s o m e b o d y  i n  t h e  f i n a l  s t a g e s  o f  t e r m i n a l  i l l n e s s ,  o r  a  m a i m e d  
b a t t l e f i e l d  v i c t i m ,  o r  a  p o s t - o p e r a t i v e  p a t i e n t :  s u c h  p e r s o n s  m a y  w e l l  b e n e f i t  f r o m  -  
a n d  s t r o n g l y  d e s ir e  -  a  ‘ h a p p i n e s s  d r u g ’ , i f  o n l y  t o  r e l i e v e  t h e i r  p a i n  o r  m i s e r y .  A n d  
in d e e d  s u c h  m e d i c a t i o n  i s  c o m m o n l y  o f f e r e d  t o  s u c h  p e r s o n s ,  i n  t h e  f o r m  o f  o p ia t e s  
a n d  a n x i o l y t i c s .  T h e  d i f f e r e n c e  b e t w e e n  s u c h  d r u g - i n d u c e d  h a p p i n e s s  a n d  t h e  
‘ u n i v e r s a l ’ f o r m  r e j e c t e d  a b o v e  l i e s  i n  t h e  l i m i t e d ,  t e m p o r a r y  a n d  v o l u n t a r y  n a t u r e  o f  
t h e  f o r m e r  c o m p a r e d  w i t h  t h e  g l o b a l ,  p e r m a n e n t  a n d  c o m p u l s o r y  n a t u r e  o f  t h e  la t t e r .
6.5.2.2.4 Individual happiness vs. the happiness of many
T h e  p o t e n t ia l  c o n f l i c t  b e t w e e n  t h e  h a p p i n e s s  o f  p a r t i c u l a r  i n d i v i d u a l s  a n d  t h e  g e n e r a l  
h a p p i n e s s  p r e s e n t s  a  d i f f i c u l t y  f o r  u t i l i t a r i a n i s m  ( G l o v e r  1 9 7 7 ;  M i l l  1 8 7 1 ;  P a r f i t t  
1 9 8 4 ;  S c a r r e  1 9 9 6 ) .  I f  t h e  g e n e r a l  h a p p i n e s s  i s  w h a t  c o u n t s ,  t h e n  i t  s e e m s  t o  f o l l o w  
t h a t  t h e  h a p p i n e s s  o f  i n d i v i d u a l s  m a y  b e  s a c r i f i c e d  f o r  t h e  h a p p i n e s s  o f  a  g r e a t e r  
n u m b e r .  U t i l i t a r i a n i s m  m i g h t  s e e m  to  f a v o u r  a  n u m b e r  o f  r e p u g n a n t  a c t i o n s  o r  
s i t u a t i o n s  s u c h  a s  c o m p u l s o r y  s t e r i l i s a t i o n  o f  i n d i v i d u a l s  a t  r i s k  o f  t r a n s m i t t i n g  a  
s e r i o u s  g e n e t ic  d i s o r d e r ,  a n d  p e r m a n e n t  q u a r a n t i n e  o r  e v e n  d e a t h  f o r  t h o s e  in f e c t e d  
w i t h  H I V .  I n  s u c h  c a s e s ,  t h e  b e n e f i t s  t o  t h e  m a j o r i t y  -  p r e v e n t i o n  o f  d i s e a s e  a n d  
a v o i d a n c e  o f  a t t e n d a n t  s u f f e r i n g  -  w o u l d  a p p e a r  t o  o u t w e i g h  t h e  c o s t s  b o r n e  b y  t h e  
m i n o r i t y .  T h u s ,  t h e  c h a r g e  i s  t h a t  u t i l i t a r i a n i s m  i s  i n h e r e n t l y  u n f a i r ,  u n j u s t  a n d  l a c k i n g  
i n  r e s p e c t  o f  i n d i v i d u a l  p e r s o n s .
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H o w e v e r ,  t h e  q u e s t i o n  n e e d s  t o  b e  a s k e d :  D o e s  u t i l i t a r i a n i s m  a c t u a l l y  i m p l y  s u c h  
r e p r e h e n s i b l e  c o u r s e s  o f  a c t i o n ?  I  s u g g e s t  t h e  a n s w e r  i s  e m p h a t i c a l l y  n o .  I n  p r a c t i c e ,  
r u n n i n g  r o u g h s h o d  o v e r  i n d i v i d u a l  l i f e  a n d  l i b e r t y  i s  l i k e l y  t o  r e s u l t  i n  a  s t a t e  o f  f e a r  
a n d  d is c o n t e n t ,  a n d  h e n c e  d e s t r o y  n o r m a l  s o c i e t y .  S i n c e  s u c h  a  d i s a s t r o u s  o u t c o m e  i s  
c l e a r l y  o n e  o f  g r e a t  d i s u t i l i t y ,  u t i l i t a r i a n i s m  c o u l d  n o t  s u p p o r t  r e p u g n a n t  a c t i o n s  
a g a i n s t  m i n o r i t i e s  o r  i n d i v i d u a l s ,  e v e n  w h e r e  a  p r im a  fa c ie  c a s e  m a y  b e  m a d e  i n  
f a v o u r  o f  s u c h  a c t i o n s  o n  t h e  g r o u n d s  o f  t h e  g e n e r a l  g o o d .  T h u s ,  i t  w o u l d  b e  h i g h l y  
s i m p l i s t i c ,  o r  a  d i s t o r t i o n ,  t o  s u p p o s e  t h a t  u t i l i t a r i a n i s m  r u n s  c o n t r a r y  t o  c o m m o n  
n o t i o n s  o f  f a i r n e s s ,  j u s t i c e  a n d  r e s p e c t .
A l t h o u g h  u t i l i t a r i a n i s m  d o e s  n o t  i m p l y  t h e  b l a t a n t  s a c r i f i c e  o f  t h e  f e w  f o r  t h e  g o o d  o f  
t h e  m a n y ,  s o m e  u t i l i t a r i a n  e t h i c i s t s  h a v e  s u g g e s t e d  t h a t  t h e  u t i l i t a r i a n  a p p r o a c h  o u g h t  
t o  b e  t e m p e r e d  b y  a n  a d d i t i o n a l  p r i n c i p l e  b e y o n d  t h e  h a p p i n e s s / m i s e r y  c a l c u l u s ,  
n a m e l y  resp ec t f o r  au ton om y  ( G l o v e r  1 9 7 7 ) .  T h i s  p r i n c i p l e  i s  p a r t i c u l a r l y  s a l i e n t  i n  
t h e  c o n t e x t  o f  d e c i s i o n s  c o n c e r n i n g  i n d i v i d u a l  p e o p l e .  T h e  p r i n c i p l e  o f  r e s p e c t  f o r  
a u t o n o m y  h o l d s  t h a t  a  c o m p e t e n t ,  i n f o r m e d  p e r s o n  ( s u c h  a s  a n  a d u l t  p a t i e n t )  o u g h t  t o  
h a v e  t h e  f r e e d o m  t o  c h o o s e  w h e t h e r  o r  n o t  t o  c o n s e n t  t o  a  p r o p o s e d  c o u r s e  o f  a c t i o n  
( s u c h  a s  a  m e d i c a l  p r o c e d u r e ) ,  r e g a r d l e s s  o f  t h e  a s s o c i a t e d  o b j e c t i v e  b e n e f i t s  ( t o  t h e  
g r e a t e r  h a p p i n e s s  o r  t o  t h e  i n d i v i d u a l  c o n c e r n e d ) .  H o w e v e r ,  i t  i s  w o r t h  n o t i n g  t h a t  t h e  
p r i n c i p l e  o f  a u t o n o m y  i s  i t s e l f  d e r i v a b l e  f r o m  u t i l i t a r i a n  c o n s i d e r a t i o n s  b e c a u s e ,  o n c e  
a g a i n ,  i n  t h e  l o n g  r u n  it  w o u l d  b e  d e t r im e n t a l  t o  t h e  g e n e r a l  w e l l b e i n g  i f  t h e  a u t o n o m y  
o f  i n d i v i d u a l s  w e r e  t o  b e  r o u t i n e l y  d i s r e g a r d e d .
A l t h o u g h  I  h a v e  c o n c l u d e d  t h a t  u t i l i t a r i a n i s m  i s  n o t  i n  f a c t  t h e  u n f a i r  a n d  u n j u s t  
s y s t e m  c l a i m e d  b y  i t s  o p p o n e n t s ,  n e v e r t h e l e s s  i t  s h o u l d  b e  n o t e d  t h a t  t h e r e  m a y  b e  
r a r e  o c c a s i o n s  w h e n  i t  w o u l d  i n d e e d  b e  b e t t e r  f o r  t h e  f e w  t o  s u f f e r  i n  o r d e r  t o  b e n e f i t  
t h e  v a s t  m a j o r i t y .  T o  t a k e  a  h y p o t h e t i c a l  s i t u a t i o n :  s u p p o s e  ( a )  t h a t  a  h i g h l y  i n f e c t i o u s  
n e w  d i s e a s e  i s  p o i s e d  t o  c a u s e  w i d e s p r e a d  h u m a n  d e a t h  a n d  m o r b i d i t y ,  ( b )  t h a t  
s c i e n t i s t s  h a v e  p r o d u c e d  a  v a c c i n e  t h a t  i s  a b l e  t o  p r e v e n t  t h e  d i s e a s e  a n d  ( c )  t h a t  t h e  
e f f e c t i v e n e s s  o f  t h e  v a c c i n e  d e p e n d s  u p o n  9 5 %  o f  t h e  p o p u l a t i o n  b e i n g  v a c c i n a t e d .  I n  
t h i s  c a s e ,  a  s t r o n g  u t i l i t a r i a n  a r g u m e n t  c o u l d  b e  m a d e  i n  f a v o u r  o f  c o m p u l s o r y  
v a c c i n a t i o n ,  d e s p it e  t h e  c o s t s  t o  t h e  m i n o r i t y  w h o  r e f u s e  t o  b e  v a c c i n a t e d  ( i . e .  l o s s  o f  
a u t o n o m y  a n d  o c c a s i o n a l  a d v e r s e  r e a c t i o n s  t o  t h e  v a c c i n e ) .  I n  e x t r a o r d i n a r y  c a s e s
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s u c h  a s  t h i s ,  t h e  a r g u m e n t s  i n  f a v o u r  o f  a c t i n g  t o  s e c u r e  t h e  g e n e r a l  g o o d  w o u l d  
a p p e a r  t o  b e  d i f f i c u l t  t o  r e f u t e .  C e r t a i n l y ,  b y  p e r m i t t i n g  s o m e  r e l a x a t i o n  o f  n o r m a l  
m o r e s  o f  b e h a v i o u r  in extrem is, u t i l i t a r i a n i s m  s t a y s  i n  c l o s e  a p p r o x i m a t i o n  t o  
c o m m o n  s e n s e  m o r a l i t y .
A  f i n a l  c o n s i d e r a t i o n  i n  t h e  c o n t e x t  o f  t h e  h a p p i n e s s  o f  t h e  f e w  v s .  t h e  h a p p i n e s s  o f  
m a n y  c o n c e r n s  t h e  f o l l o w i n g  s c e n a r io :  F o r  a n y  l a r g e  p o p u l a t i o n  o f  p e o p l e ,  a l l  w i t h  
h a p p y  l i v e s ,  t h e r e  c o u l d  i n  t h e o r y  b e  s o m e  m u c h  l a r g e r  p o p u l a t i o n  t h a t  w o u l d  c o n t a i n  
a  g r e a t e r  q u a n t i t y  o f  h a p p i n e s s ,  e v e n  t h o u g h  it s  m e m b e r s  a l l  h a d  l i v e s  t h a t  w e r e  on ly  
ju s t  h a p p y .  G i v e n  t h e  r e l a t i v e  a m o u n t s  o f  h a p p i n e s s  i n v o l v e d ,  u t i l i t a r i a n s  w o u l d  s e e m  
o b l i g e d  t o  j u d g e  t h e  l a t t e r  p o p u l a t i o n  a s  p r e f e r a b l e  t o  t h e  f o r m e r  -  b u t  t h i s  j u d g e m e n t  
c l a s h e s  s h a r p l y  w i t h  o u r  i n t u i t i v e  s e n s i b i l i t i e s  ( P a r f i t t  1 9 8 4 ) .  T h i s  p r o b l e m  t u r n s  o u t  t o  
b e  r a t h e r  in t r a c t a b l e ,  a n d  n o  s o l u t i o n  a p p e a r s  t o  h a v e  b e e n  p u b l i s h e d  t o  d a t e .  
F o r t u n a t e l y  h o w e v e r ,  t h e  i m p o r t a n c e  o f  t h i s  p r o b l e m  i s  p r i m a r i l y  t h e o r e t i c a l  r a t h e r  
t h a n  p r a c t i c a l ,  a n d  it  i s  m o r e  r e l e v a n c e  f o r  p o p u l a t i o n  e t h i c s  t h a n  i t  d o e s  f o r  b i o e t h i c s .  
T h u s ,  a  d e t a i l e d  c o n s i d e r a t i o n  o f  t h is  p r o b l e m  l i e s  o u t s i d e  t h e  m a i n  f o c u s  o f  t h e  
p r e s e n t  d i s c u s s i o n .  N e v e r t h e l e s s ,  I  h a v e  c o n s t r u c t e d  a  p r o v i s i o n a l  r e s p o n s e  t o  t h i s  
p r o b l e m  -  s e e  A p p e n d i x  I I .
6.5.2.2.5 Agents vs. actions
A  s e p a r a t io n  b e t w e e n  a g e n t s  a n d  a c t i o n s  i s  o f t e n  i m p l i e d  b y  u t i l i t a r i a n i s m .  S u c h  a  
s e p a r a t io n  h a s  d r a w n  s t r o n g  c r i t i c i s m  f r o m  d i s p a r a t e  n o n - u t i l i t a r i a n  e t h i c a l  c r e e d s  
( C o m t e - S p o n v i l l e  2 0 0 3 ;  S c a r r e  1 9 9 6 ;  W i l l i a m s  1 9 9 3 ) .  I n  c o m m o n  m o r a l i t y ,  a n d  i n  
m o s t  n o n - c o n s e q u e n t i a l i s t  e t h i c a l  s y s t e m s ,  t h e  ch a ra c te r  o f  t h e  p e r s o n  f a c i n g  a n  
e t h i c a l  d e c i s i o n  ( t h e  ‘ a g e n t ’ )  i s  d e e m e d  im p o r t a n t .  I n d e e d ,  s o m e  e t h i c i s t s  v i e w  t h e  
im provem ent  o f  t h e  a g e n t ’ s  c h a r a c t e r  a s  b e i n g  t h e  p r i m e  o b j e c t i v e  o f  m o r a l i t y .
R e l a t e d  t o  t h is  i d e a  i s  t h e  n o t i o n  t h a t  t h e  m otiva tion  f o r  p e r f o r m i n g  a n  e t h i c a l  a c t  i s  
h i g h l y  s a l ie n t .  H o w e v e r ,  u t i l i t a r i a n i s m  g e n e r a t e s  s c e n a r i o s  i n  w h i c h  g o o d  
c o n s e q u e n c e s  c a n  ( a )  f l o w  f r o m  t h e  a c t i o n s  o f  a g e n t s  o f  p o o r  c h a r a c t e r ,  ( b )  r e s u l t  i n  
n o  im p r o v e m e n t  i n  t h e  a g e n t ’ s c h a r a c t e r  a n d  ( c )  b e  b o r n e  b y  m o t i v a t i o n s  t h a t  a r e  
c l e a r l y  n e g a t i v e .  F o r  e x a m p l e ,  s u p p o s e  t h a t  a  v e r y  r i c h  -  b u t  a l s o  v e r y  g r e e d y  a n d  
s e l f i s h  -  b u s i n e s s m a n  d e c i d e s  t h a t  h e  n e e d s  t o  g a i n  l o c a l  a p p r o v a l ,  i n  o r d e r  t o  i n c r e a s e
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h i s  c h a n c e s  o f  w i n n i n g  a  l u c r a t i v e  p r o p e r t y  d e v e l o p m e n t  c o n t r a c t .  A c c o r d i n g l y ,  a n d  
i n  t h e  a b s e n c e  o f  a n y  g e n u i n e  c o n c e r n  f o r  t h e  p l i g h t  o f  i m p o v e r i s h e d  p e o p l e ,  h e  
c y n i c a l l y  m a k e s  a  h i g h l y  p u b l i c  d o n a t io n  o f  a  l a r g e  s u m  o f  m o n e y  t o  a  T h i r d  W o r l d  
c h a r i t y .  T h e  d i r e c t  ( e t h i c a l l y  r e l e v a n t )  o u t c o m e  f r o m  t h i s  a c t i o n  i s  h i g h l y  p o s i t i v e ,  i n  
t h a t  t h e  l i v e s  o f  s e v e r a l  i m p o v e r i s h e d  c h i l d r e n  i n  t h e  T h i r d  W o r l d  a r e  s a v e d  t h r o u g h  a  
v a c c i n a t i o n  p r o g r a m  p a i d  f o r  b y  t h e  d o n a t e d  m o n e y .  T h u s ,  t h e  s e l f i s h  b u s i n e s s m a n ’ s  
a c t i o n  o f  d o n a t i n g  t h e  m o n e y  o u g h t  to  b e  c o n d o n e d  b y  u t i l i t a r i a n s ,  g i v e n  t h e  p o s i t i v e  
c o n s e q u e n c e s .  H o w e v e r ,  t h e  b u s i n e s s m a n ’ s  c h a r a c t e r  w a s  n o t  p r a i s e w o r t h y  b e f o r e  h e  
m a d e  t h e  d o n a t i o n  ( g r e e d i n e s s  a n d  s e l f i s h n e s s  a r e  h a r d l y  c o m m e n d a b l e  a t t r i b u t e s ) ,  
n o r  h a s  h i s  c h a r a c t e r  i m p r o v e d  a s  a  r e s u l t  o f  m a k i n g  t h e  d o n a t i o n  ( h e  h a s  s i m p l y  
b e c o m e  a  l i t t l e  m o r e  e x p e r t  a t  s a t i s f y i n g  h i s  g r e e d y  e n d s ) ,  a n d  h i s  c y n i c a l  m o t i v a t i o n  
c a n  h a r d l y  b e  a d m i r e d .  A c c o r d i n g l y ,  t h e r e  a p p e a r s  t o  b e  a  p r o b l e m  f o r  u t i l i t a r i a n i s m .  
T h e  p r o b l e m  i s  o n e  o f  i n c o n s i s t e n c y  b e t w e e n  ( a )  t h e  e t h i c a l  s t a t u s  o f  a n  a g e n t ,  a n d  ( b )  
t h e  e t h i c a l l y  r e l e v a n t  c o n s e q u e n c e s  o f  a n  a g e n t ’ s  a c t i o n .
T h i s  d i f f i c u l t y  f o r  u t i l i t a r i a n i s m  m a y  b e  c o u n t e r e d  i n  a  n u m b e r  o f  w a y s ,  w i t h  a r g u a b l e  
d e g r e e s  o f  s u c c e s s .  F i r s t l y ,  i t  c a n  b e  a r g u e d  t h a t  a ll  c h a r i t a b l e  g i v i n g  i s  i n h e r e n t l y  
s e l f i s h ,  b e c a u s e  t h e  m o t i v a t i o n  o f  t h e  g i v e r  i s  u l t i m a t e l y  o n e  o f  s e l f - i n t e r e s t ;  o n  t h i s  
a n a l y s i s ,  e v e n  t h e  m o s t  a p p a r e n t l y  a l t r u i s t i c  a c t s  o f  c h a r i t y  a r e  s e l f i s h  b e c a u s e  s u c h  
a c t s  w i l l  b e  m o t i v a t e d  ( a t  l e a s t )  b y  t h e  d e s ir e  t o  b e c o m e  a  b e t t e r  p e r s o n .  I f  t h i s  
a n a l y s i s  i s  c o r r e c t ,  t h e n  u t i l i t a r i a n i s m  c a n  h a r d l y  b e  s i n g l e d  a m o n g s t  m o r a l  s y s t e m s  
f o r  f a i l i n g  t o  c o n s i d e r  t h e  c h a r a c t e r  a n d  m o t i v a t i o n  o f  t h e  a g e n t .  H o w e v e r ,  I  a m  n o t  
p e r s u a d e d  b y  t h i s  a r g u m e n t .  A s s u m i n g  ( a s  a l l  m o r a l  s y s t e m s  d o )  t h a t  i t  i s  a c t u a l l y  
p o s s i b l e  t o  b e  a  m o r a l l y  p r a i s e w o r t h y  a g e n t ,  t h e n  t h e  d e s ir e  t o  b e  a  m o r a l  a g e n t  w o u l d  
a p p e a r  t o  q u a l i f y  a s  a n  e t h i c a l l y  a d m i r a b l e  a s p i r a t i o n .
A  s e c o n d  p o s s i b l e  s o l u t i o n  t o  t h e  a g e n t s  v s .  a c t i o n s  p r o b l e m  m a y  b e  o b t a i n e d  f r o m  
t h e  o b s e r v a t i o n  t h a t  u t i l i t a r i a n  a c t s  a r e  n o t  n ecessa r ily  i n c o m p a t i b l e  w i t h  c o m m o n  
c o n c e p t i o n s  o f  e t h i c a l  p r a i s e w o r t h i n e s s  i n  a n  a g e n t .  V e r y  o f t e n ,  a c t i o n s  t h a t  h a v e  
g o o d  c o n s e q u e n c e s  a r e  a s s o c i a t e d  w i t h  a g e n t s  o f  g o o d  c h a r a c t e r ,  a n d  w i t h  t h e  
i m p r o v e m e n t  o f  c h a r a c t e r .  I n d e e d ,  p e r s o n s  o f  g o o d  c h a r a c t e r  m a y  w e l l  d e l i b e r a t e l y  
c h o o s e  a c t i o n s  b a s e d  o n  c l e a r l y  u t i l i t a r i a n  g r o u n d s  ( f o r  e x a m p l e ,  t h e  d o n a t i o n  o f  
m o n e y  t o  g o o d  c a u s e s  m o tiva ted  b y  t h e  d e s i r e  t o  s a v e  l i v e s  a n d  a l l e v i a t e  s u f f e r i n g ) .
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A n o t h e r  p o s s i b l e  r e s o l u t i o n  t o  t h e  i s s u e  o f  a g e n t s  v s .  a c t i o n s  i s  s i m p l y  t o  a t t e m p t  a  
reclassifica tion .  I n s t e a d  o f  c a t e g o r i s i n g  t h e  i n c o n s i s t e n c y  a s  a  p ro b lem ,  p e r h a p s  i t  
s h o u l d  i n s t e a d  b e  c o n s i d e r e d  s i m p l y  a s  a  n a tu ra l fe a tu r e  o f  u t i l i t a r i a n i s m .  T h i s  m i g h t  
b e  f o r m a l i s e d  t h u s :  “ u t i l i t a r i a n i s m  i m p l i e s  a n  u n a v o i d a b l e  d i v i s i o n  b e t w e e n  a g e n t s  
a n d  a c t i o n s ” . U t i l i t a r i a n i s m  w o u l d  t h e n  b e  l e f t  t o  s t a n d  o r  f a l l  o n  i t s  o t h e r  m e r i t s  a n d  
d e m e r it s .  O f  c o u r s e ,  i n  t h e  c a s e  o f  m o r a l  s y s t e m s  i n  w h i c h  c h a r a c t e r  a n d  m o t i v a t i o n  
a r e  i n t r i n s i c a l l y  in sep a ra b le  f r o m  c o n s e q u e n c e s ,  o r  i n  w h i c h  c h a r a c t e r  a n d  m o t i v a t i o n  
a r e  t h e  s o l e  f a c t o r s  d e e m e d  e t h i c a l l y  s a l i e n t ,  t h e  ‘ n a t u r a l  f e a t u r e ’ i n  q u e s t i o n  d i c t a t e s  
a n  a u t o m a t i c  r e j e c t i o n  o f  u t i l i t a r i a n i s m .
T h e  f o r e g o i n g  a t t e m p t e d  s o l u t i o n s  n o t w i t h s t a n d i n g ,  t h e  q u e s t i o n  m a y  b e  a s k e d :  I n  t h e  
c o n t e x t  o f  m e d i c a l  e t h i c s ,  i s  t h e  i s s u e  o f  a g e n t s  v s .  a c t i o n s  a  m a j o r  c o n s i d e r a t i o n ?  I n  
m e d i c a l  e t h i c s ,  t h e  a g e n t s  m u s t  ( o r  s h o u l d )  a l w a y s  r e m a i n  a t  s o m e  d i s t a n c e  f r o m  t h e  
a c t i o n s  i n v o l v e d .  T h i s  c o n t r a s t s  w i t h  p e rso n a l  e t h i c s ,  i n  w h i c h  m a t t e r s  o f  c h a r a c t e r  
a n d  m o t i v a t i o n  a r g u a b l y  f o r m  a  c e n t r a l  p a r t .  I n  m e d i c a l  e t h i c s ,  t h e  a g e n t s  a r e  t y p i c a l l y  
m e m b e r s  o f  a n  e t h i c s  c o m m it t e e  ( w i t h i n  a  h o s p i t a l ,  u n i v e r s i t y ,  o r  g o v e r n m e n t ,  e t c ) .  
T h e  d u t y  a n d  r a i s o n  d 'e t r e  o f  t h e  e t h i c s  c o m m i t t e e  i s  t o  m a k e  t h e  b e s t  p o s s i b l e  e t h i c a l  
d e c i s i o n s  -  f o r  e x a m p l e ,  t o  d e c i d e  w h e t h e r  a  p r o p o s e d  m e d i c a l  e x p e r i m e n t  s h o u l d  b e  
p e r m it t e d ,  t o  d e c i d e  w h e t h e r  a  n e w  m e d i c a l  p r o c e d u r e  i s  s a f e  e n o u g h  t o  b e  o f f e r e d  t o  
c h i l d r e n ,  a n d  s o  o n  ( G l a s a  e t  a l .  1 9 9 6 ;  R o s n e r  1 9 8 5 ) .  B u t ,  u n l e s s  a  c o n f l i c t  o f  in t e r e s t  
i s  i n v o l v e d ,  t h e  p e r s o n a l  c h a r a c t e r  o f  e a c h  c o m m i t t e e  m e m b e r  i s  o f  n o  r e l e v a n c e :  
c o m m it t e e  m e m b e r s  m a y  b e  p h i l a n d e r e r s ,  b e  r u t h l e s s  i n  b u s i n e s s  t r a n s a c t i o n s ,  b e  
s p i t e f u l ,  o r  n e v e r  d o n a t e  t o  c h a r i t y  -  s u c h  a t t r ib u t e s  d o  n o t  m a t t e r  a s  l o n g  a s  t h e  
c o m m it t e e  r e a c h e s  a p p r o p r ia t e  e t h i c a l  d e c i s i o n s .  S i m i l a r l y ,  t h e  f u n c t i o n  o f  t h e  e t h i c s  
c o m m it t e e  o b v i o u s l y  d o e s  n o t  i n c l u d e  a n y  r e q u i r e m e n t  t o  i m p r o v e  t h e  c h a r a c t e r  o f  t h e  
c o m m it t e e  m e m b e r s .  A n d ,  a l t h o u g h  it  m a y  b e  t h e  c a s e  t h a t  m a n y  e t h i c s  c o m m i t t e e  
m e m b e r s  a r e  m o t i v a t e d  t o  p a r t ic ip a t e  t h r o u g h  a  d e s i r e  t o  e n s u r e  t h a t  m e d i c a l  d e c i s i o n s  
a r e  e t h i c a l l y  a c c e p t a b l e ,  s u c h  m o t i v a t i o n  i s  n o t  a  p r e r e q u i s i t e  f o r  m e m b e r s h i p .  S o m e  
e t h i c s  c o m m i t t e e  m e m b e r s  m a y  b e  s e r v i n g  d if f e r e n t ,  p e r h a p s  l e s s  a d m i r a b l e  
m o t i v a t i o n s :  f o r  e x a m p l e ,  s o m e  m e m b e r s  m a y  b e  s e e k i n g  t o  i m p r o v e  t h e i r  
p r o f e s s i o n a l  s t a n d i n g  o r  c h a n c e s  o f  g a i n i n g  p r o m o t i o n ,  a n d  o t h e r s  m a y  b e  p r e s e n t  
s i m p l y  o u t  o f  p r o f e s s i o n a l  d u t y .  H o w e v e r ,  a s s u m i n g  ( a )  t h a t  t h e  c o m m i t t e e  m e m b e r s  
a r e  c o m p e t e n t  a n d  ( b )  t h a t  t h e y  p a r t ic ip a t e  e f f e c t i v e l y ,  t h e n  t h e i r  m o t i v a t i o n  f o r  b e i n g  
e t h i c s  c o m m i t t e e  m e m b e r s  i s  i m m a t e r i a l .  I n  c o n c l u s i o n ,  t h e  a g e n t s  v s .  a c t i o n s
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c r i t i c i s m  o f  u t i l i t a r i a n i s m  p e r  se  d o e s  n o t  c a u s e  a  p r o b l e m  i n  t h e  c o n t e x t  o f  m e d i c a l  
e t h i c s ,  a n d  n o r  t h e r e f o r e  d o e s  t h e  c r i t i c i s m  r e p r e s e n t  a  s i g n i f i c a n t  p r o b l e m  i n  t h e  c a s e  
o f  t h e  p r e s e n t  t h e s i s .
6.5.2.2.6 Unlimited moral demands
U t i l i t a r i a n i s m  h a s  b e e n  s t r o n g l y  c r i t i c i s e d  o n  t h e  g r o u n d s  t h a t  i t  m a k e s  u n l i m i t e d  
m o r a l  d e m a n d s  o n  t h e  i n d i v i d u a l  ( B r o c k  1 9 8 2 ;  S c h e f f l e r  1 9 8 2 ;  W o l f  1 9 8 2 ) .  B e c a u s e  
u t i l i t a r i a n i s m  a p p e a r s  c o m m i t t e d  t o  m a x i m i s i n g  h u m a n  w e l l b e i n g  r e g a r d l e s s  o f  t h e  
i d e n t i t i e s  o f  i n d i v i d u a l s ,  t h e  m o r a l  a g e n t  o u g h t  t o  p l a c e  t h e  g e n e r a l  w e l l b e i n g  a b o v e  
h i s  o w n  p e r s o n a l  c o n c e r n s .  F r o m  t h is ,  i t  s e e m s  t o  f o l l o w  t h a t  a  m o r a l  a g e n t  o u g h t  t o  
d o n a t e  a l l  h i s  m o n e y  a n d  t i m e  t o  g o o d  c a u s e s  ( s a v e  a  b a r e  m i n i m u m  f o r  b a s i c  s u r v i v a l  
n e e d s ) .  I n d e e d ,  a n  a g e n t  w o u l d  a p p e a r  t o  b e  o b l i g e d  t o  s a c r i f i c e  h i s  l i f e  o r  e n d u r e  
e x t r e m e  t o r t u r e  i n  c a s e s  w h e r e  s o  d o i n g  w o u l d  i m p r o v e  t h e  g e n e r a l  h a p p i n e s s .  T h u s ,  
i t  h a s  b e e n  a r g u e d  t h a t  u t i l i t a r i a n i s m  m a k e s  s u c h  h e a v y  d e m a n d s  o n  i n d i v i d u a l s  t h a t  i t  
i m p l i e s  a  red u ctio  a d  absurdum  o f  t h e  t h e o r y .  T h e  c r i t i c i s m ,  p u t  s i m p l y ,  i s  t h a t  m o r a l  
s a i n t h o o d  i s  i n c o m p a t i b l e  w i t h  n o r m a l  h u m a n  b e h a v i o u r .  T o  t h e  e x t e n t  t h a t  t h i s  
c r i t i c i s m  m a y  b e  v a l i d  p e r  se, i t  d o e s  l i t t l e  t o  u n d e r m i n e  u t i l i t a r i a n i s m  i n  t h e  c o n t e x t  
o f  m e d i c a l  e t h i c s .  A s  w i t h  t h e  p r e v i o u s l y  c o n s i d e r e d  q u e s t i o n  o f  ‘ a g e n t s  v s .  a c t i o n s ’ , 
t h e  p e r s o n a l  v i r t u e s  a n d  m o r a l  a t t r ib u t e s  o f  t h e  d e c i s i o n - m a k e r s  i n  m e d i c a l  e t h i c s  a r e  
n o r m a l l y  o f  n o  c o n s e q u e n c e :  t h e  o n l y  i m p o r t a n t  q u e s t i o n  i s  w h e t h e r  t h e  e t h i c s  
c o m m i t t e e  i s  r e a c h i n g  a p p r o p r ia t e  e t h i c a l  d e c i s i o n s .  A c c o r d i n g l y ,  a n y  i n - d e p t h  
e x p l o r a t i o n  o f  t h e  p r o b l e m  o f  u n l i m i t e d  m o r a l  d e m a n d s  l i e s  o u t s id e  t h e  m a i n  f o c u s  o f  
t h i s  t h e s i s .  T h i s  p r o b l e m  i s  n e v e r t h e le s s  a n  i m p o r t a n t  o n e  f o r  u t i l i t a r i a n i s m  p e r  se.
T h e  u t i l i t a r i a n  a g e n t  i n v o l v e d  i n  m e d i c a l  e t h i c s  m a y  w i s h  t o  a v o i d  a  s i t u a t i o n  o f  ‘ b a d  
f a i t h ’ i n  t e r m s  o f  a  c o n f l i c t  b e t w e e n  p r o f e s s i o n a l  e t h i c s  a n d  p e r s o n a l  e t h i c s .  I  h a v e  
p r e v i o u s l y  p u b l i s h e d  a  r e s p o n s e  t o  t h e  p r o b l e m  o f  u n l i m i t e d  m o r a l  d e m a n d s  ( S m i t h  
2 0 0 2 a )  -  s e e  A p p e n d i x  I I I .
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6.5.2.2.7 Radical, non-intuitive conclusions
T h i s  p r o b l e m  c o n c e r n s  t h e  f a c t  t h a t  r a d i c a l ,  n o n - i n t u i t i v e  c o n c l u s i o n s  a r e  s o m e t i m e s  
i m p l i e d  b y  u t i l i t a r i a n i s m .  I n  c o n t r a s t  t o  s o m e  e t h i c a l  s y s t e m s ,  u t i l i t a r i a n  d e l i b e r a t i o n s  
o f t e n  d i c t a t e  c o u r s e s  o f  a c t i o n  t h a t  c o n f l i c t  w i t h  ‘ c o m m o n s e n s e ’ m o r a l i t y  ( K u h s e  a n d  
S i n g e r  1 9 9 9 ;  S i n g e r  1 9 9 3 ) .  F o r  e x a m p l e ,  a  u t i l i t a r i a n  a r g u m e n t  c a n  b e  m a d e  i n  f a v o u r  
o f  u s i n g  p i g s  f o r  x e n o t r a n s p l a n t a t i o n ,  o n  a c c o u n t  o f  t h e  l i k e l i h o o d  t h a t  t h e  h a p p i n e s s  
r e s u l t i n g  f r o m  m o r e  t r a n s p la n t  p a t i e n t s  b e i n g  t r e a t e d  w i l l  o u t w e i g h  t h e  s u f f e r i n g  
e x p e r i e n c e d  b y  t h e  p i g s .  H o w e v e r ,  s i m i l a r  l i n e s  o f  u t i l i t a r i a n  r e a s o n i n g  s u g g e s t  t h e  
c o n c l u s i o n  t h a t  t h e  i n t e n s i v e  f a r m i n g  o f  p i g s  f o r  m e a t  s h o u l d  b e  co n d em n ed , o n  
a c c o u n t  o f  t h e  n e g a t i v e  o v e r a l l  h a p p i n e s s  i n v o l v e d  ( c a n  h a p p i n e s s  f r o m  e a t i n g  b a c o n  
r e a l l y  o u t w e i g h  t h e  a n i m a l  s u f f e r i n g  i n h e r e n t  i n  i n t e n s i v e  p i g  p r o d u c t i o n ? ) .  H o w e v e r ,  
t h e  f a c t  t h a t  r a d i c a l  c o n c l u s i o n s  a r e  s o m e t i m e s  g e n e r a t e d  c a n n o t  b e  a  g o o d  r e a s o n  f o r  
r e j e c t i n g  a n  e t h i c a l  t h e o r y .  W e  o u g h t  n o t  d i s m i s s  u t i l i t a r i a n  c o n c l u s i o n s  s i m p l y  
b e c a u s e  t h e y  h a p p e n  t o  b e  r a d i c a l  o r  n o n - i n t u i t i v e  ( u n l e s s  t h e  c o n c l u s i o n s  g e n e r a t e d  
w e r e  a c t u a l l y  repugnan t  o r  g e n u i n e l y  rid icu lou s).  I n d e e d ,  i f  i t  i s  a c c e p t e d  t h a t  m o r a l  
s y s t e m s  o u g h t  t o  b e  r e j e c t e d  u n l e s s  t h e i r  c o n c l u s i o n s  m a t c h  t h o s e  o f  c o m m o n - s e n s e  
m o r a l i t y ,  t h e n  e t h i c a l  s y s t e m s  i n  g e n e r a l  ( i n d e e d  a l l  e t h i c a l  d i s c o u r s e )  w o u l d  h a v e  n o  
f u n c t i o n .  Y e t  t h e  v e r y  t h i n g  t h a t  i s  c l e a r l y  r e q u i r e d  i s  s o m e  f o r m  o f  e t h i c a l  s y s t e m  
( a n d  a s s o c i a t e d  e t h i c a l  d i s c o u r s e )  t h a t  c a n  h e l p  u s  t o  d e a l  w i t h  t h e  s o r t s  o f  d i f f i c u l t ,  
c o m p l e x  a n d  n o v e l  p r o b l e m s  t h a t  a r e  r a i s e d  b y  c u t t i n g - e d g e  b i o m e d i c a l  t e c h n o l o g i e s .  
I  t a k e  i t  a s  a x i o m a t i c  t h a t  c o m m o n - s e n s e  m o r a l i t y  i s  i n a d e q u a t e  t o  s e r v e  s u c h  a  
f u n c t i o n .
6.5.2.2.8 Utilitarianism could be used wrongly
A  f i n a l  p r o b l e m  i s  t h e  p o s s i b i l i t y  o f  m i s u s e  ( G l o v e r  1 9 7 7 ;  S c a r r e  1 9 9 6 ;  W i l l i a m s
1 9 9 3 ) .  U t i l i t a r i a n i s m  m a y  i n d e e d  b e  u s e d  w r o n g l y ,  e i t h e r  t h r o u g h  e r r o r  o r  t h r o u g h  
d e l i b e r a t e  m i s u s e .  F o r  e x a m p l e ,  a  s i m p l e  f a i l u r e  t o  w e i g h - u p  a l l  p o s s i b l e  s i d e - e f f e c t s  
m a y  l e a d  u s  t o  c o n d o n e  a n  a p p a r e n t l y  b e n e f i c i a l  f i s h  t r a n s g e n e s i s  e x p e r i m e n t ,  w h e r e  a  
m o r e  t h o r o u g h  a n a l y s i s  w o u l d  h a v e  p i n p o i n t e d  a  h i g h  r i s k  o f  s e r i o u s  s u f f e r i n g  o f  
A f r i c a n  c o a s t a l  p e o p l e s  t h r o u g h  d a m a g e  t o  t h e i r  f i s h  s t o c k s  s h o u l d  t h e  t r a n s g e n i c  f i s h
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e s c a p e  in t o  t h e  w i l d .  M o r e  d e l i b e r a t e  m i s u s e  o f  u t i l i t a r i a n i s m  w o u l d  i n c l u d e  ( f o r  
e x a m p l e )  t h e  a c c e p t a n c e  o f  m a j o r  a n i m a l  s u f f e r i n g  i n  o r d e r  t o  p r o d u c e  y e t  a n o t h e r  
m i l d  h e a d a c h e  c u r e  ( s o m e  i n s t a n c e s  o f  m i s u s e  m a y  b e  d i s g u i s e d  b y  t h e  s l o g a n  “ t h e  
e n d  j u s t i f i e s  t h e  m e a n s ”  -  b u t  t h i s  s l o g a n  i s  a  s i m p l y  a n  i n a c c u r a t e  c o r r u p t i o n  o f  
u t i l i t a r i a n i s m ,  e m p l o y e d  a s  a  r h e t o r i c a l  d e v i c e ) .  H o w e v e r ,  t h e  r i s k  o f  m i s u s e  f a i l s  t o  
c o u n t  a g a i n s t  u t i l i t a r i a n i s m :  a l m o s t  a n y  i d e a  -  r e g a r d l e s s  o f  i t s  n a t u r e  ( s c i e n t i f i c ,  
r e l i g i o u s ,  m e t a p h y s i c a l ,  e t c )  -  m a y  b e  m i s i n t e r p r e t e d  b y  t h e  i l l - i n f o r m e d ,  o r  
d i s h o n e s t l y  d is t o r t e d  b y  t h o s e  w i t h  t h e i r  o w n  a g e n d a .  A l l  t h a t  c a n  b e  d o n e  i s  t o  g u a r d  
a g a i n s t  s u c h  m i s t a k e s  a n d  m i s u s e s .
6.6 Conclusions
T h e  a u t h o r  o f  t h i s  t h e s i s  s e e s  u t i l i t a r i a n i s m  a s  a  d e v e l o p i n g  b r a n c h  o f  e t h i c s  t h a t  h o l d s  
g r e a t  p r o m i s e  f o r  i s s u e s  r a i s e d  i n  m e d i c a l  e t h i c s  i n  g e n e r a l ,  a n d  i n  c u t t i n g - e d g e  
b i o m e d i c i n e  i n  p a r t i c u l a r .  U t i l i t a r i a n i s m  i s  c e r t a i n l y  n o t  f r e e  f r o m  p r o b l e m s .
H o w e v e r ,  I  s u g g e s t  t h a t  t h e s e  p r o b l e m s  c a n  b e  a n s w e r e d  b y ,  o r  a c c o m m o d a t e d  w i t h i n ,  
u t i l i t a r i a n i s m .  I t  s e e m s  r e a s o n a b l e  t o  c l a i m  t h a t  u t i l i t a r i a n i s m ,  i f  u s e d  c a r e f u l l y  a n d  
h o n e s t l y ,  o f f e r s  a n  e f f e c t i v e  ( a l t h o u g h  i m p e r f e c t )  g u i d e  t o  e t h i c a l  d e c i s i o n - m a k i n g .
A t  t h e  v e r y  l e a s t ,  u t i l i t a r i a n i s m  r e p r e s e n t s  o n e  v a l i d  c o n t e n d e r  a m o n g s t  s e v e r a l  e t h i c a l  
a p p r o a c h e s  t h a t  m a y  b e  u s e d  i n  t h e  c o n t e x t  o f  m e d i c a l  e t h i c s .  A c c o r d i n g l y ,  a t t e m p t s  
t o  a p p l y  c o r e  p r i n c i p l e s  o f  u t i l i t a r i a n  r e a s o n i n g  t o  p a r t i c u l a r  c a s e s  s h o u l d  b e  s e e n  a s  
i n t r i n s i c a l l y  v a l i d  a n d  p o t e n t i a l l y  u s e f u l .  T h i s  i s  t h e  a p p r o a c h  t a k e n  i n  r e s p e c t  o f  t h e  
b i o e t h i c a l  a s p e c t s  o f  t h i s  t h e s is .
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Chapter 7: Human 




T h i s  c h a p t e r  p r e s e n t s  a n  o r i g i n a l  a p p l i c a t i o n  o f  c o r e  u t i l i t a r i a n  p r i n c i p l e s  t o  t h e  e t h i c s  
o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  T h e  n a t u r e  o f  t h i s  c h a p t e r  d i f f e r s  f r o m  t h a t  o f  t h e  
s c i e n c e - b a s e d  c h a p t e r s  ( C h a p t e r s  2 - 5 )  i n  t h e  s a m e  w a y s  a s  d o e s  t h e  p r e v i o u s  c h a p t e r  
( C h a p t e r  6 ) .  T h u s ,  r e f e r e n c e s  a r e  m i n i m a l ,  a n d  f i r s t  p e r s o n  l a n g u a g e  i s  p r e s e n t .  T h e  
r e a s o n s  f o r  t h i s  a p p a r e n t  ( b u t  n e c e s s a r y )  m i s m a t c h  b e t w e e n  t h e  s c i e n t i f i c  a n d  t h e  
b i o e t h i c a l  s e c t i o n s  a r e  t h e  s a m e  a s  t h o s e  a p p l y i n g  t o  t h e  p r e v i o u s  c h a p t e r  ( s e e  6 . 1 ) .
7.2 Safety, Effectiveness and Consent
S a f e t y  i s  a  k e y  c o n c e r n  f o r  a l l  t h e r a p e u t ic  m o d a l i t i e s ,  c o n v e n t i o n a l  o r  g e n e t ic  
( B e a u c h a m p  a n d  C h i l d r e s s  2 0 0 1 ;  L i v a d a s  2 0 0 2 ;  S u b r a m a n i a n  a n d  M c C u l l o u g h  1 9 8 7 ;  
V e a t c h  1 9 8 4 ) .  F o r  t h e  u t i l i t a r i a n ,  q u e s t i o n s  o f  s a f e t y  i n v o l v e  b a l a n c i n g  r i s k s  a g a i n s t  
b e n e f i t s .  G i v e n  t h e  i n e v i t a b l e  f a c t  t h a t  n o  m e d i c a t i o n  o r  m e d i c a l  p r o c e d u r e  c a n  b e  
a b s o l u t e l y  s a f e ,  i t  i s  d i f f i c u l t  t o  s e e  a n y  p l a u s i b l e  a l t e r n a t i v e  t o  t h e  r i s k - b e n e f i t  
a s s e s s m e n t  a p p r o a c h  t o  s a f e t y  i s s u e s  i n h e r e n t  i n  u t i l i t a r i a n i s m .  T h i s  s e c t i o n  c o n s i d e r s  
t h e  r e la t e d  i s s u e s  o f  s a f e t y ,  e f f e c t i v e n e s s  a n d  c o n s e n t  f r o m  a n  e t h i c a l  s t a n d p o in t ,  w i t h  
i s s u e s  a r i s i n g  f r o m  g e r m l i n e  g e n e  t h e r a p y  b e i n g  c o n t r a s t e d  w i t h  t h o s e  a r i s i n g  f r o m  
s o m a t i c  g e n e  t h e r a p y  ( S e c t i o n  5 . 2 ) .
W h i l e  s a f e t y  i s s u e s  a p p l y  t o  b o t h  s o m a t i c  g e n e  t h e r a p y  a n d  g e r m l i n e  g e n e  t h e r a p y ,  t h e  
m a t t e r  i s  s i m p l e r  i n  t h e  c a s e  o f  t h e  f o r m e r .  F r o m  t h e  u t i l i t a r i a n  p e r s p e c t i v e ,  p o t e n t i a l  
h e a l t h  r i s k s  g i v e  r i s e  t o  t h e  m a i n  e t h i c a l  i s s u e s  a s s o c i a t e d  w i t h  s o m a t i c  g e n e  t h e r a p y .  
I n  t h e  c a s e  o f  p o s s i b l e  h a r m  t o  a d u l t  p a t i e n t s ,  t h e  m a t t e r  i s  r e l a t i v e l y  s t r a i g h t f o r w a r d :  
c o n s e n t  m u s t  b e  s o u g h t ,  w i t h  t h e  p a t i e n t ’ s  d e c i s i o n  f a c i l i t a t e d  b y  a n  e x p l a n a t i o n  o f  t h e  
r i s k s  i n v o l v e d .  T h u s ,  t h e  d e c i s i o n s  m a d e  b y  i n d i v i d u a l  p a t i e n t s  t o  a c c e p t  o r  d e c l i n e  
s o m a t i c  g e n e  t h e r a p y  a r e  e s s e n t i a l l y  t h e  s a m e  a s  t h o s e  d e c i s i o n s  m a d e  i n  t h e  c o n t e x t  
o f  c o n v e n t i o n a l  m e d i c i n e .  B y  c o n t r a s t ,  g e r m l i n e  g e n e  t h e r a p y  h a s  s a f e t y  i m p l i c a t i o n s  
t h a t  a p p l y  t o  f u t u r e  p e o p l e ,  a s  o p p o s e d  t o  e x i s t i n g  p a t i e n t s .
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A  r e l a t e d  d i s t i n c t i o n  a l s o  e x i s t s  b e t w e e n  s o m a t i c  a n d  g e r m l i n e  t h e r a p i e s  i n  r e g a r d  t o  
t h e  i s s u e  o f  c o n s e n t  W h e r e a s  i n  t h e  f o r m e r  c a s e  t h e  p a t i e n t  i s  c o m p e t e n t  t o  d e c i d e  
w h e t h e r  t o  g i v e  o r  w i t h h o l d  c o n s e n t ,  i n  t h e  l a t t e r  c a s e  t h e  ‘ p a t i e n t ’ c a n  p l a y  n o  p a r t  i n  
a n y  s u c h  d e c i s i o n .  T h i s  d i s t i n c t i o n  m a y  a t  f i r s t  s i g h t  a p p e a r  t o  b e  u n i q u e  t o  h u m a n  
g e r m l i n e  g e n e  t h e r a p y .  H o w e v e r ,  t h is  i s  n o t  e n t i r e l y  s o .
I n  m a n y  g e n e t ic  a n d  o t h e r  s e r i o u s  c o n d i t i o n s ,  t h e  p a t i e n t  i s  o f t e n  a  c h i l d .  I n  s u c h  c a s e s  
w h e r e  s o m a t i c  g e n e  t h e r a p y  i s  u n d e r  c o n s i d e r a t i o n ,  o r d i n a r y  m e d i c a l  e t h i c s  p r o v i d e s  a  
g u i d e  t o  a c t i o n  i n  s u c h  c a s e s :  t h e  a b i l i t y  o f  t h e  c h i l d  t o  b a l a n c e  t h e  b e n e f i t s  a n d  r i s k s  
f r o m  t h e  p r o p o s e d  t h e r a p y  m u s t  b e  d e t e r m i n e d .  I n  k e e p i n g  w i t h  g e n e r a l l y  e s t a b l i s h e d  
m e d i c a l  p r a c t i c e ,  t h e  a s s e s s m e n t  o f  t h e  c h i l d ’ s  a b i l i t y  t o  g i v e / w i t h h o l d  c o n s e n t  s h o u l d  
b e  d e t e r m i n e d  o n  a  c a s e - b y - c a s e  b a s i s  ( r a t h e r  t h a n  s i m p l y  b y  c h r o n o l o g i c a l  a g e ) ,  a n d  
t h e  p r e v i o u s l y  m e n t i o n e d  p r in c ip le  o f  au tonom y  s h o u l d  b e  a p p l i e d  w h e r e v e r  i t  s e e m s  
l i k e l y  t h a t  t h e  c h i l d  i s  a b l e  t o  m a k e  a  r a t i o n a l  d e c i s i o n .  H o w e v e r ,  i t  s h o u l d  b e  n o t e d  
t h a t  m a n y  o f  t h e  s e r i o u s  g e n e t i c  c o n d i t i o n s  p o t e n t i a l l y  a m e n a b l e  t o  s o m a t i c  g e n e  
t h e r a p y  o f t e n  k i l l  o r  s e r i o u s l y  d a m a g e  p a t i e n t s  i n  t h e i r  f i r s t  m o n t h s  o r  y e a r s  o f  l i f e .  
T h u s ,  c o n s e n t  d i f f i c u l t i e s  a r e  e x p e c t e d  t o  o c c u r  m o r e  f r e q u e n t l y  w i t h  s o m a t i c  g e n e  
t h e r a p y  t h a n  w i t h  o r d i n a r y  m e d i c a l  a p p r o a c h e s .  C o n s e q u e n t l y ,  t h i s  f a c t  b r i n g s  s o m a t i c  
g e n e  t h e r a p y  c l o s e r  t o  g e r m l i n e  g e n e  t h e r a p y  i n  t e r m s  o f  c o n s e n t  i s s u e s .
I n d e e d ,  a s  a  g e n e r a l i s a t i o n ,  c o n c e p t u a l l y  t h e r e  e x i s t s  a n  i n v e r s e  c o r r e l a t i o n  b e t w e e n  
t h e  a g e  o f  t h e  p a t i e n t  a n d  t h e  p r o b a b l e  e f f e c t i v e n e s s  o f  s o m a t i c  g e n e  t h e r a p y .  
A c c o r d i n g l y ,  t h e  f o e t u s  i s  o f t e n  v i e w e d  a s  a n  i d e a l  d e v e l o p m e n t a l  s t a g e  f o r  s o m a t i c  
g e n e  t h e r a p y .  I n  a d d i t i o n  t o  p e r m i t t i n g  t r e a t m e n t  p r i o r  t o  i r r e v e r s i b l e  d i s o r d e r - i n d u c e d  
d a m a g e ,  f o e t a l  s o m a t i c  g e n e  t h e r a p y  h a s  a  n u m b e r  o f  p o t e n t i a l  a d v a n t a g e s  c o m p a r e d  
w i t h  l a t e r -s t a g e  a p p r o a c h e s  ( C o u t e l l e  a n d  R o d e c k  2 0 0 2 ;  K a p l i t t  e t  a l .  1 9 9 8 ) .  T h e s e  
a d v a n t a g e s  i n c l u d e :  ( a )  b e t t e r  t r a n s g e n e  u p t a k e  e f f i c i e n c i e s  d u e  t o  t h e  h i g h  p e r c e n t a g e  
o f  r a p i d l y  d i v i d i n g  c e l l s  p o p u l a t i n g  t h e  f o e t u s  ( a s  d i s c u s s e d  p r e v i o u s l y ,  s o m e  g e n e  
t r a n s f e r  a p p r o a c h e s  d o  n o t  f u n c t i o n  w e l l  w i t h  n o n - d i v i d i n g  c e l l s ) ;  ( b )  t h e  p o s s i b i l i t y  
o f  g e n e r a t in g  w h o l e - t i s s u e / o r g a n  a lt e r a t io n s  b y  g e n e t i c a l l y  a l t e r i n g  a  s m a l l  n u m b e r  o f  
a p p r o p r ia t e  c l o n o g e n i c  c e l l s  ( s u c h  c e l l - t y p e s  a r e  a  f e a t u r e  o f  e a r l y  f o e t a l  
d e v e l o p m e n t ) ;  a n d  ( c )  t h e  a v o i d a n c e  o f  a n  i m m u n e  r e s p o n s e  a g a i n s t  t r a n s g e n e  v e c t o r s  
d u e  t o  t h e  p r e i m m u n e  s t a t u s  o f  t h e  e a r l y  f o e t u s .  T h u s ,  g i v e n  t h e  s c i e n t i f i c  a d v a n t a g e s  
a s s o c i a t e d  w i t h  t h e  f o e t u s ,  s o m a t i c  g e n e  t h e r a p y  m a y  w e l l  c o m e  t o  b e  f r e q u e n t l y
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t a r g e t e d  a t  t h e  u n b o r n  c h i l d .  I n  f o e t a l  s o m a t i c  g e n e  t h e r a p y  t h e r e  c a n  o b v i o u s l y  b e  n o  
c o n s e n t  f r o m  t h e  ‘ p a t i e n t ’ a f f e c t e d  ( b e n e f i c i a l l y  o r  d e t r i m e n t a l l y )  f r o m  t h e  t r e a t m e n t .  
A g a i n ,  t h i s  f a c t  b r i n g s  s o m a t i c  g e n e  t h e r a p y  c l o s e r  t o  g e r m l i n e  g e n e  t h e r a p y  i n  t e r m s  
o f  c o n s e n t  i s s u e s .
F r o m  t h e  c o n s e q u e n t i a l i s t  s t a n d p o in t  a d v o c a t e d  i n  t h i s  t h e s i s ,  f o e t a l  g e n e  t h e r a p y  
s h o u l d  i n  p r i n c i p l e  b e  p e r m it t e d  a g a i n s t  s e r i o u s ,  o t h e r w i s e  u n t r e a t a b le  d i s o r d e r s  i n  
c a s e s  w h e r e  t h e  f o l l o w i n g  c r i t e r i a  c a n  b e  m e t :  ( a )  w h e r e  t h e r e  i s  a  d e m o n s t r a b l y  h i g h  
p r o b a b i l i t y  o f  a  s u c c e s s f u l  c l i n i c a l  o u t c o m e ,  a n d  ( b )  w h e r e  t h e  r i s k  o f  s e r io u s  
i a t r o g e n i c  d a m a g e  i s  v e r y  l o w .  I f  t h e s e  c r i t e r i a  c a n n o t  b e  m e t ,  t h e  c h o i c e  t h e n  
b e c o m e s  o n e  o f  a l l o w i n g  a  c h i l d  t o  b e  b o m  w i t h  a  s e r i o u s  d i s o r d e r ,  o r  t e r m i n a t i n g  t h e  
p r e g n a n c y  ( t h is  c h o i c e  i s  e s s e n t i a l l y  p a r e n t a l ,  a n d  t h e  a s s o c i a t e d  e t h i c a l  
c o n s i d e r a t i o n s  a r e  o u t s i d e  t h e  s c o p e  o f  t h e  p r e s e n t  d i s c u s s i o n ) .  H o w e v e r ,  i f  h u m a n  
g e r m l i n e  g e n e  t h e r a p y  w a s  a v a i l a b l e ,  t h e n  t h i s  w o u l d  r e p r e s e n t  a n  a d d i t i o n a l  o p t i o n  
f o r  t h e  p a r e n t s :  i n s t e a d  o f  c o n c e i v i n g  a  f o e t u s  t h a t  w o u l d  b e  t r e a t e d  w i t h  s o m a t i c  g e n e  
t h e r a p y  ( o r  a b o r t e d ) ,  g e r m l i n e  g e n e  t h e r a p y  w o u l d  a v o i d  t h e  m e d i c a l  p r o b l e m  
o c c u r r i n g  i n  t h e  f i r s t  p l a c e .  T h u s ,  f r o m  a  b i o e t h i c a l  p e r s p e c t i v e ,  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  i s  v e r y  s i m i l a r  t o  f o e t a l  g e n e  t h e r a p y  t o  t h e  e x t e n t  t h a t  t h e  ‘ p a t i e n t ’ is  
u n a v a i l a b l e  t o  g i v e  o r  w i t h h o l d  c o n s e n t .
B e c a u s e  fu tu re  p e o p l e  a r e  t h e  s u b j e c t s  o f  f o e t a l  g e n e  t h e r a p i e s  a n d  g e r m l i n e  g e n e t i c  
t h e r a p i e s ,  t h e  a s s o c i a t e d  e t h i c a l  c o n s i d e r a t i o n s  g o  b e y o n d  i s s u e s  o f  p a t i e n t  c o n s e n t .  
M u c h  m o r a l  d i s c o u r s e  e x i s t s  o n  t h e  m e t a p h y s i c a l  q u e s t i o n s  a r i s i n g  f r o m  t h e  
p o s s i b i l i t y  o f  f o e t a l  g e n e  t h e r a p y  a n d  g e r m l i n e  g e n e  t h e r a p y .  F o r  e x a m p l e ,  d o e s  a  
f u t u r e  p e r s o n  h a v e  m o r a l  righ ts?  I s  a n  u n b o r n  c h i l d  e n t i t l e d  t o  a n  ‘ o p e n  f ix t u r e ’ r a t h e r  
t h a n  o n e  ‘ d e s i g n e d ’ b y  o t h e r s ?  W o u l d  t h e  g e n e t i c  a l t e r a t io n  o f  a  f u t u r e  p e r s o n  
c o n s t it u t e  a n  a s s a u l t  o n  t h e  ‘ h u m a n i t y ’ o f  t h a t  i n d i v i d u a l ?  S u c h  q u e s t i o n s  r e p r e s e n t  
v a l i d  a r e a s  f o r  p r o f e s s i o n a l  m o r a l  p h i l o s o p h e r s  a n d  t h e o l o g i a n s  t o  p u r s u e .  H o w e v e r ,  
f r o m  a  u t i l i t a r i a n  p e r s p e c t i v e ,  I  s u g g e s t  t h a t  -  i f  p r o g r e s s  i s  t o  b e  m a d e  -  t h e  e t h i c a l  
f o c u s  s h o u l d  b e  u p o n  t h e  m a t t e r  o f  in terests. T h u s ,  i t  m a y  b e  a r g u e d  t h a t  a  p r o p o s e d  
f o e t a l  o r  g e r m l i n e  g e n e  t h e r a p y  w o u l d  b e  ( o r  w o u l d  n o t  b e )  i n  t h e  b es t in terests  o f  a  
f u t u r e  p e r s o n .
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I t  w o u l d  b e  a  m i s t a k e  t o  a s s u m e  t h a t  a n  in t e r e s t s - b a s e d  a p p r o a c h  i s  u n i q u e  t o  g e n e  
t h e r a p y .  I n  t h e  c a s e  o f  p r e n a t a l  d i a g n o s i s ,  i t  i s  n e c e s s a r y  to  d e c i d e  w h e t h e r  a  f o e t u s  
h a r b o u r i n g  a  m e d i c a l  d i s o r d e r  s h o u l d  b e  a b o r t e d  o r  a l l o w e d  t o  l i v e .  S i m i l a r  
c o n s i d e r a t i o n s  a p p l y  t o  q u e s t i o n s  o f  m e d i c a l  i n t e r v e n t i o n  i n  t h e  c a s e  o f  p a t i e n t s  i n  
p e r s is t e n t  v e g e t a t i v e  c o m a s .  A n d  d e c i s i o n s  h a v e  t o  b e  m a d e  o n  b e h a l f  o f  y o u n g  
c h i l d r e n  w h o  a r e  i n s u f f i c i e n t l y  m a t u r e  t o  g i v e  o r  w i t h h o l d  c o n s e n t  t o  m e d i c a l  
p r o c e d u r e s .  I n  e a c h  o f  t h e s e  c a s e s ,  a  j u d g e m e n t  m u s t  b e  m a d e  a s  t o  w h a t  i s  l i k e l y  t o  
b e  i n  t h e  b e s t  in t e r e s t s  o f  a n o t h e r  p e r s o n .  S u c h  j u d g e m e n t s  a r e  o f t e n  v e r y  d i f f i c u l t  t o  
m a k e ,  a n d  r e q u i r e  a  g o o d  d e a l  o f  m e d i c o - s c i e n t i f i c  u n d e r s t a n d i n g  c o u p l e d  w i t h  
c a r e f u l  r e f l e c t i o n .  N e v e r t h e l e s s ,  t h e r e  i s  n o  o b v i o u s  a l t e r n a t i v e  w a y  t o  r e a c h  d e c i s i o n s  
c o n c e r n i n g  m e d i c a l  i n t e r v e n t i o n s  t h a t  w i l l  a f f e c t  p e o p l e  w h o  c a n n o t  g i v e  o r  w i t h h o l d  
c o n s e n t .  A c c o r d i n g l y ,  a n  i n t e r e s t s - b a s e d  a p p r o a c h  f o r  d e c i s i o n - m a k i n g  i n  t h e  c o n t e x t  
o f  g e r m l i n e  g e n e  t h e r a p y  w o u l d  n o t  d i f f e r  f u n d a m e n t a l l y  f r o m  t h e  a p p r o a c h  t h a t  i s  
a l r e a d y  w e l l - e s t a b l i s h e d  i n  c o n v e n t i o n a l  m e d i c a l  e t h i c s .
T h e r e  i s  h o w e v e r  a  s p e c i a l  f e a t u r e  o f  g e r m l i n e  g e n e  t h e r a p y  t h a t  c o m p l i c a t e s  e t h i c a l  
d e c i s i o n  m a k i n g .  I t  i s  t h e  i s s u e  o f  fu tu re  g en era tio n s  o f  p e o p l e .  I n  m e d i c a l  d e c i s i o n s  
c o n c e r n i n g  f o e t u s e s ,  c h i l d r e n  o r  c o m a t o s e  p a t i e n t s ,  t h e  e f f e c t s  o f  m e d i c a l  i n t e r v e n t i o n  
w i l l  b e  l i m i t e d  t o  t h e  i n d i v i d u a l s  c o n c e r n e d .  B y  c o n t r a s t ,  g e r m l i n e  g e n e  t h e r a p y  
i m p l i e s  g e n e t ic  c h a n g e s  t h a t  w o u l d  b e  t r a n s m it t e d  t o  a l l  d e s c e n d a n t  g e n e r a t io n s  
a r i s i n g  f r o m  t h e  ‘ t r e a t e d ’ i n d i v i d u a l .  F u r t h e r m o r e ,  o n c e  i n c o r p o r a t e d  i n t o  t h e  g e r m l i n e  
o f  o n e  i n d i v i d u a l ,  a  t r a n s g e n e  s e q u e n c e  c o u l d  h a v e  t h e  p o t e n t i a l  t o  ‘ s p r e a d ’ ( i . e .  
in c r e a s e  i n  f r e q u e n c y )  t h r o u g h o u t  t h e  e n t ir e  p o p u l a t i o n .
I t  i s  t h i s  i s s u e  o f  h a v i n g  p e r m a n e n t  ( a n d  p o t e n t i a l l y  d a m a g i n g )  e f f e c t s  o n  f u t u r e  
g e n e r a t io n s  t h a t  m a k e s  g e r m l i n e  g e n e  t h e r a p y  e s p e c i a l l y  c o n t e n t io u s  f r o m  a n  e t h i c a l  
p e r s p e c t i v e .  G i v e n  i t s  p o t e n t i a l  m a g n i t u d e  o f  e f f e c t ,  o n e  m a y  b e  t e m p t e d  t o  r u l e  
g e r m l i n e  g e n e  t h e r a p y  u ltra  vires, f o r  f e a r  o f  c a u s i n g  u n a l t e r a b l e  a n d  u n d e s i r a b l e  
c h a n g e s  t o  h u m a n i t y  p e r  se. H o w e v e r ,  t h e r e  a r e  g o o d  r e a s o n s  t o  b e l i e v e  t h a t  s u c h  a n  
a b s o l u t i s t  r e s p o n s e  i s  o n e  o f  e x c e s s i v e  c a u t i o n .
Firstly, germline gene therapy should not be singled-out as the only factor able to alter
the genetic constitution of future generations. As mentioned previously, medical X-
rays on occasion undoubtedly induce mutagenic changes in patients’ germline DNA.
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E n v i r o n m e n t a l  f a c t o r s ,  a n c i e n t  a n d  c o n t e m p o r a r y ,  d a m a g e  g e r m l i n e  D N A .  M o r e o v e r ,  
g e r m l i n e  m u t a t i o n s  a r e  a  f r e q u e n t  a n d  i n e v i t a b l e  o c c u r r e n c e  in v iv o , r e g a r d l e s s  o f  
e n v i r o n m e n t a l  f a c t o r s .  T h u s ,  a l t e r i n g  t h e  h u m a n  g e r m l i n e  w o u l d  h a r d l y  r e p r e s e n t  a  
n e w ,  u n p a r a l l e l e d  o c c u r r e n c e .
S e c o n d l y ,  t h e  f e a r  o f  i n d u c i n g  u n a l t e r a b l e  c h a n g e s  i s  v a l i d  i n s o f a r  a s  d e l e t e r i o u s  
( a c c i d e n t a l )  c h a n g e s  a r e  c o n c e r n e d .  H o w e v e r ,  m e d i c a l l y  s o u g h t  g e r m l i n e  a l t e r a t i o n s  
w o u l d  b e  a i m e d  t o w a r d s  b e n e f i c i a l  e f f e c t s  -  f o r  e x a m p l e ,  t h e  r e p a i r  o f  a n  o n c o g e n e ,  
o r  t h e  k n o c k o u t  o f  a  d o m i n a n t  d i s e a s e  g e n e ,  o r  t h e  a d d i t i o n  o f  a  m i s s i n g  g e n e  
f u n c t i o n .  F r o m  a n  e t h i c a l  p e r s p e c t i v e ,  s u c h  b e n e f i t s  o u g h t  t o  b e  g i v e n  w e i g h t .  T h u s ,  
f o r  a n y  p r o p o s e d  g e r m l i n e  g e n e  t h e r a p y ,  i f  t h e  b e n e f i t  ( e .g .  a  l a r g e  d e c r e a s e  i n  c a n c e r  
r i s k  t h r o u g h  t h e  r e p a i r  o f  a n  o n c o g e n e )  w e r e  t o  o u t w e i g h  t h e  r i s k s  ( e .g .  i n s e r t i o n a l  
m u t a g e n e s i s ) ,  t h e n  i t  w o u l d  b e  d i f f i c u l t  t o  e t h i c a l l y  d e f e n d  p r o s c r i p t i o n  o f  t h e  t h e r a p y  
c o n c e r n e d .  M o r e o v e r ,  t h e  i s s u e  o f  a f f e c t i n g  f u t u r e  g e n e r a t io n s  w o u l d  i n  s u c h  c a s e s  
w e i g h  in fa v o u r  o f  g e r m l i n e  g e n e  t h e r a p y ,  s i n c e  m a n y  p e o p l e  ( i . e .  t h e  d e s c e n d a n t s  o f  
t h e  ‘ t r e a t e d ’ i n d i v i d u a l )  w o u l d  s t a n d  t o  b e n e f i t  f r o m  t h e  t h e r a p y .
T h u s ,  o n  t h e  u t i l i t a r i a n  v i e w ,  t h e  e t h i c a l  i s s u e  b e c o m e s  a  s c i e n t i f i c  o n e :  n a m e l y ,  t h e  
s c i e n t i f i c  a s s e s s m e n t  o f  ( a )  e f f i c a c y  a n d  ( b )  r i s k  o f  a c c i d e n t s .  C l e a r l y ,  p r o p o s e d  
g e r m l i n e  t h e r a p e u t i c  a p p r o a c h e s  w o u l d  n e e d  t o  b e  i n d i v i d u a l l y  ( a n d  v e r y  r i g o r o u s l y )  
a s s e s s e d  i n  t e r m s  o f  ( a  &  b ) ,  o n  a  c a s e - b y - c a s e  b a s i s .
T h e  m a i n  p o t e n t i a l  h e a l t h  r i s k s  a s s o c i a t e d  w i t h  g e r m l i n e  g e n e  t h e r a p y  a r e :  ( a )  
m u t a g e n i c  ( i n c l u d i n g  p o t e n t i a l l y  c a r c i n o g e n i c )  e f f e c t s  a r i s i n g  f r o m  t r a n s g e n e  
i n t e g r a t i o n ;  a n d  ( b )  d e v e l o p m e n t a l  a b n o r m a l i t i e s  a r i s i n g  f r o m  t h e  u s e  o f  s p e c i a l i s e d  
c e l l s  s u c h  a s  E S C s  a n d  r e c o n s t r u c t e d  e m b r y o s  ( i n  N T  a p p r o a c h e s ) .  A s  d i s c u s s e d  
p r e v i o u s l y ,  a l l  t h e  p r e s e n t l y  a v a i l a b l e  r a n d o m  i n t e g r a t i o n  f o r m s  o f  g e n e  t r a n s f e r  
( p r o n u c l e a r  m i c r o i n j e c t i o n ,  R W s ,  S M G T )  a r e  a s s o c i a t e d  w i t h  s i g n i f i c a n t  r i s k s  o f  
g e n e t i c  d a m a g e .  T h e  q u e s t i o n  i s ,  d o  s u c h  r i s k s  o u t w e i g h  t h e  b e n e f i t s ?  I n  p r o n u c l e a r  
m i c r o i n j e c t i o n  a n d  S M G T ,  g e n e t ic  d a m a g e  i s  e x p e c t e d  a t  a  f r e q u e n c y  o f  l e s s  t h a n  2 % ,  
w i t h  m o s t  o c c u r r e n c e s  o f  s u c h  d a m a g e  e x p e c t e d  t o  b e  o f  m i n o r  c o n s e q u e n c e  t o  h e a l t h .  
T h i s  l e v e l  o f  r i s k  m a y  a p p e a r  t o le r a b l e ,  e s p e c i a l l y  i f  v i e w e d  a s  t h e  c o s t  o f  a v o i d i n g  a  
d e v a s t a t i n g  m o n o g e n i c  d i s e a s e  s u c h  a s  C F  o r  h a e m o p h i l i a .  H o w e v e r ,  a s  p r e v i o u s l y  
d i s c u s s e d ,  e m b r y o  p r e - s c r e e n i n g  c a n  b e  u s e d  t o  a v o i d  m o n o g e n i c  c o n d i t i o n s
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p o t e n t i a l l y  a m e n a b l e  t o  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  G i v e n  t h a t  p r e - s c r e e n i n g  i s  n o t  
a s s o c i a t e d  w i t h  g e n e t i c  d a m a g e ,  i t  a p p e a r s  i n e s c a p a b l e  t h a t  t h e  r i s k  o f  g e n e t i c  d a m a g e  
f r o m  p r o n u c l e a r  m i c r o i n j e c t i o n  o r  S M G T  e f f e c t i v e l y  p r e c l u d e s  t h e  u s e  o f  t h e s e  
t e c h n i q u e s  ( a t  l e a s t  i n  t h e i r  p r e s e n t  f o r m )  i n  t h e  c o n t e x t  o f  h u m a n  g e r m l i n e  g e n e  
t h e r a p y .  I t  w o u l d  b e  u n e t h i c a l  t o  r i s k  g e n e t i c  d a m a g e  b y  u s i n g  s u c h  f o r m s  o f  h u m a n  
g e r m l i n e  g e n e  t h e r a p y  in s t e a d  o f  p r e - s c r e e n i n g .  T h e  c a s e  a g a i n s t  R W s  w o u l d  b e  
e v e n  s t r o n g e r ,  c o n s i d e r i n g  t h e  a d d i t i o n a l  r i s k s  a s s o c i a t e d  w i t h  o f  s u c h  a g e n t s  -  
in t e g r a t i o n  in t o  o n c o g e n e s  a n d  r e a c t i v a t i o n  w i t h i n  t h e  h o s t  g e n o m e .
G e n e  t a r g e t in g  w o u l d  a v o i d  t h e  r i s k s  o f  i n s e r t i o n a l  d a m a g e .  H o w e v e r ,  N T  
t r a n s g e n e s i s  i s  t h e  o n l y  g e n e  t a r g e t in g  a p p r o a c h  p r e s e n t l y  a p p l i c a b l e  ( i n  p r i n c i p l e )  f o r  
h u m a n s .  H o w e v e r ,  b e c a u s e  N T  i s  a s s o c i a t e d  w i t h  a  v e r y  h i g h  l e v e l  o f  d i s e a s e  a n d  
d e b i l i t y  i n  t h e  f i r s t  g e n e r a t io n ,  t h i s  a p p r o a c h  i s  r u l e d  o u t  o n  s a f e t y  g r o u n d s .  A g a i n ,  i t  
w o u l d  b e  u n e t h i c a l  t o  r i s k  d e v e l o p m e n t a l  ( e p i g e n e t i c )  d a m a g e  b y  u s i n g  N T - b a s e d  
h u m a n  g e r m l i n e  g e n e  t h e r a p y  w h e n  p r e s c r e e n i n g  c o u l d  d e l i v e r  t h e  s a m e  r e s u l t s  w i t h  
n o  s u c h  r i s k s .  T h u s ,  i t  w o u l d  b e  u n e t h i c a l  t o  c a r r y  o u t  g e r m l i n e  g e n e  t h e r a p y  w h e r e  
p r e s c r e e n i n g  i s  a  s a f e r  a lt e r n a t i v e .  G i v e n  t h e  c u r r e n t  s t a t u s  o f  g e n e  t r a n s f e r  
t e c h n o l o g y ,  t h e  c o n c l u s i o n  m u s t  b e  t h a t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  o u g h t  n o t  b e  
c a r r i e d  o u t  a t  p r e s e n t .
H o w e v e r ,  t h i s  n e g a t i v e  c o n c l u s i o n  i s  n o t  i n v i o l a b l e .  A s  t h e  u n d e r l y i n g  p r o g r e s s e s ,  
g e n e  t r a n s f e r  t e c h n i q u e s  w i l l  u n d o u b t e d l y  b e c o m e  m o r e  e f f e c t i v e .  I t  i s  i m p o s s i b l e  t o  
e n v i s a g e  t h e  u l t i m a t e  d e g r e e  t o  w h i c h  G M  m e t h o d o l o g y  w i l l  p r o g r e s s ,  m u c h  l e s s  t o  
s e t  a  t i m e s c a l e  f o r  p r o g r e s s .  N e v e r t h e l e s s ,  t h e r e  a r e  n o  f u n d a m e n t a l  r e a s o n s  t o  d o u b t  
t h a t  s i g n i f i c a n t  t e c h n o l o g i c a l  i m p r o v e m e n t s  w i l l  b e  m a d e .  I t  i s  s a l u t a r y  t o  r e f l e c t  o n  
t h e  r e l a t i v e  i n f a n c y  o f  g e n e t ic  m o d i f i c a t i o n  s c i e n c e :  t h e  f i r s t  u s e  o f  G M  ( i n  
p r o k a r y o t e s )  o c c u r r e d  i n  t h e  e a r l y  1 9 7 0 s ;  m a m m a l i a n  t r a n s g e n e s i s  w a s  f i r s t  
a c c o m p l i s h e d  i n  t h e  e a r l y  1 9 8 0 s ;  a n d  t h e  f i r s t  ( s o m a t i c )  h u m a n  g e n e  t h e r a p y  t r i a l s  
b e g a n  i n  t h e  e a r l y  1 9 9 0 s .  T h u s ,  i n  l i t t l e  o v e r  3 0  y e a r s  t h e r e  h a s  b e e n  a  r e v o l u t i o n  i n  
G M  s c i e n c e  a n d  t e c h n o l o g y .  T h e  f o l l o w i n g  3 0  y e a r s  w i l l  u n d o u b t e d l y  s e e  f u r t h e r  
a d v a n c e s .  I f  G M  t e c h n o l o g y  d e v e l o p s  t o  t h e  p o i n t  a t  w h i c h  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  w o u l d  b e  s a f e r  a n d  m o r e  e f f i c i e n t  t h a n  a l t e r n a t i v e s  s u c h  a s  p r e s c r e e n i n g ,  t h e n  
u t i l i t a r i a n s  w o u l d  h a v e  n o  s a f e t y - b a s e d  g r o u n d s  f o r  o b j e c t i n g  t o  h u m a n  g e r m l i n e  g e n e  
t h e r a p y .
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7.3 Public Acceptability
H u m a n  g e r m l i n e  g e n e  t h e r a p y  m a y  b e  o b j e c t e d  t o  o n  t h e  g r o u n d s  t h a t  i t  a p p e a r s  t o  b e  
u n a c c e p t a b l e  t o  ( a t  l e a s t  s o m e  s e c t o r s  o f )  t h e  p u b l i c .  I n  t h i s  r e g a r d ,  a  d i s t i n c t i o n  n e e d s  
t o  b e  m a d e  s t r a ig h t  a w a y  b e t w e e n  h u m a n  g e r m l i n e  g e n e  t h e r a p y  u s i n g  p r e s e n t  g e n e  
t r a n s f e r  t e c h n o l o g y ,  a n d  h u m a n  g e r m l i n e  g e n e  t h e r a p y  o f  t h e  f u t u r e .  T h e  p u b l i c  w o u l d  
b e  r i g h t  t o  o b j e c t  t o  a n y  p r o p o s a l  t o  p e r f o r m  h u m a n  g e r m l i n e  g e n e  t h e r a p y  u s i n g  
p r e s e n t  t e c h n o l o g y :  a s  d i s c u s s e d  a b o v e ,  c u r r e n t  g e n e  t r a n s f e r  m e t h o d s  a r e  s i m p l y  t o o  
r i s k y  ( i n  c o m p a r i s o n  w i t h  p r e - s c r e e n i n g )  t o  b e  u s e d  a s  t h e  b a s i s  f o r  a t t e m p t e d  
g e r m l i n e  g e n e  t h e r a p y  o n  h u m a n s .  B y  c o n t r a s t ,  s a f e t y  c o n c e r n s  w o u l d  n o t  b e  v a l i d  
g r o u n d s  f o r  o b j e c t i o n  i n  t h e  f u t u r i s t i c  ( b u t  p l a u s i b l e )  s c e n a r i o  w h e r e  f u t u r e  g e n e  
t r a n s f e r  t e c h n i q u e s  h a d  a d v a n c e d  t o  t h e  p o i n t  a t  w h i c h  t h e  b e n e f i t s  o u t w e i g h e d  t h e  
r i s k s .  I n  t h i s  f u t u r e  c o n t e x t ,  i f  p u b l i c  d i s a p p r o v a l  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  
e x is t e d ,  s u c h  d i s a p p r o v a l  w o u l d  h a v e  t o  b e  b a s e d  u p o n  c o n s i d e r a t i o n s  t h a t  g o  b e y o n d  
t h e  q u e s t i o n  o f  s a f e t y  v s .  e f f e c t i v e n e s s .  S o m e  c o n t e n d e r s  a s  v a l i d  a r g u m e n t s  a g a i n s t  
( s a f e  a n d  e f f e c t i v e )  h u m a n  g e r m l i n e  g e n e  t h e r a p y  a r e  d i s c u s s e d  i n  t h e  r e m a i n i n g  
s e c t i o n s  o f  t h i s  t h e s is .  H o w e v e r ,  t h e r e  i s  a  n o t i o n  t h a t  ‘ p u b l i c  a c c e p t a b i l i t y ’ i s  a n  
e t h i c a l  e n t i t y  i n  it s  o w n  r i g h t .  I n  t h i s  r e s p e c t ,  s h o u l d  ‘ t h e  p u b l i c ’ ( o r  a  m a j o r i t y  
t h e r e o f )  n o t  w i s h  t o  h a v e  h u m a n  g e r m l i n e  g e n e  t h e r a p y  p e r m it t e d ,  t h e n  t h i s  w o u l d  b e  
s e e n  ( b y  s o m e )  a s  h a v i n g  e t h i c a l  f o r c e  a g a i n s t  h u m a n  g e r m l i n e  g e n e  t h e r a p y .
T h e r e  h a v e  b e e n  m a n y  i n s t a n c e s  o f  s c i e n t i f i c  i n n o v a t i o n s  a g a i n s t  w h i c h  ‘ t h e  p u b l i c ’ -  
a t  l e a s t  a s  r e p r e s e n t e d  b y  t h e  p o p u l a r  m e d i a  -  h a v e  t a k e n  a  n e g a t i v e  s t a n c e .  R e c e n t  
e x a m p l e s  a t  t h e  t i m e  o f  w r i t i n g  i n c l u d e  t h e  M M R  v a c c i n e  c o n t r o v e r s y  a n d  t h e  i s s u e  o f  
G M  c r o p s .  I  s u g g e s t  t h a t  s u c h  i s s u e s  o u g h t  t o  b e  d e c i d e d  b y  d e b a t e  b a s e d  o n  s c i e n t i f i c  
k n o w l e d g e  a n d  r a t i o n a l  a r g u m e n t :  i f  t h e r e  a r e  s c i e n t i f i c  a n d / o r  e t h i c a l  o b j e c t i o n s  t o  a  
p a r t i c u l a r  m e d i c a l  p r o c e d u r e  o r  t e c h n o l o g i c a l  i n n o v a t i o n ,  t h e s e  s h o u l d  b e  b r o u g h t  
f o r w a r d  f o r  o p e n  d i s c u s s i o n  b y  a l l  in t e r e s t e d  p a r t ie s .  I  s u g g e s t  t h a t  i t  i s  e r r o n e o u s  t o  
v i e w  ‘ p u b l i c  a c c e p t a b i l i t y ’ a s  a  f o r m  o f  e t h i c a l  b l a c k  b o x ,  w i t h  i t s  o w n  v a l i d i t y  t h a t  
t r a n s c e n d s  t h e  m a n y  a r g u m e n t s  f o r  a n d  a g a i n s t  w h i c h e v e r  i s s u e  i s  a t  s t a k e .
Thus, it should be open for any member of the public to raise objections to human
germline gene therapy. However, should there be widespread public apprehension o f
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h u m a n  g e r m l i n e  g e n e  t h e r a p y  ( a s  h a s  o c c u r r e d  i n  t h e  U K  w i t h  G M  c r o p s ) ,  t h i s  f a c t  o f  
p u b l i c  o p i n i o n  s h o u l d  n o t  o f  i t s e l f  c o u n t  a s  a  s t r o n g  e t h i c a l  a r g u m e n t  a g a i n s t  h u m a n  
g e r m l i n e  g e n e  t h e r a p y .  O f  c o u r s e ,  u t i l i t a r i a n i s m  i s  g e n e r a l l y  s u p p o r t i v e  o f  p o p u l a r  
d e m o c r a c y  a n d  t h e  u n d e r l y i n g  a u t o n o m y  t h a t  d e m o c r a c y  i m p l i e s  f o r  e a c h  m e m b e r  o f  
t h e  p u b l i c ,  a n d  i n  t h i s  r e s p e c t  u t i l i t a r i a n i s m  m i g h t  p e r m i t  p u b l i c  o p i n i o n  t o  p r e v a i l ,  
e v e n  i f  t h e  b a s i s  f o r  s u c h  o p i n i o n  w a s  i r r a t i o n a l .  T h i s  w o u l d  b e  j u s t i f i e d  o n  u t i l i t a r i a n  
g r o u n d s  i n  c a s e s  w h e r e  s e r i o u s  c i v i l  s t r i f e ,  s o c i e t a l  b r e a k d o w n  o r  t e r r o r  a m o n g s t  t h e  
p o p u l a c e  w o u l d  b e  a  l i k e l y  o u t c o m e  o f  r e f u s i n g  t o  a l l o w  t h e  p o p u l a r  w i l l  t o  p r e v a i l  -  
a s s u m i n g  t h a t  t h e  p o t e n t i a l  b e n e f i t s  ( f o r  e x a m p l e  i m p r o v e d  r e s i s t a n c e  t o  p a r t i c u l a r  
d is e a s e s  a m o n g s t  t h o s e  t r e a t e d  b y  h u m a n  g e r m l i n e  g e n e  t h e r a p y )  w e r e  s m a l l e r  t h a n  
t h e  d i s u t i l i t i e s  l i k e l y  t o  a r i s e  f r o m  i g n o r i n g  t h e  p u b l i c  w i l l .
I n  o t h e r  w o r d s ,  t h e  p o s s i b l e  s i d e - e f f e c t s  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  w o u l d  n e e d  
t o  b e  t a k e n  in t o  a c c o u n t ,  a n d  s u c h  s i d e  e f f e c t s  m i g h t  i n c l u d e  p u b l i c  u p s e t .  O n e  f o r m  
o f  s i d e - e f f e c t  t h a t  i s  o f  p a r t i c u l a r  im p o r t a n c e  t o  u t i l i t a r i a n s  i s  t h e  i n t u i t i v e  r e s p o n s e .  I  
h a v e  p r e v i o u s l y  a r g u e d  t h a t  i n t u i t i v e  r e s p o n s e s  a r e  p o o r  g u i d e s  t o  e t h i c a l  d e c i s i o n  
m a k i n g ,  a n d  a r e  i n c o m p a t i b l e  w i t h  u t i l i t a r i a n i s m  ( S e c t i o n  6 . 4 . 1 ) .  N e v e r t h e l e s s ,  
i n t u i t i v e  r e s p o n s e s  e x i s t  a s  r e a l  f e a t u r e s  o f  h u m a n  p s y c h o l o g y  a n d  h e n c e  o f  t h e  p u b l i c  
a t  l a r g e .  I f  a  l a r g e  n u m b e r  o f  p e o p l e  f o u n d  h u m a n  g e r m l i n e  g e n e  t h e r a p y  d i f f i c u l t  t o  
p a la t e ,  d e s p it e  v a l i d  a r g u m e n t s  i n  i t s  f a v o u r ,  t h i s  w o u l d  c o u n t  a g a i n s t  p e r m i t t i n g  
h u m a n  g e r m l i n e  g e n e  t h e r a p y .  T h i s  i s  s o  b e c a u s e  i g n o r i n g  a  d e e p - s e a t e d  i n t u i t i v e  
r e s p o n s e  w o u l d  c a u s e  p s y c h o l o g i c a l  u p s e t  a n d  t h u s  b e  a  d i s u t i l i t y .  A  c o n t e m p o r a r y  
e x a m p l e  i l l u s t r a t e s  t h i s :  la t e  a b o r t i o n  o r  e v e n  i n f a n t i c i d e  m a y  b e  j u s t i f i e d  o n  u t i l i t a r i a n  
g r o u n d s ,  i n  c a s e s  i n v o l v i n g  u n b e a t a b l e  d i s o r d e r s  t h a t  w o u l d  s e r i o u s l y  r e d u c e  t h e  
q u a l i t y  o f  l i f e  ( G l o v e r  1 9 7 7 ;  S i n g e r  1 9 9 3 ) .  T o  a  u t i l i t a r i a n ,  s u c h  t e r m i n a t i o n  o f  l i f e  
w o u l d  b e  s u p p o r t e d  b y  s e v e r a l  c o n s i d e r a t i o n s  i n c l u d i n g :  ( a )  t h e  r e d u c t i o n  i n  p o t e n t i a l  
s u f f e r i n g  f o r  t h e  a f f l i c t e d  i n d i v i d u a l  a n d  t h e  p a r e n t s ;  ( b )  t h e  l a c k  o f  ‘ p e r s o n h o o d ’ o f  
f o e t u s  o r  in f a n t ;  a n d  ( c )  t h e  p o s s i b i l i t y  o f  ‘ r e p l a c i n g ’ t h e  t e r m in a t e d  l i f e  w i t h  a n o t h e r .  
N o t w i t h s t a n d i n g  s u c h  s t r o n g  u t i l i t a r i a n  a r g u m e n t s ,  i t  r e m a i n s  t h e  c a s e  t h a t  m a n y  
p e o p l e  f i n d  la t e  a b o r t io n  a n d  -  i n  p a r t i c u l a r  -  i n f a n t i c i d e  i n t u i t i v e l y  r e p u g n a n t .  I t  m a y  
b e  a s k i n g  t o o  m u c h  o f  t h e  p u b l i c  to  a c c e p t  i n f a n t i c i d e ,  d e s p it e  t h e  a r g u a b l y  g o o d  
r e a s o n s  i n  it s  f a v o u r ,  i n  t h e  f a c e  o f  s t r o n g  i n t u i t i v e  r e a c t i o n  a g a i n s t  it .  T h u s ,  t h e  b e s t  
c o n s e q u e n c e s  w o u l d  c o m e  f r o m  a  p r o s c r i p t i v e  p o s i t i o n ,  i f  it  w e r e  l i k e l y  t h a t  t h e
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m e r i t s  o f  a l l o w i n g  i n f a n t i c i d e  ( a  r e d u c t i o n  i n  d i s e a s e - r e l a t e d  s u f f e r i n g )  w o u l d  b e  
o u t w e i g h e d  b y  t h e  d e m e r it s  ( s e r i o u s  p s y c h o l o g i c a l  u p s e t  a n d  p o s s i b l e  s o c i e t a l  s t r i f e ) .
W o u l d  t h e r e  b e  a  w i d e s p r e a d ,  d e e p - s e a t e d  i n t u i t i v e  r e a c t i o n  a g a i n s t  h u m a n  g e r m l i n e  
g e n e  t h e r a p y ,  o f  s i m i l a r  m a g n i t u d e  t o  t h e  p r o b a b l e  r e s p o n s e  a g a i n s t  i n f a n t i c i d e ?  I t  i s  
d i f f i c u l t  t o  b e  p r o v i d e  a  p r e c i s e  a n s w e r ,  b e c a u s e  p u b l i c  o p i n i o n  i s  s u b j e c t  t o  c u l t u r a l  
i n f l u e n c e s :  f o r  e x a m p l e ,  v o c i f e r o u s  p r o t e s t  g r o u p s  m a y  b e  a b l e  t o  h i j a c k  t h e  d e b a t e  
a n d  s w a y  t h e  p u b l i c  a g a i n s t  a c c e p t i n g  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  A  p e r t i n e n t  
e x a m p l e  h e r e  w o u l d  b e  G M  c r o p s ,  w h i c h  h a v e  b e e n  l a r g e l y  a c c e p t e d  i n  t h e  U S A  b u t  
r e j e c t e d  b y  a  l a r g e  p r o p o r t i o n  o f  t h e  U K  p o p u l a c e .  H o w e v e r ,  w h e r e a s  h u m a n s  a r e  
p r o b a b l y  i n n a t e l y  r e p u l s e d  b y  t h e  i d e a  o f  k i l l i n g  i n f a n t s  ( a l t h o u g h  e v e n  h e r e  c u l t u r e  
p l a y s  a  p a r t :  i n  s o m e  c o m m u n i t i e s ,  i n f a n t i c i d e  o f  d i s a b l e d  i n f a n t s  h a s  b e e n  a n  
e n d u r i n g  c u l t u r a l  n o r m ) ,  i t  i s  l e s s  c l e a r  t h a t  w e  s h o u l d  b e  s i m i l a r l y  ‘ p r o g r a m m e d ’ 
a g a i n s t  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  O n e  r e a s o n  f o r  e m p l o y i n g  n o n - i n t u i t i v e  
d e l i b e r a t i o n s  t o  e t h i c a l  p r o b l e m s  i s  t o  c i r c u m v e n t  t h e  f a c t  t h a t  o u r  i n t u i t i v e  r e s p o n s e  
‘ s y s t e m ’ h a s  n o t  e v o l v e d  t o  c o p e  w i t h  n o v e l  i s s u e s  s u c h  a s  h u m a n  g e r m l i n e  g e n e  
t h e r a p y :  t h u s ,  t h e r e  i s  n o  r e a s o n  t o  a s s u m e  a  s t r o n g  i n t u i t i v e  r e s p o n s e  a g a i n s t  h u m a n  
g e r m l i n e  g e n e  t h e r a p y .  M o r e o v e r ,  h u m a n  g e r m l i n e  g e n e  t h e r a p y  h a s  n o  o b v i o u s  
p a r a l l e l  i n  o r d i n a r y / h i s t o r i c  h u m a n  e x p e r i e n c e .  T h i s  i s  i n  c o n t r a s t  t o  s o m e  o t h e r  
m o d e m  i s s u e s :  f o r  e x a m p l e ,  w h i l e  s u r g i c a l  la t e  a b o r t i o n  i s  r e l a t i v e l y  n e w  t o  h u m a n  
e x p e r i e n c e ,  it  i n v o l v e s  f u n d a m e n t a l  e l e m e n t s  ( b l o o d ,  i n f a n t s ,  d e a t h ,  e t c )  t h a t  e v o k e  
d e e p - s e a t e d  i n t u i t i v e  r e a c t i o n s  i n  h u m a n s .  S i m i l a r  f u n d a m e n t a l  e l e m e n t s  a r e  a b s e n t  
f r o m  a n y  p l a u s i b l e  a c c o u n t  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  F u r t h e r m o r e ,  i t  s h o u l d  
b e  c l e a r  e v e n  t o  n o n - r e f l e c t i v e  p e r s o n s  t h a t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  i s  a  
t e c h n o l o g y  in t e n d e d  t o  h a v e  p o s i t i v e  o u t c o m e s  -  i . e .  i t s  r a i s o n  d 'e t r e  i s  t o  p r e v e n t  
d i s e a s e .  T h u s ,  b e c a u s e  n o  c o u n t e r i n t u i t i v e  l o g i c  i s  r e q u i r e d ,  i t  s h o u l d  b e  r e l a t i v e l y  
e a s y  f o r  h u m a n  g e r m l i n e  g e n e  t h e r a p y  t o  g a i n  a c c e p t a n c e  e v e n  a m o n g s t  
u n s o p h i s t i c a t e d  p e r s o n s .  T h i s  c o n t r a s t s  w i t h  t h e  e x a m p l e  o f  i n f a n t i c i d e ,  w h i c h  
i n v o l v e s  t h e  c o u n t e r i n t u i t i v e  n o t i o n  t h a t  k i l l i n g  i n f a n t s  m a y  b e  e t h i c a l l y  d e s i r a b l e .
A  s m a l l  b o d y  o f  r e s e a r c h  h a s  b e e n  p u b l i s h e d  t h a t  i n v e s t i g a t e s  t h e  v i e w s  o f  t h e  p u b l i c  
t o w a r d s  g e n e  t h e r a p y  ( H e d g e c o e  2 0 0 4 ;  M a c e r  1 9 9 2 ;  M a c e r  1 9 9 4 ;  M a c e r  e t  a l .  1 9 9 5 ;  
S c u l l y  e t  a l .  2 0 0 4 ) .  I n  g e n e r a l ,  p e o p l e  p e r c e i v e  b o t h  b e n e f i t s  a n d  r i s k s  f r o m  g e n e t i c  
m a n i p u l a t i o n .  F u r t h e r  r e s e a r c h  w o u l d  b e  v e r y  w e l c o m e ,  e s p e c i a l l y  i n  r e g a r d s  t o
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g e r m l i n e  ( c f .  s o m a t i c )  g e n e  t h e r a p y .  B u t  i t  w o u l d  b e  s u r p r i s i n g  i f  a  s e r i o u s  d e e p -  
s e a t e d  i n t u i t i v e  r e s p o n s e  a g a i n s t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  w e r e  t o  b e  d i s c o v e r e d ,  
c o n s i d e r i n g  t h e  f o r e g o i n g  d i s c u s s i o n .
7.4 Cost and Access
C u r r e n t  g e r m l i n e  G M  t e c h n o l o g y  i s  e x p e n s i v e .  F o r  e x a m p l e ,  t h e  c o s t  o f  p r o d u c i n g  
o n e  ( f o u n d e r )  t r a n s g e n i c  s h e e p  b y  p r o n u c l e a r  m i c r o i n j e c t i o n  i s  a r o u n d  £ 3 0 , 0 0 0  ( W a l l  
1 9 9 6 ;  W a l l  e t  a l .  1 9 9 2 ) .  I f  t h e  p r e s e n t  t e c h n o l o g y  i s  i m p r o v e d  i n c r e m e n t a l l y  t o  t h e  
p o i n t  o f  b e i n g  s u f f i c i e n t l y  s a f e  a n d  e f f e c t i v e  t o  p e r m i t  h u m a n  g e r m l i n e  g e n e  t h e r a p y ,  
i t s  h i g h  c o s t  w o u l d  r e s t r ic t  a c c e s s .  I n  n o n - s t a t e  f u n d e d  h e a l t h c a r e  s y s t e m s  ( s u c h  a s  i n  
t h e  U S A ) ,  t h i s  w o u l d  p r o b a b l y  m e a n  t h a t  o n l y  f i n a n c i a l l y  b e t t e r  o f f  i n d i v i d u a l s  w o u l d  
b e  a b l e  t o  a f f o r d  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  I n  p u b l i c  h e a l t h c a r e  s y s t e m s  ( s u c h  a s  
i n  t h e  U K ) ,  s o m e  f o r m  o f  r a t i o n i n g  w o u l d  p r o b a b l y  b e  r e q u i r e d .  A n d  h u m a n  g e r m l i n e  
g e n e  t h e r a p y  w o u l d  p r o b a b l y  b e  t o t a l l y  u n a v a i l a b l e  f o r  t h e  c i t i z e n s  o f  p o o r  c o u n t r i e s .
O f  c o u r s e ,  s u c h  a  s i t u a t i o n  i s  i n v i d i o u s .  U t i l i t a r i a n i s m  ( i n  c o m m o n  w i t h  m a n y  e t h i c a l  
s y s t e m s )  i s  s u p p o r t i v e  o f  t h e  w i d e s t  p o s s i b l e  a c c e s s  t o  m e d i c a l  g o o d s :  r e s t r i c t i v e  
a c c e s s  w o u l d  ( a )  l i m i t  t h e  d e c r e a s e  i n  s u f f e r i n g  a v a i l a b l e  f r o m  d i s e a s e - p r e v e n t i n g  
m e a s u r e s ,  a n d  ( b )  i n c r e a s e  d is c o n t e n t  a n d  u n h a p p i n e s s  a m o n g s t  t h o s e  u n a b l e  t o  a c c e s s  
m e d i c a l  g o o d s .  H o w e v e r ,  i t  w o u l d  b e  e r r o n e o u s  t o  i s o l a t e  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  a s  a  s p e c i a l  c a s e  i n s o f a r  a s  c o s t  i s  c o n c e r n e d .  M a n y  m e d i c a l  p r o c e d u r e s  ( s u c h  
a s  e s s e n t i a l  t r a n s p l a n t  s u r g e r y )  a r e  e x t r e m e l y  e x p e n s i v e ,  a s  a r e  m a n y  l i f e - s a v i n g  d r u g s  
( s u c h  a s  a n t i - H I V  m e d i c a t i o n ) .  I t  w o u l d  b e  d i f f i c u l t  t o  c o n s t r u c t  a  u t i l i t a r i a n  a r g u m e n t  
i n  f a v o u r  o f  p r o h i b i t i n g  t h e  d e v e l o p m e n t  o r  u s e  o f  a n  e x p e n s i v e  m e d i c a l  a p p r o a c h  
s o l e l y  o n  g r o u n d s  t h a t  t h e  h i g h  c o s t  w o u l d  l i m i t  a c c e s s .  T h e  r e a s o n s  f o r  t h i s  a r e  
t w o f o l d .  F i r s t l y ,  t h e  d e v e l o p m e n t  o f  i n i t i a l l y  e x p e n s i v e  m e d i c a l  t e c h n o l o g y  m a y  p a v e  
t h e  w a y  f o r  t h e  e v o l u t i o n  o f  c h e a p e r  f o r m s  o f  t h e  t e c h n o l o g y .  S e c o n d l y ,  e v e n  i f  o n l y  a  
s m a l l  n u m b e r  o f  p e o p l e  c a n  b e  t r e a t e d  b y  a n  e x p e n s i v e  m e d i c a l  t e c h n o l o g y ,  t h e s e  
p e r s o n s  w o u l d  e x p e r i e n c e  a n  i n c r e a s e  i n  h a p p i n e s s ;  t h u s  a  p o s i t i v e  c o n t r i b u t i o n  w o u l d  
b e  m a d e  t o  t h e  o v e r a l l  a m o u n t  o f  h a p p i n e s s  i n  t h e  w o r l d .
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O f  c o u r s e ,  t h e r e  i s  a  s t r o n g  u t i l i t a r i a n  a r g u m e n t  i n  f a v o u r  o f  s p e n d i n g  a  l i m i t e d  b u d g e t  
o n  s i m p l e ,  c o s t - e f f e c t i v e  m e a s u r e s  t h a t  b e n e f i t  m a n y  p e o p l e ,  r a t h e r  t h a n  s p e n d i n g  i t  
o n  e x p e n s i v e ,  h i g h - t e c h  m e a s u r e s  t h a t  b e n e f i t  a  s m a l l e r  n u m b e r  o f  p e o p l e .  F o r  
e x a m p l e ,  s u p p o s e  a  p o o r  c o u n t r y  h a s  £ 1 , 0 0 0 , 0 0 0  t o  s p e n d  o n  h e a l t h c a r e :  t h i s  m o n e y  
w o u l d  p r o b a b l y  b e  b e t t e r  s p e n t  o n  a  c h i l d  i m m u n i s a t i o n  p r o g r a m  t h a n  o n  a  c a r d i a c  
s u r g e r y  u n i t .  T h e  s a m e  a r g u m e n t  w o u l d  a p p l y  t o  d e c i s i o n s  t o  s p e n d  l i m i t e d  f u n d s  o n  
h u m a n  g e r m l i n e  g e n e  t h e r a p y  v e r s u s  ( s a y )  a  c l e a n  n e e d l e  f o r  h o s p i t a l s  p r o g r a m .  
H o w e v e r ,  i t  i s  im p o r t a n t  t o  n o t e  t h a t  t h i s  t y p e  o f  a r g u m e n t  s a y s  n o t h i n g  w h a t s o e v e r  
a b o u t  t h e  i n t r i n s i c  e t h i c a l  d e s i r a b i l i t y / r e p r e h e n s i b i l i t y  o f  h u m a n  g e r m l i n e  g e n e  
t h e r a p y .
A  m a j o r  p r o b l e m  w o u l d  a r i s e  i f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  c a m e  t o  b e  u s e d  n o t  
s i m p l y  t o  a v o i d  p a r t i c u l a r  g e n e t i c  d i s e a s e s ,  b u t  t o  e n d o w  g e n e t ic  a d v a n t a g e s .  S u c h  
a d v a n t a g e s  m i g h t  i n c l u d e  c a n c e r  r e s i s t a n c e ,  i n c r e a s e d  l i f e - s p a n ,  p h y s i c a l  p r o w e s s ,  
e n h a n c e d  I Q ,  e t c .  I t  i s  d e b a t a b l e  w h e t h e r  s u c h  ‘ e n h a n c e m e n t s ’ t o  t h e  h u m a n  g e n o m e  
a r e  d e s i r a b l e  p e r  se;  b u t  i t  s e e m s  c l e a r  t h a t  s h o u l d  a c c e s s  t o  s u c h  e n h a n c e m e n t s  c o m e  
t o  b e  r e s t r i c t e d  t o  r i c h  i n d i v i d u a l s  ( a n d  h e n c e  t h e i r  c h i l d r e n ) ,  t h e n  s o c i e t a l  h a r m o n y  
w o u l d  b e  s e v e r e l y  j e o p a r d i s e d .  A c c o r d i n g l y ,  t h e  u s e  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  
f o r  g e n e t i c  e n h a n c e m e n t  o f  a  s u b g r o u p  o f  h u m a n s  w o u l d  n o t  b e  s u p p o r t e d  b y  
u t i l i t a r i a n  m o r a l i t y .  T h e  i s s u e  o f  g e n e t ic  e n h a n c e m e n t  -  a n d  i t s  p o s s i b l e  c o r o l l a r y ,  
e u g e n i c s  -  i s  d i s c u s s e d  i n  m o r e  d e t a i l  l a t e r  i n  t h i s  c h a p t e r .
T h e  a b o v e  d i s c u s s i o n s  a r e  b a s e d  o n  t h e  p o s s i b i l i t y  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  
b e c o m i n g  t e c h n o l o g i c a l l y  f e a s i b l e  b y  i n c r e m e n t a l  i m p r o v e m e n t  i n  c u r r e n t  t e c h n o l o g y .  
A n  a l t e r n a t i v e  s c e n a r i o ,  a n d  o n e  t h a t  w o u l d  b e  e q u a l l y  c o n s i s t e n t  w i t h  t h e  g e n e r a l  
h i s t o r y  o f  s c i e n t i f i c  p r o g r e s s ,  i s  t h a t  t e c h n o l o g i c a l  im p r o v e m e n t s  revo lu tio n ise  g e n e  
t r a n s f e r  s u c h  t h a t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  b e c o m e s  n o t  o n l y  s a f e  a n d  e f f e c t i v e ,  
b u t  a l s o  i n e x p e n s i v e .  I t  i s  i m p o s s i b l e  t o  e n v i s a g e  e x a c t l y  w h a t  s u c h  h u m a n  g e r m l i n e  
g e n e  t h e r a p y  w o u l d  l o o k  l i k e ,  b u t  a  f e w  p o i n t s  a r e  w o r t h  m a k i n g .  F i r s t l y ,  t h e r e  w o u l d  
h a v e  t o  b e  n o  n e e d  t o  r e m o v e / r e t u m  e g g s  o r  e m b r y o s  f f o m / t o  t h e  b o d y ,  s i n c e  t h e  
n e c e s s a r y  s t e p s  a r e  i n t r i n s i c a l l y  e x p e n s i v e  i n  t e r m s  o f  t r a in e d  s t a f f  a n d  f a c i l i t i e s .  
S e c o n d l y ,  t h e r e  w o u l d  h a v e  t o  b e  n o  n e e d  t o  p e r f o r m  t r a n s g e n e  a d d i t i o n  t o  i n d i v i d u a l  
c e l l s ,  s i n c e  t h e  r e q u i r e d  p r o c e d u r e s  a n d  e q u i p m e n t  a r e  a g a i n  i n h e r e n t l y  c o s t l y .  T h e s e  
f e a t u r e s  o f  f u t u r e  l o w - c o s t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  d ic t a t e  t h a t  s o m e  f o r m  o f
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S M G T  w o u l d  h a v e  t o  b e  i n v o l v e d ,  w i t h  t h e  u s e  o f  a  h i g h - e f f i c i e n c y  v e c t o r  t o  d e l i v e r  a  
t a r g e t in g  t r a n s g e n e  t o  s p e r m  v i a  e it h e r  in v ivo  i n j e c t i o n  p r i o r  t o  i n t e r c o u r s e  o r  in v itro  
e x p o s u r e  p r i o r  t o  A I .  I f  s u c h  im p r o v e m e n t s  a r e  e v e r  r e a l i s e d ,  t h e n  e t h i c a l  c o n c e r n s  
o v e r  t h e  c o s t s  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  a n d  a c c e s s  t o  i t  w o u l d  l a r g e l y  
d is a p p e a r .
7.5 Human Embryos
T h e  u s e  o f  h u m a n  e m b r y o s  i n  b i o m e d i c i n e  g e n e r a t e s  c o n t r o v e r s y  ( C h u  2 0 0 3 ;  
F i t z P a t r i c k  2 0 0 3 ;  G e o r g e  2 0 0 4 ;  K a r p o w i c z  e t  a l .  2 0 0 4 ;  W i l l i a m s  e t  a l .  2 0 0 3 ) .  T h i s  i s  
u n f o r t u n a t e  f o r  h u m a n  g e r m l i n e  g e n e  t h e r a p y ,  s i n c e  r e s e a r c h  w i t h  h u m a n  e m b r y o s  
w o u l d  b e  a n  u n a v o i d a b l e  p r e c o n d i t i o n  t o  t h e  e s t a b l i s h m e n t  o f  e f f e c t i v e  h u m a n  
g e r m l i n e  G M  m e t h o d s .  A d d i t i o n a l l y ,  m o s t  p r e s e n t l y  a v a i l a b l e  g e n e  t r a n s f e r  m e t h o d s  
e n t a i l  t h e  l o s s  o f  e m b r y o s  d u r i n g  t h e  G M  p r o c e s s .  A  d e t a i l e d  d i s c u s s i o n  o f  t h e  e t h i c s  
o f  h u m a n  e m b r y o  r e s e a r c h  i s  o u t s id e  t h e  s c o p e  o f  t h e  p r e s e n t  t h e s i s .  S u f f i c e  i t  t o  s a y  
t h a t  u t i l i t a r i a n i s m  d o e s  n o t  p l a c e  s p e c i a l  e t h i c a l  i m p o r t a n c e  o n  t h e  h u m a n  e m b r y o .  T o  
p u t  t h e  u t i l i t a r i a n  c a s e  s i m p l y :  o n l y  b e i n g s  t h a t  h a v e  in t e r e s t s  c a n  b e  h a r m e d ,  a n d  
h a v i n g  in t e r e s t s  p r e s u p p o s e s  s e n t i e n c e ;  e m b r y o s  ( i n  c o n t r a s t  t o  l a t e - s t a g e  f o e t u s e s ,  
c h i l d r e n  a n d  a d u l t s )  c l e a r l y  a r e  n o n - s e n t i e n t ,  a n d  t h e r e f o r e  n o  in t e r e s t s  a r e  d e f e a t e d  i f  
e m b r y o s  a r e  e x p e r i m e n t e d  u p o n .  D e s t r o y i n g  a  h u m a n  e m b r y o  d o e s  n o t  k i l l  a  p e r s o n ,  
r a t h e r  i t  p r e v e n t s  a  p e r s o n  f r o m  c o m i n g  in t o  e x i s t e n c e .  T h e  k i l l i n g  o f  a  h u m a n  e m b r y o  
h a r m s  n o  p e r s o n .
I  s u g g e s t  t h a t  t h e  o n u s  s h o u l d  b e  o n  t h o s e  w h o  o p p o s e  h u m a n  e m b r y o  r e s e a r c h  t o  
m a k e  c o n v i n c i n g  a r g u m e n t s  i n  s u p p o r t  o f  t h e i r  c a s e .  M u c h  i s  a t  s t a k e ;  n o t  o n l y  h u m a n  
g e r m l i n e  g e n e  t h e r a p y ,  b u t  b i o m e d i c a l  r e s e a r c h  i n  g e n e r a l  w i l l  b e  u n d o u b t e d l y  b e  
s e r i o u s l y  r e t a r d e d  i f  r e s e a r c h  o n  h u m a n  e m b r y o s  i s  -  a s  i t  i s  i n  t h e  U S A  -  p r o h i b i t e d .  
O f  c o u r s e ,  m a n y  o f  t h o s e  w h o  a r e  i m p l a c a b l y  o p p o s e d  t o  h u m a n  e m b r y o  r e s e a r c h  a r e  
m o t i v a t e d  b y  r e l i g i o u s  b e l i e f s ,  a n d  r e g r e t t a b l y  t h e r e  m a y  b e  l i t t l e  h o p e  o f  t a k i n g  t h e  
a r g u m e n t  f o r w a r d  w i t h  s u c h  p e r s o n s .
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P r e - s c r e e n i n g  a s  a n  a l t e r n a t i v e  t o  h u m a n  g e r m l i n e  g e n e  t h e r a p y  h a s  a l r e a d y  b e e n  
d i s c u s s e d ,  w i t h  t h e  c o n c l u s i o n  b e i n g  d r a w n  t h a t  p r e - s c r e e n i n g  i s  p r e f e r a b l e  t o  h u m a n  
g e r m l i n e  g e n e  t h e r a p y  g i v e n  t h e  s a f e t y  p r o b l e m s  a n d  e f f e c t i v e n e s s  l i m i t a t i o n s  o f  
p r e s e n t l y  a v a i l a b l e  G M  t e c h n o l o g y .  H o w e v e r ,  s u p p o s e  h u m a n  g e r m l i n e  g e n e  t h e r a p y  
b e c a m e  e q u i v a l e n t  t o  p r e - s c r e e n i n g  i n  t e r m s  o f  s a f e t y  a n d  e f f e c t i v e n e s s :  w h i c h  
a p p r o a c h  w o u l d  b e  p r e f e r a b l e ?  I t  h a s  b e e n  s u g g e s t e d  t h a t  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  m a y  b e  p r e f e r a b l e  t o  s e l e c t i v e  a b o r t i o n  o r  d i s c a r d  “sh o w s g r e a te r  re sp e c t f o r  
ch ildren  a n d  a du lts  w ho a re  a fflic ted  w ith  d isea se  o r  d isa b il ity ” ( W a l t e r s  a n d  P a l m e r
1 9 9 7 ) .  U t i l i t a r i a n i s m  c a n  h a v e  n o  s p e c i a l  o b j e c t i o n  t o  s e l e c t i v e  a b o r t i o n  o r  d i s c a r d ;  
h o w e v e r ,  t h e  i s s u e  o f  s i d e - e f f e c t s  w o u l d  t e n d  t o  s u p p o r t  t h e  v i e w p o i n t  e x p r e s s e d  i n  
t h e  a b o v e  q u o t e .  T h u s ,  s h o u l d  h u m a n  g e r m l i n e  g e n e  t h e r a p y  d e v e l o p  t o  t h e  p o i n t  a t  
w h i c h  i t  i s  o n  a  p a r  w i t h  p r e - s c r e e n i n g  i n  a l l  e t h i c a l l y  r e l e v a n t  r e s p e c t s  ( i n c l u d i n g  
s a f e t y ,  e f f e c t i v e n e s s ,  c o s t ) ,  t h e n  i t  w o u l d  p r o b a b l y  b e  b e s t  t o  f a v o u r  h u m a n  g e r m l i n e  
g e n e  t h e r a p y .
7.6 Sequence Alteration
G e n e t i c  m o d i f i c a t i o n  e n t a i l s  t h e  d e l i b e r a t e  a l t e r a t i o n  o f  g e n e t i c  s e q u e n c e s  w i t h i n  t h e  
g e n o m e .  I n  n a t u r e ,  t h e  s a m e  f u n d a m e n t a l  p r o c e s s  o f  s e q u e n c e  a l t e r a t i o n  o c c u r s  a s  a  
r e s u l t  o f  n a t u r a l  s e l e c t i o n  a n d  a s s o c i a t e d  e v o l u t i o n a r y  m e c h a n i s m s .  S i m i l a r l y ,  t h e  
p r o c e s s  o f  s e q u e n c e  a lt e r a t io n  o c c u r s  i n  t h e  s e l e c t i v e  b r e e d i n g  o f  d o m e s t i c a t e d  
a n i m a l s  a n d  p l a n t s .  I n  t e r m s  o f  s e q u e n c e  a lt e r a t io n ,  t h e  o n l y  s i g n i f i c a n t  d i f f e r e n c e  
b e t w e e n  g e n e t i c  m o d i f i c a t i o n  a n d  g e n e t ic  s e l e c t i o n  i s  t h a t  t h e  f o r m e r  p r o c e s s  i s  v e r y  
m u c h  f a s t e r  t h a t  t h e  la t t e r .  T h u s ,  e t h i c a l  o b j e c t i o n s  a g a i n s t  g e n e  t h e r a p y  b a s e d  o n  a  
n o t i o n  o f  t h e  i n t r i n s i c  w r o n g n e s s  o f  s e q u e n c e  m a n i p u l a t i o n  w o u l d  b e  s u s t a i n a b l e  o n l y  
a s  a  s u b s e t  o f  a  m u c h  b r o a d e r  o b j e c t i o n  t o  a l l  f o r m s  o f  d e lib e ra te  seq u en ce  a lte ra tio n  
( D S A )  ( S m i t h  2 0 0 2 b ) .  A  c o h e r e n t  a n t i - D S A  a r g u m e n t  w o u l d  e n t a i l  t h e  a p p r o v a l  o r  
a c c e p t a n c e  o f  s e q u e n c e  a lt e r a t io n s  o c c u r r i n g  n a t u r a l l y  ( f r o m  e v o l u t i o n )  a n d  t h e  
r e j e c t i o n  o f  d e l i b e r a t e  f o r m s  o f  a l t e r a t io n  ( b r e e d i n g  a n d  g e n e t ic  m o d i f i c a t i o n ) .  T h u s ,  
t o  a s s u m e  a n  e t h i c a l  s t a n c e  a g a i n s t  D S A  w o u l d  b e  t o  s u b s c r i b e  t o  a n  u n s u b t l e  
‘ n a t u r a l i s t i c  f a l l a c y ’ : i n  o t h e r  w o r d s ,  D S A  w o u l d  b e  d e e m e d  m o r a l l y  u n a c c e p t a b l e  o n  
t h e  g r o u n d s  t h a t  i t  i s  ‘u n n a t u r a l ’ . O n e  n e e d  o n l y  c o n s i d e r  ( a )  u n d e s i r a b l e  ‘ n a t u r a l ’
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e v e n t s  ( e .g .  i n f e c t i o n  b y  H I V )  a n d  ( b )  b e n e f i c i a l  ‘ u n n a t u r a l ’ e v e n t s  ( e .g .  t h e  u s e  o f  
a n a e s t h e t i c s )  t o  s e e  t h e  f a l l a c i o u s  n a t u r e  o f  ‘ n a t u r a l i s t i c ’ a r g u m e n t s .
A d d i t i o n a l l y ,  i t  i s  d i f f i c u l t  t o  s e e  h o w  a n y  f o r m  o f  r a t i o n a l  e t h i c a l  a r g u m e n t  c o u l d  b e  
m a d e  a g a i n s t  D S A  i n  r e s p e c t  o f  i t s  a c t u a l  h i s t o r i c a l  c o n s e q u e n c e s ,  c o n s i d e r i n g  t h e  
v a s t  e x p a n s i o n  o f  t h r i v i n g  h u m a n i t y  t h a t  w o u l d  n o t  h a v e  b e e n  p o s s i b l e  w i t h o u t  
c e n t u r i e s  o f  s e l e c t i v e  b r e e d i n g  o f  d o m e s t i c a t e d  a n i m a l s  a n d  p l a n t s .  O f  c o u r s e ,  
n e g a t i v e  a p p l i c a t i o n s  o f  D S A  a r e  p e r f e c t l y  p o s s i b l e :  f o r  e x a m p l e ,  a  t e r r o r i s t  r e g i m e  
e m p l o y i n g  g e n e t i c  m o d i f i c a t i o n  t o  w o r s e n  t h e  e f f e c t s  o f  a  b i o l o g i c a l  w e a p o n .  
H o w e v e r ,  s u c h  ( h y p o t h e t i c a l )  u s e s  o f  D S A  s a y  n o t h i n g  a b o u t  t h e  i n t r i n s i c  m o r a l i t y  o f  
a l t e r i n g  g e n e t i c  s e q u e n c e s .
A s s u m i n g  g e n e t i c  s e q u e n c e  a l t e r a t io n  p e r  se  t o  b e  e t h i c a l l y  a c c e p t a b l e ,  i t  f o l l o w s  t h a t  
t h e  g e n e t i c  s e q u e n c e  a l t e r a t i o n  in h e r e n t  i n  g e n e  t h e r a p y  m u s t  a l s o  b e  c o n s i d e r e d  
e t h i c a l l y  a c c e p t a b l e .
7.7 Animal Experimentation
T h e  d e v e l o p m e n t  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  w o u l d  r e l y  h e a v i l y  u p o n  t h e  u s e  o f  
l a b o r a t o r y  a n i m a l s .  I n  p a r t i c u l a r ,  t r a n s g e n e s i s  w o u l d  n e e d  t o  b e  p e r f o r m e d  u s i n g  
e x p e r i m e n t a l  a n i m a l s .  T h i s  w o u l d  b e  n e c e s s a r y  i n  o r d e r  t o  t e s t  a n d  d e v e l o p  d e l i v e r y  
s y s t e m s  a n d  t r a n s g e n e s  p r i o r  t o  t h e i r  u s e  w i t h  h u m a n s .
I  h a v e  p r e v i o u s l y  s u g g e s t e d  t h a t  a n i m a l  s u f f e r i n g  g i v e s  u t i l i t a r i a n  g r o u n d s  f o r  
o b j e c t i o n  t o  t r a n s g e n e s i s  ( S m i t h  2 0 0 2 b ) .  S p e c i f i c a l l y ,  I  h a v e  p r o p o s e d  t h a t  p ro h ib itio n  
s h o u l d  b e  c o n s i d e r e d  i n  c a s e s  w h e r e  e it h e r  o f  t h e  f o l l o w i n g  n e g a t i v e  c o n s e q u e n c e s  a r e  
e n t a i l e d :
A .  S i g n i f i c a n t  s u f f e r i n g  a r i s i n g  i n  a n y  a n i m a l s  u s e d  i n  t h e  p r o c e s s  o f  t r a n s g e n e s i s .
B .  S i g n i f i c a n t  s u f f e r i n g  a r i s i n g  i n  t r a n s g e n i c s  f r o m  t h e  d e v e l o p m e n t  o f  a  
p a t h o l o g i c a l  c o n d i t i o n  e n g i n e e r e d  in t o  t h e  a n i m a l s ’ g e n e t i c  m a k e u p .
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I  u s e  t h e  t e r m  ‘sign ifican t sufferin g  ’ t o  e x c l u d e  s u f f e r i n g  l i k e l y  t o  o c c u r  t o  a n  a n i m a l  
i n  a  n o n - e x p e r i m e n t a l  s i t u a t i o n .  F o r  e x a m p l e ,  a n i m a l s  l i v i n g  i n  t h e  w i l d  c o m m o n l y  
s u c c u m b  t o  p r e d a t o r s ,  a n  o c c u r r e n c e  t h a t  o f t e n  i n v o l v e s  a  d e g r e e  o f  s u f f e r i n g ,  a n d  a l l  
a n i m a l s  - i n c l u d i n g  h o u s e h o l d  p e t s -  a r e  a t  r i s k  f r o m  v a r i o u s  u n p l e a s a n t  d i s e a s e s .  I f  t h e  
e x t e n t  o f  s u f f e r i n g  u n a v o i d a b l y  e n t a i l e d  b y  a  p a r t i c u l a r  t r a n s g e n i c  a p p r o a c h  i s  c l e a r l y  
l e s s  t h a n  t h a t  l i k e l y  t o  o c c u r  i n e v i t a b l y  i n  t h e  l i f e  o f  t h e  a n i m a l ,  u t i l i t a r i a n s  h a v e  n o  
c l e a r  g r o u n d s  f o r  o b j e c t i o n .
A l t h o u g h  I  p r o p o s e  t h a t  p r o h i b i t i o n  s h o u l d  b e  c o n s i d e r e d  f o r  n e g a t i v e  c o n s e q u e n c e s  
A  &  B  ( a b o v e ) ,  t h i s  s h o u l d  n o t  b e  t a k e n  t o  m e a n  t r a n s g e n i c  c a s e s  e n t a i l i n g  A  o r  B  
o u g h t  a u t o m a t i c a l l y  b e  p r e v e n t e d .  R a t h e r ,  i t  i s  n e c e s s a r y ,  a t  l e a s t  i n  p r i n c i p l e ,  t o  
w e i g h  c o s t s  ( s i g n i f i c a n t  s u f f e r i n g )  a g a i n s t  p o t e n t i a l  b e n e f i t s  ( f o r  e x a m p l e ,  a  
c o n t r i b u t i o n  t o  t h e  d e v e l o p m e n t  o f  a  n e w  a n t i c a n c e r  d r u g ) .
F r o m  t h e  p e r s p e c t i v e  o f  s u f f e r i n g ,  t h e r e  a r e  t w o  k e y  m o r a l l y  s a l i e n t  f e a t u r e s  o f  
g e n e t i c  m o d i f i c a t i o n  t h a t  c a n  l e a d  t o  n e g a t i v e  m e n t a l  s t a t e s ,  s u c h  a s  p a i n  a n d  f e a r .  
T h e s e  f e a t u r e s  a r e  ( i )  i n v a s i v e  p r o c e d u r e s  t o  r e c o v e r  a n d  t r a n s f e r  e m b r y o s ,  a n d  ( i i )  
k i l l i n g  o f  a n i m a l s  i n v o l v e d  i n  o r  a r i s i n g  f r o m  t r a n s g e n e s i s .  A l t h o u g h  k i l l i n g  m a y  i n  
p r i n c i p l e  b e  f r e e  o f  s u f f e r i n g ,  I  s u g g e s t  t h a t  t h i s  i s  s o  d i f f i c u l t  t o  a c h i e v e  i n  p r a c t i c e  
t h a t  t h e  s a f e s t  o p t io n  i s  t o  a s s u m e  so m e  s u f f e r i n g ,  e v e n  u n d e r  t h e  m o s t  h u m a n e  
c o n d i t i o n s .
I t  s e e m s  u n d e n i a b l e  t h a t  t h e  p r o c e s s  o f  t r a n s g e n e s i s  i n e v i t a b l y  e n t a i l s  so m e  
( s i g n i f i c a n t )  s u f f e r i n g .  T h e  q u e s t i o n  n o w  b e c o m e s :  i s  t h i s  s u f f e r i n g  o u t w e i g h e d  b y  
g o o d  c o n s e q u e n c e s ?  I  s u g g e s t  t h a t  - a s s u m i n g  i m p e c c a b l e  w e l f a r e  p r o v i s i o n s -  a n  
a f f i r m a t i v e  a n s w e r  s h o u l d  b e  g i v e n .  T h e  ‘ g o o d  c o n s e q u e n c e s ’ a r i s i n g  f r o m  
t r a n s g e n e s i s  m a y  b e  s u m m a r i s e d  u n d e r  t h e  h e a d i n g  o f  ‘ s c i e n t i f i c  p r o g r e s s ’ . A s  
d i s c u s s e d  p r e v i o u s l y ,  t h e  s c i e n t i f i c  v a l u e  o f  t r a n s g e n e s i s  c a n  b e  i n  n o  d o u b t .  M o s t  
f o r m s  o f  u t i l i t a r i a n i s m  v i e w  s c i e n t i f i c  p r o g r e s s  ( i n  t e r m s  o f  a n  i n c r e a s e d  
u n d e r s t a n d i n g  o f  n a t u r e ,  a n d  o f  t h e  p o s s i b l e  b e n e f i c i a l  u s e s  f r o m  s u c h  u n d e r s t a n d i n g )  
a s  m o r a l l y  d e s i r a b l e .  T h u s ,  p r e v e n t i o n  o f  t r a n s g e n i c  r e s e a r c h  p e r  se  w o u l d  o n l y  b e  
j u s t i f i a b l e  o n  t h e  g r o u n d s  o f  m a j o r  n e g a t i v e  c o n s e q u e n c e s .  I  c o n t e n d  t h a t  t h e  
i n e v i t a b l e  s i g n i f i c a n t  s u f f e r i n g  e n t a i l e d  b y  t r a n s g e n e s i s  i s  i n s u f f i c i e n t l y  l a r g e  t o  
o u t w e i g h  t h e  b e n e f i t s  to  s o c i e t y  a r i s i n g  f r o m  t h e  c o n t r i b u t i o n  o f  t r a n s g e n e s i s  t o
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s c i e n t i f i c  p r o g r e s s .  T h e  a m o u n t  o f  s i g n i f i c a n t  s u f f e r i n g  i m p l i c i t  i n  t r a n s g e n e s i s  c a n n o t  
b e  q u a n t i f i e d .  H o w e v e r ,  t h e  s u f f e r i n g  a c t u a l l y  e n t a i l e d  b y  t h e  i n v a s i v e  p r o c e d u r e s  a n d  
k i l l i n g  u s e d  i n  t r a n s g e n e s is  o u g h t  t o  b e  r e l a t i v e l y  m i n i m a l .  T y p i c a l l y ,  d o n o r  a n d  
r e c i p i e n t  a n i m a l s  a r e  u s e d  o n l y  o n c e  i n  t h e i r  l i f e t i m e s :  t h i s  i s  i n  m a r k e d  c o n t r a s t  t o  t h e  
m a n y  p r o t r a c t e d  e x p e r i m e n t s  t h a t  ‘ o r d i n a r y ’ l a b o r a t o r y  a n i m a l s  e n d u r e .  M o r e o v e r ,  t h e  
p r o c e d u r e s  t h e m s e l v e s  a r e  n o t  o f  a  s e v e r e  n a t u r e :  a t  w o r s t  ( b u t  u n d e r  p r o p e r  w e l f a r e  
c o n d i t i o n s ) ,  e m b r y o  c o l l e c t i o n  o r  t r a n s f e r  i s  a k i n  t o  t h e  s t e r i l i s a t i o n  o p e r a t io n s  
c o m m o n l y  u s e d  w i t h  h o u s e h o l d  p e t  a n i m a l s .  S i m i l a r l y ,  e u t h a n a s i a  i s  t h e  m o s t  
f r e q u e n t  f a t e  o f  p e t  a n i m a l s  ( i n  u s i n g  a  c o m p a r i s o n  w i t h  h o u s e h o l d  p e t s  t o  p u t  t h e  
p r o c e s s  o f  t r a n s g e n e s is  i n t o  s o m e  c o n t e x t ,  I  a s s u m e  t h a t  m o s t  u t i l i t a r i a n s  s h a r e  m y  
n o n - o b j e c t i o n  t o  t h e  c a r e f u l  k e e p i n g  o f  p e t  a n i m a l s ) .
T h e  ou tcom es  o f  t r a n s g e n e s i s  t h a t  h a v e  r e l e v a n c e  h e r e  a r e  t h o s e  t h a t  a r e  l i k e l y  t o  
c a u s e  s u f f e r i n g .  T a k i n g  t h i s  c a t e g o r y  o f  t r a n s g e n i c  o u t c o m e s  i n  g e n e r a l ,  t h e  
c o n s e q u e n c e s  a r e  o f  t h e  s a m e  t y p e  a s  t h o s e  f o r  t r a n s g e n e s is  p e r  se :  s c i e n t i f i c  p r o g r e s s  
i s  t h e  b e n e f i t ,  a n d  s u f f e r i n g  i s  t h e  c o s t .  H o w e v e r ,  t h e  d e g r e e  o f  s u f f e r i n g  i m p l i c i t  i n  
t h i s  c a t e g o r y  o f  o u t c o m e s  i s  g r e a t e r  t h a n  i s  t h e  c a s e  f o r  t h e  p r o c e s s  o f  t r a n s g e n e s i s .
O n  p r im a  fa c ie  g r o u n d s ,  I  c o n t e n d  t h a t  t r a n s g e n i c  o u t c o m e s  t h a t  c a u s e  s i g n i f i c a n t  
s u f f e r i n g  a r e  c o n t e n d e r s  f o r  p r o h i b i t i o n .  I  s u g g e s t  t h a t  u t i l i t a r i a n s  t a k e  a  ‘ d e f a u l t ’ 
p o s i t i o n  i n  w h i c h  e x p e r i m e n t a t i o n  e n t a i l i n g  s u c h  n e g a t i v e  t r a n s g e n i c  o u t c o m e s  i s  
d e e m e d  u n a c c e p t a b l e ,  u n l e s s  ( o n  a  c a s e - b y - c a s e  b a s i s )  a  w a t e r t i g h t  a r g u m e n t  h a s  b e e n  
m a d e  t o  t h e  e f f e c t  t h a t  s u f f e r i n g  i s  c l e a r l y  o u t w e i g h e d  b y  g o o d  c o n s e q u e n c e s .  F o r  
e x a m p l e ,  t h e  g e n e r a t io n  o f  t r a n s g e n i c s  t h a t  d e v e l o p  a n  a n a l o g u e  o f  a  p a i n f u l  h u m a n  
c a n c e r  o u g h t  t o  b e  p e r m i s s i b l e  o n l y  i f  t h e  e x p e r i m e n t e r s  c o u l d  c l e a r l y  d e m o n s t r a t e  a  
m a j o r  t a n g i b l e ,  h i g h  p r o b a b i l i t y  p a y o f f  i n  t e r m s  o f  a  s p e c i f i c  a d v a n c e  i n  c a n c e r  
t r e a t m e n t .  T h e  d i f f i c u l t i e s  i n  p r a c t i c e  o f  c o n v i n c i n g l y  d e m o n s t r a t i n g  s u c h  b e n e f i t s  
s h o u l d  n o t  b e  u n d e r e s t im a t e d :  t h e  m a j o r i t y  o f  r e s e a r c h  u s i n g  t r a n s g e n i c  d i s e a s e  
m o d e l s  i s  n o t  e x p e c t e d  t o  y i e l d  d i s c e r n i b l e  i m m e d i a t e  m e d i c a l  b e n e f i t s .  M o r e o v e r ,  
t h e r e  a r e  m a n y  f o r m s  o f  t r a n s g e n i c  e x p e r i m e n t a t i o n  f o r  w h i c h  a  c o s t - b e n e f i t  
j u s t i f i c a t i o n  i s  im possib le:  f o r  e x a m p l e ,  p a i n  r e s e a r c h  m a y  w e l l  f a l l  in t o  t h i s  c a t e g o r y .
B y  c o n t r a s t ,  t r a n s g e n i c  r e s e a r c h  d e s i g n e d  t o  s u p p o r t  h u m a n  g e r m l i n e  g e n e  t h e r a p y  i s ,
I  s u g g e s t ,  c l e a r l y  j u s t i f i a b l e  o n  a  c o s t - b e n e f i t  b a s i s .  P r o t r a c t e d  o r  a c u t e  s i g n i f i c a n t  
s u f f e r i n g  s h o u l d  c e r t a i n l y  n o t  b e  a  k e y  f e a t u r e  o f  s u c h  t r a n s g e n e s i s .  M o r e o v e r ,
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d i r e c t e d  r e s e a r c h  a i m e d  a t  d e v e l o p i n g  h u m a n  g e r m l i n e  g e n e  t h e r a p y  m e t h o d s  w o u l d  
h a v e  c l e a r  p o t e n t i a l  u t i l i t y :  a s  d i s c u s s e d  a d  infinitum  i n  t h i s  t h e s i s ,  G M  t e c h n o l o g y  
l o o k s  s e t  t o  p r o d u c e ,  s o o n e r  o r  l a t e r ,  a  r e v o l u t i o n  i n  m e d i c i n e .  T h u s ,  t h e  p a y o f f s  f r o m  
t r a n s g e n e s i s  e m p l o y e d  i n  t h e  p u r s u i t  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  a r e  v e r y  h i g h :  
s u f f e r i n g  w o u l d  b e  g r e a t l y  a l l e v i a t e d  i f  e f f e c t i v e  a n d  s a f e  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  w e r e  t o  b e c o m e  w i d e l y  a v a i l a b l e .  I  c o n c l u d e  t h a t ,  a s s u m i n g  s c r u p u l o u s  
w e l f a r e  a r r a n g e m e n t s  f o r  t h e  a n i m a l s  i n v o l v e d ,  t h e  a n i m a l  t r a n s g e n e s i s  n e c e s s a r y  f o r  
t h e  d e v e l o p m e n t  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y  i s  e t h i c a l l y  j u s t i f i e d  o n  u t i l i t a r i a n  
g r o u n d s .
7.8 Future Generations
F u t u r e  g e n e r a t io n s  o f  p e o p l e  a r e  m o r a l l y  s i g n i f i c a n t  ( E h r l i c h  2 0 0 3 ;  G l o v e r  1 9 7 7 ;  
S i n g e r  1 9 9 3 ;  V a n  N i e k e r k  2 0 0 2 ) .  T h e  i s s u e  o f  h a v i n g  p e r m a n e n t  e f f e c t s  o n  f u t u r e  
g e n e r a t io n s  r e n d e r s  g e r m l i n e  g e n e  t h e r a p y  e s p e c i a l l y  c o n t e n t io u s  f r o m  a n  e t h i c a l  
p e r s p e c t i v e .  G i v e n  it s  p o t e n t i a l  m a g n i t u d e  o f  e f f e c t ,  u t i l i t a r i a n s  a n d  o t h e r s  m a y  b e  
t e m p t e d  t o  r u l e  g e r m l i n e  g e n e  t h e r a p y  u ltra  vires,  t h r o u g h  f e a r  t h a t  i t  m i g h t  c a u s e  
u n a l t e r a b l e  a n d  u n d e s i r a b l e  c h a n g e s  to  h u m a n i t y  p e r  se. H o w e v e r ,  t h e r e  a r e  g o o d  
r e a s o n s  t o  b e l i e v e  t h a t  s u c h  a n  a b s o l u t i s t  r e s p o n s e  i s  o n e  o f  e x c e s s i v e  c a u t i o n .
F i r s t l y ,  g e r m l i n e  g e n e  t h e r a p y  s h o u l d  n o t  b e  s i n g l e d - o u t  a s  t h e  o n l y  f a c t o r  a b l e  t o  a lt e r  
t h e  g e n e t i c  c o n s t i t u t i o n  o f  f u t u r e  g e n e r a t io n s .  A s  m e n t i o n e d  p r e v i o u s l y ,  m e d i c a l  X -  
r a y s  o n  o c c a s i o n  u n d o u b t e d l y  i n d u c e  m u t a g e n i c  c h a n g e s  i n  p a t i e n t s ’ g e r m l i n e  D N A .  
E n v i r o n m e n t a l  f a c t o r s ,  a n c i e n t  a n d  c o n t e m p o r a r y ,  d a m a g e  g e r m l i n e  D N A .  M o r e o v e r ,  
g e r m l i n e  m u t a t i o n s  a r e  a  f r e q u e n t  a n d  i n e v i t a b l e  o c c u r r e n c e  in v iv o , r e g a r d l e s s  o f  
e n v i r o n m e n t a l  f a c t o r s .  T h u s ,  a l t e r i n g  t h e  h u m a n  g e r m l i n e  w o u l d  h a r d l y  r e p r e s e n t  a  
n e w ,  u n p a r a l l e l e d  o c c u r r e n c e .
S e c o n d l y ,  t h e  f e a r  o f  i n d u c i n g  u n a l t e r a b l e  c h a n g e s  i s  v a l i d  i n s o f a r  a s  d e l e t e r i o u s  
( a c c i d e n t a l )  c h a n g e s  a r e  c o n c e r n e d .  H o w e v e r ,  m e d i c a l l y  s o u g h t  g e r m l i n e  a lt e r a t i o n s  
w o u l d  b e  a i m e d  t o w a r d s  b e n e f i c i a l  e f f e c t s  -  f o r  e x a m p l e ,  t h e  r e p a i r  o f  a n  o n c o g e n e ,  
o r  t h e  k n o c k o u t  o f  a  d o m i n a n t  d i s e a s e  g e n e ,  o r  t h e  a d d i t i o n  o f  a  m i s s i n g  g e n e
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f u n c t i o n .  F r o m  a n  e t h i c a l  p e r s p e c t i v e ,  s u c h  b e n e f i t s  o u g h t  t o  b e  g i v e n  w e i g h t .  T h u s ,  
f o r  a n y  p r o p o s e d  g e r m l i n e  g e n e  t h e r a p y ,  i f  t h e  b e n e f i t  ( e .g .  a  l a r g e  d e c r e a s e  i n  c a n c e r  
r i s k  t h r o u g h  t h e  r e p a i r  o f  a n  o n c o g e n e )  w e r e  t o  o u t w e i g h  t h e  r i s k s  ( e .g .  i n s e r t i o n a l  
m u t a g e n e s i s ) ,  t h e n  it  w o u l d  b e  d i f f i c u l t  t o  e t h i c a l l y  d e f e n d  p r o s c r i p t i o n  o f  t h e  t h e r a p y  
c o n c e r n e d .  M o r e o v e r ,  t h e  i s s u e  o f  a f f e c t i n g  f u t u r e  g e n e r a t io n s  w o u l d  i n  s u c h  c a s e s  
w e i g h  in fa v o u r  o f  g e r m l i n e  g e n e  t h e r a p y ,  s i n c e  m a n y  p e o p l e  ( i . e .  t h e  d e s c e n d a n t s  o f  
t h e  ‘ t r e a t e d ’ i n d i v i d u a l )  w o u l d  s t a n d  t o  b e n e f i t  f r o m  t h e  t h e r a p y .
F i n a l l y ,  w h i l e  i t  i s  u n d o u b t e d l y  t r u e  t h a t  m i s t a k e s  w i l l  b e  m a d e  i n  h u m a n  g e r m l i n e  
g e n e  t h e r a p y  ( s i n c e  m i s t a k e s  a n d  a c c i d e n t s  a r e  a n  u n a v o i d a b l e  f e a t u r e  o f  a l l  m e d i c a l  
p r o c e d u r e s ,  e s p e c i a l l y  n e w  t e c h n i q u e s ) ,  t h e  s a m e  t e c h n o l o g i e s  t h a t  w e r e  u s e d  t o  
i n t r o d u c e  g e r m l i n e  c h a n g e s  c o u l d  p r e s u m a b l y  b e  u s e d  t o  r e p a i r  a c c i d e n t a l  g e n e t i c  
d a m a g e .  I n  t h i s  t h e s is  I  h a v e  a r g u e d  t h a t  g e n e  t a r g e t in g  w o u l d  b e  h i g h l y  d e s i r a b l e ,  i f  
n o t  e s s e n t i a l ,  f o r  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  A s s u m i n g  h u m a n  g e r m l i n e  g e n e  
t h e r a p y  t o  b e  p e r m i s s i b l e  o n l y  i f  g e n e  t a r g e t in g  i s  a v a i l a b l e ,  t h e n  a  ‘ f a u l t y ’ t r a n s g e n e  
s h o u l d  b e  a b l e  t o  b e  r e p a i r e d  o r  r e m o v e d  b y  g e n e  t a r g e t in g ,  a s  s h o u l d  e n d o g e n o u s  
s e q u e n c e s  d a m a g e d  b y  t r a n s g e n e  i n s e r t i o n .  T h u s ,  t h e r e  a r e  s t r o n g  g r o u n d s  f o r  
d e l a y i n g  h u m a n  g e r m l i n e  g e n e  t h e r a p y  a t t e m p t s  u n t i l  t h e  n e c e s s a r y  i m p r o v e m e n t s  i n  
g e n e  t a r g e t in g  t e c h n o l o g y  h a v e  b e e n  a c h i e v e d .  H o w e v e r ,  i f  a n d  w h e n  g e n e  t a r g e t in g  
b e c o m e s  r o u t i n e l y  a c h i e v a b l e  i n  t h e  h u m a n  g e r m l i n e ,  t h e n  a c c i d e n t s  a r i s i n g  w i t h  
h u m a n  g e r m l i n e  g e n e  t h e r a p y  w o u l d  n o  l o n g e r  r e p r e s e n t  a  t h r e a t  t o  f u t u r e  
g e n e r a t io n s .
7.9 Gene therapy vs. Genetic Enhancement
I f  g e r m l i n e  g e n e  t h e r a p y  i s  i n  p r i n c i p l e  e t h i c a l l y  a c c e p t a b l e  w h e n  t h e  t e c h n o l o g y  i s  
p e r f e c t e d ,  t h e n  t h e  q u e s t i o n  b e c o m e s :  W h i c h  d i s o r d e r s  w o u l d  b e  s e r i o u s  e n o u g h  t o  
w a r r a n t  g e r m l i n e  m o d i f i c a t i o n ?  I t  m u s t  f a l l  t o  e t h i c s  c o m m i t t e e s  t o  d e c i d e  i f  a  
p a r t i c u l a r  d i s o r d e r  i s  s e r io u s  e n o u g h  to  w a r r a n t  g e r m l i n e  g e n e  t h e r a p y .  F r o m  a  
c o n s e q u e n t i a l i s t  p e r s p e c t i v e ,  s u c h  d e c i s i o n s  s h o u l d  i n  p r i n c i p l e  b e  s i m p l e :  t h e  r i s k s  
a n d  b e n e f i t s  m u s t  b e  c a r e f u l l y  w e i g h e d ,  a n d  t h e  in t e r e s t s  o f  a l l  p e r s o n s  i n v o l v e d  m u s t  
b e  c o n s i d e r e d .  O f  c o u r s e ,  m a n y  p e o p l e  ( i n  f u t u r e  g e n e r a t io n s )  s t a n d  t o  b e  a f f e c t e d  b y
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a  p r o p o s e d  g e r m l i n e  m o d i f i c a t i o n ,  a n d  t h u s  t h e  in t e r e s t s  o f  t h e s e  f u t u r e  p e o p l e  m u s t  
w e i g h  h e a v i l y  i n  t h e  d e l i b e r a t i o n s  o f  t h e  e t h i c s  c o m m i t t e e .  H o w e v e r ,  g i v e n  g o o d  
s c i e n t i f i c  k n o w l e d g e ,  t h e  a c t u a l  d e c i s i o n  w i l l  o f t e n  b e  s t r a ig h t f o r w a r d .  T o  t a k e  a  
h y p o t h e t i c a l  e x a m p l e :  s u p p o s e  a  g e r m l i n e  G M  p r o c e s s  f o r  i n a c t i v a t i n g  a  d o m i n a n t  
c a n c e r - i n d u c i n g  g e n e  h a s  b e e n  s h o w n  t o  b e  e f f e c t i v e  i n  m o r e  t h a n  9 9 %  a n i m a l s  s o  
t r e a t e d ;  s u p p o s e  a l s o  t h a t  t h e  r i s k  o f  a  d a m a g i n g  m u t a t i o n a l  s i d e - e f f e c t  h a s  b e e n  
s h o w n  t o  b e  l e s s  t h a t  0 . 0 1 % ;  g i v e n  t h e s e  s c i e n t i f i c  f a c t s ,  t h e  e t h i c a l l y  c o r r e c t  c o u r s e  
o f  a c t i o n  w o u l d  b e  t o  p e r m i t  t h a t  p a r t i c u l a r  g e r m l i n e  G M  p r o c e s s  t o  b e  c a r r i e d  o u t  o n  
h u m a n s .  ( O n  t h e  o t h e r  h a n d ,  s u b s t a n t i a l l y  h i g h e r  r i s k  /  l o w e r  s u c c e s s  v a l u e s  w o u l d  o f  
c o u r s e  s w a y  t h e  e t h i c s  c o m m i t t e e  t o w a r d s  t h e  o p p o s i t e  c o n c l u s i o n . )  A d d i t i o n a l l y ,  t h e  
p o t e n t i a l  f o r  c o n v e n t i o n a l  t r e a t m e n t  o u g h t  t o  b e  f a c t o r e d - i n  t o  t h e  d e c i s i o n  p r o c e s s .  I n  
t h e  a b o v e  e x a m p l e ,  i f  t h e  u n w a n t e d  g e n e  c a u s e d  a  h i g h l y  i n v a s i v e ,  i n o p e r a b l e  c a n c e r ,  
t h i s  w o u l d  w e i g h  i n  m o r e  f a v o u r  o f  g e r m l i n e  g e n e  t h e r a p y ,  c o m p a r e d  w i t h  t h e  c a s e  o f  
a  g e n e  c a u s i n g  a  s l o w  g r o w i n g ,  e a s i l y  o p e r a b l e  c a n c e r .
W h a t  o f  m i n o r  d i s o r d e r s ,  s u c h  a s  c o l o u r - b l i n d n e s s  o r  p o l y d a c t y l y ?  T h e  p o t e n t i a l  
d i s r u p t i o n  t o  t h e  p a r e n t s  ( d u e  t o  t h e  a s s o c i a t e d  m e d i c a l  p r o c e d u r e s )  m i g h t  w e l l  
d i s s u a d e  p o t e n t i a l  p a r e n t s  f r o m  c o n s i d e r i n g  g e r m l i n e  g e n e  t h e r a p y  f o r  r e l a t i v e l y  
t r i v i a l  d is o r d e r s .  I n  c a s e s  w h e r e  p a r e n t s  n e v e r t h e l e s s  w i s h e d  t o  p r o c e e d  w i t h  g e r m l i n e  
g e n e  t h e r a p y ,  o n c e  a g a i n  i t  w o u l d  b e  t h e  t a s k  o f  t h e  e t h i c s  c o m m i t t e e  t o  r e a c h  a  
d e c i s i o n .  A g a i n ,  t h e  p r e v i o u s l y  m e n t i o n e d  p r i n c i p l e s  w o u l d  a p p l y ,  w i t h  t h e  m in or  
n a t u r e  o f  t h e  d i s o r d e r  p r o v i d i n g  le ss  w e i g h t  i n  f a v o u r  o f  a p p r o v a l .  A n d  t h e  s c o p e  f o r  
c o n v e n t i o n a l  t r e a t m e n t  w o u l d  b e  im p o r t a n t :  f o r  e x a m p l e  p o l y d a c t y l y  i s  t r e a t a b l e  b y  
s i m p l e  s u r g e r y ,  w h e r e a s  n o  t r e a t m e n t  e x i s t s  f o r  c o l o u r - b l i n d n e s s ;  a  l a c k  o f  
c o n v e n t i o n a l  t r e a t m e n t  w o u l d  w e i g h  i n  f a v o u r  o f  g e r m l i n e  g e n e  t h e r a p y .  T h u s ,  e v e n  
f o r  m i n o r  c o n d i t i o n s ,  i t  w o u l d  i n  p r i n c i p l e  b e  e t h i c a l l y  a c c e p t a b l e  t o  p e r f o r m  g e r m l i n e  
g e n e  t h e r a p y ,  g i v e n  a  h i g h  e f f i c a c y  o f  t r e a t m e n t  a n d  a n  e x t r e m e l y  l o w  r i s k  o f  
d e l e t e r io u s  e f f e c t s .  N e v e r t h e l e s s ,  i t  i s  w o r t h  r e - e m p h a s i s i n g  t h a t  p r e s e n t  G M  
t e c h n o l o g y  i s  c e r t a i n l y  n o t  s u f f i c i e n t l y  d e v e l o p e d  t o  d e l i v e r  a n y t h i n g  a p p r o a c h i n g  t h e  
n e c e s s a r y  l e v e l s  o f  e f f e c t i v e n e s s  a n d  s a f e t y .
The ethical problems become greatest in the context o f germline genetic
enhancement. In contrast to germline gene therapy, in which the goal is to avoid or
mitigate an otherwise inevitable disorder, enhancem ent implies the manipulation of
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g e n e r a l  p h e n o t y p i c  t r a it s  ( w h e r e  s u c h  t r a it s  a r e  u n d e r  g e n e t i c  c o n t r o l ,  a n d  h e n c e  
p o t e n t i a l l y  a m e n a b l e  t o  G M )  t o  p r o d u c e  ‘ i m p r o v e d ’ i n d i v i d u a l s .  S u c h  p h e n o t y p i c  
t r a it s  m i g h t  i n c l u d e  n a t u r a l  l i f e  s p a n ,  h e i g h t ,  d i s e a s e  r e s i s t a n c e ,  I Q ,  b o d y - s h a p e ,  s i z e  
o f  f a c i a l  f e a t u r e s ,  e t c .
I n  t h e  f u t u r e ,  g i v e n  s a f e  a n d  e f f e c t i v e  g e r m l i n e  G M  t e c h n o l o g y ,  i t  a p p e a r s  i n e v i t a b l e  
t h a t  m a n y  p r o s p e c t i v e  p a r e n t s  w i l l  w i s h  t o  e m p l o y  ( a n d  b e  w i l l i n g  t o  p a y  f o r )  
g e r m l i n e  g e n e t ic  e n h a n c e m e n t s  f o r  t h e i r  u n b o r n  o f f s p r i n g .  M a n y  c o m m e n t a t o r s ,  
i n c l u d i n g  t h e  p r e s e n t  a u t h o r ,  v i e w  t h e  d e v e l o p m e n t  o f  a  ‘ g e n e t i c  e l i t e ’ -  a n d  i t s  
c o r o l l a r y ,  a  ‘ g e n e t i c  u n d e r c l a s s ’ -  a s  b e i n g  a n  e t h i c a l l y  r e p u g n a n t  f o r m  o f  e u g e n i c s .  
H o w e v e r ,  t h is  p o s i t i o n  o u g h t  t o  b e  t e m p e r e d  b y  t h r e e  c o n s i d e r a t i o n s .
F i r s t l y ,  t h e r e  i s  a  d a n g e r  t h a t ,  i n  a t t e m p t i n g  t o  a v o i d  t h e  a b o v e - m e n t i o n e d  e u g e n i c  
s c e n a r i o ,  l e g i s l a t o r s  p r e v e n t  a ll  f o r m s  o f  h u m a n  g e r m l i n e  m a n i p u l a t i o n .  I m p l i c i t  i n  
s u c h  n o t i o n s  o f  p r o h i b i t i o n  i s  t h e  v i e w  t h a t  t h e r a p e u t ic  g e r m l i n e  G M  r e p r e s e n t s  t h e  
‘ t h i n  e n d  o f  a  w e d g e ’ l e a d i n g  i n e x o r a b l y  t o  t h e  r e p r e h e n s i b l e  e u g e n i c  u s e  o f  G M  
t e c h n o l o g y  d e s c r i b e d  a b o v e .  A s  d i s c u s s e d  p r e v i o u s l y ,  m e d i c a l l y  u s e f u l  f o r m s  o f  
g e r m l i n e  G M  m a y  w e l l  b e c o m e  a v a i l a b l e  a s  g e n e  d e l i v e r y  t e c h n o l o g y  i m p r o v e s .  I t  
w o u l d  b e  h i g h l y  u n f o r t u n a t e  i f  l e g i s l a t o r s  f a i l  t o  d i s t i n g u i s h  b e t w e e n  p o t e n t i a l l y  
b e n e f i c i a l  t h e r a p i e s  a n d  u n d e s i r a b l e  u s e s  o f  g e r m l i n e  G M .  I t  i s  a x i o m a t i c  t h a t  m e d i c o -  
s c i e n t i f i c  p r o g r e s s  p e r  s e  w o u l d  b e  i m p o s s i b l e  i f  p r o h i b i t i o n  w e r e  t o  b e  a p p l i e d  t o  
t e c h n o l o g i e s  s i m p l y  o n  t h e  g r o u n d s  t h a t  s u c h  t e c h n o l o g i e s  c o u ld  b e  m i s u s e d .
S e c o n d l y ,  a s  p r e v i o u s l y  o u t l i n e d ,  i t  s h o u l d  b e  r e c o g n i s e d  t h a t  n o  c l e a r  b o u n d a r y  
n e c e s s a r i l y  e x i s t s  b e t w e e n  t h e r a p e u t ic  G M  a n d  e n h a n c e m e n t  G M .  F o r  e x a m p l e ,  
g e r m l i n e  G M  u s e d  a g a i n s t  A l z h e i m e r ’ s  d i s e a s e  m i g h t  a l s o  b e  e f f e c t i v e  i n  e n h a n c i n g  
m e m o r y  p e r  se, i n  p e o p l e  n o t  p r e d i s p o s e d  t o  t h e  d i s o r d e r .  S i m i l a r l y ,  g e r m l i n e  G M  
u s e d  a g a i n s t  a  p a r t i c u l a r  in h e r i t e d  c a n c e r  m i g h t  a l s o  p r o v i d e  a  g e n e r a l  r e s i s t a n c e  
a g a i n s t  c a n c e r  i n  n o n - s u s c e p t i b l e  p e o p l e .  A n o t h e r  e x a m p l e  w o u l d  b e  g e r m l i n e  G M  t o  
t r e a t  m u s c u l o - s k e l e t a l  d i s o r d e r s ,  w h e r e  s i m i l a r  G M  a p p l i e d  n o n - c l i n i c a l l y  m i g h t  
e n h a n c e  b o d y - s h a p e  o r  e v e n  a t h l e t i c  p o t e n t ia l .  A l t h o u g h  t h e s e  e x a m p l e s  a r e  
n e c e s s a r i l y  s p e c u l a t i v e  a n d  f u t u r i s t i c ,  t h e y  s e r v e  t o  d e m o n s t r a t e  t h a t  g e r m l i n e  G M  
c a n n o t  b e  s i m p l y  d i v i d e d  in t o  t h e r a p e u t ic  v e r s u s  e n h a n c e m e n t  c a t e g o r i e s .
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T h e  f i n a l  c o n s i d e r a t i o n  c o n c e r n i n g  g e r m l i n e  g e n e t i c  e n h a n c e m e n t s  i s  t h a t  s o m e  
e n h a n c e m e n t s  m a y  a c t u a l l y  b e  d e s i r a b l e  f o r  h u m a n i t y .  I t  w o u l d  c e r t a i n l y  b e  e r r o n e o u s  
t o  a s s u m e  t h a t  t h e  h u m a n  g e n o m e  p e r  s e  i s  n o t  p o t e n t i a l l y  a m e n a b l e  t o  i m p r o v e m e n t .  
F o r  e x a m p l e ,  i t  i s  n o w  w e l l  a c c e p t e d  t h a t  e v o l u t i o n a r y  p r e s s u r e s  h a v e  b e e n  r e l a t i v e l y  
w e a k  i n  t h e  c o n t e x t  o f  l a t e - o n s e t  ( p o s t - r e p r o d u c t i v e  a g e )  d i s o r d e r s  s u c h  a s  c a n c e r ,  t h e  
r e s u l t  b e i n g  t h a t  h u m a n s  p o s s e s s  o n l y  a  m o d e s t  d e g r e e  o f  c a n c e r  r e s i s t a n c e .  G e r m l i n e  
G M  t e c h n o l o g y  c o u l d  i n  p r i n c i p l e  b e  u s e d  t o  a d d  ‘ a n t i - c a n c e r ’ g e n e t i c  s e q u e n c e s  
( s u c h  a s  e x t r a  c h e c k p o i n t  g e n e s  o r  t u m o u r - s u p p r e s s o r  g e n e s )  i n t o  t h e  h u m a n  g e n o m e .  
G i v e n  t h a t  t h e s e  a d d i t i o n a l  a n t i - c a n c e r  g e n e s  w o u l d  b e  e x p e c t e d  t o  g r e a t l y  r e d u c e  t h e  
r i s k  o f  c a n c e r ,  i t  f o l l o w s  t h a t  i t  w o u l d  b e  b e n e f i c i a l  -  a n d  t h e r e f o r e  e t h i c a l l y  d e s i r a b l e  
f r o m  t h e  u t i l i t a r i a n  v i e w p o i n t  -  t o  c a r r y  o u t  t h i s  f o r m  o f  g e r m l i n e  e n h a n c e m e n t  a s  
w i d e l y  a s  p o s s i b l e ,  i n  o r d e r  t h a t  f u t u r e  g e n e r a t io n s  o f  p e o p l e  w e r e  p r o t e c t e d  a g a i n s t  
c a n c e r .  E x a m p l e s  o f  h u m a n  f e a t u r e s  t h e  i m p r o v e m e n t  o r  a l t e r a t i o n  o f  w h i c h  b y  G M  
m i g h t  b e  b e n e f i c i a l  t o  h u m a n k i n d  i n c l u d e  m e m o r y ,  m o o d ,  n a t u r a l  l i f e  s p a n ,  a n d  
b e h a v i o u r s  s u c h  a s  a g g r e s s i o n  ( F r a n k e l  2 0 0 0 ;  R e s n i k  1 9 9 9 ;  R e s n i k  a n d  L a n g e r  2 0 0 1 ;  
S t o c k  1 9 9 9 ) .
T h e  p r o -e n h a n c e m e n t  v i e w p o i n t  i s  h i g h l y  c o n t r o v e r s i a l ,  b u t  i t  w o u l d  b e  a  m i s t a k e  t o  
d i s m i s s  i t  m e r e l y  a s  a n  e x t r e m i s t  v i e w ,  c o n s i d e r i n g  t h e  f a c t  t h a t  s e v e r a l  w e l l - r e p u t e d  
s c i e n t i s t s  h a v e  r e c e n t l y  a d v o c a t e d  g e r m l i n e  g e n e t i c  e n h a n c e m e n t .  T o  t a k e  o n e  
s p e c i f i c  e x a m p l e ,  J a m e s  W a t s o n ,  t h e  b i o l o g i s t  w h o  w o n  a  N o b e l  P r i z e  f o r  h i s  r o l e  i n  
u n l o c k i n g  t h e  s t r u c t u r e  o f  D N A ,  h a s  r e c e n t l y  a d v o c a t e d  t h e  u s e  o f  g e n e  t h e r a p y  t o  
i n c r e a s e  i n t e l l i g e n c e  i n  p e r s o n s  w h o  w o u l d  o t h e r w is e  b e  b o m  w i t h  a  l o w  I Q .  O f  
c o u r s e ,  s u p p o r t  b y  n u m b e r s  o r  s u p p o r t  f r o m  e x p e r t  a u t h o r i t y  d o e s  n o t  a m o u n t  t o  a n  
e t h i c a l  c a s e  i n  s u p p o r t  o f  h u m a n  g e r m l i n e  g e n e  t h e r a p y .  H o w e v e r ,  I  s u g g e s t  t h a t  t h e  
p r o -e n h a n c e m e n t  v i e w s  o f  t h o s e  s u c h  a s  W a t s o n  a r e  i n  p r i n c i p l e  j u s t i f i e d  o n  t h e  
a b o v e - m e n t i o n e d  u t i l i t a r i a n  g r o u n d s .
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7.10 Eugenics
T h e  i n t r o d u c t i o n  o f  g e n e t i c  e n h a n c e m e n t s  in t o  t h e  h u m a n  g e r m l i n e  w o u l d  
i n d i s p u t a b l y  c o n s t it u t e  a  f o r m  o f  e u g e n i c s ,  w h e r e  t h e  t e r m  ‘ e u g e n i c s ’ r e f e r s  t o  t h e  
i m p r o v e m e n t  o f  t h e  h u m a n  g e n e  p o o l .  T h i s  i s  a  p r o b l e m  f o r  d i s c u s s i o n s  o n  h u m a n  
g e r m l i n e  g e n e  t h e r a p y ,  b e c a u s e  t h e  t e r m  ‘ e u g e n i c s ’ h a s  c o m e  t o  b e  a s s o c i a t e d  w i t h  
h i g h l y  n e g a t i v e ,  s o c i a l l y  c o e r c i v e  a t t e m p t s  b y  o v e r z e a l o u s  o r  t o t a l i t a r i a n  a u t h o r i t i e s  t o  
c o n t r o l  h u m a n  r e p r o d u c t i o n .  I n  p a r t i c u l a r ,  i t  i s  w e l l  k n o w n  t h a t  N a z i  G e r m a n y  
c o m m i t t e d  h o r r i f i c  a t r o c i t i e s  i n  t h e  n a m e  o f  e u g e n i c s  a g a i n s t  p e r s o n s  d e e m e d  
‘ g e n e t i c a l l y  i n f e r i o r ’ . C o n s e q u e n t l y ,  t h e  t e r m  ‘ e u g e n i c s ’ h a s  b e c o m e  s o  t a i n t e d  t h a t  i t  
m a y  b e  b e y o n d  r e h a b i l i t a t i o n .
I f  d i s c u s s i o n s  o n  t h e  e t h i c s  o f  h u m a n  g e r m l i n e  g e n e t ic  m o d i f i c a t i o n  a r e  t o  p r o g r e s s ,  
t h e n  i t  i s  n e c e s s a r y  t o  a v o i d  b e c o m i n g  e m b r o i l e d  i n  r h e t o r i c a l  a n d  p e j o r a t i v e  
l a n g u a g e .  T h u s ,  w h i l e  a c k n o w l e d g i n g  t h a t  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  c l e a r l y  
r e p r e s e n t s  a  f o r m  o f  e u g e n i c s ,  I  s h a l l  a t t e m p t  t o  e x a m i n e  h u m a n  g e r m l i n e  g e n e t i c  
e n h a n c e m e n t  o n  i t s  o w n  m e r i t s  a n d  d e m e r it s ,  i n  a  c o o l  a n d  r a t i o n a l  m a n n e r .  S u c h  a n  
a p p r o a c h  i s  c e n t r a l  t o  u t i l i t a r i a n  r e a s o n i n g .
A  c e n t r a l  i s s u e  f o r  h u m a n  g e r m l i n e  g e n e t ic  e n h a n c e m e n t  c o n c e r n s  e q u i t y .  T a k i n g  a  
p r e v i o u s  e x a m p l e ,  i t  w o u l d  b e  a d v a n t a g e o u s  f o r  h u m a n i t y  i f  a n  a n t i c a n c e r  s e q u e n c e  
w a s  e n g i n e e r e d  in t o  t h e  g e n o m e ,  s u c h  t h a t  a l l  p e o p l e s ’ c a n c e r  r i s k  w a s  s i g n i f i c a n t l y  
r e d u c e d .  H o w e v e r ,  s u p p o s e  t h a t  o n l y  a  s u b s e t  o f  p a r e n t s  w e r e  a b l e  t o  a f f o r d  t h i s  
t e c h n o l o g y .  T h i s  s u b s e t  m i g h t  p l a u s i b l y  c o m p r i s e  v e r y  r i c h  p a r e n t s  i n  W e s t e r n  
n a t i o n s .  T h e  r e s u l t a n t  c h i l d r e n  w o u l d  f o r m  a  g e n e t i c a l l y  d i s t i n c t  s e t  o f  i n d i v i d u a l s .  
M o r e o v e r ,  t h e  d e s c e n d a n t s  o f  s u c h  i n d i v i d u a l s  w o u l d  a l s o  b e  g e n e t i c a l l y  d i s t i n c t  f r o m  
t h e  r e s t  o f  t h e  h u m a n  p o p u l a t i o n .  T h i s  w o u l d  b e  p a r t i c u l a r l y  s o  i f  t h e  G M  ( a n t i c a n c e r  
s e q u e n c e  c o n t a i n i n g )  i n d i v i d u a l s  r e p r o d u c e d  o n l y  w i t h  e a c h  o t h e r :  a n d  i t  w o u l d  b e  
r a t i o n a l  f o r  s u c h  i n d i v i d u a l s  t o  r e p r o d u c e  i n  t h i s  w a y ,  s i n c e  t h i s  w o u l d  m a x i m i s e  t h e  
c h a n c e s  o f  t h e i r  o f f s p r i n g  a l s o  b e i n g  p r o t e c t e d  a g a i n s t  c a n c e r .  ( I f  t h e  ‘ a n t i c a n c e r ’ 
s e q u e n c e  w a s  p r e s e n t  ( a n d  f u n c t i o n a l )  i n  h e m i z y g o u s  f o r m ,  t h e n  e a c h  o f f s p r i n g  f r o m  
a  m a t i n g  b e t w e e n  t w o  G M  i n d i v i d u a l s  w o u l d  h a v e  a  7 5 %  c h a n c e  o f  i n h e r i t i n g  t h e  
s e q u e n c e ,  c o m p a r e d  t o  a  5 0 %  c h a n c e  f r o m  a  m a t i n g  b e t w e e n  a  G M  i n d i v i d u a l  a n d  a
288
n o n - G M  i n d i v i d u a l .  I f  t h e  ‘ a n t i c a n c e r ’ s e q u e n c e  n e e d e d  to  b e  p r e s e n t  i n  h o m o z y g o u s  
f o r m ,  t h e n  o n l y  G M - G M  m a t i n g s  w o u l d  p r o d u c e  o f f s p r i n g  w i t h  c a n c e r  r e s i s t a n c e . )  I t  
i s  i m m e d i a t e l y  a p p a r e n t  t h a t  t h i s  w o u l d  e f f e c t i v e l y  s p l i t  t h e  h u m a n  s p e c i e s  a p a r t ,  o n  a  
m o s t  f u n d a m e n t a l  -  a n d  i n d e e d  h e r i t a b l e  -  b a s i s .  U t i l i t a r i a n i s m  d o e s  n o t  e n c o m p a s s  
e q u a l i t y  a s  a  g o o d  i n  i t s  o w n  r i g h t ;  h o w e v e r ,  u t i l i t a r i a n  r e a s o n i n g  j u d g e s  u n e t h i c a l  
i n e q u a l i t i e s  t h a t  a r e  l i k e l y  t o  in c r e a s e  s u f f e r i n g .
I t  s e e m s  c l e a r  t h a t  t h e  d i v i s i o n  o f  h u m a n i t y  in t o  G M  c a n c e r - r e s i s t a n t  a n d  n o n - c a n c e r -  
r e s i s t a n t  i n d i v i d u a l s  w o u l d  h a v e  a  n e g a t i v e  e f f e c t  i n  t e r m s  o f  t h e  o v e r a l l  b a l a n c e  o f  
h a p p i n e s s / m i s e r y  i n  t h e  W o r l d .  A l t h o u g h  t h e  G M  c o n t i n g e n t  w o u l d  b e  e x p e c t e d  t o  b e  
h a p p i e r ,  t h r o u g h  n o t  s u f f e r i n g  f r o m  c a n c e r ,  t h i s  a d d i t i o n  to  t h e  n e t  h a p p i n e s s  w o u l d  
a l m o s t  c e r t a i n l y  b e  o u t w e i g h e d  b y  s e v e r a l  n e g a t i v e  e f f e c t s .  A  m a j o r  e f f e c t  w o u l d  b e  
r e s e n t m e n t  o n  t h e  p a r t  o f  t h o s e  w h o  a s  p a r e n t s  w e r e  u n a b l e  t o  a f f o r d  t h e  G M ,  a n d  a l s o  
o n  t h e  p a r t  o f  t h e  n o n - G M  c h i l d r e n  ( a n d  t h e i r  o f f s p r i n g ) .  I t  s e e m s  u n a v o i d a b l e  t h a t  
s u c h  r e s e n t m e n t  w o u l d  b e  m a g n i f i e d  w h e n e v e r  n o n - G M  p e o p l e  d e v e l o p e d  c a n c e r .
T h e  l i k e l i h o o d  t h a t  G M  p e o p l e  w o u l d  r e f u s e  t o  m a r r y  n o n - G M  p e o p l e  w o u l d  f u r t h e r  
e x a c e r b a t e  t h e  r e s e n t m e n t .  S u c h  r e s e n t m e n t  w o u l d  b e  b a d  i n  i t s e l f ,  b e c a u s e  s e r i o u s  
r e s e n t m e n t  i s  a  f o r m  o f  p s y c h o l o g i c a l  d i s t r e s s ,  a n d  t h u s  w o u l d  w e i g h  h e a v i l y  i n  t h e  
u t i l i t a r i a n  c a l c u l u s .  B u t  i t  w o u l d  b e  n a i v e  t o  i m a g i n e  t h a t  t h e  n e g a t i v e  e f f e c t s  o f  s u c h  
s e r i o u s  r e s e n t m e n t  w o u l d  b e  l i m i t e d  t o  it s  d i r e c t  e f f e c t s  o n  m e n t a l  s t a t e .  M o s t  l i k e l y ,  
t h e r e  w o u l d  b e  a  r i s k  o f  c i v i l  o r  e v e n  g l o b a l  u n r e s t  a n d  s t r i f e :  i t  h a r d l y  n e e d s  s a y i n g  
t h a t  a  s i t u a t i o n  o f  s o c i e t a l  b r e a k d o w n  o r  v i o l e n c e  ( o r  a t  l e a s t  t h e  r i s k  t h e r e o f )  w o u l d  
c o u n t  v e r y  s t r o n g l y  a g a i n s t  a l l o w i n g  a  s u b s e t  o f  t h e  p o p u l a t i o n  t o  b e n e f i t  f r o m  G M .
T h u s ,  i t  s e e m s  c l e a r  t h a t  a n t i c a n c e r  G M  a p p l i e d  t o  a n  e l i t e  s u b s e t  o f  H o m o  s a p i e n s  
w o u l d  h a v e  d e l e t e r io u s  c o n s e q u e n c e s .  Y e t  i t  s h o u l d  b e  n o t e d  t h a t  t h i s  e x a m p l e  o f  G M  
l i e s  o n  t h e  m i l d e r ,  l e s s  c o n t r o v e r s i a l  a n d  d i v i s i v e  e n d  o f  t h e  h u m a n  g e r m l i n e  g e n e t i c  
e n h a n c e m e n t  s p e c t r u m .  A n t i c a n c e r  G M  w o u l d  b e  o f  m e d i c a l  b e n e f i t  ( a l b e i t  
p r e v e n t i v e ) ,  b u t  i t  w o u l d  n o t  i m p a r t  a n y  f u r t h e r  a d v a n t a g e s  o n  t h e  G M  i n d i v i d u a l s  
c o n c e r n e d .  H u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  d e s i g n e d  t o  i m p r o v e  c e r t a i n  n o n ­
m e d i c a l  p a r a m e t e r s  w o u l d  b e  e v e n  m o r e  d i v i s i v e  t o  h u m a n i t y .  T a k e  f o r  e x a m p l e  a  
G M  e l i t e  w i t h  e n h a n c e d  m e n t a l  f u n c t i o n i n g ,  s u c h  a s  b e t t e r  m e m o r y  o r  h i g h e r  I Q  o r  
f r e e d o m  f r o m  a n x i e t y .  S u c h  i n d i v i d u a l s  w o u l d  b e  a b l e  t o  s e c u r e  f o r  t h e m s e l v e s  a n d  
t h e i r  o f f s p r i n g  e c o n o m i c  a d v a n t a g e s ;  m o r e o v e r ,  t h e y  m i g h t  w e l l  c o n s i d e r  t h e m s e l v e s
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a s  i n h e r e n t l y  s u p e r i o r  t o  t h e i r  n o n - G M  c o u n t e r p a r t s .  I f  I  a m  c o r r e c t  i n  p o s i t i n g  o v e r a l l  
n e g a t i v e  c o n s e q u e n c e s  f r o m  t h e  u s e  o f  a n t i c a n c e r  G M  t o  c r e a t e  a n  e l i t e  g r o u p ,  t h e n  
t h e  c a s e  i s  e v e n  s t r o n g e r  a g a i n s t  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  f o r  n o n - m e d i c a l  
f e a t u r e s .
T o  a  l a r g e  e x t e n t ,  t h e  o b v i o u s  s e v e r i t y  o f  t h e  b a d  c o n s e q u e n c e s  l i k e l y  t o  a r i s e  f r o m  
e l i t i s t  u s e  o f  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  s h o u l d  b e  e x p e c t e d  t o  f u n c t i o n  t o  
p r e v e n t  s u c h  d is a s t e r s  f r o m  o c c u r r i n g .  I t  i s ,  I  h o p e ,  n o t  u n d u l y  o p t i m i s t i c  t o  e x p e c t  
t h a t  s o c i e t i e s  t h a t  o b t a i n  t h e  t o o l s  f o r  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  w o u l d  p r o h i b i t  i t s  
u s e  f o r  n o n - m e d i c a l ,  s o c i a l l y  d i v i s i v e  p u r p o s e s .  C e r t a i n l y ,  a s  l o n g  a s  s c i e n t i s t s  a n d  
e t h i c i s t s  a r e  a b l e  t o  e x a m i n e  e a c h  p r o p o s e d  g e r m l i n e  g e n e t ic  e n h a n c e m e n t  w i t h  
p r e c i s i o n ,  i t  s h o u l d  n o t  b e  d i f f i c u l t  t o  p r e d i c t  w h i c h  e n h a n c e m e n t s  t o  p e r m i t  a n d  
w h i c h  t o  p r o h i b i t ,  w h e n  p a r t i c u l a r  i n d i v i d u a l s  o r  g r o u p s  ( e .g .  t h e  w e a l t h y )  a r e  
i n v o l v e d .  O f  c o u r s e ,  i n d i v i d u a l  c o u n t r i e s  m i g h t  b e  u n w i l l i n g  t o  c o n f o r m  t o  
in t e r n a t i o n a l  r u l e s ,  a n d  t h i s  w o u l d  p r e s e n t  a  p r o b l e m  f o r  t h e  W o r l d  c o m m u n i t y .
T h u s  f a r  i n  t h i s  d i s c u s s i o n  o f  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t ,  I  h a v e  a s s u m e d  
t h a t  p a r t i c u l a r  i n d i v i d u a l s  m i g h t  w i s h  t o  s e c u r e  a d v a n t a g e s  f o r  t h e m s e l v e s  t h r o u g h  
G M ,  a n d  i n  t h i s  c o n t e x t  i t  s e e m s  c l e a r  t h a t  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  
o u g h t  t o  b e  v e r y  h e a v i l y  c i r c u m s c r i b e d .  H o w e v e r ,  t h e r e  m a y  w e l l  b e  j u s t i f i c a t i o n  i n  
p e r m i t t i n g  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  f o r  p e r s o n s  w h o  a r e  i n  s p e c i a l  n e e d  o f  
p a r t i c u l a r  e n h a n c e m e n t s .  I n  o t h e r  w o r d s ,  i t  m a y  b e  j u s t i f i a b l e  t o  u s e  h u m a n  g e r m l i n e  
g e n e t i c  e n h a n c e m e n t  to  g i v e  s o m e  i n d i v i d u a l s  a  h e l p i n g  h a n d  ( a s  o p p o s e d  t o  a n  
a d v a n t a g e )  i n  l i f e .  F o r  e x a m p l e ,  c o n s i d e r  p a r e n t s  o f  v e r y  s h o r t  s t a t u r e  d u e  t o  g e n e t i c  
f a c t o r s .  T o  a v o i d  a  s i m i l a r  v e r y  l o w  s t a t u r e  i n  t h e i r  c h i l d r e n ,  i n  p r i n c i p l e  g e r m l i n e  
g e n e t i c  e n h a n c e m e n t  c o u l d  b e  o f f e r e d  t o  s u c h  p a r e n t s .  A  m o r e  c o n t r o v e r s i a l  e x a m p l e  
w o u l d  b e  p a r e n t s  o f  g e n e t i c a l l y  c o n f e r r e d  l o w  I Q .  O f  c o u r s e ,  i n  n e i t h e r  c a s e  i s  i t  e a s y  
t o  d r a w  a  l i n e  w h e r e b y  t r e a t m e n t  s h o u l d  b e  o f f e r e d :  e x a c t l y  w h a t  p r e d i c t e d  h e i g h t  o r  
I Q  i n  a  c h i l d  o u g h t  t o  b e  d e e m e d  l o w  e n o u g h  f o r  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  t o  b e  
i n v o k e d ?  T h e r e  a r e  n o  e a s y ,  c l e a r - c u t  a n s w e r s  t o  s u c h  p r o b l e m s :  d r a w i n g  s u c h  l i n e s  i s  
i n e v i t a b l y  s o m e w h a t  a r b i t r a r y .  E t h i c s  c o m m i t t e e s  m u s t  d o  t h e i r  b e s t  i n  s u c h  c a s e s  t o  
p r o d u c e  c o n s e n s u s  d e c i s i o n s .  B u t  t h e  f a c t  t h a t  d r a w i n g  s u c h  l i n e s  i s  d i f f i c u l t  s h o u l d  
n o t  d e t r a c t  f r o m  t h e  u t i l i t a r i a n  c o n s i d e r a t i o n  t h a t  e n h a n c e m e n t s  d e s i g n e d  t o  
a m e l i o r a t e  d i s a d v a n t a g e s  s h o u l d  i n c r e a s e  o v e r a l l  h a p p i n e s s .
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T h i s  s o r t  o f  c a s e  i s  m a d e  m o r e  c o m p l i c a t e d  b y  t h e  f a c t  t h a t  t h e  g e n e t i c  b a s i s  o f  m a n y  
im p o r t a n t  f e a t u r e s  -  p r o b a b l y  i n c l u d i n g  h e i g h t  a n d  I Q  -  i s  o f  t h e  p o l y g e n i c  v a r i e t y ,  
a n d  t h u s  i t  i s  m o r e  d i f f i c u l t  t o  p r e d i c t  t h e  p h e n o t y p e  o f  f u t u r e  o f f s p r i n g .  M o r e o v e r ,  
w h e r e  h u m a n  f e a t u r e s  -  e s p e c i a l l y  p s y c h o l o g i c a l  o n e s  -  a r e  u n d e r  p o l y g e n i c  c o n t r o l ,  
i t  i s  w o r t h  c o n s i d e r i n g  t h a t  s o m e  o f  t h e  g e n e t i c  v a r i a t i o n  m a y  b e  b e n e f i c i a l .  P u t  
s i m p l y ,  t h e  u s e  o f  G M  t o  a lt e r  t h e  g e n e t i c  c o n s t i t u t i o n  o f  t h o s e  w h o  m a n i f e s t  e x t r e m e  
p h e n o t y p e s  m i g h t  h a v e  t h e  d e l e t e r io u s  s i d e  e f f e c t  o f  r e m o v i n g  i n t r i n s i c a l l y  u s e f u l  
a l l e l e s  f r o m  a  g e n e t ic  l i n e a g e .  A t  p r e s e n t ,  s u c h  c o n s i d e r a t i o n s  a r e  u n a v o i d a b l y  
s p e c u l a t i v e :  o u r  u n d e r s t a n d i n g  o f  t h e  m o l e c u l a r  g e n e t i c s  o f  h u m a n  b e h a v i o u r  i s  a t  a  
r u d i m e n t a r y  s t a t e  o f  d e v e l o p m e n t .  W e  s i m p l y  d o  n o t  k n o w  w h e t h e r  h u m a n  g e r m l i n e  
g e n e t i c  e n h a n c e m e n t  t o  p r o m o t e ,  s a y ,  l e s s  a g g r e s s i v e  b e h a v i o u r  m i g h t  r e m o v e  g e n e s  
t h a t  p r o m o t e  ( s a y )  p e r s e v e r a n c e .  A  s i m i l a r  e x a m p l e  m i g h t  b e  a u t i s t i c  p e r s o n a l i t y  
f e a t u r e s  a n d  m a t h e m a t i c a l  a b i l i t y :  b y  r e m o v i n g  g e n e s  i m p l i c a t e d  i n  t h e  f o r m e r  b y  
h u m a n  g e r m l i n e  g e n e t ic  e n h a n c e m e n t ,  m i g h t  g e n e s  c o n f e r r i n g  t h e  la t t e r  b e  
d i m i n i s h e d ?  G i v e n  t h e  p r e s e n t  l a c k  o f  m o l e c u l a r  g e n e t i c  e l u c i d a t i o n  o f  h u m a n  
b e h a v i o u r  a n d  p s y c h o l o g y ,  a l l  t h a t  c a n  b e  d o n e  c o n c e r n i n g  t h i s  i s s u e  o f  p o l y g e n i c  
t r a it s  a n d  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  i s  t o  r e c o g n i s e  i t  a s  a  p o t e n t i a l  
p r o b l e m ,  a n d  o n e  t h a t  m a y  o r  m a y  n o t  p r o v e  t o  b e  o f  s i g n i f i c a n c e .  F o r t u n a t e l y ,  j u s t  a s  
t h e  t e c h n o l o g i e s  t h a t  w o u l d  a l l o w  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  a r e  
d e v e l o p i n g ,  t h e  m o l e c u l a r  g e n e t i c s  o f  t h e  h u m a n  c o n d i t i o n  a r e  b e g i n n i n g  t o  b e  
u n r a v e l l e d .  I t  i s  p r o b a b l e  t h a t ,  w h e n  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  b e c o m e s  a  
r e a l i s t i c  p r o s p e c t ,  s c i e n c e  w i l l  h a v e  a m a s s e d  a  t h o r o u g h  u n d e r s t a n d i n g  o f  t h e  g e n e s  
u n d e r l y i n g  c o n t e n d e r  p h e n o t y p e s  f o r  e n h a n c e m e n t .
T h i s  d i s c u s s i o n  h a s  b e e n  c o n s i d e r i n g  t h e  a p p l i c a b i l i t y  o f  h u m a n  g e r m l i n e  g e n e t i c  
m o d i f i c a t i o n  t o  s u b g r o u p s  o f  t h e  h u m a n  p o p u l a t i o n .  I  n o w  t u r n  t o  t h e  p o s s i b i l i t y  o f  
a p p l y i n g  h u m a n  g e r m l i n e  g e n e t i c  m o d i f i c a t i o n  t o  a l l  o f  h u m a n k i n d .  J u s t  a s  
v a c c i n a t i o n  a g a i n s t  s e r i o u s  i n f e c t i o u s  d i s e a s e s  h a s  b e e n  a p p l i e d  t o  a s  m a n y  c h i l d r e n  a s  
p o s s i b l e ,  i n  t h e  f u t u r e  h u m a n  g e r m l i n e  g e n e t i c  m o d i f i c a t i o n  m a y  c o m e  t o  a p p l i e d  
g l o b a l l y ,  t o  t h e  g r e a t e s t  n u m b e r  o f  ( f u t u r e )  p e o p l e  p o s s i b l e .
Such global possibilities would alter the ethical status of certain genetic
enhancements. For example, I previously suggested that anticancer germline genetic
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e n h a n c e m e n t  w o u l d  b e  a  g r e a t  d i s u t i l i t y  i f  i t s  u s e  w a s  r e s t r ic t e d  t o  a n  e l i t e  s u b s e t  o f  
h u m a n s .  H o w e v e r ,  i f  t h e  s a m e  G M  p r o c e s s  w e r e  t o  b e  m a d e  a v a i l a b l e  t o  a l l  ( o r  a s  
m a n y  a s  p r a c t i c a l l y  p o s s i b l e )  p e o p l e ,  t h e n  t h e  b e n e f i t s  ( l e s s  c a n c e r - c a u s e d  s u f f e r i n g  
a n d  f e w e r  p r e m a t u r e  d e a t h s )  w o u l d  n o t  b e  a c c o m p a n i e d  w i t h  t h e  p r o b l e m s  a s s o c i a t e d  
w i t h  G M  e l i t i s m  ( r e s e n t m e n t ,  s o c i a l  b r e a k d o w n  a n d  s t r i f e ) .  I  s u g g e s t  t h a t  s u c h  
m e d i c a l  e n h a n c e m e n t s  a r e  s u p p o r t e d  b y  u t i l i t a r i a n i s m ,  s i n c e  t h e  b e n e f i t s  w o u l d  b e  s o  
g r e a t .
H o w e v e r ,  n o n - m e d i c a l  g e r m l i n e  g e n e t ic  e n h a n c e m e n t s  a r e  m o r e  p r o b l e m a t i c  f o r  
u t i l i t a r i a n s .  W h e r e a s  t h e r e  w o u l d  b e  o b v i o u s  b e n e f i t  i n  i m p r o v i n g  t h e  h e i g h t  o r  I Q  o f  
f u t u r e  p e r s o n s  o t h e r w is e  d e s t i n e d  t o  b e c o m e  v e r y  s h o r t  o r  v e r y  u n i n t e l l i g e n t  a d u l t s ,  i t  
i s  n o t  o b v i o u s  t h a t  i n c r e a s i n g  t h e  h e i g h t  o r  I Q  o f  a l l  p e r s o n s  w o u l d  l e a d  t o  a n  i n c r e a s e  
i n  h a p p i n e s s  -  e s p e c i a l l y  i f  t h e  r e l a t i v e  d i f f e r e n t i a l s  w e r e  m a i n t a i n e d .  C e r t a i n l y ,  a  
v e r y  s t r o n g  c a s e  w o u l d  n e e d  t o  b e  e s t a b l i s h e d  i n  t e r m s  o f  t h e  p o t e n t i a l  u t i l i t y  o f  a n y  
s u c h  g l o b a l  n o n - m e d i c a l  a p p l i c a t i o n  o f  h u m a n  g e r m l i n e  g e n e t ic  m o d i f i c a t i o n .
A n o t h e r  p r o b l e m  f o r  g l o b a l  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  c o n c e r n s  p o l y g e n i c  
t r a it s .  I  h a v e  s u g g e s t e d  t h a t  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  o f  u n w a n t e d  p e r s o n a l i t y  o r  
b e h a v i o u r a l  t r a it s  m a y  d e p le t e  a  p a r t i c u l a r  g e n e t i c  l i n e a g e  o f  d e s i r a b l e  g e n e s .  T h i s  
s a m e  c o n c e r n  a p p l i e s  w i t h  g l o b a l  g e r m l i n e  g e n e t i c  e n h a n c e m e n t ,  b u t  w i t h  m o r e  f o r c e  
i n  v i e w  o f  t h e  f a c t  t h a t  a n y  l o s s  o f  d e s i r a b l e  g e n e s  w o u l d  i n v o l v e  t h e  e n t i r e  h u m a n  
g e n e  p o o l .  A g a i n ,  d e t a i l e d  m o l e c u l a r  k n o w l e d g e  o f  t h e  g e n e s  i n v o l v e d  i n  h u m a n  
p s y c h o l o g y  a n d  b e h a v i o u r  w o u l d  b e  r e q u i r e d  b e f o r e  a n y  s u c h  g e r m l i n e  g e n e t i c  
e n h a n c e m e n t  c o u l d  b e  e t h i c a l l y  c o u n t e n a n c e d .
I f  g l o b a l  h u m a n  g e r m l i n e  g e n e t ic  m o d i f i c a t i o n  w a s  t o  b e c o m e  p o s s i b l e ,  i t  w o u l d  
r e q u i r e  a  m e t h o d o l o g y  t h a t  w o u l d  b e  e a s y  t o  a p p l y ,  w o u l d  n o t  r e q u i r e  a  c o m p l e x  
b i o m e d i c a l  i n f r a s t r u c t u r e ,  a n d  w o u l d  b e  i n e x p e n s i v e .  A s  o u t l i n e d  i n  t h e  s e c t i o n  o n  
c o s t  ( 7 . 4 ) ,  t h i s  w o u l d  a l m o s t  c e r t a i n l y  h a v e  t o  i n v o l v e  s o m e  f o r m  o f  S M G T .  T h e  
p o s s i b i l i t y  t h a t  S M G T  c o m e s  t o  b e  d e v e l o p e d  s u c h  t h a t  i t  c o u l d  b e  e a s i l y  a p p l i e d  -  a s  
h a s  a l r e a d y  b e e n  c l a i m e d  w i t h  s o m e  r e c e n t  a g r i c u l t u r a l  t r a n s g e n e s i s  e x p e r i m e n t s  
( L a v i t r a n o  e t  a l .  2 0 0 3 )  -  s u g g e s t s  t h e  p o s s i b i l i t y  o f  s o m e  e t h i c a l l y  v e r y  p o t e n t i a l l y  
p e r p l e x i n g  s i t u a t i o n s  a r i s i n g .  T h e  c e n t r a l  p r o b l e m  i s  t h a t  a  c h e a p ,  e a s i l y  a p p l i e d
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h u m a n  g e r m l i n e  g e n e  t r a n s f e r  t e c h n i q u e  c o u l d  a l l o w  h u m a n  G M  t o  b e  c a r r i e d  o u t  i n  
s i t u a t i o n s  b e y o n d  t h e  c o n t r o l  o f  d e m o c r a t i c  g o v e r n m e n t .
O n e  s u c h  s i t u a t i o n  m i g h t  b e  h u m a n  g e r m l i n e  g e n e t i c  e n h a n c e m e n t  o f f e r e d  b y  p r i v a t e  
c o m m e r c i a l  b o d i e s ,  i n  c o u n t r i e s  w i t h  r e l a t i v e l y  l a x  l a w s  o n  b i o m e d i c a l  p r o c e d u r e s .  
J u s t  a s  s o m e  p e o p l e  h a v e  s h o w n  t h e m s e l v e s  t o  b e  w i l l i n g  t o  s e l e c t  t h e  s e x  o f  t h e i r  
c h i l d r e n  ( e it h e r  b y  p r e n a t a l  s e x i n g  f o l l o w e d  b y  e m b r y o / f o e t u s  d i s c a r d ,  o r  -  l e s s  
r e l i a b l y  -  b y  s p e r m  s e p a r a t io n  t e c h n i q u e s ) ,  i t  s e e m s  i n e v i t a b l e  t h a t  s o m e  p e o p l e  
w o u l d  b e  w i l l i n g  t o  p r o c u r e  g e n e t i c  a d v a n t a g e s  f o r  t h e i r  o f f s p r i n g ,  i f  t h e  t e c h n o l o g y  
b e c o m e s  c o m m e r c i a l l y  a v a i l a b l e .  G i v e n  t h e  f o r e g o i n g  e t h i c a l  o b j e c t i o n s  t o  h u m a n  
s u b g r o u p s  f o r m i n g  g e n e t ic  e l i t e s ,  i t  i s  c l e a r  t h a t  u t i l i t a r i a n s  s h o u l d  b e  o p p o s e d  t o  s u c h  
c o m m e r c i a l  t r e n d s .
P e r h a p s ,  m o r e  w o r r y i n g l y  o n  a c c o u n t  o f  t h e  p o t e n t i a l  s c a l e  o f  t h e  p r o b l e m ,  w o u l d  b e  
t h e  s i t u a t i o n  i n  w h i c h  o n e  g o v e r n m e n t  t o o k  a  u n i l a t e r a l  d e c i s i o n  t o  a p p l y  h u m a n  
g e r m l i n e  g e n e t i c  e n h a n c e m e n t  t o  m a n y  o r  a l l  o f  t h e  c o u n t r y ’ s  ( f u t u r e )  i n h a b i t a n t s .  
S o m e  c o u n t r i e s  h a v e  d e m o n s t r a t e d  a  w i l l i n g n e s s  t o  p u s h  a h e a d  t e c h n o l o g i c a l l y ,  a n d  
a r e  u n l i k e l y  t o  b e  c o n s t r a i n e d  b y  t h e  b i o e t h i c a l  c o n s i d e r a t i o n s  a n d  p r o c e s s e s  t h a t  h a v e  
d e v e l o p e d  i n  t h e  W e s t e r n  w o r l d .  C h i n a  i s  o f  in t e r e s t  h e r e  ( D i k o t t e r  1 9 9 8 ;  D o r i n g  
2 0 0 3 ;  M a o  1 9 9 8 ) .  I t  i s  w e l l  k n o w n  t h a t  t h e  g o v e r n m e n t  h a s  b e e n  v i g o r o u s  i n  a p p l y i n g  
r e p r o d u c t i v e  c o n t r o l  o v e r  i t s  s u b j e c t s .  S u c h  c o n t r o l  i n c l u d e s  t h e  o n e - c h i l d  p e r  f a m i l y  
p o l i c y ,  l a w s  r e q u i r i n g  p r e m a r i t a l  g e n e t ic  h e a l t h  c h e c k s ,  a n d  e v e n  c o m p u l s o r y  
s t e r i l i s a t i o n  f o r  s o m e  g e n e t i c  d is o r d e r s .  M o r e o v e r ,  C h i n a  h a s  e m b r a c e d  G M  
t e c h n o l o g y :  s e v e r a l  G M  c r o p s  h a v e  b e e n  c r e a t e d  b y  ( a n d  a r e  n o w  g r o w n  i n )  C h i n a ,  
a n d  t h e  c o u n t r y ’ s  f i r s t  s o m a t i c  g e n e  t h e r a p y  p r o d u c t  h a s  r e c e n t l y  b e e n  a p p r o v e d  f o r  
g e n e r a l  u s e .  O n e  m a y  r e a s o n a b l y  s p e c u l a t e  t h a t ,  s h o u l d  S M G T - b a s e d  h u m a n  g e r m l i n e  
G M  b e c o m e  a v a i l a b l e ,  n o n - d e m o c r a t i c ,  t e c h n o l o g i c a l l y  a d v a n c e d  c o u n t i e s  s u c h  a s  
C h i n a  m a y  b e  t h e  f i r s t  t o  a p p l y  i t  -  p o s s i b l y  r e g a r d l e s s  o f  i n d i v i d u a l  p a r e n t ’ s  
p r e f e r e n c e s  a n d  p o s s i b l y  w it h o u t  t h o r o u g h  b i o e t h i c a l  d i s c u s s i o n .
T o  u t i l i t a r i a n s ,  a n y  p i e c e  o f  t e c h n o l o g y  i s  e t h i c a l l y  n e u t r a l :  e t h i c a l  c o n s i d e r a t i o n s  
a p p l y  t o  q u e s t i o n s  c o n c e r n i n g  t h e  u s e s  t o  w h i c h  t h e  t e c h n o l o g y  i s  a p p l i e d .  
A c c o r d i n g l y ,  S M G T - b a s e d  h u m a n  g e r m l i n e  g e n e t i c  m o d i f i c a t i o n  w o u l d  b e  e t h i c a l l y  
n e u t r a l ;  b u t  it s  i n c e p t i o n  w o u l d  r a i s e  m a n y  b i o e t h i c a l  i s s u e s .  T h u s ,  t h e r e  i s  a n
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i n t e r p l a y  b e e n  t h e  b a s i c  s c i e n c e  &  t e c h n o l o g y  o f  h u m a n  g e r m l i n e  G M  o n  t h e  o n e  
h a n d ,  a n d  b i o e t h i c s  o n  t h e  o t h e r .  A s  h u m a n i t y  i s  p o i s e d  t o  e n t e r  a  n e w  r e v o l u t i o n  i n  
g e n e t i c  s c i e n c e ,  u t i l i t a r i a n i s m  r e p r e s e n t s  a  p o w e r f u l  b i o e t h i c a l  t o o l  t h a t  s h o u l d  b e  
p r o m o t e d  f o r  u s e  a m o n g s t  a l l  c o n c e r n e d ,  f r o m  e t h i c s  c o m m i t t e e s  t o  s t a t e  
g o v e r n m e n t s .
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Chapter 8: Conclusions: 
the Prospects for Human 
Germline GM
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G enetic m odification  tech n ology  is steadily b ecom in g  more effective . There is n o w  a 
broad armamentarium o f  gen e transfer m ethods available to deliver transgenes to  a 
broad range o f  ce ll types. Several o f  these m ethods have proved effectiv e  in 
generating transgenic m am m als including prim ates, and som e o f  these m ethods cou ld  
alm ost certainly be used  w ith  a m inim um  o f  adaptation to gen etica lly  m od ify  the  
hum an germ line.
H ow ever, the m ost established germ line gen e transfer m ethod, pronuclear 
m icroinjection, has a num ber drawbacks, includ ing expense, lo w  overall e ffic ien cy , 
unreliable/unpredictable transgene expression , and a relatively h igh  risk o f  
endogenous genetic dam age. A ccordingly , it w ou ld  be d ifficu lt in practical term s, and  
unethical from  the perspective o f  risk to the (unborn) ‘patient’, to attempt hum an  
germ line gene therapy using pronuclear m icroinjection .
A lthough  not in  w idespread use in anim al transgenesis, retroviral transfer is an 
established m ethod that has the advantage o f  a relatively  high overall effic ien cy . 
M oreover, retroviral transfer (w ith R W s  b ein g  p h ysica lly  m icroinjected into eg g s)  
has been  the on ly  m ethod to have produced transgenic primates. H ow ever, control 
over transgene expression  is lim ited, and the risk o f  genetic dam age is h igher than  
w ith  pronuclear m icroinjection. Thus, as w ith  pronuclear m icroinjection, b ioeth ica l 
considerations concerning patient safety vs. the probability o f  an effective  result 
dictate that retroviral transfer at its present le v e l o f  developm ent is not feasib le for use  
in hum an germ line gene therapy.
A n alternative approach is SM G T. In reports o f  su ccessfu l SM G T -based anim al 
transgenesis, the approach appears to offer h igh  overall e ffic ien cy  levels. M oreover, 
SM G T offers the p ossib ility  o f  a lo w  cost, relatively  low -tech  m eans to  germ line GM ; 
this w ould  in principle m ake human germ line gen e therapy w id e ly  available.
H ow ever, SM G T has not y et been established as a reliable form  o f  transgenesis, 
esp ecia lly  in its (potentially m ost usefu l) in vivo and A I m odes. Furthermore, 
problem s o f  unreliable/unpredictable transgene expression, and a relatively  h igh  risk  
o f  endogenous genetic  dam age, are likely  to apply to SM G T m uch as they apply to 
pronuclear m icroinjection.
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A s scien ce and tech n o logy  progress, it is to be exp ected  that the foregoing  m ethods o f  
gene transfer w ill b e  gradually im proved, such that they are m ore efficient. H ow ever, 
all o f  these m ethods are inherently lim ited in  that transgene integration takes p lace  
into random sites w ith in  the host genom e. It is  this random  m ode o f  integration that 
underlies the expression  problem s and genetic  dam age risks that accom pany gene  
transfer.
W hile im proved transgene design  m ay am eliorate som e o f  these problem s, the on ly  
know n w ay  to avo id  these problem s entirely is to  target transgenes to chosen  gen om ic  
loci. Indeed, gen e targeting has the potential not on ly  to avoid  problem s o f  expression  
and dam age problem s, but a lso  to alter the host gen om e such that endogenous gen es  
can be rem oved, replaced or repaired. C learly, gene targeting is  the ultim ate too l for  
human germ line gen e therapy.
G ene targeting is routinely ach ieved  in anim al transgenesis. H ow ever, the standard  
approach in vo lves the u se o f  totipotent E SC s, w h ich  to date have on ly  been  
established for m ice. It is not know n w hether totipotent E SC s cou ld  be d evelop ed  for  
humans: certainly, hum an ESC s w ould  b e a m ajor breakthrough for hum an germ line  
gene therapy b ecause gene targeting in the hum an germ line w ou ld  b ecom e p ossib le . 
R egrettably, how ever, b ioeth ical constraints e ffec tiv e ly  exclude the research  
necessary for the establishm ent o f  human E SC s. T his is not (from  a utilitarian  
perspective) due to fact that m any human em bryos w ou ld  have to b e experim ented  
upon; rather, the problem  is that the on ly  w a y  (as far as can be foreseen) to  
dem onstrate totipotency w ould  be to use hum an E SC s to  produce hum an chim eras  
that develop  su ccessfu lly  into an adult. Thus, E SC -based  gene targeting does not lo o k  
like a practical proposition  for human germ line gene therapy.
In recent years, N T -based  transgenesis has been  developed. This approach has 
permitted gene targeting in a variety o f  (non-m urine) anim als. It is likely  that, g iven  
suitable em pirical m odifications, N T  could  be used  to ach ieve gene-targeted hum an  
germ line gene therapy. I f  this w as ever to happen, it w ou ld  also be necessary for the  
process to be m ade m ore efficient, since in its present form, N T  requires a supply o f  
eggs that w ou ld  render the approach im practical for hum an applications. M ore
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fundam entally, the ‘founder’ anim als produced v ia  N T  have very  h igh  rates o f  
debility  and developm ental abnorm ality, probably due to ep igenetic dam age. U ntil 
such tim e as the source o f  these health problem s com es to be elim inated , it w o u ld  be  
unethical to use N T  for hum an germ line gene therapy.
R esearch into the parameters controlling H R, the underlying p rocess o f  gene  
targeting, continues apace. From  such research it is  to b e hoped that the e ffic ien cy  o f  
gene targeting can b e substantially im proved. I f  gene targeting cou ld  becom e the  
norm, and random integration a m inority event, then it m ight be p ossib le  to ach ieve  
gene targeting w ithout the need  for in vitro selection . I f  so, gene targeting in hum an  
germ line gene therapy cou ld  be ach ieved  w ithout the need  for E SC s or N T .
There is a need  for m ore system atic research into transgene design , such that targeting  
transgenes can be designed  that w ill g ive  optim um  targeting effic ien c ies. H ow ever, it 
is un likely  that adjusting transgene sequence alone w ill prove su fficien t to im prove  
the rates o f  targeted integration to lev e ls  that w ou ld  a llo w  selection -free gene  
targeting. A  second  necessary avenue for exploration concerns the recom binase  
enzym es that drive HR. A gain , research is gathering pace into this presently little  
understood area o f  m olecular b io logy . Specu latively , it m ay be p ossib le  to co ­
transferred potent recom binase enzym es or enzym e com p lexes (natural or synthetic) 
alongside/attached to transgene m olecu les during gene transfer, such that H R  is 
stim ulated in  the host cell, resulting in h igh  e ffic ien cy  gene targeting.
To ach ieve this, not on ly  w ou ld  there need  to be a m uch-enhanced understanding o f  
the processes o f  H R, it w ou ld  also  be necessary to design  appropriate transgene 
delivery system s for gene targeting. W hile the m ost conceptually  straightforward w ay  
to co-introduce recom binase m olecu les w ou ld  be pronuclear m icroinjection , this 
w ould  still encum ber human germ line gen e therapy w ith  a techn ica lly  d ifficu lt basic  
procedure. It w ould  be desirable i f  instead o f  pronuclear m icroinjection, en masse 
delivery system s cou ld  be im proved and adapted to co-deliver recom binase en zym es. 
In this regard, liposom e-m ediated  gene transfer represents a prom ising area. In tensive  
efforts are underway to im prove liposom es (prim arily for som atic gen e therapy  
applications) in terms o f  ce ll specificity , cell-uptake effic ien cy , and nuclear  
localisation  ability. I f  such efforts are fruitful, it m ay be p ossib le that in  the future
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such liposom es cou ld  be used  to  deliver transgenes plus recom binase m olecu les to  
gam etes, p ossib ly  in vivo. In this regard, transgene delivery system s are m ovin g  into  
the rapidly develop ing  sphere o f  nanotechnology.
This thesis has explored the ethics o f  human germ line gene therapy from a utilitarian  
perspective. From  this perspective, several con clusion s fo llow . T hese conclusions  
form the rem ainder o f  this chapter.
In technical terms, it is clear that -  unless an unpredictable ‘quantum leap ’ 
breakthrough occurs -  it w ill take several years o f  developm ent before germ line G M  
m ethods b ecom e su fficien tly  reliable, safe and co st-effective  to a llow  hum an germ line  
gene therapy to be attempted. Practical problem s (such as the need  for m any hum an  
eggs from  a parent) aside, the relatively lo w  effectiven ess o f  present germ line G M  
tech n ology  w ou ld  not be enough to eth ically  ju stify  exposing  a ‘patient’ to the 
associated  genetic dam age risks. This proscriptive position  is reinforced b y  the 
im possib ility  o f  obtaining consent from the ‘patient’ in  hum an germ line gene therapy. 
M oreover, genetic  pre-screening is presently a safer proposition that hum an germ line  
gene therapy, and m ost o f  the conditions potentially  am enable to hum an germ line  
gene therapy are also inherently avoidable v ia  pre-screening.
Thus, human germ line gen e therapy is prohibited at present on straightforward  
ethical grounds. H ow ever, i f  and w hen gen e transfer tech n ology  im proves such that 
hum an germ line gene therapy b ecom es efficien t, effectiv e  and safe, utilitarians have  
no safety grounds for m aintaining a prohibitive stance. Indeed, it is  probably true that 
human germ line gene therapy accords better w ith  p eo p le ’s natural inclinations than 
does pre-screening, since the latter in volves elim ination  o f  life  w hereas the form er is 
life-enhancing -  a side effect that w ould  lend som e support to hum an germ line gen e  
therapy over pre-screening, w here the tw o  options w ere otherw ise on  a par.
The p u b lic’s response to human germ line gene therapy represents op in ion  that should  
be considered by  p o licy  m akers, but the p u b lic’s response is not an eth ical entity o f  
itself. Utilitarian deliberations need  to consider the p u b lic’s v ie w  o f  hum an germ line  
gene therapy as a side-effect. A lthough there m ay be a strong reaction against hum an  
germ line gene therapy, this is  anticipated to be culturally sensitive rather than
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reflecting any deep-seated  intuitive em otions. It seem s likely  that, i f  the public can be  
show n the potential m edical value o f  (safe & effectiv e) human germ line gene therapy, 
support w ill be g iven .
The cost o f  hum an germ line gene therapy and associated  lim itations o f  access to  
human germ line gen e therapy are o f  ethical concern. I f  human germ line gene therapy  
w ere to be available on ly  to an elite subset o f  hum ans, this w ou ld  quite probably lead  
to social d ivision . This w ould  be esp ecia lly  so  in the case o f  genetic enhancem ent, as 
opposed to gen e therapy. A ccordingly , utilitarianism  w ould  not support ‘e litist’ 
hum an germ line gen e therapy. H ow ever, i f  the sort o f  im provem ents in gene transfer  
tech n ology  outlined p reviously  are ever realised, such that hum an germ line gen e  
therapy becam e cheap and easy  to apply, then eth ical concerns over the costs o f  
human germ line gene therapy and access to it w ou ld  largely disappear.
The issue o f  future generations o f  people is  im portant in utilitarian d iscu ssions o f  
human germ line gene therapy, since the effects o f  germ line G M  are not lim ited  to 
individual patients but apply also to subsequent generations -  and hence u ltim ately  to  
the entire hum an gen e pool. Thus, any m istake m ade w ith  hum an germ line gen e  
therapy m ay threaten m any (future) people, or even  hum anity itself. H ow ever, 
m istakes are lik e ly  to be repairable by the h igh  tech  procedures that w ou ld  be u sed  for  
hum an germ line gene therapy. M oreover, hum an germ line gene therapy w ould  be  
directed at im proving the hum an germ line. Therefore, accidents aside, the fact that 
future generations stand to be affected b y  hum an germ line gene therapy represents a 
beneficia l consequence.
G enetic enhancem ent, as opposed  to  gene therapy, is a d ifficu lt issue in ethical 
considerations o f  hum an germ line gene therapy. This is  so  because there is no clear  
divid ing line betw een  purely therapeutic applications o f  human germ line gen etic  
m odification, and alterations designed to  im prove non-m edical phenotypic features. 
U tilitarianism  is supportive o f  the former, but som ew hat prohibitive o f  the latter, s in ce  
therapeutic G M  should  increase overall happiness (less  d isease) w h ile  enhancem ent 
GM  m ay lead to p sy ch o log ica l distress and even  socia l breakdown. H ow ever, it is 
important to realise that som e people m ay leg itim ately  benefit from  genetic  
enhancem ent (e .g . those destined to have a lo w  IQ w ould  benefit from  genetic
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correction to produce a norm al IQ ), w here the sam e G M  m ight otherw ise be  
em ployed  to g iv e  an unfair advantage to those w h o  have no legitim ate requirem ent for  
the enhancem ent (e.g . peop le o f  normal in telligence).
F inally, the issu e o f  eugen ics is central to ethical consideration o f  hum an germ line  
gene therapy. H ow ever, the term  ‘eu g en ics’ is rather pejorative, and should  not be  
perm itted to function as a rhetorical device to prevent rational debate. O ne valid  
utilitarian argum ent that needs to be m ade is that provided desirable gen es are not 
inadvertently elim inated, the use o f  human germ line gene therapy to im prove the 
human gene p o o l (by reducing the frequency o f  deleterious a lleles) should be  
recognised  as a w orthy goal.
N evertheless, several risks remain. U se o f  hum an germ line genetic m od ification  b y  
one subset o f  p eop le w ou ld  threaten to establish  a gen etic  elite — a situation o f  
disutility considering the probable p sych o log ica l and societal effects that w ou ld  
result. The situation cou ld  be even  w orse i f  an entire country w as to  unilaterally apply  
human germ line genetic  m odification, esp ecia lly  i f  this w as for enhancem ent 
purposes.
Clearly, these eth ical problem s, and their solutions, are located in the dom ain o f  so c ia l 
p o licy  and p olitics. M oreover, these problem s are not o f  im m ediate concern, s in ce  the  
requisite G M  tech n ology  has not yet been  d eveloped  su fficien tly  to perm it hum an  
germ line genetic m odification . H ow ever, despite the relative infancy o f  G M  
technology, it is salutary to rem ember that the germ lines o f  m any m am m als in clud ing  
primates have already been su ccessfu lly  gen etica lly  altered. C onsidering the 
accelerating pace o f  genetic scien ce, it seem s inevitable that technologica l 
im provem ents w ill over the forthcom ing years p lace such ethical problem s firm ly into  
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Population Ethics: A Hedonistic Response to Parfitt’s Repugnant Conclusion
1. Introduction
In his sem inal w ork Reasons and Persons, D erek  Parfitt claim s that ‘total v ie w ’ 
consequentialism  (T V C ) generates the Repugnant Conclusion:
RC: for any large population o f  p eop le, a ll w ith  lives w e ll worth liv in g ,
there w ill be som e m uch larger population  w h ose ex istence w ould  be a better 
alternative even  though its m em bers all have liv es  that are on ly  barely w orth  
liv in g  (Parfitt 1984).
In the descriptive terms used  by Parfitt, the large population o f  peop le a ll w ith  liv es  
w ell worth liv in g , experience “M ozart”, w hereas the m uch larger population a ll w ith  
lives on ly  barely worth liv ing , experience “m usak”.
A s Parfitt’s negative term ‘repugnant’ su ggests, it is d ifficu lt to accept RC as a good  
consequence. H ow ever, a rejection o f  RC seem s to  entail the rejection o f  T V C . I shall 
refer to th isprima facie paradox or tension  as R C /TV C . Parfitt considers and rejects
various attempts to reso lve R C/TVC.
2. Argument Framework and Premises
M y arguments are expressed w ithin a fram ew ork o f  hedonistic (m ental-state) 
utilitarianism . (This form  o f  consequentialism  is em ployed  for the sake o f  sim plicity; 
alternative form s, such as D esire Fulfilm ent or A ct U tilitarianism  could  a lso  be used . 
H ow ever, the reasoning entailed w ould  be h igh ly  com p lex .) The force o f  this response  
from hedonism  rests upon certain prem ises, as fo llow s:
P I Pleasure exits in different form s. (T his v iew  is a lso  held  b y  Parfitt. It is 
opposed  to classical v iew s o f  pleasure (such as that o f  B entham ), but
307
should  not be confused w ith  M ill’s notions o f  ‘h igher’and ‘lo w er’ 
p leasu res1
P2 G eneration o f  pleasure depends u ltim ately  upon energy and matter in  
the physica l sense, and;
P3 Energy and matter (call them  ‘R esou rces’) are in lim ited  supply w ith in  the 
U niverse. Furthermore, h is is  a deeply true fact; it w ou ld  apply to any
con ceivab le universe. (A n infinite universe might change P3 -  but even  w ith in
such a un iverse it m ight not b e practical to  actually  access R esources in a 
lim itless w ay .)
3. Hierarchy of Pleasure
For the sake o f  sim plicity , arguing from P I I shall deal w ith  on ly  tw o  different form s 
o f  pleasure. O ne is very  lo w  level, call it ‘B a sa l’. This is  akin to Parfitt’s ‘M u sak ’: 
B asal refers to the state o f  m ind prevailing w hen  on ly  very basic needs are m et.
The other form o f  pleasure is h igh leve l, ca ll it ‘U ltra’. This is akin to  Parfitt’s 
‘M ozart’. H ow ever, note that B asal and Ultra refer sp ecifica lly  and absolutely  to 
m ental states; Parfitt’s M usak and M ozart im p ly  environm ental experiences, leav in g  
the corresponding m ental states som ew hat unclear.
The p o ssib le  ex istence o f  B asal and Ultra appears incontrovertible. (O f  course, there 
m ay ex ist a gradient com prising more than tw o form s o f  pleasure; k n ow led ge here 
aw aits scien tific (e .g . neurobiological) elucidation . This in  no w ay  alters the basic  
tenor o f  the argum ent from  hedonism .) Extending from this, tw o  p lausib le cla im s m ay  
be made:
C l A  person cannot experience Ultra u n less B asal is  already present.
C2 B asal and Ultra each have intrinsic value.
1 See Scarce (1996) for an overview o f  the views o f Bentham and Mill on pleasure.
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From  C 2, it m ay be asked: A re the intrinsic va lu es B asal and Ultra directly additive?
O n prima facie grounds at least, this does not appear likely. I f  P I (“pleasure ex ists  in
different form s”) is correct, because B asal and Ultra are different form s o f  pleasurable  
m ental states, then it b ecom es an open question  as to whether a B asal va lu e and an 
Ultra value can be added together.
In general, tw o different entities cannot be added together. A  sim ple but pertinent 
analogy is that o f  apples and oranges: 3 apples +  2  oranges =  [3 apples and 2 
oranges]; it w ould  b e absurd to claim  that 3 apples +  2  oranges =  5 o f  any entity. (O f  
course, it can be said that 3 apples +  2 oranges =  5 fruits, but this is  m erely  a sem antic  
fix .)
It m ay rem ain m athem atically p ossib le to add values for separate entities such as 
B asal and Ultra. H ow ever, the onus o f  p ro o f m ust rest w ith those w ish in g  to reject the 
com m on-sense notion  that B asal and U ltra are not additive. Thus, I m ake the 
fo llo w in g  claim:
C3 Intrinsic values o f  B asal and Ultra are not d irectly additive.
This cla im  is central to the argument from  hedonism .
4. Compensation?
Can extra peop le com pensate for a reduction in  Ultra? A ccording to C 2, B asal and  
Ultra each have value. Suppose, for sim plicity , that there is a on e-to -on e relationship  
betw een  the tw o m ental states. In num erical term s, assum e that one unit o f  B asal is  
equivalent to one unit o f  Ultra. It is important to note that this equ ivalence derives 
from  the quantity o f Resources required to produce pleasure. Thus, although the
‘U n its’ are m easures o f  pleasure, this does not im ply  that the tw o  m ental states are
additive.
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N o w  com pare tw o very sm all p ossib le worlds:
W 1 This w orld has a population o f  tw o  peop le. B oth  experience Ultra. From  C l &  
C2, Table 1 provides a summ ary o f  the relative am ounts o f  pleasure involved:
T a b le  1 U nits o f  Pleasure in W 1
B asal 1 1
Ultra 1 1
Person I II
W 2 This w orld has a population o f  four peop le. A ll experience B asal, but none  
experience Ultra. Table 2 sum m arises this:
T a b le  2 U nits oj 'P leasure in W 2
B asal 1 1 1 1
Ultra 0 0 0 0
Person III IV V V I
W hich  is the best world? A ccord ing to R C, neither w orld  is better than the other. I 
su ggest that this v iew  is m istaken. B oth  w orlds contain 4  U nits o f  pleasure. H ow ever, 
on ly  W 1 contains the higher type o f  pleasure. Thus, at least on  prima facie grounds,
w e  ought to prefer W1 to W 2.
So, in this sim ple com parison betw een  W 1 and W 2, it w ould  appear that extra p eop le  
are inadequate com pensation for the loss o f  Ultra.
5. Consolidation
Suppose w e  have to decide b etw een  tw o alternatives, as outlined b elow .
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W 1 has the opportunity for increased pleasure, due to the d iscovery  o f  additional 
R esources. Suppose that the d ecision  is constrained b etw een  (a) not u tilising the new  
R esources and therefore keep ing  W 1 unchanged, or (b) u tilising the n ew  R esources, 
such that W 1 changes to W l+, as show n in Table 3:
T a b le  3 U nits o f  Pleasure in W 1+
Basal 1 1 1 1 1 1
Ultra 1 1 0 0 0 0
Person I II VII VIII IX X
From  Table 3, there seem s to be no doubt that W l+ is better than W l.
H ow ever, i f  the decision  w ere not constrained as above, rather than u tilising  the n ew  
resources to increase population size , it w ould  have been  better to apply a Principle o f 
Consolidation. This principle is  based on m y previous claim  that, despite the total
U nits o f  pleasure rem aining num erically unaltered, extra p eop le are prima facie 
inadequate com pensation w here a loss o f  Ultra is entailed. C onsolidation  operates as 
fo llow s:
C onsolidation: R esources should  be allocated  such that, for a g iven  total num ber
o f  U nits o f  pleasure, the m axim um  lev e l o f  U ltra should be
attained.
I f  C onsolidation is applied to W l facing a decision  on h ow  to u tilise  n ew  resources, 
the best p ossib le w orld (W l* ) w ou ld  result:
T a b le  4 U nits ol "Pleasure in W l*
Basal 1 1 1 1
Ultra 1 1 1 1
Person I II VII VIII
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So, C onsolidation should, w herever possib le, be applied to the question o f  utilisation  
o f  R esources to generate pleasure. C onsolidation is therefore an important principle
w hen  considering “m ore p eop le vs a higher quantity o f  pleasure” dilem m as. 
C onsolidation form s a central part o f  the argum ent from  hedonism .
N o w  consider tw o alternative populations, A and Z. (The designations A and Z  are
taken from  Parfitt.) Population A com prises individuals all w ith  lives w e ll worth
living. Population Z  is a larger population, the m em bers o f  w h ich  have lives that are 
on ly  barely worth liv ing . T hese tw o alternatives m ay be expressed  thus:
T a b le  5 Population A Population  Z
Persons (num bers x  106) 100 1 ,000 ,000
B asal (U nits o f  Pleasure) 100 1 ,000 ,000
Ultra (U nits o f  Pleasure) 100 0
W hich is best, A or Z? O f course, the Repugnant C onclusion  suggests that Z  w ins. A s
Parfitt’s negative term  ‘repugnant’ suggests, it is  d ifficu lt to accept this. W e need  to  
consider: Is it likely  that, through tim e, C onsolidation  cou ld  be applied to  Z? In other 
words, cou ld  population numbers be reduced (by birth control) and R esources  
reallocated to generate ultra? I f  so, C onsolidation w ou ld  convert Population Z  into a 
population com prising few er persons, each w ith  a balanced a llocation  o f  B asal and 
Ultra:
T ab le  6 Population Z *
Persons (numbers x  106) 5 0 0 ,0 0 0
Basal (U nits o f  Pleasure) 5 0 0 ,0 0 0
Ultra (U nits o f  Pleasure) 5 0 0 ,0 0 0
Population Z* is clearly better than either A or Z. Therefore, go in g  back to  the A vs Z  
judgem ent, w e should prefer Z  i f  C onsolidation is possib le.
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H ow ever, suppose that it becom es absolutely im p ossib le, in the near or far future, to  
apply C onsolidation  (due perhaps to the rise to total dom ination o f  a governm ent o f  
extrem ists?) w ith in  Populations A or Z. In this case, I b e lieve  that A m ust be  
preferable to Z, for the fo llo w in g  reasons:
From C3 (intrinsic values o f  B asal and Ultra are not directly additive), it 
w ould  be invalid to add together B asal and U ltra pleasure valu es w ith in  A 
(“ 100 +  100 =  2 0 0 ”) to compare it w ith  the quantity o f  p leasure in Z  
(1 ,0 0 0 ,0 0 0 ). Therefore, no valid  con clusion s can be drawn from  such a 
com parison. This leaves on ly  the d ifference in  types o f  pleasure as a va lid  
basis for com parison: since only A contains the higher type o f  pleasure, I 
conclude that A is preferable to Z.
W ould  this con clusion  still hold  i f  the d ifferences b etw een  A and Z  w ere even  
sharper? For exam ple:
T a b le  7 P op u lation ^ ® Population Z®
Persons (numbers x  106) 10 1 ,0 0 0 ,0 0 0 ,0 0 0 ,0 0 0
B asal (U nits o f  Pleasure) 10 1 ,0 0 0 ,0 0 0 ,0 0 0 ,0 0 0
Ultra (U nits o f  Pleasure) 10 0
A gain , the argum ent from  C3 g ives  the sam e answer: A is preferable to Z  .
The problem  here is that this argument seem s to  be generating an absurd con clusion , 
w here phenom enally huge populations experiencing on ly  B asal are deem ed w orse  
than m uch sm aller populations experiencing Ultra. So, RC has been  avoided, but the 
alternative “absurd” conclusion  is sim ilarly d ifficu lt to  accept.
But does this apparent reductio ad absurdum actually  hold? It is  h igh ly  d ifficu lt, i f  not 
im possib le, to en visage a realistic scenario in w h ich  C onsolidation  is absolutely  
unattainable, even  in the distant future. (E ven  a very  sm all degree o f  C onsolidation  in  
Z®(for exam ple, a population reduction o f  0 .000000001% ) w ou ld  render Z® better
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than A 0.) B ecau se a situation o f  perm anent non-C onsolidation  seem s h igh ly  
im plausible, I conclude that no absurd con clusion s are im plied  in the argum ent from  
hedonism .
6. Conclusion
Prem ised upon (a) the ex istence o f  a Hierarchy o f  Pleasure and (b) a Principle o f  
C onsolidation, the argum ent from  hedonism  proposed  in  this appendix offers a 
p ossib le w ay  o f  avoid ing Parfitt’s Repugnant C onclusion . In so doing, this argum ent 
m ay save Total V iew  C onsequentialism  from  the rejection im plied  by  the R epugnant 
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